Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
1
COMPRESSIBLE, MINIMALLY INVASIVE IMPLANTS AND RELATED
SYSTEMS AND METHODS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit under 35 U.S.C. 119(e) and the Paris
Convention of U.S. Provisional Patent
Application No. 63/295,068 filed on December 30, 2021, and titled "Apparatus,
Systems, And Methods For Minimally
Invasive Implants And Implantation In Tissue" and U.S. Non-provisional Patent
Application No. 17/650,459 filed on
February 9, 2022. The aforementioned application is incorporated herein by
reference in its entirety.
SUMMARY
Disclosed herein are various examples of implants, such as compressible
implants, that are configured for delivery
through preferably minimally invasive entrance incisions into implant pockets,
along with related systems and methods.
More specific examples of implants, systems, and methods for delivery of
implants within subcutaneous and/or soft-tissue
implant pockets are disclosed below in connection with the following numbered
paragraphs.
EXAMPLES/CLAIMS
Examples of implants, systems, and methods for delivery of implants within
subcutaneous and/or soft-tissue implant
pockets are disclosed below in connection with the following numbered
paragraphs.
1. A compressible implant configured for positioning within an implant
pocket, comprising:
an implant comprising a flexible material, wherein the implant is
reconfigurable in two configurations,
the two configurations comprising:
a first, compressed configuration, wherein the implant is configured to be
delivered through a
minimally invasive entrance incision while in the compressed configuration;
and
a second, uncompressed configuration, wherein the implant is configured to be
reconfigured
from the compressed configuration to the uncompressed configuration while
being positioned within an
implant pocket formed within a patient such that the implant can be maintained
in the uncompressed
configuration within the implant pocket in a functional state following
implantation; and
wherein the implant comprises a footprint having an area in the uncompressed
configuration, wherein the footprint
comprises a maximal footprint dimension, wherein the implant comprises a
maximal thickness measured in a
direction at least substantially perpendicular to the footprint and wherein
the implant is configured such that the
maximal thickness is no greater than about 25% of the maximal footprint
dimension.
2. The compressible implant of claim 1, wherein the implant comprises a
footprint having an area in the
uncompressed configuration, wherein the footprint comprises a maximal
footprint dimension, wherein the implant
comprises a maximal thickness measured in a direction at least substantially
perpendicular to the footprint and wherein the
implant is configured such that the maximal thickness is no greater than about
25% of the maximal footprint dimension.
3. The compressible implant of claim 1, wherein the implant is configured
to be delivered through a very minimally
invasive entrance incision while in the compressed configuration.
4. The compressible implant of claim 3, wherein the implant is configured
to be delivered through an ultra-
minimally invasive entrance incision while in the compressed configuration.
5. The compressible implant of claim 1, wherein the implant comprises a
therapeutic agent delivery implant.
Date Recue/Date Received 2022-12-30
2
6. The compressible implant of claim 1, wherein the implant comprises at
least one macro-positioning/instrument
engaging hole configured to engage at least one selected from the group of: an
instrument to facilitate implantation of the
implant and a stitch.
7. The compressible implant of claim 6, further comprising an x-ray
detectable marker positioned adjacent to the at
least one hole.
8. The compressible implant of claim 6, further comprising a protruding
tab, wherein the at least one hole is formed
in the protruding tab.
9. The compressible implant of claim 6, further comprising at least one
structural reinforcement region, wherein the
at least one structural reinforcement region is positioned about the at least
one macro-positioning/instrument engaging
hole.
10. The compressible implant of claim 9, wherein the at least structural
reinforcement region is positioned adjacent
to a peripheral edge of the implant without protruding from the implant.
11. The compressible implant of claim 1, wherein the implant comprises a
bladder, and wherein the bladder is
formed between two adjacent laminates of the one or more laminates.
12. The compressible implant of claim 1, wherein the implant comprises a
footprint area of at least 50 square cm.
13. The compressible implant of claim 1, wherein the implant is at least one
of configured to deliver drugs within the
implant pocket and comprises one or more electrical components.
14. The compressible implant of claim 1, wherein the implant comprises a
footprint area of at least 100 square cm.
15. The compressible implant of claim 1, wherein the implant comprises at
least one macro-vascularization hole
configured to facilitate at least one selected from the group of: vascular
ingrowth, vascular passage, vascular
communication and measurement of vessel contents.
16. The compressible implant of claim 15, wherein macro-vascularization holes
may be configured to accommodate
at least one selected from the group of: a microfluidic channel, a biosensing
probe and a fiberoptic.
17. The compressible implant of claim 1, further comprising intersecting
strands of materials.
18. The compressible implant of claim 17, wherein the intersecting strands are
formed into a mesh.
19. The compressible implant of claim 1, wherein the implant is configured to
be at least one selected from the group
of: rollable, and foldable.
20. The compressible implant of claim 1, wherein the compressed implant
comprises 2 turns and/or 2 folds.
21. The compressible implant of claim 1, wherein the compressed implant
comprises 5 turns and/or 6 folds.
22. The compressible implant of claim 1, wherein the flexible material
comprises a protective mesh configured to
provide physical protection to a user at a location of the compressible
implant within the implant pocket.
23. The compressible implant of claim 22, wherein the protective mesh
comprises Kevlar or graphene.
24. The compressible implant of claim 22, further comprising a biocompatible
plastic coating.
25. The compressible implant of claim 22, further comprising a therapeutic
agent incorporated into the
biocompatible plastic coating.
26. The compressible implant of claim 25, wherein the therapeutic agent
comprises an antimicrobial agent and is
configured to be released upon impact with a penetrating object.
27. The compressible implant of claim 22, wherein the implant comprises at
least one peripheral fold configured to
aid in mitigating a penetrating wound.
28. The compressible implant of claim 22, further comprising a zone of overlap
secured by a binding element.
29. The compressible implant of claim 22, further comprising at least one
selected from the group of: an inductance
coil, a PCB, a sensor, and an antenna.
30. The compressible implant of claim 29, configured to communicate data of
the status of the wearer.
Date Recue/Date Received 2022-12-30
3
31. A system comprising the compressible implant of claim 22, further
comprising a second compressible implant
configured to be positioned within the implant pocket in an overlapping
configuration with the compressible implant to
effectively create a larger implant.
32. The compressible implant of claim 1, wherein the flexible material
comprises a mesh configured to allow for at
least one selected from the group of: containment of a therapeutic agent,
storage of a therapeutic agent and release of a
therapeutic agent.
33. The compressible implant of claim 32, wherein the mesh comprises a
plurality of layers.
34. The compressible implant of claim 33, wherein at least one of the
plurality of layers comprises a pH-sensitive
layer.
35. The compressible implant of claim 32, wherein the implant comprises a
plurality of macro-vascularization holes
configured to allow for vascularization across the implant through the
plurality of macro-vascularization holes.
36. The compressible implant of claim 1, further comprising a superstructure
configured to bias the implant towards
the uncompressed configuration.
37. The compressible implant of claim 36, wherein the superstructure is
configured to automatically rigidify upon
encountering body fluids.
38. The compressible implant of claim 36, wherein the superstructure is
further configured to deliver at least one
selected from the group of: a drug and biologics therefrom.
39. The compressible implant of claim 36, wherein the superstructure comprises
opposing cross-members defining a
plus shape.
40. The compressible implant of claim 36, wherein the superstructure comprises
a shape that at least substantially
matches a shape of the implant in its uncompressed configuration.
41. The compressible implant of claim 36, wherein the superstructure comprises
at least one selected from the group
of: a circular shape and a polygonal shape, and wherein the superstructure is
inset from the outer perimeter of the implant
in its uncompressed configuration.
42. The compressible implant of claim 36, wherein the superstructure comprises
at least one selected from the group
of: a circular shape and a polygonal shape, and wherein the superstructure is
located on the perimeter of the implant in its
uncompressed configuration.
43. The compressible implant of claim 36, further comprising an injection port
fluidly coupled with the
superstructure, wherein the injection port is configured for at least one
selected from the group of: (a) inflating the
superstructure and (b) delivering a therapeutic agent into the superstructure
for ultimate release into a patient.
44. The compressible implant of claim 36, wherein the superstructure is
inflatable.
45. The compressible implant of claim 36, wherein the superstructure comprises
a therapeutic agent contained
therein.
46. The compressible implant of claim 45, further comprising a micro-pump
configured to selectively pump the
therapeutic agent from the superstructure.
47. The compressible implant of claim 1, comprising at least one selected from
the group of: one or more inductance
coils, a battery, a capacitor, a CPU, a microfluidic channel, a probe, a Lab-
on-a-chip, a fiberoptic, an LED, a pump, an
antenna, and a sensor.
48. The compressible implant of claim 47, wherein the inductance coils
comprise an array of micro-coils configured
for use as an inductive link receiver.
49. The compressible implant of claim 47, wherein the inductance coils
comprise stacked inductance coils.
50. The compressible implant of claim 1, wherein the implant comprises an
elongated strip comprising a plurality of
spaced apart implant payload bays positioned thereon.
Date Recue/Date Received 2022-12-30
4
51. The compressible implant of claim 50, wherein each of at least a subset of
the implant payload bays comprises a
biologic cell cluster.
52. The compressible implant of claim 1, further comprising a blood vessel
growth stimulating hormone.
53. The compressible implant of claim 52, wherein the blood vessel growth
stimulating hormone comprises at least
one selected from the group of: proliferin, prolactin, growth hormone, and
placental lactogen.
54. The compressible implant of claim 1, wherein the implant comprises a neuro
stimulative implant comprising a
plurality of electrodes configured to stimulate nerves of at least one type
selected from the group of: sensory nerves, and
muscle nerves.
55. The compressible implant of claim 54, further comprising a heartrate
sensor, wherein the heartrate sensor is
configured to adjust at least one selected from the group of: (a) signal
strength and (b) signal frequency to the plurality of
electrodes based upon a heartrate detected by the heartrate sensor.
56. The compressible implant of claim 54, wherein the plurality of electrodes
is configured to fire at a
preprogrammed firing pattern that changes over time.
57. The compressible implant of claim 54, wherein each of at least a subset of
the plurality of electrodes comprises a
circumferential electrode extending along a band about a portion of the
implant.
58. A system for positioning a compressible implant within an implant pocket,
comprising:
an implant configured to be reconfigurable in two configurations, the two
configurations comprising:
a first, compressed configuration, wherein the implant is configured to be
delivered through a
minimally invasive entrance incision while in the compressed configuration;
and
a second, uncompressed configuration, wherein the implant is configured to be
reconfigured
from the compressed configuration to the uncompressed configuration while
being positioned within an
implant pocket formed within a patient such that the implant can be maintained
in the uncompressed
configuration within the implant pocket following implantation; and
an instrument comprising:
a tip configured to extend through the minimally invasive entrance incision;
and
a shaft configured to engage the implant in the compressed configuration and
deliver the
implant through the minimally invasive entrance incision.
59. The system of claim 58, wherein the instrument is configured to facilitate
reconfiguring the implant from the
compressed configuration to the uncompressed configuration after extending the
implant through the minimally invasive
entrance incision.
60. The system of claim 58, wherein the tip comprises a dilator configured to
expand a size of the minimally
invasive entrance incision.
61. The system of claim 60, wherein the tip comprises screw threads.
62. The system of claim 58, wherein the instrument comprises means for
securing the implant to the instrument.
63. The system of claim 62, wherein the means for securing comprises one or
more protrusions coupled to the shaft,
wherein each of the one or more protrusions is configured to engage a hole
formed on the implant.
64. The system of claim 63, wherein the one or more protrusions comprise
spherical protrusions.
65. The system of claim 62, wherein the means for securing comprises a tab
fastener configured to engage a tab
extending from the implant.
66. The system of claim 58, wherein the instrument further comprises a
releasable handle.
67. An implant configured for positioning within a tissue implant pocket,
comprising:
Date Recue/Date Received 2022-12-30
5
an arm extending in a spiral shape from an outer terminus at a periphery of
the implant to an inner
terminus adjacent to a center of the implant, wherein the arm defines a
plurality of adjacent bands, wherein the
implant comprises at least one configuration selected from the group of:
(a) comprising a space defined between adjacent bands; and
(b) comprising a flexible material configured to allow for temporary creation
of space between
adjacent bands so as to facilitate insertion of the implant through a
minimally invasive entrance
incision; and
wherein the implant is configured to at least substantially maintain the
spiral shape both before and
after implantation within the implant pocket through a minimally invasive
entrance incision.
68. A system comprising the implant of claim 67, and further comprising an
auxiliary implant electrically coupled
with the implant, wherein the auxiliary implant comprises at least one
selected from the group of: an antenna, a CPU, a
battery and an inductance coil.
69. The implant of claim 67, wherein the implant is configured to function as
an inductance coil.
70. The implant of claim 67, wherein the implant is configured for selective
delivery of a therapeutic agent
therefrom.
71. The implant of claim 67, wherein the implant comprises a polymeric
external laminate configured to deliver a
therapeutic agent therefrom.
72. The implant of claim 67, wherein the implant comprises a nanoscale agent
responsive to at least one selected
from the group of: light, magnetic fields, ultrasound, radio frequency, and x-
ray radiation for release of a therapeutic
agent.
73. The implant of claim 67, wherein the implant comprises a plurality of
selectively openable pores configured to
be opened via thermoporation.
74. The implant of claim 73, wherein the thermoporation is configured to be
selectively induced via at least one
selected from the group of: electricity, ultrasound, and radiation.
75. The implant of claim 67, wherein the implant comprises at least one
selected from the group of: an electrical
component and a micropump.
76. The implant of claim 67, wherein the implant comprises at least one
selected from the group of: a
radiographically, sonically, and electromagnetically identifiable material.
77. The implant of claim 67, wherein the implant comprises a protective
sheath.
78. The implant of claim 67, wherein the implant comprises a protective inner
sheath and a protective outer sheath,
and wherein a fluid is contained between the protective inner sheath and the
protective outer sheath.
79. The implant of claim 67, wherein the implant comprises a temperature
sensor.
80. The implant of claim 79, wherein the implant comprises an inductance coil,
and wherein the temperature sensor
is configured to reduce or terminate charging from an external wireless
inductance coil in response to the temperature
sensor detecting a threshold temperature.
81. The implant of claim 67, wherein the implant comprises a drug reservoir
comprising a selectively openable gate.
82. The implant of claim 81, wherein the gate is configured to be selectively
dissolved electrochemically by
application of a wirelessly induced current.
83. The implant of claim 67, wherein the implant is non-compressible, and
wherein the arm comprises a solid core.
84. The implant of claim 67, wherein the implant comprises a superstructure.
85. The implant of claim 84, wherein the superstructure is fluidly coupled
with an injection port.
86. The implant of claim 67, wherein the arm comprises a hollow center.
87. The implant of claim 86, further comprising a guidewire positioned within
the hollow center.
Date Recue/Date Received 2022-12-30
6
88. The implant of claim 86, further comprising at least one selected from the
group of: an electronic component, a
battery, one or more inductance coils, a capacitor, a data storage element, a
heating element, a heart rate sensor, an oxygen
saturation monitor, an EMI suppression element, a printed circuit board/CPU,
antenna, a data storage element, a lab-on-a-
chip, a polymeric protective sheath, a microfluidic channel, a fiberoptic,
positioned within the hollow center.
89. The implant of claim 86, further comprising an EMI suppression element
configured to protect one or more
electrical elements positioned within the hollow center.
90. The implant of claim 86, further comprising a microfluidic channel
configured to deliver fluid from outside of
the hollow center to the hollow center and vice versa.
91. The implant of claim 90, wherein the microfluidic channel terminates at a
location corresponding to one of the
spaces between adjacent bands of the arm.
92. The implant of claim 67, wherein the implant defines a circular shape in
plan view.
93. The implant of claim 67, wherein the implant defines a polygonal shape in
plan view.
94. The implant of claim 67, wherein the outer arm terminus comprises a
bulbous tissue passage facilitator
configured to facilitate passage of the arm through the minimally invasive
entrance incision and to inhibit tissue catching
on the outer arm terminus during installation.
95. The implant of claim 94, wherein the bulbous tissue passage facilitator
further comprises a port providing access
to an inner passage defined within the arm.
96. The implant of claim 67, wherein the implant comprises one or more
flexible flaps extending from the arm, and
wherein each of the one or more flexible flaps is configured to compress
against the arm during installation through the
minimally invasive entrance incision and automatically decompress to extend
away from the arm once within the implant
pocket.
97. The implant of claim 96, wherein each of the one or more flexible flaps is
configured to deliver a therapeutic
agent therefrom.
98. The implant of claim 96, wherein each of the one or more flexible flaps is
configured to provide increased
surface area for wireless inductance charging.
99. The implant of claim 67, wherein the implant is configured to at least one
selected from the group of: (a)
function as an inductance coil, (b) function as a drug eluting implant, and
(c) function as an antenna.
100. The implant of claim 67, wherein the arm comprises at least two complete
turns to form the spiral shape.
101. The implant of claim 67, wherein the implant has a diameter of at least 2
cm.
102. The implant of claim 101, wherein the implant has a diameter of at least
10 cm.
103. The implant of claim 67, further comprising a plurality of electrodes
positioned on an outer surface of the
implant, wherein the arm comprises a hollow center, and wherein at least one
selected from the group of: a battery, a CPU,
a PCB, a heartrate sensor, a temperature sensor, and an antenna is positioned
within the hollow center.
104.A system comprising the implant of claim 67, further comprising an
elongated strand configured to be positioned
in an elongated, subcutaneous implant tunnel via a minimally invasive entrance
incision.
105. The system of claim 104, wherein the elongated strand comprises a
plurality of electrodes configured to
stimulate nerves.
106. The system of claim 105, wherein the elongated strand is configured for
neurostimulation of at least one selected
from the group of: sensory nerves and muscular nerves.
107. The system of claim 106, wherein the elongated strand is configured for
neurostimulation of at least one selected
from the group of: male genital sensory nerves and female genital sensory
nerves.
108. The system of claim 107, configured for neurostimulation in coordination
with an external source.
Date Recue/Date Received 2022-12-30
7
109. The system of claim 108, wherein the external source is at least one
selected from the group of: a cellphone, a
transmitter, a visual image, a video, and a sound.
110. The system of claim 107, wherein the elongated strand comprises at least
one selected from the group of: nerve
stimulating electrodes nerves piezoelectric generator, piezoelectric actuator,
miniaturized eccentric rotating mass motors,
linear resonant actuators, and solenoids.
111. The system of claim 104, wherein the elongated strand comprises a
cardioverter defibrillator.
112. The system of claim 104, further comprising an EKG implant comprising a
plurality of leads.
113. The system of claim 112, wherein the plurality of leads of the EKG
implant are resiliently flexible and
configured to be delivered in a compressed configuration through a minimally
invasive entrance incision and then
automatically decompress once within an implant pocket to position the
plurality of leads in a configuration targeting at
least one selected from the group of: a particular heart configuration and a
range of heart configurations.
114. The system of claim 104, wherein the system further comprises an
implantable motor unit system electrically
coupled with the elongated strand, wherein the implantable motor unit system
comprises a plurality of motor drives
configured to be coupled to one another across a human joint to provide force
to pivot the human joint.
115. The system of claim 104, further comprising a second elongated strand
configured to be positioned in an
elongated, subcutaneous implant tunnel via a minimally invasive entrance
incision electrically coupled with the elongated
strand to allow for signals to be sent from the elongated strand to the second
elongated strand and to at least one of the
plurality of motor drives to accomplish selective pivoting of the human joint.
116. The system of claim 115, wherein each of the plurality of motor drives is
independently actuatable.
117. The system of claim 116, further comprising at least one implantable
sensor coupled with at least one of the
plurality of motor drives.
118. The implant of claim 67 further comprising a plurality of LEDs.
119. The implant of claim 118, wherein each of the plurality of LEDs is
positioned on an exterior surface of the arm
of the implant.
120. An elongated, flexible implant, comprising:
a plurality of pods, wherein each of the plurality of pods is selectively
coupleable with an adjacent pod
of the plurality of pod to form a pod chain, and wherein the pod chain is
configured to be positioned within an
implant pocket through a minimally invasive entrance incision.
121.A system comprising the elongated, flexible implant of claim 120, and
further comprising:
a spiral implant comprising an arm extending in a spiral shape from an outer
terminus at a periphery of
the implant to an inner terminus adjacent to a center of the implant, wherein
the arm defines a plurality of
adjacent bands wherein the implant comprises at least one configuration
selected from the group of:
(a) comprising a space defined between adjacent bands; and
(b) comprising a flexible material configured to allow for temporary creation
of space between adjacent
bands so as to facilitate insertion of the implant through a minimally
invasive entrance incision, and
wherein the implant is configured to at least substantially maintain the
spiral shape both before and
after implantation within the subcutaneous and/or soft tissue implant pocket
through a minimally invasive
entrance incision; and
wherein the spiral implant comprises a hollow core defining a space configured
to receive one or more
elements; and
wherein the spiral implant comprises at least 2 turns.
122. The system of claim 121, wherein the hollow core comprises at least one
partition configured to separate the
hollow core into separate functional regions.
Date Recue/Date Received 2022-12-30
8
123. The system of claim 121 further comprising a bladder-like compressible
implant.
124. The system of claim 123, wherein the spiral implant and/or the bladder-
like compressible implant is configured
to collect body fluids from a patient once within an implant pocket.
125. The system of claim 124, wherein the spiral implant and/or the bladder-
like compressible implant is further
configured to generate water from the body fluids, wherein at least one of the
plurality of pods comprises a mixing pod
comprising a dry and/or superconcentrated medication, and wherein the mixing
pod is configured to receive the water
generated from the body fluids from the spiral implant to generate a liquid
medication therefrom.
126. The system of claim 125, wherein the mixing pod comprises a plurality of
bays, wherein at least one bay of the
plurality of bays comprises a storage bay for storage of a dry medication,
wherein at least one bay of the plurality of bays
comprises a mixing bay, and wherein the mixing bay is coupled with the storage
bay and the spiral implant to allow for
mixing of the dry medication with the water generated from body fluids from
the spiral implant and/or a bladder-like
compressible implant.
127.A method for implantation of a spiral implant through a minimally invasive
entrance incision, the method
comprising the steps of:
forming a minimally invasive entrance incision;
forming a subcutaneous and/or soft tissue implant pocket within a patient
adjacent to the entrance
incision;
inserting a terminal end of the spiral implant through the minimally invasive
entrance incision, wherein
the spiral implant comprises an arm extending in a spiral shape from an outer
terminus at a periphery of the
implant to an inner terminus adjacent to a center of the implant; and
rotating the spiral implant to advance the spiral implant through the
minimally invasive entrance
incision until the spiral implant is placed subcutaneously within the patient.
128. The method of claim 127, wherein the step of forming an implant pocket
comprises forming an implant pocket
comprising an implant delivery pocket portion and an implant pocket portion,
wherein the implant delivery pocket portion
is configured to receive the spiral implant during implantation, and wherein
the implant pocket portion is configured to
receive the spiral implant indefinitely following implantation.
129. The method of claim 128, wherein the implant delivery pocket portion is
positioned on a first side of the
minimally invasive entrance incision, and wherein the implant pocket portion
is positioned on a second side of the
minimally invasive entrance incision opposite the first side.
130. The method of claim 128, further comprising advancing the spiral implant
from a position at which the spiral
implant is at least partially positioned within the implant delivery pocket
portion to a position at which the spiral implant is
fully positioned within the implant pocket portion.
131. The method of claim 130, wherein the step of advancing the spiral implant
from a position at which the spiral
implant is at least partially positioned within the implant delivery pocket
portion to a position at which the spiral implant is
fully positioned within the implant pocket portion is performed by
manipulating the spiral implant using finger pressure on
the outer skin of the patient.
132. The method of claim 128, wherein the implant pocket portion comprises a
polygonal shape.
133. The method of claim 127, wherein the spiral implant comprises a coating
configured to reduce friction during
installation.
134. The method of claim 127, wherein the terminal end comprises the outer
terminus of the spiral implant.
135.An implant configured for positioning within a subcutaneous and/or soft
tissue implant pocket, comprising:
Date Recue/Date Received 2022-12-30
9
an arm extending in a spiral shape from an outer terminus at a periphery of
the implant to an inner
terminus adjacent to a center of the implant, wherein the arm defines a
plurality of adjacent bands, wherein the
implant comprises at least one configuration selected from the group of:
(a) comprising a space defined between adjacent bands; and
(b) comprising a flexible material configured to allow for temporary creation
of space between adjacent
bands so as to facilitate insertion of the implant through a minimally
invasive entrance incision, and
wherein the implant is configured to at least substantially maintain the
spiral shape both before and
after implantation within the implant pocket through a minimally invasive
entrance incision; and
wherein the implant comprises at least 2 turns; and
wherein the implant comprises a source of electromagnetic radiation.
136. The implant of claim 135, wherein the source of electromagnetic radiation
comprises a light source, and wherein
the implant is configured such that the light source is viewable from beneath
the skin while in the implant pocket.
137. The implant of claim 136, wherein the light source comprises an LED.
138. The implant of claim 137, wherein the light source comprises at least one
selected from the group of: a mLED,
an OLED, a multilayer LED stack and an array of LED lights.
139. The implant of claim 138, further comprising a polydimethylsiloxane
coating.
140. The implant of claim 135, further comprising a thin film encapsulation.
141. The implant of claim 135, further comprising an organic nanocomposite
layer.
142. The implant of claim 135, further comprising a barrier layer configured
to insulate the light source from the
biological environment within the implant pocket.
143. The implant of claim 135, wherein the source of electromagnetic radiation
comprises a therapeutic radiation
source.
144. The implant of claim 135, wherein the source of electromagnetic radiation
comprises an OLED panel, and
wherein the implant further comprises a peeling reduction layer.
145. The implant of claim 135, wherein the source of electromagnetic radiation
comprises an OLED panel, and
wherein the implant further comprises a multi-layer encapsulation film.
146. The implant of claim 135, wherein the source of electromagnetic radiation
comprises an mLED device, and
wherein the implant comprises a selectively illuminable internal tattoo.
147. The implant of claim 146, further comprising a wireless receiver, wherein
the wireless receiver is configured to
receive wireless signals for adjusting a light display associated with the
selectively illuminable internal tattoo.
148. The implant of claim 135, wherein the source of electromagnetic radiation
comprises a flexible mLED device
comprising:
a flexible substrate;
an upper insulating film;
a lower insulating film;
a metal layer positioned between the upper insulating film and the lower
insulating film; and
a plurality of mLED chips positioned on the flexible substrate.
149. The implant of claim 148, wherein the flexible substrate comprises a
reflective layer.
150. The implant of claim 135, wherein the implant comprises an illuminable
internal tattoo, and wherein the source
of electromagnetic radiation comprises an organic polymer LED.
151. The implant of claim 150, further comprising a protective passivation
layer.
152. The implant of claim 135, wherein the source of electromagnetic radiation
comprises an OLED, and further
comprising a thin film encapsulation structure comprising alternating organic
and inorganic layers.
Date Recue/Date Received 2022-12-30
10
153. The implant of claim 135, further comprising a biocompatible polymer,
wherein the source of electromagnetic
radiation comprises a mesh-like array of LEDs.
154. The implant of claim 135, wherein the implant is configured to be
delivered through a very minimally invasive
entrance incision while in the compressed configuration.
155. The implant of claim 154, wherein the implant is configured to be
delivered through an ultra-minimally invasive
entrance incision while in the compressed configuration.
156.A system comprising the implant of claim 135, and further comprising:
an energy source; and
an inductance coil electrically coupled with the energy source to allow the
energy source to be
wirelessly recharged, wherein the inductance coil is configured to be inserted
through a minimally invasive
entrance incision.
157. The system of claim 156, wherein the energy source comprises at least one
selected from the group of: a battery
and a capacitor.
158. The implant of claim 135, wherein the source of electromagnetic radiation
comprises a light sheet.
159. The implant of claim 158wherein the light sheet is configured to display
images.
160. The implant of claim 159, further comprising an antenna configured to
receive a signal for use in altering images
displayed on the light sheet.
161. The implant of claim 135, further comprising a heartrate sensor.
162. The implant of claim 161, wherein the heartrate sensor is configured to
change a light display generated by the
source of electromagnetic radiation based upon a heartrate detected by the
heartrate sensor.
163.A system for selective illumination of a spiral implant configured for
positioning within an implant pocket,
comprising:
an external device comprising a processor and a wireless transmitter;
an implantable energy source;
an implantable inductance coil electrically coupled with the implantable
energy source;
an implantable wireless receiver;
at least one selected from the group of: an external a heartrate sensor and
internal heart rate sensor.
164. The system of claim 163, wherein the external device comprises at least
one selected from the group of: a
wristband, an armband, and a smartphone.
165. The system of claim 163, wherein the implantable inductance coil
comprises an arm extending in a spiral shape
from an outer terminus at a periphery of the implantable inductance coil to an
inner terminus adjacent to a center of the
implantable inductance coil, wherein the arm defines a plurality of adjacent
bands wherein the implant comprises at least
one configuration selected from the group of:
(a) comprising a space defined between adjacent bands; and
(b) comprising a flexible material configured to allow for temporary creation
of space between adjacent
bands so as to facilitate insertion of the implant through a minimally
invasive entrance incision, and
wherein the implant is configured to at least substantially maintain the
spiral shape both before and
after implantation within the implant pocket through a minimally invasive
entrance incision; and
wherein the implant comprises at least 2 turns.
166. The system of claim 163, wherein the implantable energy source comprises
at least one selected from the group
of: a battery and a capacitor, and wherein the implantable energy source is
part of the implant.
Date Recue/Date Received 2022-12-30
11
167. The system of claim 163, wherein the implant is formed in the shape of a
heart, and wherein the implant is sized
and configured to be positioned in an implant pocket adjacent to a user's
heart.
168. The system of claim 163, wherein the implant is configured to adjust a
light display of the light source according
to a heartrate detected by the heartrate sensor.
169.A method for subcutaneously illuminating an ink tattoo, the method
comprising the steps of:
forming a subcutaneous implant pocket from a minimally invasive entrance
incision, wherein the
subcutaneous implant pocket is formed below an ink tattoo;
rotating in an illuminable spiral implant to fit through the minimally
invasive entrance incision; and
advancing the illuminable implant into the subcutaneous implant pocket;
170. An implant configured to be inserted within an implant pocket via a
minimally invasive entrance incision,
comprising:
a bioresorbable material forming a substrate for the implant; and
a plurality of RFID chips interspersed throughout the substrate, wherein the
substrate is configured to
be absorbed by a patient's tissue once within the implant pocket to leave the
plurality of RFID chips within the
implant pocket following implantation.
171. The implant of claim 170, wherein the implant is compressible to allow
for insertion through the minimally
invasive entrance incision and selectively decompressible for positioning
within the implant pocket.
172. The implant of claim 170, wherein each of the plurality of RFID chips is
positioned on the substrate randomly
about the substrate relative to each of the remaining RFID chips of the
plurality of RFID chips.
173. The implant of claim 170, wherein at least a subset of the plurality of
RFID chips comprises rechargeable power
stores.
174.A neuro-stimulative dendritic implant configured to be positioned within a
subcutaneous and/or soft tissue
implant pocket, comprising:
a primary trunk extending along an elongated axis of the implant;
a plurality of branches extending from the primary trunk; and
a plurality of neuro-stimulative electrodes positioned on at least a subset of
the plurality of branches.
175.A neuro-stimulative spiral implant configured to be positioned within a
subcutaneous and/or soft tissue implant
pocket, comprising:
an arm extending in a spiral shape from an outer terminus at a periphery of
the implantable inductance
coil to an inner terminus adjacent to a center of the implantable inductance
coil, wherein the arm defines a
plurality of adjacent bands, wherein the implant comprises at least one
configuration selected from the group of:
(a) comprising a space defined between adjacent bands; and
(b) comprising a flexible material configured to allow for temporary creation
of space between adjacent
bands so as to facilitate insertion of the implant through a minimally
invasive entrance incision, and
wherein the implant is configured to at least substantially maintain the
spiral shape both before and
after implantation within the implant pocket through a minimally invasive
entrance incision; and
wherein the implant comprises at least 2 turns.
176. The compressible implant of claim 1, wherein the compressible implant is
configured for neurostimulation of at
least one selected from the group of: sensory nerves and muscular nerves.
177. The dendritic implant of claim 174, wherein the dendritic implant is
configured for neurostimulation of at least
one selected from the group of: sensory nerves and muscular nerves.
178. The spiral implant of claim 175, wherein the spiral implant is configured
for neurostimulation of at least one
selected from the group of: sensory nerves and muscular nerves.
Date Recue/Date Received 2022-12-30
12
179. The neuro-stimulative implant of claim 174, wherein each of the plurality
of branches extends towards a proximal
end of the implant.
180. The neuro-stimulative implant of claim 176 further comprising an
inductance coil configured to generate
wireless electrical energy and a plurality of peripheral electrodes.
181. The neuro-stimulative implant of claim 176 or 177, further comprising a
spiral inductance coil configured for
generating wireless electrical energy and/or rotating spirally into an implant
pocket via a minimally invasive entrance
incision.
182. The neuro-stimulative implant of any one of claims 176 to 178, wherein
the neuro-stimulative electrodes are
configured to fire in a wave-like pattern.
183. The neuro-stimulative implant of any one of claims 176 to 178, further
comprising a heartrate sensor, wherein
the heartrate sensor is coupled with at least a subset of the plurality of
neuro-stimulative electrodes such that at least one
selected from the group of: (a) strength and (b) firing rate is configured to
automatically change according to a heartrate
detected by the heartrate sensor.
184.A neuro-stimulative implant configured to be positioned within an implant
pocket, comprising:
an elongated strand comprising a serpentine shape comprising a plurality of
repeated bends, wherein
each bend extends in an opposite direction relative to its adjacent bends; and
a plurality of neuro-stimulative electrodes positioned on the elongated
strand, wherein at least a subset
of the plurality of neuro-stimulative electrodes is positioned on a bend of
the plurality of repeated bends.
185. The strand/string implant of claim 184, configured for neurostimulation
at least one selected from the group of:
sensory nerves and muscular nerves.
186. The neuro-stimulative implant of claim 184, wherein each of the plurality
of repeated bends comprises a neuro-
stimulative electrode.
187. The neuro-stimulative implant of claim 184, wherein the elongated strand
is formed into a sinusoidal shape.
188.A sensory processing feedback implant system, comprising: a plurality of
implants coupled with one another,
wherein each of the plurality of implants is configured to be received in a
corresponding, subcutaneous and/or soft-tissue
implant pocket via a minimally invasive entrance incision, and:
wherein at least one of the plurality of implants is configured to harvest
electrical energy,
wherein at least one of the plurality of implants comprises a distant
auxiliary implant, and
wherein at least one of the plurality of implants comprises an elongated
flexible strand implant
configured to be positioned in an implant tunnel to electrically couple two
implants of the plurality of implants.
189. The sensory processing feedback implant system of claim 188, wherein the
at least one of the plurality of
implants is spiral shaped and configured to harvest electrical energy
comprises an inductance coil.
190. The sensory processing feedback implant system of claim 188, wherein the
at least one of the plurality of
implants configured to harvest electrical energy comprises a thermoelectric
generator.
191. The sensory processing feedback implant system of claim 188, wherein the
at least one of the plurality of
implants configured to harvest electrical energy comprises at least one
selected from the group of: (a) an electrostatic
generator and (b) a piezoelectric device configured to convert kinetic energy
from movement of a user's body into
electrical energy.
192. The sensory processing feedback implant system of claim 188, wherein the
at least one of the plurality of
implants configured to harvest electrical energy comprises a bio-fuel cell.
193. The sensory processing feedback implant system of claim 188, wherein at
least one of the plurality of implants
comprises a distant auxiliary implant comprising at least one selected from
the group of: a wireless communication
device/antenna, a transcutaneous sound receiver, and a subcutaneously
implanted microphone.
Date Recue/Date Received 2022-12-30
13
194. The sensory processing feedback implant system of claim 188, wherein the
sensory implant comprises an
acoustic implant.
195. The sensory processing feedback implant system of claim 188, further
comprising at least one selected from the
group of: smart glasses, a hearing aid/speaker communicatively coupled with at
least one of the plurality of implants.
196. An implantable pacemaker system, comprising:
at least one selected from the group of a first inductance coil and a
thermoelectric implant configured to
be positioned in a first implant pocket via a minimally invasive entrance
incision;
a second inductance coil configured to be positioned in a second implant
pocket via a minimally
invasive entrance incision;
an elongated flexible strand implant configured to be positioned within a
tunnel implant pocket via a
minimally invasive entrance incision and configured to electrically couple the
at least one selected from the
group of a first inductance coil and a thermoelectric implant with the second
inductance coil; and
a wireless cardiac pacemaker configured to be positioned on or adjacent a
patient's heart, wherein the
wireless cardiac pacemaker comprises a third inductance coil configured to
receive wireless energy from the at
least one selected from the group of: a first inductance coil and a
thermoelectric implant.
197. The implantable pacemaker system of claim 196, further comprising an
auxiliary implant configured to be
electrically coupled with at least one of the first and second inductance
coils, wherein the auxiliary implant comprises at
least one selected from the group of: a battery, a capacitor, a CPU, a PCB,
and an antenna.
198. The implantable pacemaker system of claim 196, wherein the at least one
selected from the group of: a first
inductance coil and a thermoelectric implant comprises a thermoelectric
implant, and wherein the thermoelectric implant
comprises a spiral shape configured to be positioned through a minimally
invasive entrance incision.
199.A subcutaneously implantable energy delivery system, comprising:
a first implantable inductance coil comprising an arm extending in a spiral
shape from an outer
terminus at a periphery of the implantable inductance coil to an inner
terminus adjacent to a center of the
implantable inductance coil, wherein the arm defines a plurality of adjacent
bands wherein the implant comprises
at least one configuration selected from the group of:
(a) comprising a space defined between adjacent bands; and
(b) comprising a flexible material configured to allow for temporary creation
of space between adjacent
bands so as to facilitate insertion of the implant through a minimally
invasive entrance incision, and
wherein the implant is configured to at least substantially maintain the
spiral shape both before and
after implantation within the subcutaneous and/or soft tissue implant pocket
through a minimally invasive
entrance incision,
a second implantable inductance coil comprising an arm extending in a spiral
shape from an outer
terminus at a periphery of the implantable inductance coil to an inner
terminus adjacent to a center of the
implantable inductance coil, wherein the arm defines a plurality of adjacent
bands wherein the implant comprises
at least one configuration selected from the group of:
(a) comprising a space defined between adjacent bands; and
(b) comprising a flexible material configured to allow for temporary creation
of space between adjacent
bands so as to facilitate insertion of the implant through a minimally
invasive entrance incision; and
wherein the implant is configured to at least substantially maintain the
spiral shape both before and
after implantation within the subcutaneous and/or soft tissue implant pocket
through a minimally invasive
entrance incision; and
Date Recue/Date Received 2022-12-30
14
an elongated flexible strand implant configured to be positioned within a
tunnel implant pocket via a
minimally invasive entrance incision and configured to electrically couple the
first inductance coil with the
second inductance coil; and
wherein the second implantable inductance coil is configured to wirelessly
deliver electrical energy to
an implantable device.
200. The system of claim 199, further comprising an auxiliary implant
configured to be positioned within an implant
pocket via a minimally invasive entrance incision, wherein the auxiliary
implant comprises at least one selected from the
group of: an antenna, a CPU, a battery, a capacitor, a data storage element, a
heartrate sensor, and a lab-on-a-chip element.
201. The system of claim 199, wherein the implantable device comprises at
least one selected from the group of: a
gastric implant, a motor nerve implant, a chemical pump implant, a brain
implant, a cochlear implant, and an implantable
motor unit.
202.A method for implantation of a flexible implant via a minimally invasive
entrance incision, the method
comprising the steps of:
forming an implant pocket through a minimally invasive entrance incision;
coupling one or more sutures to a compressible implant;
extending at least one of the one or more sutures into the implant pocket
through the minimally
invasive entrance incision and out through a needle puncture formed in the
implant pocket;
extending the compressible implant through the minimally invasive entrance
incision in a compressed
configuration on an instrument; and
decompressing the compressible implant while in the implant pocket by pulling
on at least one of the
one or more sutures.
203. The method of claim 202, wherein the compressible implant comprises one
or more holes, and wherein the step
of coupling the one or more sutures to the compressible implant comprises
securing the one or more sutures to the one or
more holes.
204. The method of claim 202, wherein the compressed configuration comprises a
rolled configuration, and wherein
the step of decompressing the compressible implant comprises unrolling the
compressible implant.
205. The implant of claim 1 further comprising a source of electromagnetic
radiation.
206. The implant of claim 205, wherein the source of electromagnetic radiation
comprises a light source, and wherein
the implant is configured such that the light source is viewable from beneath
the skin while in the implant pocket.
207. The implant of claim 206, wherein the light source comprises an LED.
208. The implant of claim 206, wherein the light source comprises at least one
selected from the group of: an mLED,
an OLED, a multilayer LED stack, and array of LED lights.
209. The implant of claim 206 wherein the light sheet is configured to display
images.
210. The implant of claim 206, further comprising an antenna configured to
receive a signal for use in altering images
displayed on the light source.
211. The electrodes of claim 103, comprising a plurality of electrodes
configured to stimulate nerves.
212. The plurality of electrodes of claim 105, wherein the electrodes are
configured for neurostimulation of at least
one selected from the group of: sensory nerves and muscular nerves.
213. The implant of claim 67, configured for neurostimulation in coordination
with an external source.
214. The implant of claim 67, wherein the implant comprises an inductance
coil, wherein the inductance coil is
configured to function as at least one selected from the group of: receive
transmitted wireless energy, transmit signals as
an antenna and receive signals as an antenna.
215. The implant of claim 67, wherein the implant may comprise a multiplicity
of stacked inductance coils.
Date Recue/Date Received 2022-12-30
15
216. The macro-vascularization hole of claim 15 comprising at least one
selected from the group of: a microfluidic
channel and a fiberoptic.
217.A system comprising the implant of claim 105, further comprising an
abdominal tension detecting belt
configured to be communicatively coupled with one or more implants.
218.A system comprising the implant of claim 174, further comprising an
abdominal tension detecting belt
configured to be communicatively coupled with one or more implants.
219.A system comprising the implant of claim 176, further comprising an
abdominal tension detecting belt
configured to be communicatively coupled with one or more implants.
220. The system of claim 105 comprising lab-on-a-chip configured to activate
implant electrodes to stimulate/signal
muscle-nerves activating muscles to control glucose.
221. The implant of claim 174 comprising lab-on-a-chip configured to activate
implant electrodes to stimulate/signal
muscle-nerves activating muscles to control glucose.
222. The implant of claim 176 comprising lab-on-a-chip configured to activate
implant electrodes to stimulate/signal
muscle-nerves activating muscles to control glucose.
223. The spiral implant superstructure of claim 84 configured to be in at
least one selected from the group of
positions: external, internal, peripheral, non-peripheral, top, and bottom.
224. The compressible implant superstructure of claim 36 configured to be in
at least one selected from the group of
positions: external, internal, peripheral, non-peripheral, top, and bottom.
225. The therapeutic agent-delivery implant of claim 5 configured to discharge
therapeutic agents into the adjacent
vasculature to achieve a therapeutic result in at least one selected from the
group of (a) local tissues adjacent to the implant
and (b) non-adjacent (distant) tissues.
226. The therapeutic agent delivery implant of claim 32 configured to
discharge therapeutic agents into the adjacent
vasculature to achieve a therapeutic result in at least one selected from the
group of (a) local tissues adjacent to the implant
and (b) non-adjacent (distant) tissues.
227. The therapeutic agent delivery implant of claim 70 configured to
discharge therapeutic agents into the adjacent
vasculature to achieve a therapeutic result in at least one selected from the
group of (a) local tissues adjacent to the implant
and (b) non-adjacent (distant) tissues.
228. The implant of claim 86, further comprising a thermoelectric implant.
229.A device configured for illumination, comprising:
an arm extending in a spiral shape from an outer terminus at a periphery of
the implant to an inner
terminus adjacent to a center of the implant, wherein the arm defines a
plurality of adjacent bands, wherein the
device comprises at least one configuration selected from the group of:
(a) comprising a space defined between adjacent bands; and
(b) comprising a flexible material configured to allow for temporary creation
of space between
adjacent bands so as to facilitate positioning;
and wherein the implant comprises an inductance coil configured to be
inductively charged and
electromagnetic radiation source, and wherein power from the inductance coil
energizes the electromagnetic
radiation source; and wherein the implant comprises at least 2 turns.
230. The compressible implants of claim 1 comprising a range of numbers of
turns chosen from the group of: 2-3
turns, 3-5 turns, 5-7 turns, 7-10 turns, 10-15 turns, 15-20 turns, 20-30
turns, 30-40 turns, 40-50 turns, 50-75 turns, and 75-
100 turns.
231. The compressible implants of claim 1 comprising a range of numbers of
turns chosen from the group of: 2-10
turns, 3-8 turns 4-7 turns, and 4-5 turns.
Date Recue/Date Received 2022-12-30
16
232. The compressible implants of claim 1 comprising a range of numbers of
folds chosen from the group of: 2-3
folds, 4-5 folds, 6-7 folds, 8-9 folds, 10-14 folds, 15-19 folds, 20-29 folds,
30-39 folds,40-49 folds, 50-74 folds, and 75-
100 folds.
233. The compressible implants of claim 1 comprising a range of numbers of
folds chosen from the group of: 2-10
folds, 4-9 folds 5-8 folds, and 6-7 folds.
234. The macro-vascularization hole of claim 15 comprising mini-tubules
configured to be at least one of: (a)
terminating mini-tubules and/or (b) non-terminating mini-tubules.
235. The superstructure of claim 36 configured to be positioned in at least
one location chosen from the group of:
external, internal, peripheral, non-peripheral, top, and/or bottom.
236. The compressible mesh implant of claim 32 comprising therapeutic agents
configured to be discharged into the
adjacent vasculature to achieve a therapeutic result in at least one of: (a)
local tissues adjacent to the implant and/or (b)
non-adjacent (distant) tissues.
237. The compressible mesh implant of claim 32 comprising a plurality of
compartment divisions configured to hold
and release respective medication(s).
238. The spiral implant of claim 67 comprising a range of numbers of turns
chosen from the group of: 2-3 turns, 3-5
turns, 5-7 turns, 7-10 turns, 10-15 turns, 15-20 turns, 20-50 turns, 50-100
turns.
239. The spiral implant of claim 67 comprising a range of numbers of turns
chosen from the group of: 2-30 turns, 3-
25 turns 4-15 turns, 5-10 turns.
240. The spiral implant of claim 67 comprising a range of diameters chosen
from the group of: 1-3cm, 3-5cm, 5-7cm,
7-10cm, 10-15cm, 15-20cm, 20-50 cm.
241. The spiral implant of claim 67 comprising a range of diameters chosen
from the group of: 1-30cm, 2-20cm, 3-
15cm, 5-10cm.
242. The spiral implant of claim 67 comprising a range of overall spiral arm
lengths chosen from the group of: 3.5-
10cm, 10-20cm, 20-50cm, 50-100cm, 100-250cm, 250-500cm.
243. The spiral implant of claim 67 comprising a range of overall spiral arm
lengths chosen from the group of: 3.5-
200cm, 4-100cm, 20-80cm, 30-75cm.
244. The compressible implants of claim 1 comprising at least one chosen from
the group of: a macro-vascularization
hole, a macro-positioning/instrument engaging hole, a reinforcement tab, a
structural reinforcement region and/or zone, a
reinforcing fiber, a mesh reinforcement, and/or a superstructure.
245. The compressible protective mesh implant of claim 22 comprising at least
one chosen from the group of: an
antenna, a PCB, a folded end, an inductance coil, a capacitor, an antibiotic
drug, an adrenergic drug, a battery, a macro-
vascularization hole, a macro-positioning/instrument engaging hole, a
reinforced tab, a mesh reinforcement, and a
superstructure.
246. The compressible protective mesh implant of claim 22 configured to be
communicatively coupled with at least
one of a heart rate sensor and/or a blood pressure sensor
247. The neuro-stimulative implants of claim 54 configured to be
communicatively coupled with at least one of: a
heart rate sensor and/or a blood pressure sensor.
248. The spiral implant of claim 67 comprising a of number of turns chosen
from the group of: 2 turns, 3 turns, 4
turns, 5 turns, 8 turns, 10 turns, 15 turns, 20 turns, and 25 turns.
249. The sensory-processing-feedback-system of claim 188 configured to be
coupled by flexible strand/string implant
with at least one of: a wireless communication device/antenna and/or a
transcutaneous sound receiver.
250. The compressible implant of claim 25, wherein the therapeutic agent is
configured to be released upon impact
with a penetrating object and comprises at least one selected from the group
of: an inotropic agent, dobutamine, dopamine,
Date Recue/Date Received 2022-12-30
17
milrinone, vasopressors, an adrenergic drug, phenylephrine, epinephrine,
norepinephrine. ephedrine, pseudoephedrine, and
vasopressin.
251. The compressible implant of claim 1, wherein when the compressible
implant is in the compressed configuration,
the compressible implant is rolled and/or folded, and wherein the compressible
implant comprises at least two turns when
rolled or at least two folds when folded.
252. The implant of claim 67, wherein the implant is configured to at least
substantially maintain the spiral shape
during implantation within the implant pocket through the minimally invasive
entrance incision.
253.A system comprising the implant of claims 1 and 67, further comprising an,
auxiliary implant configured to be
positioned within an implant pocket via a minimally invasive entrance
incision, wherein the auxiliary implant comprises at
least one selected from the group of: an antenna, a CPU, a battery, a
capacitor, a data storage element, a heartrate sensor,
and a lab-on-a-chip element.
254. The implant of any one of claims selected from the group of: claim 1,
claim 67, claim 121, claim 135, claim 175,
claim 199 and claim 229, further comprising a spiral-shaped thermoelectric
generator.
255. The implants of claims 1 and 67 further comprising a superstructure
and/or wherein the superstructure may be
segmented and/or discontinuous and/or wherein the superstructure may comprise
at least one selected from the group of: a
battery, an inductance coil, a capacitor, a data storage element, an EMI
suppression element, an antenna.
256. The implant of clams 1 and 67 wherein the implant pocket comprises a soft
tissue implant pocket; and/or wherein
the implant pocket comprises a subcutaneous implant pocket.
BRIEF DESCRIPTION OF THE FIGURES
[0001] The written disclosure herein describes illustrative embodiments that
are non-limiting and non-exhaustive.
Reference is made to certain of such illustrative embodiments that are
depicted in the figures, in which
[0002] Fig. la depicts a top plan view of the distal portion of a minimally
invasive electro-dissection device with a 2-bead
tip.
[0003] Fig. lb depicts a top plan view of a minimally invasive electro-
dissection device with a tip having 2 beads and a
bead-like structure therebetween.
[0004] Fig. lc depicts a minimally invasive electro-dissection device with a 2
beaded tip protruding from a shaft with a
handle.
[0005] Fig. 2a depicts a human torso having undergone comparative bilateral
surgical procedures to form distinct types
of implant pockets, one comprising an enlarged implant pocket that may be
formed using a plurality of strokes of an
electrosurgical device, and the other comprising an elongated implant pocket
that may be formed by a single stroke of such
an instrument or, as shown in the drawing, by a mechanical device such as
scissors.
[0006] Fig. 2b depicts traditional surgical blunt scissors, elongated scalpel,
and electrosurgery pencil.
[0007] Fig. 3a depicts a top plan view of a circular, flexible, and
compressible implant.
[0008] Fig. 3b depicts a side view of implant.
[0009] Fig. 3c depicts a top perspective view of implant.
[0010] Fig. 4a depicts a top plan view of a circular, flexible, and
compressible implant according to another embodiment.
[0011] Fig. 4b depicts a side view of the implant of Fig. 4a.
[0012] Fig. 4c depicts an enlarged side view of the implant.
[0013] Fig. 4d depicts a top perspective view of the implant.
[0014] Fig. 5a depicts a side view of an implant according to another
embodiment rolled into a compressed state.
[0015] Fig. 5b depicts a side view of the implant rolled into a compressed
state.
Date Recue/Date Received 2022-12-30
18
[0016] Fig. 5c depicts a perspective view of the implant rolled into its
compressed state.
[0017] Fig. 6a depicts a side view of an instrument configured for inserting a
compressible implant.
[0018] Fig. 6b depicts a perspective view of an implant rolled into a
compressed state.
[0019] Fig. 6c depicts a perspective view of a sheath that may be used to
protect an implant during installation.
[0020] Fig. 6d depicts a perspective view of an embodiment of a flexible
tissue implant facilitating system (FTIFS).
[0021] Fig. 6e depicts a side view of the flexible tissue implant facilitating
system of Fig. 6d.
[0022] Fig. 7a depicts a side view of an instrument that may be used in
connection with an FTIFS.
[0023] Fig. 7b depicts a side view of an FTIFS.
[0024] Fig. 7c depicts a side view of an FTIFS according to another
embodiment.
[0025] Fig. 8a depicts a top plan view of a compressible implant according to
other embodiments.
[0026] Fig. 8b depicts a cross-sectional view of the implant in its folded
state within a sheath
[0027] Fig. 8c depicts a side view of the implant in its uncompressed state.
[0028] Fig. 8d depicts a top perspective view of a compressible implant
according to an embodiment.
[0029] Fig. 9a depicts a surgical instrument that may be used to remove
surgical instruments.
[0030] Fig. 9b depicts a surgical instrument that may be used to remove
surgical instruments.
[0031] Fig. 10a depicts a top plan view of an embodiment of a compressible
implant according to an embodiment.
[0032] Fig. 10b depicts a side view of the implant in its
uncompressed/unrolled state.
[0033] Fig. 10c depicts an alternative side view of the implant in its
compressed/rolled state.
[0034] Fig. 10d depicts a top perspective view of the implant.
[0035] Fig. ha depicts a top plan view of an embodiment of a circular implant
comprising non-protruding reinforcement
regions.
[0036] Fig. lib depicts a top plan view of an embodiment of a macro
vascularization hole comprising mini-tubules
[0037] Fig. 12 depicts a top plan view of an embodiment of a square implant
comprising non-protruding reinforcement
regions.
[0038] Fig. 13 depicts a top plan view of an embodiment of a rectangular
implant comprising non-protruding
reinforcement regions.
[0039] Fig. 14 depicts a top plan view of an embodiment of a circular implant
comprising non-protruding reinforcement
regions.
[0040] Fig. 15 depicts a top plan view of an embodiment of a square implant
comprising non-protruding reinforcement
regions.
[0041] Fig. 16 depicts a top plan view of an embodiment of a rectangular
implant comprising non-protruding
reinforcement regions.
[0042] Fig. I7a depicts a side view of an embodiment of a FTIFS instrument.
[0043] Fig. 17b depicts a side view of a complete FTIFS.
[0044] Fig. 17c depicts a side view of a complete FTIFS.
[0045] Fig. 18a depicts a side view of an alternative embodiment of a FTIFS
instrument.
[0046] Fig. 18b depicts a perspective view of an implant in its rolled state,
according to an embodiment.
[0047] Fig. 18c depicts a perspective view of a sheath according to an
embodiment.
[0048] Fig. 18d depicts a side view of a partner instrument used to couple
holes of an implant according to an embodiment.
[0049] Fig. I9a depicts a bottom plan view of a circular, flexible, and
compressible implant with a circular superstructure
according to an embodiment.
[0050] Fig. 19b depicts a side view of a circular, flexible, and compressible
implant with a circular superstructure
according to an embodiment wherein the superstructure comprises various
electronics.
Date Recue/Date Received 2022-12-30
19
[0051] Fig. 19c depicts a bottom perspective view of a circular, flexible, and
compressible implant with a circular
superstructure according to an embodiment.
[0052] Fig. 19d depicts a side view of implant in its rolled state according
to an embodiment.
[0053] Fig. 20a depicts a bottom view of a circular, flexible, and
compressible implant with a '+' shaped superstructure
according to an embodiment.
[0054] Fig. 20b depicts a bottom view of a rectangular, flexible, and
compressible implant with a '+' shaped superstructure
according to an embodiment.
[0055] Fig. 20c depicts a bottom view of a rectangular, flexible, and
compressible implant also with a rectangular shaped
superstructure according to an embodiment.
[0056] Fig. 21 depicts a top view of an alternative, oval, flexible,
compressible implant, which may comprise an oval
inductance coil according to an embodiment.
[0057] Fig. 22 depicts a top view of an alternative, rectangular, flexible,
compressible implant, which may comprise a
rectangular inductance coil according to an embodiment.
[0058] Fig. 23 depicts a top view of an alternative compressible elongated
rectangular shaped implant which may serve
as a substrate for a plurality of inductance coils according to an embodiment.
[0059] Fig. 24a depicts a top view of a circular, flexible, compressible mesh
implant.
[0060] Fig. 24b depicts a side view of a circular, flexible, compressible mesh
implant.
[0061] Fig. 24c depicts a top perspective view of a circular, flexible,
compressible mesh implant.
[0062] Fig. 24d depicts a side view of a rolled/compressed implant.
[0063] Fig. 25 depicts a top view of an alternative embodiment of a
compressible, circular, flexible, mesh implant.
[0064] Fig. 26 depicts a top view of an alternative embodiment of a
compressible, rectangular, flexible, mesh implant.
[0065] Fig. 27 depicts a top view of an alternative embodiment of a
compressible, polygonal, flexible, mesh implant.
[0066] Fig. 28 depicts a top view of an alternative embodiment of a
compressible, rectangular, flexible, mesh implant.
[0067] Fig. 29 depicts a top view of a mesh implant that may comprise openings
and an inductance coil according to an
embodiment.
[0068] Fig. 30 depicts a top view of a mesh implant which may comprise
reinforcement regions, holes, and/or batteries
according to an embodiment.
[0069] Fig. 31 depicts a top view of a mesh implant which may comprise
reinforcement regions, holes, and/or capacitors
according to an embodiment.
[0070] Fig. 32 depicts a side view of an implant, which shows how various
elements may be stacked or otherwise applied
to a single implant according to an embodiment.
[0071] Fig. 33 depicts a bottom view of a circular, flexible, and compressible
implant with a hollow, fillable, circular
shaped superstructure according to an embodiment.
[0072] Fig. 34 depicts a bottom view of a circular, flexible, and compressible
implant with a hollow fillable '+' shaped
superstructure according to an embodiment.
[0073] Fig. 35 depicts a lower view of a rectangular, flexible, and
compressible implant with a hollow fillable rectangular
shaped superstructure on one side according to an embodiment.
[0074] Fig. 36 depicts a lower view of a rectangular, flexible, and
compressible implant with a hollow tillable '+' shaped
superstructure according to an embodiment.
[0075] Fig. 37a depicts a top view of a circular, spiral implant.
[0076] Fig. 37b depicts a side view of the circular, spiral implant.
[0077] Fig. 37c depicts a top perspective view of the circular, spiral
implant.
[0078] Fig. 37d depicts an enlarged cross-sectional view of an embodiment of
circular, spiral implant.
Date Recue/Date Received 2022-12-30
20
[0079] Fig. 38 depicts a perspective view of a circular, spiral implant with a
circular solid cross section according to an
embodiment.
[0080] Fig. 39 depicts a perspective view of another circular, spiral implant
with a circular hollow cross section according
to an embodiment.
[0081] Fig. 40 depicts a perspective view of another circular, spiral implant
with a circular cross section comprising an
internal guidewire according to an embodiment.
[0082] Fig. 41 depicts a top view of a rectangular, spiral implant.
[0083] Fig. 42a depicts a top view of a polygonal, spiral implant.
[0084] Fig. 42b depicts an enlarged view of a terminus of a spiral implant
according to an embodiment.
[0085] Fig. 43 depicts an enlarged view of an oval cross section of a spiral
band according to an embodiment.
[0086] Fig. 44 depicts a spaghetti-like, flexible implant.
[0087] Fig. 45a depicts a side view of a portion of an embodiment of a
flexible, spaghetti-like implant, which may contain
electronics.
[0088] Fig. 45b depicts a side view of a rigid hollow cannula/trocar, which
may facilitate implanting of spaghetti-like
implants according to an embodiment.
[0089] Fig. 45c depicts a side view of a plunger that may be used to drive a
spaghetti-like implant through a cannula/trocar.
[0090] Fig. 46 depicts a side view of a flexible/spaghetti-like implant system
according to an embodiment.
[0091] Fig. 47a depicts an implant pocket, implant delivery pocket, and
entrance incision.
[0092] Fig. 47b depicts an implant pocket and delivery pocket, with a spiral
implant on the surface of the skin.
[0093] Fig. 47c depicts an implant pocket and delivery pocket, with a spiral
implant having undergone several turns
through an incision for implanting.
[0094] Fig. 47d depicts an implant pocket and delivery pocket, with a spiral
implant implanted through incision.
[0095] Fig. 47e depicts a spiral implant completely implanted and situated in
an implant pocket.
[0096] Fig. 48a depicts a flat implant viewed from the side.
[0097] Fig. 48b depicts a circular cross-section of an implant.
[0098] Fig. 48c depicts a cross-sectional view of an implant comprising an
encasement.
[0099] Fig. 48d depicts a circular cross-section of an implant comprising an
encasement.
[00100] Fig. 48e depicts a cross-sectional view of an implant comprising an
encasement of multiple layers.
[00101] Fig. 48f depicts a circular cross-section of an implant comprising an
encasement of multiple layers.
[00102] Fig. 48g depicts a cross-sectional view of a fully encased implant.
[00103] Fig. 48h depicts a rectangular cross-section of an implant.
[00104] Fig. 48i depicts a cross-sectional view of a flattened implant
comprising an internal mesh.
[00105] Fig. 48j depicts a rectangular cross-section of a fully encased
implant.
[00106] Fig. 48k depicts an oval-shaped cross-section of a fully encased
implant.
[00107] Fig. 481 depicts a cross-section of an implant comprising a full
encasement of multiple layers
[00108] Fig. 49 depicts a human torso having undergone surgery using a lysing
tip to form implant pockets which may
contain subcutaneous light sources.
[00109] Fig. 50 depicts a human patient having subcutaneous, compressible
implants positioned in implant pockets.
[00110] Fig. 51a depicts a top plan view of an implant in its
deployed/uncompressed state according to an embodiment.
[00111] Fig. 5 lb depicts a side view of the implant in its
deployed/uncompressed state.
[00112] Fig. 51c depicts a side view of the implant in its rolled state.
[00113] Fig. 52a depicts a top plan view of an implant in its
deployed/uncompressed state according to another
embodiment.
Date Recue/Date Received 2022-12-30
21
[00114] Fig. 52b depicts a side view of the implant in its
deployed/uncompressed state.
[00115] Fig. 52c depicts a side view of the implant in its rolled state.
[00116] Fig. 53a depicts a top plane view of a compressible, subcutaneous
implant, comprising a lighting screen.
[00117] Fig. 53b depicts a side view of an implant, illustrating how each of
the elements may be coupled to the screen
according to an embodiment.
[00118] Fig. 53c depicts a side view of the implant with a barrier element.
[00119] Fig. 54a depicts another compressible implant comprising an auxiliary
implant which may be electrically coupled
to implant according to an embodiment.
[00120] Fig. 546 depicts an implant in its uncompressed configuration from the
side, showing an inductance coil on one
side of the implant.
[00121] Fig. 54c depicts a full system comprising an implant and an auxiliary
implant.
[00122] Fig. 55a depicts a human patient's abdomen having subcutaneous,
compressible mesh implants.
[00123] Fig. 55b depicts a side view of a mesh implant with optional mesh
implant peripheral folds.
[00124] Fig. 55c depicts a side view of a mesh implant with optional zone of
overlap.
[00125] Fig. 56a depicts a soldier who having multiple subcutaneous,
compressible mesh implants, positioned in implant
pockets.
[00126] Fig. 566 depicts two implants that are positioned within a shared
subcutaneous pocket and overlap with one another
to an extent, as indicated by the overlapping region.
[00127] Fig. 57a depicts a patient's abdomen having subcutaneous, compressible
implants, positioned in respective implant
pockets.
[00128] Fig. 57b depicts a top view of an implant containing RFID chips placed
in less predictable patterns.
[00129] Fig. 58a depicts a minimally invasive electro-dissection device with a
2 bead tip according to an embodiment.
[00130] Fig. 58b depicts a human torso after having undergone comparative
bilateral surgical procedures.
[00131] Fig. 58c depicts a side view of an alternative embodiment of an
implant expelling cannula that is configured to
expel implants from a side opening.
[00132] Fig. 58d depicts detailed side view of an implant expelling cannula
attached to a shaft, depicting implant expelling
plunger, pushing a series of the expellable implants through a frontal/distal
shaft opening.
[00133] Fig. 59a depicts a human torso having undergone comparative bilateral
surgical procedures whereupon stem cell
incubator implant strips were placed in respective implant pockets.
[00134] Fig. 59b depicts a side view of an embodiment of a minimally invasive
stem cell incubator implant strip.
[00135] Fig. 59c depicts a side view of an alternative embodiment of a
minimally invasive stem cell incubator implant
wherein payload bays are sandwiched within laminate layers.
[00136] Fig. 60a depicts a torso of a human patient having a rectangular
compressible subcutaneous electronic neuro
simulative (SQENS) implant system positioned in an implant pocket made via a
minimally invasive entrance incision.
[00137] Fig. 60b depicts a side elevation view of an implant of system
illustrating how each element may be coupled to the
implant according to an embodiment.
[00138] Fig. 60c depicts a top plan view of the implant in its
deployed/uncompressed state
[00139] Fig. 60d depicts a top plan breakaway view of the implant in its
deployed/uncompressed state.
[00140] Fig. 61a depicts the right side of a torso of a human patient having a
spiral subcutaneous electronic neuro simulative
(SSENS) implant system having a plurality of implants each preferably
positioned in a respective implant pocket made via
a minimally invasive entrance incision.
[00141] Fig. 61b depicts a top view of a single 3 turn SSENS implant with an
outer terminal end and electrodes dispersed
along one or more sides of the faces or sides of the spiral with space between
adjacent bands.
Date Recue/Date Received 2022-12-30
22
[00142] Fig. 61c depicts an enlarged view of a cross section of an embodiment
of a spiral implant.
[00143] Fig. 62a depicts the right side of a torso of a human patient having a
flexible strand/string subcutaneous electronic
neuro simulative (FSQENS) implant system positioned in a respective implant
pocket made via a minimally invasive
entrance incision.
[00144] Fig. 62b depicts a side elevation view of a FSQENS flexible
strand/string implant, illustrating how each of the
elements may be coupled the strand
[00145] Fig. 62c depicts an enlarged transparency view of an embodiment of a
wiring scheme for various terminal
electrodes along a flexible strand/string subcutaneous electronic neuro
simulative (FSQENS) implant.
[00146] Fig. 63a depicts the right side of a torso of a human patient having
flexible strand/string subcutaneous implants
positioned in respective implant pockets made adjacent minimally invasive
entrance incisions.
[00147] Fig. 63b depicts a top view of an upright beveled relatively sharp
tipped trocar.
[00148] Fig. 63c depicts a top view rotated 90 degrees on its axis of the same
trocar.
[00149] Fig. 63d depicts a top view of an upright alternative embodiment of
beveled relatively blunt spatula tipped trocar.
[00150] Fig. 63e depicts a top view rotated 90 degrees on its axis of the same
trocar.
[00151] Fig. 63f depicts a trocar with a curved shaft.
[00152] Fig. 63g depicts a side view of an alternative embodiment of an
implant expelling cannula that is configured to
expel an implant from a side opening rather than through the distal end of the
device.
[00153] Fig. 64a depicts the front side of a torso of a human patient having
rectangular compressible subcutaneous
electronic muscle simulative (SQEMS) implant systems positioned in respective
implant pockets made via a minimally
invasive entrance incision.
[00154] Fig. 641) depicts a bottom view of an implant of the system,
illustrating how each of the elements may be coupled
on the implant.
[00155] Fig. 64c depicts a front view of an abdominal tension detecting belt
that may be optionally used in conjunction
with an implant according to an embodiment.
[00156] Fig. 65a depicts a front side of a torso of a human patient having a
plurality of spiral subcutaneous electronic
muscular stimulative (SSEMS) implants.
[00157] Fig. 65b depicts a plan view of a single 3 turn SSEMS implant.
[00158] Fig. 65c depicts an enlarged view of a cross section of an arm of a
SSEMS implant.
[00159] Fig. 66a depicts a front side of a torso of a human patient having a
flexible strand/string subcutaneous electronic
muscular stimulative (FSQEMS) implant.
[00160] Fig. 661) depicts an embodiment of an auxiliary implant that may
comprise an antenna, a CPU/PCB, and a battery.
[00161] Fig. 66c depicts an enlarged transparency view of a wiring scheme for
terminal electrodes on a FSQEMS implant.
[00162] Fig. 67a depicts an embodiment of a spiral implant comprising a
plurality of LEDs interspersed throughout the
implant.
[00163] Fig. 67b depicts a cross sectional view spiral implant with a
rectangular cross section.
[00164] Fig. 67c depicts a cross sectional view spiral implant with a
relatively flat cross section.
[00165] Fig. 67d depicts a cross sectional view spiral implant with an oval-
shaped cross section
[00166] Fig. 67e depicts a cross sectional view spiral implant with a
pentagonal cross section
[00167] Fig. 67f depicts a spiral implant's inner terminus, which comprises an
open loop/handle.
[00168] Fig. 67g depicts a spiral implant's inner terminus, which comprises a
notch.
[00169] Fig. 67h depicts a cross sectional view of a spiral implant comprising
a superstructure adhered to one side of the
implant.
[00170] Fig. 67i depicts a cross sectional view of a spiral implant comprising
a superstructure positioned within the lumen
Date Recue/Date Received 2022-12-30
23
the implant.
[00171] Fig. 67j depicts a cross sectional view of a spiral implant comprising
a superstructure positioned within the lumen
the implant, sandwiched between other functional elements, such as a battery
and inductance coil.
[00172] Fig. 67k depicts a cross-sectional view of another spiral implant
comprising an externally attached superstructure
on the outer side of a spiral arm.
[00173] Fig. 67L depicts a cross-sectional view of another spiral implant
comprising a fully contained semicircular
superstructure.
[00174] Fig. 67m depicts a cross-sectional view of another spiral implant
comprising an externally attached superstructure
on the inner side of a spiral arm.
[00175] Fig. 67n depicts a cross-sectional view of a spiral implant comprising
a superstructure positioned on the upper and
lower surfaces of the implant.
[00176] Fig. 68a depicts a top plan view of a compressible implant comprising
a peripheral superstructure.
[00177] Fig. 68b depicts a cross sectional view of an embodiment of a
compressible implant comprising a peripheral
superstructure.
[00178] Fig. 68c depicts a cross sectional view of an embodiment of a
compressible implant comprising a peripheral
superstructure.
[00179] Fig. 68d depicts a cross sectional view of an embodiment of a
compressible implant comprising a peripheral
superstructure.
[00180] Fig. 68e depicts a cross sectional view of an embodiment of a
compressible implant comprising a peripheral
superstructure.
[00181] Fig. 69 depicts a spiral implant having little to no space between
spiral arms.
[00182] Fig. 70a depicts a front view of a torso of a human patient having a
flexible strand/string electronic genital
stimulative (FSEGS) implant system.
[00183] Fig. 70b depicts a side elevation view of a FSEGS implant and an
embodiment of an auxiliary implant that may
comprise an antenna, a CPU/PCB, and a battery.
[00184] Fig. 70c depicts an enlarged transparency view of an embodiment of a
wiring scheme for various terminal
electrodes along a FSEGS implant.
[00185] Fig. 70d depicts a string implant extending into the glans of the
clitoris.
[00186] Fig. 70e depicts string implants extending into the crux of the
clitoris.
[00187] Fig. 70f depicts a FSEGS implant extending down the shaft of a penis
and partially into the glans of the penis.
[00188] Fig. 70g depicts two implants positioned side by side within the
penis.
[00189] Fig. 71a depicts an example of a sensory-processing-feedback-system
comprising a flexible strand/string electronic
implant (F SEI).
[00190] Fig. 71b depicts a perspective view of an auxiliary implant that may
comprise a battery, storage device, antenna,
and a CPU/PCB.
[00191] Fig. 71c depicts a side perspective view of another auxiliary implant
which may be positioned at the terminus of a
F SEI.
[00192] Fig. 72a depicts a front view of a torso having an example of a
subcutaneous electrocardiogram (EKG/ECG)
comprising a FSEI-EKG implant.
[00193] Fig. 72b depicts a perspective view of an auxiliary implant that may
comprise a battery, storage device, antenna,
and a CPU/PCB.
[00194] Fig. 73a depicts a front view of a torso having an example of a
subcutaneous power delivery system comprising a
F SEI.
Date Recue/Date Received 2022-12-30
24
[00195] Fig. 73b depicts a perspective view of an auxiliary implant that may
comprise a battery, storage device, antenna,
and a CPU/PCB.
[00196] Fig. 73c depicts a side elevation view of a powering system comprising
an almost fully implanted thermoelectric
implant.
[00197] Fig. 74a depicts s front view of a human torso having an example of a
subcutaneous power delivery system and a
subcutaneous implantable cardioverter defibrillator system.
[00198] Fig. 74b depicts a perspective view of an auxiliary implant that may
comprise a battery, storage device, antenna,
and a CPU/PCB.
[00199] Fig. 75a depicts a frontal side view of a subcutaneous power delivery
system comprising a FSEI to power a variety
of other implanted devices.
[00200] Fig. 75b depicts a perspective view of an auxiliary implant that may
comprise a battery, storage device, antenna,
and a CPU/PCB.
[00201] Fig. 75c depicts a side view of a wirelessly powered gastric/stomach
implant comprising an inductance coil.
[00202] Fig. 75d depicts a side view of a wirelessly powered foot drop/leg
implant comprising an inductance coil.
[00203] Fig. 75e depicts a side view of a wirelessly powered drug/chemical
pump implant comprising an inductance coil.
[00204] Fig. 75f depicts a side view of a wirelessly powered brain/nervous
system implant comprising an inductance coil.
[00205] Fig. 75g depicts a side view of a wirelessly powered ear/internal-
stimulator implant comprising an inductance coil.
[00206] Fig. 76a depicts frontal side view of an example of a Subcutaneous
Power Delivery System comprising FSEI
providing power to implantable motor units.
[00207] Fig. 76b depicts a perspective view of an auxiliary implant that may
comprise a battery, storage device, antenna,
and a CPU/PCB.
[00208] Fig. 77 depicts a top plan partially transparent view of a flexible
implant facilitating system (FTIFS).
[00209] Fig. 78a depicts a cross sectional side view of a wireless charging
system.
[00210] Fig. 78b depicts a perspective view of a bladder used to cool a
wireless charging system.
[00211] Fig. 79a depicts a top plan view of a branched/dendritic flexible
subcutaneous electronic neuro stimulative implant.
[00212] Fig. 79b depicts a top plan view of a branched/dendritic flexible
subcutaneous electronic neuro stimulative implant
according to another embodiment.
[00213] Fig. 79c depicts a top plan view of a serpentine/sinuous flexible
subcutaneous electronic neuro stimulative implant.
[00214] Fig. 80a depicts a top view of a circular, spiral implant.
[00215] Fig. 80b depicts a cross-sectional view of a spiral implant.
[00216] Fig. 80c depicts a cross sectional view of a spiral implant according
to other embodiments.
[00217] Fig. 80d depicts a cross-sectional view of a spiral implant according
to still other embodiments.
[00218] Fig. 81a depicts a top plan view of a composite system comprising a
minimally invasive implant for
prolonged/controlled drug/chemical delivery.
[00219] Fig. 81b depicts a cross-sectional view of a spiral implant of the
system of Fig. 81a.
[00220] Fig. 81c depicts a cross-sectional view of a bladder-like compressible
implant of the system of Fig. 81a.
[00221] Fig. 8Id depicts an enlarged cross-sectional view of an upper portion
of a spiral implant according to some
embodiments.
[00222] Fig. 81e depicts a perspective view of an auxiliary implant of the
system of Fig. 81a.
[00223] Fig. 81f depicts an enlarged view of a powder mixing/distributing
segmentation pod of the system of Fig. 81a.
[00224] Fig. 8Ig depicts an enlarged view of a gas bubble delivery
segmentation pod of the system of Fig. 81a.
[00225] Fig. 8Ih depicts an enlarged view of a liquid mixing/distributing
segmentation pod of the system of Fig. 81a.
Date Recue/Date Received 2022-12-30
25
DETAILED DESCRIPTION
[00226] Fig. la depicts a top plan view of the distal portion of a minimally
invasive electro-dissection device with a 2 bead
tip having two beads protruding distally from a shaft. Tip 102 comprises a
beaded structure that may be positioned at the
distal end of a shaft.
[00227] Fig. lb depicts a top plan view of a minimally invasive electro-
dissection device with a tip having two beads and
a bead-like structure therebetween. Tip 103 comprises a beaded structure that
may also be positioned at the distal end of a
shaft.
[00228] Fig. lc depicts a minimally invasive electro-dissection device with a
2 beaded tip 104 protruding distally from a
shaft 105 with handle 106 at the proximal end. Some such and similar devices
may be found in U.S. Patents 10,603,101
titled "Apparatus, Systems and Methods for Minimally Invasive Dissection of
Tissues"; 10,952,786 titled "Apparatus,
Systems and Methods for Minimally Invasive Dissection of Tissues", and
continuations in part thereof.
[00229] Fig. 2a depicts a human torso after having undergone comparative
bilateral surgical procedures. On the patient's
right side (the left side of the figure), a lysing tip, such as a lysing tip
having beads and adjacent recesses for delivery of
energy therefrom (for example in Fig. 1c), was used to form an implant pocket
202, with one or more dimensions
substantially greater than that of the entrance incision 250a (about 5mm, for
example) used to begin to create the pocket.
The outward arrows depict the initial forward paths of the dissection device
radiating away from the entrance incision 250a;
the device shown may also be configured to dissect in a rearward direction.
However, for space considerations rearward
arrows are not shown in the schematic. On the patient's left side (the right
side of the figure), an elongated blunt tipped
Metzenbaum surgical dissection scissors 205 is shown extended to its fullest
length until the finger rings are adjacent to
entrance incision 250b. Notice the dissection pocket 203 is limited in size
due to the inability to spread the scissors caused
by the diminutive entrance incision size. Thus, even if 2506 were expanded to
1.5cm (triple the size of 250a, and not desired
by most patients), then scissors with overall combined shank widths of 8mm
would only allow a scissor blade tip spread at
a distance of 15cm from the finger rings in the order of less than a few
millimeters in the depicted scenario. This minimal
scissor blade tip spread would be very inefficient surgically for dissection
and likely impractical resulting in diminutive
pockets let alone the prospect of distant bleeding that is practically
difficult and time consuming to stop. Also shown are
other elongated, typical surgical devices.
[00230] Fig. 2b depicts traditional surgical blunt scissors 205, an elongated
scalpel 204, and an electrosurgery pencil 206.
It is noteworthy that elongated scalpel 204 and electrosurgical pencil 206
each which would typically encounter dissection
limitations and timeliness impracticalities. Dissecting large areas in the
subcutaneous tissue with simultaneous
electrocoagulation/electro-cutting may be attempted with such instruments as
ultrasound and/or radio frequency-capable
insulated endoscopic scissors and/or clamping instruments (some of which may
also use ultrasound). However, such scissors
present a much greater energized surface area and even though their blade tips
may be blunt, when electrified and being
used blindly to dissect large areas rapidly may unwantedly cut through to the
outside skin due to lack of precise control with
such instruments; presenting a larger forward-facing energized surface area
may risk damaging critical nerves and creating
a more irregular dissection plane, thus increasing risks and complications.
Using progressive clamping and unclamping of
endoscopic clamping instruments to dissect large areas of the subcutaneous (as
if a surgeon were working in the peritoneal
cavity) may be very time-consuming, tedious, and may leave a highly irregular
dissection area, which in itself would provide
a greater surface area for complications and risks, including, but not limited
to infection, hematomas, seromas, and excess
fibrosis. Using energized or non-energized single-point-probe devices such as
ultrasound or laser-powered liposuction
cannulas and the like rarely completely cut the fibrous septae, which course
vertically through the subcutaneous fat, thus
leaving a Swiss cheese-like appearance in the subcutaneous, which would not
practically permit sizeable implant placement.
Even if the aforementioned instruments were to be using in a fanning fashion,
as described in Fig. 2a, with the
accompaniment of an endoscope to observe bleeding or plane placement, the
procedure may have time inefficiencies as well
Date Recue/Date Received 2022-12-30
26
as the requirement for having two instruments occupy a minimally invasive
entrance incision, thus possibly doubling the
required entrance incision and/or increasing the trauma to the entrance
incision due to a multiplicity of instruments constantly
rubbing against the entrance incision in both forward and rearward directions.
Thus, endoscopic scissors and/or clamping
instruments may be used to create minimally invasive body cavity (for example
peritoneal, pleural) implant pockets
practically; however their use to create subcutaneous minimally invasive
implant pockets may be problematic or impractical
in a significant portion of pockets, for example, exceeding 10sqcm.
[00231] Fig. 3a depicts a top view of a circular, flexible, and compressible
implant 301. Implant 301 is compressible by
being rollable and/or foldable (for possible subcutaneous placement). Implant
301 is shown in FIG. 3a in its unrolled or
otherwise uncompressed/native state. Implant 301 may comprise, in some
embodiments, a flexible solid or semisolid
material, such as a hydrogel, plastic, metal, organic polymer, biopolymer or
the like. Other embodiments may comprise
nanomers or even rigid solids (such as glasses, quartz, etc.), which, when
fragmented into small enough pieces and
encapsulated in flexible material, may be functional for the procedures
described herein. Drugs, vitamins, or other chemicals,
including biologics, may also be bound or dissolved or exist in a portion or
all of the structure of implant 301 by methods
including but not limited to 3D printing. Different regions and/or portions of
the structure may have different medications
or chemicals printed or otherwise designed into them, some perhaps in the
shape of a pie-chart if multiple materials are
envisioned, for eventual delivery into a patient.
[00232] Implant 301 may comprise one or more protruding tabs 302 that may aid
in placement into a minimally invasive
entrance incision. Fig. 3b is a side view of implant 301 depicting edge 304
and tab 302. Fig. 3c is a top perspective view of
implant 301. Implant 301 may be deployed in a compressed state, such as a
rolled state, and then unrolled or otherwise
decompressed once inserted through the entrance incision and positioned within
the implant pocket, as will be discussed.
Various embodiments disclosed herein, including but not limited to implant
301, may specifically be configured to lack any
sharp edges and/or points, which may be useful to preclude, or at least
inhibit, tissue irritation and/or damage, such as
inflammation, which may be triggered by sharp edges, points, and the like.
[00233] In various preferred embodiments, including implant 301, the implant
may be not only compressible and
decompressible, but may be configured to be expanded to a flat or relatively
flat shape following decompression. Breast or
tissue expander implants may differ in that they may have a non-flat and/or
much thicker shape in its non-footprint
dimension.
[00234] Implant 301 may comprise one or more of the following or related
materials: highly aqueous pH sensitive
hydrogels may include those of copolymers of PMMA (polymethacry late) and
PHEMA (polyhydroxyethyl methyl acrylate),
swelling in neutral or high pH, without swelling in low pH. Highly aqueous
thermosensitive hydrogels may include those
of poly-organophosphazene with alpha-amino omega-methylpolyethylene glycol,
which may deliver drugs such as human
growth hormone. Highly aqueous glucose sensitive hydrogels may include cross-
linked polymers of polyethyleneglycol and
methylacryluc acid, which may deliver drugs such as insulin when glucose
concentrations rise. Nanohydrogels may be
formed from natural polysaccharides like dextran, pullulan, or other
cholesterol-containing polysaccharides, which may be
used for controlled release of proteins like lysozyme, albumin, and
immunoglobin. Hydrogels may be composed of
polysaccharides that are functionalized with methacrylate and aldehyde groups
to create a network from which chondrocyte
cells may be released. Drugs such as pilocarpine and timolol may be infused in
hydrogels such as xyloglucan. Microgels
may also be used to deliver macromolecules, such as phagosomes, into the
cytoplasms of antigen-presenting cells and mold
themselves to the pattern of membrane of the tissue for cartilage repair. The
aforementioned information and other drugs
and hydrogels may be found in 'Hydrogels as Potential Drug Delivery Systems',
Amin, Scientific Research and Essay, Vol.
3(11), 1175-1183, 2009, which is hereby incorporated in its entirety by
reference.
[00235] Hydrogels may be fabricated from synthetic polymers, such as PVA,
poly(hydroxyl alkyl methacrylate), and
biopolymers, such as alginate, collagen, and chitosan. Such hydrogels may be
used to deliver drugs, such as recombinant
Date Recue/Date Received 2022-12-30
27
human granulocyte-macrophage colony-stimulating factor (rhGMC-SF), to treat
burns, for example. Hydrogels that contain
hydrophobic domains may include synthetic polymers, such as poly(N-
isopropylacrylamide) (PNIPAm), which may be used
to deliver hydrophobic drugs, such as doxorubicin. Degradable hydrogels may
include families of biodegradable PED
hydrogels that may release proteins or drugs thanks to slowly hydrolyzing
ester bonds. Covalent linkages between
therapeutic cargo and hydrogel (such as amide bonds that have been used to
conjugate TGF-Beta 1 to PEG hydrogels)
polymer may also, or alternatively, be used to increase stability. The
aforementioned information and other combinations of
drugs and hydrogels may be found in 'Designing Hydrogels for Controlled Drug
Delivery', Li, Nat Rev Mater, 2016, which
is hereby incorporated in its entirety by reference.
[00236] Hydrogels sensitive to pH may also be used for certain applications,
which hydrogels may include, for example,
poly(acrylic acid), and may be used to deliver drugs such as 2-
Methoxyestradiol to, for example, tumor sites.
Thermoresponsive hydrogels may also be used for various applications, and
therefore may be incorporated into one or more
of the implants disclosed herein. Examples of such hydrogels include poly(N-
isopropylacrylamide) (PNIPAm), which may
be used to deliver intravenous docetaxel (DTX). Photosensitive hydrogels may
also be used in connection with one or more
of the implants disclosed herein, and which may include, for example, those of
[Mn(C0)3(qbt)(4-vpy)](CF3S03)(qbt-2-
(quinolypbenzothiazole) photoCORM, covalently bonded through 4-vinylpyridyne
(4-vpy) to a 2-hydroxyethyl
methacrylate polymer chain (HEMA) used to deliver carbon monoxide (CO) as an
antiproliferative measure. Hydrogels
sensitive to magnetic fields may also be used for certain embodiments and
implementations, and which may include SPION-
containing hydrogels synthesized from polymers with PEGMMA backbones
crosslinked by poly(ethylene glycol)
dimethacrylate (PEGDMA), coupling drug eluting and hyperthermic treatments.
Bioresponsive hydrogels may be
synthesized from PEG and MMP-sensitive cross-linking agents, resulting in a
biodegradable system responsive to proteins
such as metalloproteinase (MMP). Smart hydrogels may be used, some of which
may be made to respond to numerous
external stimuli to combine various methods of treatment. The aforementioned
and other smart hydrogels and deliverable
drugs may be found in 'Smart Hydrogels ¨ Synthetic Stimuli-Responsive
Antitumor Drug Release Systems', Kasinski,
International Journal of Nanomedicine, 2020, which is hereby incorporated in
its entirety by reference.
[00237] In some embodiments, biodegradable, hydrophilic hydrogels may comprise
dispersed lipophilic particles with low
water solubility. Such lipophilic particles may comprise, for example,
hydrophobic therapeutic agents. Additional details
regarding the disclosed hydrogel drug delivery system may be found in U.S.
Patent No. 10,226,417, titled "Drug Delivery
Systems and Applications", which is hereby incorporated in its entirety by
reference.
[00238] In some embodiments, polymeric hydrogels may be implanted for delivery
of therapeutic agents (such as, for
example, Insulin, Diclofenac, et al.). Such hydrogels may comprise, for
example, covalently-crosslinked hydrogels,
providing controlled release of therapeutic agents. Aqueous polymeric
precursors may be combined ex vivo in flowable
viscosities with a therapeutic agent before being injected. In some instances,
the hydrogel may be designed to adhere to
certain tissues, crosslink in place, and/or to degrade into biocompatible
products. Such hydrogel systems may be created
using biocompatible precursors (which may include, for example, vinyl
caprolactam, acrylate-capped polyethylene glycol,
et al) and/or may contain high proportions of water. In a preferred
embodiment, the implanted hydrogel may be soft,
hydrophilic, configured to conform to spaces without hard edges, and/or to
degrade into biocompatible products. Some
hydrogels for drug delivery may include, for example, succinimidyl succinate,
succinimidyl glutarate and the like.
Additional information may be found in U.S. Patent No. 10,251,954 titled
"Hydrogel Polymeric Compositions and
Methods", which is hereby incorporated in its entirety by reference.
[00239] Systems for localized drug delivery may include, for example, drug
eluting resorbable devices anchored to tissues
and/or organs. In some embodiments, the drug eluting device may comprise a
biodegradable binder and at least one
resorbable anchor. Some anchor embodiments may comprise resorbable barbs,
coils, or hooks. In some instances, the device
may comprise, for example, a pin configuration, hook-pin configuration, chip
configuration, or the like. In some
Date Recue/Date Received 2022-12-30
28
embodiments, the rate of degradation may be modulated to yield longer/shorter
drug delivery durations. Materials used for
drug delivery may comprise, for example, polylactic-co-glycolic acid.
Additional information regarding drug delivery
systems that may be useful in connection with various embodiments disclosed
herein may be found in U.S. Patent
Application Publication No. 2015/0080855, titled "Systems, Devices, and
Methods for Localized Drug Delivery", which is
hereby incorporated in its entirety by reference.
[00240] Implanted drug eluting devices may comprise substances such as, for
example, hydrogels and xerogels. In some
instances, drug eluting hydrogels may be formed by crosslinking precursors
around therapeutic agents. Precursors may be
dissolved into organic solvents to create organogels, which may be formed by
natural (such as, for example,
polysaccharides), synthetic, or biosynthetic polymers. Synthetic organogels or
hydrogels may be formed by biostable
precursors, such as, for example, poly(hydroxyalkyl methacrylate) and/or
polyacrylamides. Precursors may also constitute
hydrophilic portions, which may comprise, for example, polyethylene oxide.
Precursors may also comprise, for example,
synthetic precursors, natural proteins, polysaccharides,
hydrophobic/hydrophilic portions, functional groups, multi-armed
precursors, dendrimers, peptides, et al. Factors such as crosslinking density
of the hydrogel and molecular weight of the
diffused agent may influence the rate of agent diffusion. Additional details
regarding hydrogel drug delivery systems may
be found in U.S. Patent Application Publication No. 2016/0166504, titled
"Hydrogel Drug Delivery Implants", which is
hereby incorporated in its entirety by reference.
[00241] In some embodiments, drug eluting hydrogels may be implanted so that
cross-linking occurs in situ. Such hydrogel
delivery systems allow for delivery of a myriad of therapeutic cargo, such as,
for example, hydrophobic/hydrophilic agents.
Some embodiments may comprise aqueous polymeric precursors combined in
flowable viscosities with an agent and
implanted into the body, where the cross-linked hydrogel forms in situ. Some
embodiments may comprise hydrogels
formulated to adhere to tissues, which may enhance therapeutic cargo release
and stability. A preferable embodiment may
comprise hydrogels that may degrade over time into biocompatible products
without causing inflammation. Additional
details regarding hydrogel drug delivery systems may be found in U.S. Patent
Application Publication No. 2016/0331738,
titled "Drug Delivery from Hydrogels", which is hereby incorporated in its
entirety by reference.
[00242] Further systems for implantable drug eluting devices may comprise
refillable drug-delivery devices. In some
embodiments, the drug delivery device may comprise a carrier and a target
recognition moiety, which may, for example,
form a two-component binding pair. Drugs that may be released in this manner
may include anti-cancer drugs (such as
Doxorubicin), vascularization-promoting drugs, restenosis prevention drugs,
and the like. In some instances, the carrier may
comprise, for example, polymers, proteins, synthetic/biological hydrogels,
composites, and the like. Hydrogels may
comprise, for example, polyethylene glycol, collagen, alginate,
polysaccharides, hyaluronic acid, et al. In some
embodiments, the drug delivery system may comprise at least two drug delivery
devices, which may be in the same location
or in different locations within the body. In some embodiments, the target may
comprise a bioorthogonal functional group
and the target recognition moiety may comprise a complementary functional
group, wherein both groups are capable of
chemically reacting. In some embodiments, therapeutic cargo may comprise small
molecules or biologics. Biologics may
comprise, for example, antibodies, vaccines, gene therapy, cell therapy, and
the like. Drug refills may be administered orally,
intraperitoneally, intravenously, or intra-arterially. In some embodiments,
the pharmaceutical composition may be attached
to the target via cleavable linker, allowing the drug refill to mask the
potential toxicity of the pharmaceutical composition.
In certain implementations and embodiments, the pharmaceutical composition may
be unmasked after delivery into the drug
delivery device via cleaving the link between the pharmaceutical composition
and the target. Additional details regarding
such drug delivery methods may be found in U.S. Patent Application Publication
No. 2020/0197526, titled "Refillable Drug
Delivery Devices and Methods of Use Thereof", which is hereby incorporated in
its entirety by reference.
[00243] In some embodiments, biodegradable polymer drug carriers may be used
to deliver treatments for extended periods
of time. Drugs that may be administered by implanted polymer drug carriers may
include, for example, clonidine, which
Date Recue/Date Received 2022-12-30
29
may alleviate pain caused by a plethora of sources. When implanted with a
biodegradable polymer, such relief may be
continued from days to months. One embodiment of a delivery system may
comprise clonidine delivered by a biodegradable
polymer, which may comprise, for example, poly(lactic-co-glycolide). Another
embodiment may comprise, for example,
clonidine hydrochloride released by poly(lactic-co-glycolide). Additional
details regarding suitable methods of clonidine
delivery may be found in U.S. Patent No. 9,763,917, titled "Clondine
Formulations in a Biodegradable Polymer Carrier",
which is hereby incorporated in its entirety by reference.
[00244] In some embodiments, implanted hydrogels may be engineered to respond
to stimuli such as, for example,
temperature. In certain embodiments, such hydrogels may comprise, for example,
chitosan and nucleic acids. In some
instances, the hydrogel may be adjusted such that it is in a sol at room
temperature and transitions into a gel once in the
body. In a preferred embodiment, the weight ratio of a nucleic acid and
chitosan may be from about 50:1 to about 2000:1,
with DNA as the nucleic acid. In some embodiments, the nucleic acid may be
DNA, RNA, or a mixture thereof. In certain
instances, the DNA may include oligonucleotides, polynucleotides, and
polydeoxyribonucleotides. In some embodiments,
the hydrogel may comprise an additional polymer material, which may comprise,
for example, hyaluronic acid, cellulose,
alginate, et al. Additional details regarding hydrogel systems may be found in
U.S. Patent Application Publication No.
2019/0054015, titled "Temperature Sensitive Hydrogel Composition Including
Nucleic Acid and Chitosan", which is hereby
incorporated in its entirety by reference.
[00245] Bioactive agent-containing gels may be used in certain applications,
which may include, for example, treatment of
vascular conditions. In certain embodiments, gels may be, for example,
thixotropic and turbid, having high viscosity at low
shear and containing bioactive agents. Therefore, under conditions of no/low
blood flow, the gel may reside in the luminal
space of blood vessels; the gel may be blood-soluble such that upon resumption
of blood flow, the gel may dissolve. The
gel may be used, in certain embodiments, to deliver bioactive agents to
vascular treatment sites. Certain embodiments may
comprise, for example, a cyclodextrin polymer-based composition comprising
cyclodextrin, a polymer (comprising, for
example, ethylene glycol units that may form a hydrogel with cyclodextrin,
wherein the cyclodextrin and the polymer self-
assemble to form a hydrogel), and at least one drug. Additional information
regarding gel-based drug delivery systems may
be found in U.S. Patent Application Publication No. 2019/0247306, titled
"Articles and Methods of Treating Vascular
Conditions", which is hereby incorporated in its entirety by reference.
[00246] In some embodiments, non-erodible polymeric devices may be implanted
subcutaneously to administer therapeutic
cargo over extended periods, ranging from months to years. In certain
embodiments, cargo, such as dopamine agonist, may
be released through pores in the polymeric matrix. In some instances, the
polymeric device may comprise ethylene vinyl
acetate (EVA), while the dopamine agonist may comprise products such as
apomorphine, ropinerole, rotigotine, and the
like. In certain embodiments, anti-inflammatory agents (such as antihistamine)
and/or antioxidants may be contained within
the polymeric matrix. Such agents may be co-administered with the dopamine
agonist. Additional information regarding
such agents and delivery methods may be found in U.S. Patent No. 9,278,163,
titled "Implantable Polymeric Device for
Sustained Release of Dopamine Agonist", which is hereby incorporated in its
entirety by reference.
[00247] In some instances, microcapsules containing therapeutic agents may be
used for drug delivery. In some
embodiments, the microcapsule may comprise polymers, such as, for example,
polylactic acid, polyglycolic acid, and
copolymers thereof Such microcapsules may provide delayed or immediate release
of therapeutic agents. In some
embodiments, the microcapsules may be dispersed within a carrier such as, for
example, water, a gel, and/or a nonaqueous
solvent. Additional details regarding microcapsule drug delivery systems may
be found in U.S. Patent Application
Publication No. 2021/0077114 titled "Implantable Drug Eluting System and
Method of Use", which is hereby incorporated
in its entirety by reference.
[00248] Herein, Threshold Minimally Invasive Surgery in the skin, to alter or
change any of the components which
comprise the skin (which includes the subcutaneous fat), is to be defined as:
a skin incision that measures <10% of the total
Date Recue/Date Received 2022-12-30
30
perimeter or the convex perimeter of the area beneath the surface of the skin
that is to be or has been altered by the
proposed/completed surgery. Thus if a 10x10cm rectangular area (=40cm
perimeter) is undermined within the subcutaneous
area any incision below 4cm would be considered THRESHOLD minimally invasive.
[00249] Herein, Very Minimally Invasive Surgery in the skin, to alter or
change any of the components which comprise
the skin (which includes the subcutaneous fat), is to be defined as: a skin
incision that measures <5% of the total perimeter
or the convex perimeter of the area beneath the surface of the skin that is to
be or has been altered by the proposed/completed
surgery, which may include, for example, the size of the implant pocket and/or
the size of the decompressed implant itself
Thus if a 10x10cm rectangular area (=40cm perimeter) is undermined within the
subcutaneous area any incision below 2cm
would be considered VERY minimally invasive.
[00250] Herein, Ultra Minimally Invasive Surgery in the skin, to alter or
change any of the components which comprise
the skin (which includes the subcutaneous fat), is to be defined as: a skin
incision that measures <3% of the total perimeter
or the convex perimeter of the area beneath the surface of the skin that is to
be or has been altered by the proposed/completed
surgery, which, again, may include the size of the implant pocket and/or the
size of the decompressed implant. Thus if a
10x10cm rectangular area (=40cm perimeter) is undermined within the
subcutaneous area any incision below 1.2cm would
be considered ULTRA minimally invasive.
[00251] For irregular areas/perimeters (even amoeba like areas of implants)
measuring the convex perimeter (perimeter of
the convex hull that encloses the object) as per Wirth may be carried out for
a perimeter calculation using the methods and
formulas presented in Shape Analysis & Measurement,
Wirth M, 2004
http://www.cyto.purdue.edu/cdroms/micro2/content/education/wirth10.pdf which
is hereby incorporated herein in its
entirety by reference. Another simple method may be to estimate the perimeter
of an irregular area using lattice points.
[00252] Herein, Threshold Minimally Invasive Implant (placed and/or configured
for placement into a layer of the skin or
adjacent), is to be defined as: an implant that is configured to achieve
successful implantation and, in preferred
embodiments/implementations, maintain function to the expectant life of the
implant, after it has been inserted in a skin
incision that measures <10% of the total perimeter or the convex perimeter of
the implant. For the
embodiments/implementations disclosed herein, a threshold minimally invasive
implant comprises an implant that is
insertable in a skin incision that measures less than 10% of the total
perimeter or, in the case of an implant having infolds,
recessions, concavities, or the like, less than 10% of the convex perimeter,
of the implant's "footprint" (i.e., as used herein,
the implant's two-dimensional shape from a plan view looking down at the
region of the patient's skin under which the
implant is configured to lie after complete installation, including
decompression for compressible implants, within a patient's
implant pocket; the implant's footprint would typically extend at least
roughly parallel to the patient's skin, giving leeway
for the various folds and curves of the skin). An implant's "footprint area"
may therefore be considered, for purposes of
this disclosure, the area of the implant's "footprint" using this definition.
Thus, for example, an 8x8cm rectangular implant
(from the aforementioned perspective) (=32cm perimeter) must be able to pass
through a 3.2cm incision to meet this
Threshold Minimally Invasive Implant definition.
[00253] Herein, Very Minimally Invasive Implant (placed and/or configured for
placement into a layer of the skin or
adjacent), is to be defined as: an implant that is configured to achieve
successful implantation and, in preferred
embodiments/implementations, maintains function to the expectant life of the
implant, after it has been inserted in a skin
incision that measures <7% of the total perimeter or the convex perimeter of
the implant. For the
embodiments/implementations disclosed herein, a very minimally invasive
implant comprises an implant that is insertable
in a skin incision that measures less than 7% of the total perimeter or, in
the case of an implant having infolds, recessions,
concavities, or the like, less than 7% of the convex perimeter, of the
implant's "footprint" (i.e., as used herein, the implant's
two-dimensional shape from a plan view looking down at the region of the
patient's skin under which the implant is
configured to lie after complete installation, including decompression for
compressible implants, within a patient's implant
Date Recue/Date Received 2022-12-30
31
pocket; the implant's footprint would typically extend at least roughly
parallel to the patient's skin, giving leeway for the
various folds and curves of the skin). An implant's "footprint area" may
therefore be considered, for purposes of this
disclosure, the area of the implant's "footprint" using this definition. Thus,
for example, an 8x8cm rectangular implant
(=32cm perimeter) must be able to pass through a 2.2cm incision to meet this
Very Minimally Invasive Implant definition.
[00254] Herein, Ultra Minimally Invasive Implant (placed and/or configured for
placement into a layer of the skin or
adjacent), is to be defined as: an implant that achieves successful
implantation and, in preferred
embodiments/implementations, maintains function to the expectant life of the
implant, after it has been inserted in a skin
incision that measures <5% of the total perimeter or the convex perimeter of
the implant. For the
embodiments/implementations disclosed herein, an ultra minimally invasive
implant comprises an implant that is insertable
in a skin incision that measures less than 5% of the total perimeter or, in
the case of an implant having infolds, recessions,
concavities, or the like, less than 5% of the convex perimeter, of the
implant's "footprint" (i.e., as used herein, the implant's
two-dimensional shape from a plan view looking down at the region of the
patient's skin under which the implant is
configured to lie after complete installation, including decompression for
compressible implants, within a patient's implant
pocket; the implant's footprint would typically extend at least roughly
parallel to the patient's skin, giving leeway for the
various folds and curves of the skin). An implant's "footprint area" may
therefore be considered, for purposes of this
disclosure, the area of the implant's "footprint" using this definition. Thus,
for example, an 8x8cm rectangular implant
(=32cm perimeter) must be able to pass through a 1.6cm incision to meet this
Ultra Minimally Invasive Implant definition.
[00255] Herein, successful implantation and function is to be defined as the
ability to maintain the expectant conformation
(no folding over on itself) and/or the ability to remain in the expectant
position to the expectant life of the implant after it
has been inserted into a defined size limited skin incision. Heretofore, many
published designs' delicate electronics or
membranes would not tolerate implantation through such size proportionate
incisions with many common surgical tools and
thus expectant function/lifespan may be affected.
[00256] Fillable Breast and tissue expansion implants are commonly expanded to
a final thickness (3rd dimension) of >50%
of their largest two-dimensional footprint dimension, such as
diagonal/diameter in the case of a rectangular/circular implant
footprint shape; such shapes may be akin to fillable bladders. However, during
a port filling phase(s), which is/are often
sequential with such implants, the non-final thicknesses may range from near
to 0 to the final percentage thickness. Fillable
Breast and tissue expansion implants are also usually not intended for fluid
storage that may contain chemicals or drugs for
later delivery.
[00257] The non-linear implant embodiments described herein may be the result
of pliable, expandable laminations or area
intended for fluid storage that may contain chemicals or drugs for later
delivery. In preferred embodiments, the non-linear
implant embodiments described herein are therefore preferably configured to be
more "flat" than, for example, breast and
other tissue expansion implants. More particularly, in preferred embodiments,
these implants are configured to avoid
expansion to a final thickness of more than 25% of their largest footprint
dimension.
[00258] In the case of an inflatable implant, uncompressed should be
considered to encompass the implant in its final, fully
inflated configuration. It should also be understood that, whereas typical
tissue implants in the prior art that are wirelessly
rechargeable are relatively small and therefore consume/utilize relatively
small of amounts of electrical energy, due to the
unique structures and methods disclosed herein, various embodiments disclosed
herein may be much larger and therefore
may be able to receive, generate, and/or utilize relatively much larger
amounts of electrical energy, which vastly expands
the potential capabilities of implants, as disclosed throughout herein, such
as providing power for light emission, powering
larger motors, and other larger and/or a larger number devices that,
individually or collectively, require more energy.
[00259] Fig. 4a depicts a top view of an alternative compressible implant 401.
Implant 401 again comprises a circular,
flexible, and compressible implant that may be rollable and/or foldable for
possible subcutaneous placement. Fig. 4a depicts
implant 401 in its unrolled or otherwise uncompressed/native state. Implant
401 may be comprised of similar materials as
Date Recue/Date Received 2022-12-30
32
implant 301. Implant 401 may also comprise protruding tabs 402 that may aid in
placement into a minimally invasive
entrance incision. However, implant 401 may also comprise macro
positioning/instrument engaging holes 403 in one or
more (in some cases, all) of the protruding tabs 402 or elsewhere about its
structure that may be configured to receive and/or
engage an instrument, or a portion of an instrument, to facilitate placement
of the implant 401 into a minimally invasive
entrance incision. In some embodiments and implementations, instruments may be
used that may comprise protrusions
capable of dragging or pulling the material surrounding the hole, and thereby
advancing implant 401, into proper position
through such small entrance incisions.
[00260] Fig. 4b is a side view of implant 401, which depicts the use of
optional laminates that may also comprise the
implant of Fig. 4a. Fig. 4b depicts edge 404 of implant 401 with optional
upper laminate 405 and lower laminate 406.
[00261] In some embodiments, laminates 405 and 406 may be sealed only at their
respective outer edges to create a bladder
therebetween, which may contain various fluids for eventual delivery into the
patient. In some such embodiments, the
structure in between the two laminates may be partially or fully removed. For
example, there may be holes or other openings
formed to allow fluids captured between the laminates 405/406 to pass back and
forth, effectively creating a single bladder
or chamber. Thus, it should be understood that one or both of the laminates
405/406 may have a surface entirely in contact
with the main body of the implant 401 (despite the appearance of spaces
therebetween in the figure), or there may be space
adjacent to one or both laminates 405/406, which, again, may allow for
containing fluids. In further contemplated
embodiments, laminates may comprise ethylene vinyl alcohol co-polymers.
[00262] Laminates 405 & 406 may further comprise pores/holes/spaces 407h which
may allow drugs, molecules,
chemicals, and the like to exit from implant 401, preferably following
implantation. Such substances may be configured to
exit from the implant 401 passively by, for example, osmosis or actively by
being driven, for example, indirectly by
electromagnetic fields. Pores/holes/spaces 407h may be gated by structures
such as gates 407g which may, for example,
comprise electrically actuatable smart nanoporous membranes (as per Langer,
Wireless on-Demand Drug Delivery, Nature
Electronics, 2021).
[00263] Laminates 405 & 406 may comprise, in some embodiments,
electroresponsive gels, such as poly(dimethyl
aminopropyl acrylamide) (PDMAPAA) loaded with drugs (for example, insulin).
Such gels may be configured to release
the drugs and/or other chemicals/materials when stimulated by an externally
applied electric field. Similarly, hydrogels
prepared from chitosan-graft-polyaniline copolymer and oxidized dextran loaded
with amoxicillin/ibuprofen have shown a
controllable release rate set by the applied voltage. Electrically actuatable
smart nanoporous membranes may also, or
alternatively, be used in some embodiments, and which may be made of, for
example, polypyrrole (PPy) doped with
dodecylbenzenesulfonate (DBS) for pulsatile drug release. The aforementioned
information and other examples of porous
membranes allowing actuatable drug release that may be used in connection with
one or more of the embodiments disclosed
herein may be found in Wireless on-Demand Drug Delivery, Langer, Nature
Electronics, 2021, which is hereby incorporated
herein in its entirety by reference.
[00264] In some embodiments, thermally actuated lipid membranes may be used
for on-demand drug delivery, which may
be incorporated into various embodiments disclosed herein. In some instances,
an inductively coupled coil may be used to
deliver electrical energy to resistive heating elements. In certain
embodiments, the lipid membrane may comprise, for
example,
dipalmitoy 1pho sphatidy lchol ine, 1,2-di lauroyl- sn-glycero-3-
phosphoethano lamine,
dipalmitoylphosphatidylglycerol, and/or 1,2-dioleoy1-3-trimethylammonium-
propane and cholesterol. The implant may
comprise, in some embodiments, an array of individually addressable thermal
actuators, each consisting of a receiver coil
coupled to a resistor, and a layered coating of the thermally actuatable lipid
membrane enclosing the drug. In a preferred
embodiment, drug release may occur at a temperature above normal body
temperature, but below maximum allowable
temperatures, which may allow for selective actuation of drug delivery.
Additional details regarding drug delivery systems
may be found in "Biological Lipid Membranes for On-Demand, Wireless Drug
Delivery from Thin, Bioresorbable
Date Recue/Date Received 2022-12-30
33
Electronic Implants", Lee, NPG Asia Materials, 2015, 10.1038/am.2015.114,
which is hereby incorporated in its entirety by
reference.
[00265] Fig. 4c depicts an enlarged side view of implant 401 with target
binding materials 409 binding target/subject
materials 410 along the edge 404 of the implant 401, as denoted by their
diagrammatic proximity. After release, target
binding materials 408 may be unassociated.
[00266] Fig. 4d is a top perspective view of implant 401 also depicting the
edge 404 of the implant. As previously
mentioned, implant 401 may be deployed in a compressed state, such as a rolled
state, and then unrolled or otherwise
decompressed once inserted through the entrance incision and positioned within
the implant pocket as will be discussed.
[00267] Fig. 5a depicts a side view of an implant 501 after it has been
compressed for entry through an incision. Implant
501 is compressible by being rollable and/or foldable. In the depicted
configuration, implant 501 has been rolled into the
compressed configuration shown. Implant 501 may be similar to one or more of
the implants previously discussed and may
therefore be made up of any of the materials previously mentioned. Implant 501
may further comprise protruding tabs 502
that may, as previously discussed, be configured to facilitate placement into
a minimally invasive entrance incision with
instruments to be discussed. For purposes of this disclosure, entrance
incisions may be considered as forming an opening in
the epidermis and dermis in order to reach the subcutaneous and/or deeper
tissues.
[00268] Fig. 5b is a side view of the rolled compressible implant 501
depicting edge 504 and tab 502. Fig. Sc is a perspective
view of the implant 501 depicting edge 504 and tab 502. As demonstrated by
FIGS. 5a-5c, implant 501 may be configured
to allow for an implant having a large surface area, such as a rectangular-
shaped implant, to be rolled in order to maximize
the surface area capabilities and/or minimize the restriction of a rolled
implant as it passes through the entrance incision. In
some embodiments, implants comprising electronics and/or implants configured
to deliver drugs may, in its respective
uncompressed configuration, have a footprint area of at least 50 square cm. In
some such embodiments, implants comprising
electronics and/or implants configured to deliver drugs may, in its respective
uncompressed configuration, have a footprint
area of at least 100 square cm. Implant 501 and implant edge 504, as seen from
the side when compressed, in Fig. 5b,
comprise 2 turns. In alternative embodiments, rolled compressible implants may
comprise a range of numbers of turns from
1 to 100. In further embodiments, rolled compressible implants may comprise a
range of numbers of turns chosen from the
group of: 2-3 turns, 3-5 turns, 5-7 turns, 7-10 turns, 10-15 turns, 15-20
turns, 20-30 turns, 30-40 turns, 40-50 turns, 50-75
turns, and 75-100 turns. In further embodiments, rolled implants may comprise
a range of numbers of turns chosen from the
group of: 2-10 turns, 3-8 turns 4-7 turns, and 4-5 turns.
[00269] As also depicted in Fig. 5b, the implant 501 has been rolled and/or
folded multiple times, the number of which
may depend on the thickness and dimensions of the implant, possibly along with
the desired central space following
compression. Delicate electronics may not function following extremely tight
rolling of certain implants, such as small yet
flexible implants. Thus, the nature of the implant and the components
contained thereon may also dictate the number of
rolls/folds/turns. Similarly, the size of the entrance incision may warrant
tighter, or looser, folding/rolling/compression.
Again, the number of rolls/folds/turns may depend upon the inner diameter
(internal space), implant thickness(es), gaps
between implant sheets/rolls, and/or surface irregularities/variances, etc.
[00270] Figs. 6a-6e depict side views of a flexible tissue implant
facilitating system (FTIFS) 600 and devices. Fig. 6a
depicts an instrument (in this case a portion of a more complete instrument or
a "sub-instrument") comprising a blunt
introducing tip 609, a dilator 608 with widest diameter 610 and tapering to a
narrower diameter at tip 609. Tip 609 is coupled
to a shaft 614 having a distal portion 614d and a proximal portion 614p. In
the depicted embodiment, the distal portion 614d
of the shaft may comprise an implant engaging member, which in the depicted
embodiment comprises a tab fastener 612.
Tab fastener 612 may engage rolled implant tab 602. For example, in some
embodiments and implementations, tab 602 may
be inserted, either partially or fully, through the slot formed by tab
fastener 612. Screw threads 611 may, in some
embodiments, be oriented normal, or at least substantially normal, to the
shaft axis, thus the screw threads may cut through
Date Recue/Date Received 2022-12-30
34
dermis (as the entrance incision is dilated/stretched) at an angle that is
close to parallel to the skin surface, thus
cuts/scarification may be more difficult to notice as they are deeper than the
surface mimicking the technique of subcision.
[00271] In some embodiments, a macro positioning/instrument engaging hole 603
may be formed in tab 602, which may
further facilitate placement of implant 601 on the instrument. For example, in
some embodiments, a surgeon may use a pair
of forceps or the like, which may be inserted through the hole 603 during the
procedure of coupling the implant 601 to the
instrument, such as to pull the tab 602 through the slot formed by tab
fastener 612. As will be described below in greater
detail, in some embodiments, holes, which may be similar to hole 603, may be
used to facilitate this coupling by receiving
protruding members formed in the instrument, such as on the shaft of the
instrument, which protruding members may extend
through and engage (thus, a relatively flexible implant material and a
relatively inflexible protruding member may be
preferred) the material of the implant forming the hole(s).
[00272] Fig. 6b shows an implant 601 rolled up into a compressed configuration
for insertion through a preferably
minimally invasive entrance wound. Tab 602 is shown protruding from an edge of
implant 601 that extends perpendicular
to edge 604 in this configuration. Implant 601 may comprise any of the
previously mentioned materials.
[00273] Fig. 6c illustrates a sheath 607 that may be used in certain
embodiments and implementations. Fig. 6d shows sheath
607 after it has been coupled with the instrument with the implant 601
therein. Thus, in some implementations, sheath 607
may simply be slid over the rolled/compressed implant 601, either before or
after the implant 601 has been coupled with the
instrument. Sheath 607 may comprise, for example, a thin sheet of
polyethylene, polyurethane, or other suitable polymer.
[00274] In FIG. 6d, the instrument is shown with sheath 607 encasing an
underlying rolled implant (hidden in this view),
which is in turn wrapped around the distal portion 614d of the instrument
shaft, as previously mentioned. As also shown in
this figure, the proximal portion 614p of this shaft may be coupled with a
removable handle 615. Handle 615 may be a
slidable, adjustable handle that may simply comprise a central, axial hole
shaped and configured to receive the shaft therein.
As also shown in the figure, handle 615 may further comprise one or more
frictional features to provide for traction during
use by a surgeon. In the depicted embodiment, a plurality of elongated,
parallel depressions 615f are formed for this purpose
(of course, these may be protruding ribs or other protruding features in
alternative embodiments).
[00275] Fig. 6e shows a complete FTIF System 600. As shown in the figure,
dilator 608 may comprise screw threads 611.
Threads 611 may facilitate advancement of the tip 609, and the adjacent
portion of the instrument and underlying implant
601, through a relatively small entrance wound. For example, a surgeon may
initially advance the distal, pointed portion of
tip 609 through the entrance wound. In order to stretch the wound opening to
ultimately accommodate the implant 601, the
surgeon may then rotate the instrument, which may cause the threads to engage
the surrounding tissue and further advance
the instrument (and implant 601) along the tapering section of tip 609.
[00276] FIG. 6e also shows sheath 607 fully enclosing the rolled implant (also
hidden in this view). This figure also shows
most of the proximal portion 614p of the shaft covered by releasable handle
615, which may be made to firmly couple, such
as lock, to the shaft 614p via a lever latch 616. Lever latch 616 may have an
asymmetric protuberance and asymmetric hole
through which a pin may pass from the handle through the latch 616 to form a
friction fit against the shaft when engaged
and flush. Thus, by rotating the lever latch 616, a user may be able to lock
an engagement region of the latch portion of the
lever latch 616 against the shaft.
[00277] Figs. 7a-7c depict side views of a flexible tissue implant
facilitating system (FTIFS) 700 according to other
embodiments. System 700 does not use a sheath but instead uses a ribbon 717r
to restrain implant 701. Fig. 7a depicts a
blunt introducing tip atop dilator 708 which is attached to the shaft,
comprising tab fastener 712, eventuating in proximal
shaft portion 714p. Fig. 7b shows a dilator with a dilator hole 708h atop a
rolled implant 701, which may be comprised of
previously mentioned materials. Fig. 7c illustrates one limb of a ribbon 717r
passing through a dilator hole 708h wrapped
around an implant in a candy-cane fashion to secure the implant when held by
the surgeon's hand against handle 715. The
other limb of the ribbon 717r may be kept straight but preferably secured by
the surgeon's hand until the entire implant 701
Date Recue/Date Received 2022-12-30
35
is delivered through the entrance wound successfully whereupon the wound limb
of the ribbon is unwound rubbing against
the entrance wound thereafter the entire ribbon can be pulled by one limb
through the dilator hole. As before, lever latch
716 may be used to releasably couple handle 715 with proximal shaft portion
714p.
[00278] Fig. 8a depicts a top view of an alternative compressible implant 801.
Implant 801 is compressible by being rollable
and/or foldable. Implant 801 may comprise a fan shaped implant that may be
polygonal, flexible, and/or compressible.
More particularly, implant 801 may be foldable for subcutaneous placement
through a relatively small entrance wound. In
some implementations, the implant may be rollable and/or rolled rather than
folded, as previously discussed.
[00279] Fig. 8a depicts implant 801 in its unfolded or otherwise
uncompressed/native state. Implant 801 may be made up
of similar materials as implant 301. Implant 801 may also comprise one or more
protruding tabs 802 that may aid in
placement into a minimally invasive entrance incision. However, implant 801
may also comprise macro
positioning/instrument engaging holes 803 in one or more (in some cases, all)
of the protruding tabs 802 or elsewhere about
its structure that may be configured to receive and/or engage an instrument,
or a portion of an instrument, to facilitate
placement of the implant 801 into a minimally invasive entrance incision. In
some embodiments and implementations,
instruments may be used that may comprise protrusions capable of dragging or
pulling the material surrounding the hole,
and thereby advancing implant 801, into proper position through such small
entrance incisions.
[00280] Fig. 8b depicts an enlarged side view of implant 801 depicting a
folded plane 804 and fold 809, encircled by
implant sheath 807. Implant 801 and implant edge 804 when compressed, as seen
from the side, comprise 6 folds.
[00281] Fig. 8c is a side view of implant 801 with edge 804.
[00282] Fig. 8d is a top perspective view of implant 801 also depicting the
edge 804 and fold 809 of the implant. As
previously mentioned, implant 801 may be deployed in a compressed state, such
as a folded state, and then unfolded or
otherwise decompressed once inserted through the entrance incision and
positioned within the implant pocket, as will be
discussed in greater detail below. Compressible implant 801 comprises 6-fold
lines (for example, representative fold 809).
In alternative embodiments, some compressible implants may comprise numbers of
folds ranging from 1 to 100. In further
embodiments, foldable compressible implants may comprise a range of numbers of
folds chosen from the group of: 2-3
folds, 4-5 folds, 6-7 folds, 8-9 folds, 10-14 folds, 15-19 folds, 20-29 folds,
30-39 folds,40-49 folds, 50-74 folds, and 75-100
folds. In further embodiments, foldable compressible implants may comprise a
range of numbers of folds chosen from the
group of: 2-10 folds, 4-9 folds 5-8 folds, and 6-7 folds.
[00283] Figs. 9a-b depict surgical tools that may aid in the removal of non-
biodegradable implants. The forceps 911 in Fig.
9a may terminate in non-sharp points whereas forceps 912 in Fig. 9b may
terminate in ring like shapes. Such forceps may
be introduced into an entrance wound after the implant has served its
usefulness or has developed a problem. An edge of the
implant may be clamped and the instrument spun on its axis through the
entrance wound until part or all of the implant is
wound around the tool whereupon the tool and implant are pulled through the
entrance wound whole (or in pieces if the
surgeon has chosen to divide the implant whilst still inside the patient prior
to removal).
[00284] Fig. 10a depicts a top view of an alternative compressible implant
1001 according to other embodiments. Implant
1001 again comprises a circular, flexible, and compressible implant that may
be foldable for subcutaneous placement. In
some embodiments, the implant may be rollable and therefore may be rolled into
the configuration shown in FIG. 10c. Fig.
10a depicts implant 1001 in its unrolled or otherwise uncompressed/native
state. Implant 1001 may be made up of similar
materials as any of the other implants disclosed herein, as previously
mentioned.
[00285] Implant 1001 lacks protruding tabs that may catch on tissue near the
entrance wound or occupy valuable diametric
dimensions reducing the ease of which the implant may pass through a minimally
invasive entrance incision. However,
implant 1001 may comprise internal and/or non-protruding tabs 1002, which may
otherwise be referred to herein as hole-
defining and/or structural reinforcement regions. One or more of internal tabs
1002 may define one or more macro
positioning/instrument engaging holes 1003. Various non-biodegradable
materials such as polypropylene, poly-para-
Date Recue/Date Received 2022-12-30
36
phenylene terephthalamide or polytetrafluoroethylene (PTFE) may be used to
reinforce the implant and therefore may be
used to form internal tabs 1002. In addition, biodegradable materials, such as
polylactic acid or poliglecaprone and the like
may be used. Holes 1003 may be configured to receive and/or engage an
instrument, or a portion of an instrument, to
facilitate placement of the implant 1001 into a minimally invasive and/or
relatively (relative to the implant) small entrance
incision. In some embodiments and implementations, instruments may be used
that may comprise protrusions capable of
dragging or pulling the material surrounding the hole, and thereby advancing
implant 1001 into the proper position through
such small entrance incisions. Fig. 10b depicts a side view of unrolled or
uncompressed implant 1001 with edge 1004.
Implant 1001 when compressed and edge 1004, as seen from the side, in Fig.
10b, comprises about 2 1/2 turns. In alternative
embodiments, compressible implants may comprise numbers of rolls/folds/turns
ranging as previously described with
reference to Fig. 5.
[00286] Implantable patch 1001 may contain drugs such as gentamicin or
methotrexate, suspended in hydrogels such as
PLA (polylactic acid). Also, the drugs niclosamide or IP6 (inositol phosphate)
may be mixed in PCL (polycaprolactone)
and/or graphene nanoplatelets in some embodiments. Biologic scaffolds may also
be used, which may include drugs such
as rhBMP-2 (recombinant bone morphogenetic protein-2) incorporated into PCL,
PLGA (poly lactic co-glycolic acid), or
Beta-TCP (tricalcium phosphate). Another example of a suitable biologic
scaffold is dexamethasone, which may be
embedded in Sr-MBG (strontium mesoporous bioactive glass). Bioceramics for
bone generation and infections may also be
used in some embodiments, which may include VNC (vancomycin), rhBMP-2, and/or
heparin, and may be embedded in
materials such as brushite, unreacted alpha or beta-TCP, chitosan, and/or
HPMC. VNC and ceftazidime may also be mixed
into PLA cages and PLGA nanofibers. Other drugs and materials for implantable
patches, stents, meshes, scaffolds, and/or
bioceramics may be found in '3D Printed Drug Delivery and Testing Systems __
a Passing Fad or the Future?', Lim,
Advanced Drug Delivery Reviews 132 (2018) p.139-168, 2018, which is hereby
incorporated in its entirety by reference.
[00287] In some embodiments, polymers such as silicones, poly(urethane),
poly(acrylates), or copolymers may be used in
preparing non-biodegradable implants. Such polymers may be formed into
matrices wherein the drug is homogenously
dispersed, or may be formed into reservoir-type implants, which may comprise a
drug core covered by a permeable
membrane. In some instances, polymers such as poly(caprolactone), poly(lactic
acid), or poly(lactic-co-glycolic acid) may
be used to prepare biodegradable drug eluting devices. Additional details
regarding suitable polymers for drug delivery may
be found in 'Implantable Polymeric Drug Delivery Devices: Classification,
Manufacture, Materials, and Clinical
Applications', Stewart, MDPI, 2018, doi.org/10.3390/po1ym10121379, which is
hereby incorporated in its entirety by
reference.
[00288] Fig. 10c depicts a side view down the axis of a rolled or compressed
implant 1001 with edge 1004.
[00289] Fig. 10d is a top perspective view of implant 1001 also depicting the
edge 1004 of the implant. As previously
mentioned, implant 1001 may be deployed in a compressed state, such as a
rolled state, and then unfolded or otherwise
decompressed once inserted through the entrance incision and positioned within
the implant pocket, as will be discussed in
greater detail below.
[00290] Fig. 10e depicts another side view of implant 1001, this time viewed
from the side extending along the full axis of
the rolled or compressed circular implant 1001 with edge 1004 rather than
looking down the axis as in Fig. 10c. Note that
in implants that have fewer corners (less corner material) than a rectangular
implant, such as the depicted circular implant,
the ends of a rolled/folded implant may taper and/or step so that in their
compressed configuration they are thicker in the
center than along one or both opposing ends, as shown in Fig. 10e. In some
contemplated implementations, tapered and/or
stepped ends may facilitate manual insertion of the implant into a minimally
invasive entrance wound by resulting in a
compressed implant having one or more smaller ends to facilitate introduction
through the entrance wound, especially if
rotated in a direction that the implant was folded so that the implant running
edge may be less prone to rub against the
entrance incision whilst being rotated and pushed. Such manual insertion may
be by sterile gloved fingertips. In some
Date Recue/Date Received 2022-12-30
37
implementations, implant 1001 may be unfurled subcutaneously using holes 1003
and a sterile probe/instrument with
protrusion 1824b as seen in Fig. 18d.
[00291] Fig. 11a depicts an alternative embodiment of an implant 1101
comprising non-protruding structural reinforcement
regions 1102, each of which defines a macro positioning/instrument engaging
hole 1103, which is positioned at an
edge/periphery of the implant 1101, and therefore, as described above in
connection with implant 1001, provides structural
reinforcement to improve the structural integrity of each hole 1103. In
addition, implant 1101 differs from implant 1001 in
that in its uncompressed configuration it defines an oval shape rather than a
circular shape. Implant 1101 further comprises
a plurality of macro vascularization holes 1177 ("macro" refers to the size of
the hole rather than the size of the vessels that
may grow therethrough), one or more of which may comprise a reinforcement
region 1178, which may be concentric with
the hole(s) 1177, to provide protection and prevent or at least inhibit
tearing. The use of relatively large (10-20cm or greater
in diameter or greatest dimension following implantation/decompression, as
shown in FIG. 11) implants in areas such as the
abdomen that derive most of their blood supply from deeper tissues, rather
than tangentially from adjacent tissues, may
result in a diminution of blood supply and other elements to the tissues
overlying the center of the implant. If vascularization
holes are present in the implant and sufficiently wide large to allow vascular
ingrowth and communication with the more
superficial tissues through the implant, the superficial tissues of the
abdomen may experience better growth conditions and
blood supply rather than only being granted blood supply from the relatively
distant periphery of the implant. If the holes
are under lmm in diameter, it may be difficult for blood vessel ingrowth to
traverse from one side of the implant to the
other. Therefore, one or more vascularization hole(s) 1177 exceeding lmm
(preferably at least several mm) in diameter may
be made to allow vascular ingrowth and/or vascular crossing of the implant to
benefit tissues on the opposite side of the
implant. The area around hole(s) 1177 may comprise a ring or other shape of
reinforcement 1178 in order to maintain the
integrity of the implant. In some such embodiments, an array of holes may be
present in the implant, which may include
dozens or even hundreds or thousands of holes, as desired. In contemplated
embodiments, peripheral placement of holes
may not benefit the tissues as much as centrally placed holes, as the tissues
overlying the center are farther from the
periphery, thus some preferred implants may comprise primarily, or exclusively
in some cases, central or at least
substantially centrally positioned vascularization holes. For purposes of this
disclosure, a macro vascularization hole should
be considered at least substantially centrally positioned if it is positioned
within any point of the implant's footprint lying
within about one-third of the distance from the implant footprint's
mathematical centroid point and a point on the perimeter
intersected by a line passing through the centroid. Some embodiments may
comprise macro vascularization holes lying
within a "relative center" position, which for purposes of this disclosure
should be considered within any point of the
implant's footprint lying within 50% of the distance from the implant
footprint's mathematical centroid point and a point on
the perimeter intersected by a line passing through the centroid.
[00292] In other contemplated embodiments, such holes for vascularization and
biological cross communication may be
present throughout the implant in desired areas. Vascularization may be more
plentiful to nourish tissues distant from a
blood supply in greater need. Such through/through and through holes (meaning
fully penetrating the implant's thickness)
may be beneficial for tissue fluid sampling in that neovascularization may not
be closed end and thus pass in greater velocity
and/or volume per vessel/capillary. Microfluidic channels 1188 and/or probes
may allow access for Lab-on-a-chip 1185
technology within the implant or in a wired/wirelessly connected auxiliary
implant to assess body fluids. Proximity of new
active vessels to a protected inner wall may also be beneficial for optical
sampling by fiberoptics 1189 to aid in optical
analysis of body fluids passing by a through & through hole 1187
[00293] In some embodiments, microfluidic lab-on-a-chip devices may comprise
dual optical fibers used for manipulation.
In some instances, such devices may comprise channels for precise fiber optic
alignment, a sample channel, and/or a zig-
zag structure incorporated in the sample channel. In some embodiments, the
fiber-optics may be used to trap different-sized
microscopic particles and/or stretch cells. In certain instances, the device
may be fabricated via soft lithography using
Date Recue/Date Received 2022-12-30
38
Polydimethylsiloxane (PDMS). In a preferred embodiment, the fiber optic system
may comprise two aligned optical fibers
delivering counterpropragating laser beams, which may be used for functions
such as, for example,
capturing/sorting/identifying particles/cells. Additional details regarding
the disclosed lab-on-a-chip devices that may be
used on various implants disclosed herein may be found in "3D printed
microfluidic lab-on-a-chip device for fiber-based
dual beam optical manipulation", Wang, Scientific Reports, 2021, 11:14584,
which is hereby incorporated by reference in
its entirety by reference.
[00294] In some embodiments, microfluidic devices may be incorporated into
implants, which may comprise microfluidic
probes (MFP). In such MFP devices, a microfluidic stream may be applied to the
sample such that the MFP uses a
hydrodynamic flow confinement instead of walls to constrain a microfluidic
stream. In some embodiments, such MFPs may
be open microfluidic systems. Applications for such MFP devices may include,
for example, control of cellular
microenvironments, local processing of tissue slices, generating concentration
gradients, and the like. In some embodiments,
such MFPs may be fabricated in Si wafers which may be bonded to PDMS chips,
which may serve as world-to-chip
interfaces and/or comprise holes. Microfluidics may offer several advantages
such as, for example, greater control over
microenvironments. MFPs may be used in conjunction with continuous laminar
perfusion for purposes such as, for example,
electrophysiological studies, biomarker discovery, toxicology study, and the
like. In other embodiments, MFP devices may
be used for immunohistochemistry on cancerous tissue slices, which may allow
for implants to be used for tissue analysis.
Additional details regarding such MFP devices may be found in "Microfluidic
probes for use in life sciences and medicine",
Qasaimeh, The Royal Society of Chemistry 2012, DOI: 10.1039/c21c40898h, which
is hereby incorporated by reference in
its entirety by reference.
[00295] In some embodiments, microfluidic chips may comprise optical
refractive-index (RI) sensors comprising a long-
period grating (LPG) inscribed within a small-diameter single-mode fiber
(SDSMF). Such devices may be fabricated via,
for example, layer-by-layer self-assembly techniques, which may deposit
poly(ethylenimine) and poly (acrylic acid)
multilayer films the on SDSMF-LPG sensor. In certain embodiments, such SDSMF-
LPG sensors may comprise a layer used
for molecule sensing, such as glucose oxidase for glucose sensing. In some
embodiments, the microfluidic chip may be
completed by embedding the molecule sensing layer and the SDSMF-LPG into a
microchannel of the chip. In some
embodiments, a mixture (for example 10:1) of PDMS and crosslinker may be used
for chip fabrication. In a preferred
embodiment, a microchannel may comprise a spiral-shaped mixing portion, which
may aid in mixing solutions
homogenously before passing through sensors. Additional details regarding such
biosensors may be found in "Optical fiber
LPG biosensor integrated microfluidic chip for ultrasensitive glucose
detection", Yin, Biomedical Optics Express, Vol. 7,
No. 5, 2016, which is hereby incorporated by reference in its entirety by
reference.
[00296] In some embodiments, photomultiplier tubes may be used to deliver
light to and from microfluidic systems via
launch-and-detect fiber probes. In some instances, such probes may be used for
DNA analysis, blood cell analysis, particle
counting/sorting, and the like. In some embodiments, moving particles may also
be detected by LED light; however, filters
may be necessaryused in some embodiments to suppress background noise from the
upper side of the LED spectrum. In
some instances, velocities of moving microparticles may be calculated by
measuring the dynamic measurements of their
fluorescence. Additional details regarding such microfluidic devices may be
found in "Lab-on-a-chip optical detection
system using plastic fiber optics", McMullin, Applications of Photonic
Technology 6, Vol. 5620, 2003, which is hereby
incorporated by reference in its entirety by reference.
[00297] In some instances, microfluidic platforms may be driven by capillary,
pressure, electrokinetic, and/or acoustic
forces. Microfluidic platforms may offer several advantages, such as on-demand
generation of liquid micro-cavities, which
may enable precise manipulation of quantities of reagents down to single cells
while maintaining high throughput, achieved
by a favorable aspect of surface-to-volume ratio. In some instances,
microfluidic platforms may be used for
biotransformation (via enzymes, bacteria, eukaryotic cells, and the like),
analytics (of biomolecules, proteins, nucleic acids,
Date Recue/Date Received 2022-12-30
39
and the like), and/or cellular assays (to assess the effects of pharmaceutical
entities). In some embodiments, microfluidic
chips may displace liquid by linear actuation, pressure driven laminar flow,
and the like. In some embodiments, phase
transfer magnetophoresis, involving magnetic microparticles flowing through a
microchannel network, may be used for
DNA purification, PCR, electrophoretic separation, and the like. In some
embodiments, microfluidic devices may comprise
microfluidic channel circuitry with chip-integrated microvalve systems that
may be used to form more complex units such
as micropumps, mixers, and the like. In some instances, such chips may be
fabricated with a layer of planar glass sandwiched
between two layers of PDMS. Such chips may be used in applications such as,
for example, protein crystallization,
immunoassays, automated cell culture, and the like. In some embodiments,
microfluidic devices may employ segmented
flow microfluidics, which may permit the merging/splitting of droplets. In
some instances, electrokinetics may be used in
microfluidic operations to control electric field gradients acting on electric
dipoles to have effects such as, for example,
electroosmosis, electrophoresis, polarization, and the like. In some
instances, electrowetting may be used to generate,
transport, split, merge, and/or process microdroplets by containing droplets
on a hydrophobic surface comprising arrays of
addressable electrodes. In some embodiments, microfluidic devices may comprise
dedicated systems for massively parallel
analysis. Such arrays may comprise microarrays and/or bead-based assays in
combination with picowell plates. Additional
details regarding such microfluidic platforms may be found in "Microfluidic
lab-on-a-chip platforms: requirements,
characteristics and applications", Mark, Chemical Society Reviews, Issue
3,2010, which is hereby incorporated by reference
in its entirety by reference.
[00298] Fig. lib depicts a top plan view of an alternative embodiment of a
macro vascularization hole 1177 that may also
comprise reinforcement region 1178. Macro vascularization hole 1177 may also
comprise mini-tubules which may lie within
the hole and/or exterior to the implant; mini-tubules may be configured to be
at least one of: (a) terminating 1199e and/or
(b) non-terminating 1198e within the hole. Mini-tubule portion 1198i lies
within the implant. Mini-tubule walls may be
configured to be with at least one chosen from the group of: porous or gated
(actively or passively). In some embodiments,
therapeutic agents may be discharged into the adjacent vasculature to achieve
a therapeutic result in the (a) local tissues
adjacent to the implant and/or (b) non-adjacent (distant) tissues. A narcotic
may be an example of a therapeutic agents
capable of non-adjacent (distant) tissue effects if the discharging implant is
located, for example, in the subcutaneous tissues.
Non-terminating 1198e mini-tubules may however have a terminus within the
implant. Non-terminating 1198e mini-tubules
may extend across the hole whereas terminating 1199e mini-tubules may extend
only part-way across the hole 1177. Mini-
tubules may have a diameter ranging from 10microns to 3mm.
[00299] Fig. 12 depicts another alternative embodiment of an implant 1201
comprising non-protruding structural
reinforcement regions 1202, each of which again defines a macro
positioning/instrument engaging hole 1203 and therefore,
as described above, provides structural reinforcement to improve the
structural integrity of each hole 1203. In addition,
implant 1201 differs from implants 1001 and 1101 in that in its uncompressed
configuration it defines a square shape.
[00300] Fig. 13 depicts yet another alternative embodiment of an implant 1301
comprising non-protruding structural
reinforcement regions 1302, each of which again defines a macro
positioning/instrument engaging hole 1303 and therefore,
as described above, provides structural reinforcement to improve the
structural integrity of each hole 1303. In addition,
implant 1301 differs from the previous implants in that in its uncompressed
configuration it defines a rectangular but not
square shape, the elongated nature of which may be preferred for certain
applications.
[00301] Fig. 14 depicts still another alternative embodiment of an implant
1401, which again comprises non-protruding
structural reinforcement regions 1402, each of which again defines a macro
positioning/instrument engaging hole 1403 and
therefore, as described above, provides structural reinforcement to improve
the structural integrity of each hole 1403. In
addition, however, implant 1401 comprises reinforcing fibers 1411f
interspersed throughout the implant 1401. In some
embodiments, including the depicted embodiment, these fibers 1411f
interconnect with the structural reinforcement regions
1402. However, this need not be the case in all contemplated embodiments.
These fibers 1411f may assist in maintaining
Date Recue/Date Received 2022-12-30
40
the overall structural integrity of the implant 1401 during use, as the
implant may be stretched, pulled, etc. as it is being
installed. Thus, although each of FIGS. 14-16 depicts structural fibers being
used in connection with structural reinforcement
regions, it is contemplated that these fibers may be used without accompanying
structural reinforcement regions in other
embodiments.
[00302] Fig. 15 depicts a further alternative embodiment of an implant 1501,
which again comprises non-protruding
structural reinforcement regions 1502, each of which again defines a hole 1503
and therefore, as described above, provides
structural reinforcement to improve the structural integrity of each macro
positioning/instrument engaging hole 1503. In
addition, however, implant 1501 comprises reinforcing fibers or other strands
of a material, including a hollow material in
some embodiments. However, in this embodiment, these fibers are formed into a
fibrous mesh 1511m. In some
embodiments, including the depicted embodiment, the fibers of mesh 1511m
interconnect with the structural reinforcement
regions 1502. However, this need not be the case in all contemplated
embodiments. For example, various other mesh
implants are disclosed herein that may simply comprise a mesh made up of
intersecting strands of material that make up the
implant, rather than serve as structural reinforcement for the implant. Such
intersecting strands may, in some embodiments,
be coated with laminates or other biocompatible materials that may allow
passage of internal substances, such as drugs,
therethrough to modulate their bioavailability.
[00303] Fig. 16 depicts another alternative embodiment of an implant 1601,
which again comprises non-protruding
structural reinforcement regions. In this embodiment, there are both
peripheral structural reinforcement regions 1602p,
which are positioned at each corner, and central structural reinforcement
regions 1602c, which are positioned on both sides
of the implant 1601 along a central region thereof As with the previous
embodiments, each of the structural reinforcement
regions may again define a macro positioning/instrument engaging hole (holes
1603p and 1603c) and therefore, as described
above, may provide structural reinforcement to improve the structural
integrity of each hole. In addition, however, implant
1601 comprises reinforcing fibers. However, in this embodiment, these fibers
are formed into separate sections, namely, a
series of centrally positioned columns 1611c and a series of intersecting
angled lines along both peripheral/lateral sections
adjacent thereto, as indicated at 1611p.
[00304] Figs. 17a-17c depict side views of a flexible tissue implant
facilitating system (FTIFS) 1700 according to other
embodiments. System 1700 may, in some embodiments, use a sheath (not shown in
the figures) to restrain implant 1701
beneath dilator 1708. Fig. 17a depicts protrusions 1712, which may be spheres
in some embodiments (including the depicted
embodiment) attached to the shaft 1714. Shaft 1714 may be of varying lengths
to accommodate varying dimensions of
implants. In some embodiments, it may be preferable to have uniform spacing of
protrusions along a shaft that may match
distances between implant holes in a system, such as macro
positioning/instrument engaging holes 1703. If the holes of an
implant with or without reinforcement are slightly elastic, the use of
spherical protrusions may give a more secure grip
around the inner shaft-fixated portions of the spheres and a more definitive
possibly palpable or audible release as the hole
would act like a sphincter around the sphere. A size differential between the
sphere and the hole may be beneficial as the
surgeon can 'load' the implant onto the shaft's spheres outside the body with
force and when the implant is inside the body
detach by twisting or minimal force against another object introduced into the
entrance wound. When flexible implant
materials are used, it may therefore be useful to form the holes in the
implant of smaller diameter than that of the spherical
protrusions 1712 such that the protrusions 1712 stretch the hole, which snaps
back to secure the implant to the instrument.
Of course, a wide variety of alternative features may be used for securing the
implant to the instrument, such as snaps or
other reclosable fasteners, for example. In other contemplated embodiments,
the holes may be larger than placement device
protrusions such that the loose fitting facilitates/accelerates unhooking the
placement device.
[00305] Fig. 17b shows handle 1715 securing the proximal or base portion of
the implant 1701 with lever latch 1716,
thereby releasably maintaining fixation in Fig. 17c.
[00306] Figs. 18a-18d depict side views of various elements in a flexible
tissue implant facilitating system (FTIFS)
Date Recue/Date Received 2022-12-30
41
according to other embodiments wherein a shaft 1814 of an instrument may be
bent into a handle-like shape which may
reduce costs, parts and medical waste. Shaft 1814 may be bent into a ledge-
like area to restrict proximal movement of
implant 1801. The depicted embodiment shows sheath 1807 to restrain implant
1801 beneath dilator 1807. In other
embodiments, a sheath may be optional. Fig. 18a depicts protrusions 1812,
preferably spheres, coupled with the shaft 1814,
which in turn bends into handle ledge 1816 to restrict implant movement and
handle 1815 to facilitate rotational
implantation. As before, shaft 1814 may be of varying lengths to accommodate
varying dimensions of implants. As
previously mentioned, a size differential between the sphere and the macro
positioning/instrument engaging hole may be
beneficial as the surgeon can 'load' the implant onto the shaft's spheres
outside the body with force and when the implant
is inside the body detach by twisting or applying minimal force against
another object. The instrument may further comprise
a dilator 1808, which may comprise threads 1811, as previously mentioned. In
further contemplated embodiments,
protrusions 1812 may be cylindrical with rounded tips, which may protrude, for
example, between about 4 and about 8 mm
from shaft 1814. Preferably, protrusions 1812 are about 1 mm smaller in
diameter than the corresponding hole(s) 1803
within which they are configured to be received. In some embodiments,
protrusions 1812 may extend from the distal portion
of the shaft at an angle between about 20 and about 90 degrees; such
protrusions 1812 may be of a smaller diameter than
the holes of the implant to facilitate unhooking.
[00307] In the depicted embodiment, an additional instrument may be used, such
as that shown in Fig. 18d with shaft 1824,
which may also be introduced into the entrance wound/incision. Fig. 18d shows
a partner instrument in the system that may
couple implant holes 1803 via protrusions 1822 and/or branch 1824b, which
extends from shaft 1824 at an angle relative to
shaft 1824. Shaft 1824 is attached to handle 1825; this hooking instrument may
be used in concert with that of Fig. 18a or
separately to, for example, unwind an implant forced into the entrance wound
manually as well in some implementations.
Other instruments, such as endoscopy graspers and the like, may also be used
as desired.
[00308] Fig. 19a depicts a bottom plan view of a circular, flexible, and
compressible implant 1901 with the addition of
superstructure 1919 on one or more sides. In some embodiments, superstructure
1919 is circular in overall shape and/or
cross section and may be present only on one side of implant 1901, which may
be directed inward in a patient when
implanted. It is also contemplated, however, that in alternative embodiments,
one or more such superstructures may be
present on both sides of an implant. In further contemplated embodiments,
compressible implant superstructures may be
configured to be positioned in locations including but not limited to:
external, internal, peripheral, non-peripheral, top, and/or
bottom.
[00309] Implant 1901 may be compressible by being rollable and/or foldable.
Implant 1901 is shown in FIG. 19a in its
unrolled or otherwise uncompressed/native state. Implant superstructure 1919
may likewise be compressible. Implant
superstructure 1919 may comprise, in some embodiments, a flexible solid or
semisolid material, such as a hydrogel, plastic,
metal, organic polymer, biopolymer or the like. Other embodiments may comprise
a polymeric external lamination or
containment to retain more dissolvable materials such as hydrogels and the
like. Thus, in some embodiments, superstructure
1919 may be configured to automatically rigidify upon encountering body
fluids. This may allow implant 1901 to be
implanted with the entire structure, including superstructure 1919, in a
compressed configuration and then, upon unrolling,
unfolding, or otherwise decompressing implant 1901, having superstructure 1919
provide rigidity to maintain implant 1901
in its decompressed configuration.
[00310] Drugs, vitamins, or other chemicals, including biologics, may also be
bound, dissolved, or otherwise present in a
portion or all of the structure of implant 1901 and/or superstructure 1919.
Different regions and/or portions of the
superstructure 1919 may also have different medications or chemicals printed
or otherwise incorporated into them, some
perhaps in the shape of a pie-chart if multiple materials are envisioned, for
eventual delivery into a patient. In addition,
electronics, micro-pumps, and/or printed circuit boards may be positioned on
or within implant superstructure 1919 when
properly protected.
Date Recue/Date Received 2022-12-30
42
[00311] Fig. 19b is a side view of the implant 1901 depicting implant
superstructure 1919 extending above the lower/distal
surface of the implant 1901, wherein the superstructure may comprise
electronics including but not limited to: a battery
1951, an inductance coil 1952, a capacitor 1953, a data storage element 1954,
an EMI suppression element 1955, and an
antenna 1956. In some embodiments, a superstructure may be segmented and/or
discontinuous and/or may comprise
electronics on the internal to the wall, external to the wall and/or within
the wall parts of the superstructure.
[00312] Fig. 19c is a bottom perspective view of the implant 1901. Implant
1901 together with implant superstructure 1919
may be deployed in a compressed state, such as a rolled state, and then
unrolled or otherwise decompressed once inserted
through the entrance incision and positioned within the implant pocket, as
will be discussed. Implant superstructure 1919
may be decompressed and/or shrunken on implantation if it is surrounded by a
semipermeable plastic membrane annealed
to implant 1901 and filled with a relatively water lacking hydrogel/xerogel or
the like, for example. After implantation, fluid
osmotically moving into the superstructure 1919 may provide turgor and
rigidity. In some embodiments, micro-pumps,
which may either be part of the implant 1901 or temporarily coupled therewith,
may aid in filling the implant superstructure
1919. In addition, in some embodiments, such pump(s) may be used to drive
fluids out of superstructure 1919 and/or other
portions of implant 1901.
[00313] In some embodiments, semipermeable membranes may be used to allow for
diffusion of water into a medical
implant. In certain instances, such devices may have high water permeability,
and may restrict the diffusion of other
compounds. Such semipermeable membranes may comprise, for example, a
separating functional layer comprising, for
example, polyamide, which is formed from an aromatic polyfunctional amine and
a polyfunctional acid halide. In some
embodiments, the semipermeable membrane may comprise a base material layer and
a porous support membrane layer in
addition to the separating functional layer. Additional details regarding such
semipermeable membranes may be found in
U.S. Patent No. 9,486,745, titled "Semipermeable Membrane and Manufacturing
Method Therefor", which his hereby
incorporated in its entirety by reference.
[00314] In some embodiments, polymeric membranes may also be used as
permselective membranes. In some instances, a
suitable derivative of a tri/tetracarboxylic acid may be reacted with a
diamine to form a polyamic acid, which may be used
to form a film, which may be imidized to form a polyamide-imide film, which
may be treated to open the imide rings. Such
a process may be used to form a permselective membrane. Additional details
regarding such permselective membranes may
be found in U.S. Patent No. 3,835,207, titled "Method for Forming Reverse
Osmosis Membranes Composed of Polyamic
Acid Salts", which is hereby incorporated in its entirety by reference.
[00315] As also shown in Fig. 19c, implant 1901 may comprise one or more tabs
1902, one or more of which may comprise
a macro positioning/instrument engaging hole 1903 for coupling with a suitable
instrument, as previously described.
[00316] Fig. 19d is a side view of the rolled implant 1901 depicting tab 1902
and a portion of implant superstructure 1919.
Implant 1901 when compressed and implant edge, as seen from the side, in Fig.
19d, comprises 2 1/4 turns. Again, the number
of rolls/folds/turns may depend upon the inner diameter (internal space),
implant thickness(es), gaps between implant
sheets/rolls, and surface irregularities/variances, superstructures, etc. In
alternative embodiments, compressible implants
may comprise numbers of rolls/folds/turns ranging as previously described with
reference to Fig. 5.
[00317] Fig. 20a depicts a bottom view of a circular, flexible, and
compressible implant 2001 with a '+' shaped
superstructure 2020 on one side along with a pair of opposing macro
positioning/instrument engaging hole s 2003. These
elements may be similar to those described previously in connection with other
embodiments.
[00318] Fig. 20b depicts a bottom view of a rectangular, flexible, and
compressible implant 2011 also with a '+' shaped
superstructure 2022, on one side and holes in each corner.
[00319] Fig. 20c depicts a bottom view of a rectangular, flexible, and
compressible implant 2021 also with a rectangular
shaped superstructure 2033 on one side and instrument holes in each corner. In
addition to the circular and rectangular-
shaped superstructures, it is contemplated that other embodiments may comprise
other polygonal shapes, as desired.
Date Recue/Date Received 2022-12-30
43
[00320] Fig. 21 depicts a top view of an alternative compressible implant 2101
according to other embodiments. Implant
2101 again comprises an oval, flexible, and compressible implant that may be
rollable for subcutaneous placement. In some
embodiments, the implant 2101 may be foldable. Implant 2101 may be made up of
similar materials as any of the other
implants disclosed herein, and as previously mentioned. Implant 2101 lacks
protruding tabs that may catch on tissue near
the entrance wound or occupy valuable diametric dimensions reducing the ease
of which the implant may pass a minimally
invasive entrance incision. However, as previously mentioned, macro
positioning/instrument engaging hole s 2103 with
surrounding optional reinforced zones 2102 may be provided, which may be
configured to receive and/or engage an
instrument, or a portion of an instrument, to facilitate placement of the
implant 2101 into a minimally invasive and/or
relatively (relative to the implant) small entrance incision.
[00321] Implant 2101 may also serve as a substrate for an inductance coil
2111, which may serve as an antenna or wireless
energy charger for other elements in or about the implant. This may be useful
for a variety of purposes to take in energy for
various purposes. For example, coil 2111 may be used to generate wireless
power for LEDs, batteries, and the like, or to
generate an electric field to drive a drug delivery element or system, such as
to open a gate for delivery of such a drug. Coil
2111 may also be used as an antenna to facilitate wireless communication with
an electrical component of an implant. For
example, signals may be received and/or sent from sensors and/or a CPU to
provide instructions to and/or receive data from
an internal sensor or another element of an implant.
[00322] Fig. 22 depicts a top view of an alternative compressible implant 2201
that may be similar to the implant shown in
Fig. 21, aside from the shape of the implant 2201 and that of its
corresponding inductance coil 2211, both of which are
rectangular-shaped. Macro positioning/instrument engaging holes 2203 with
surrounding optional reinforced zones 2202
may be configured to receive and/or engage an instrument, or a portion of an
instrument, to facilitate placement of the
implant 2201 into a minimally invasive and/or relatively (relative to the
implant) small entrance incision. Implant 2201 may
also serve as a substrate for the aforementioned inductance coil 2211,
although a variety of shapes of coil other than the
depicted shape may be used.
[00323] In some embodiments, RF energy transmission systems may be used to
transmit energy and/or data. Such devices
may comprise, for example, circular radiating patches and circular ground
planes printed on a circular substrate. In some
embodiments, two slots, such as circular slots, may be cut away from the patch
to allow for two different operating
frequencies. In order to improve biocompatibility, the receiving antenna may
be covered by a substrate. In a preferred
embodiment, power in the receiving circuit may flow through a voltage doubler
in order to be converted into DC. In some
embodiments, diodes, such as Skyworks 7630 or HSMS 2850, may be used for power
rectifying. In some embodiments, the
rectifying circuit may fit in a surface of the same, or at least substantially
the same, size as the antenna. Also, in certain
instances, another circuit layer may be added to the back side of the antenna.
In some embodiments, the antenna's ground
plane and the circuit's ground plane may be electrically connected. Additional
details regarding such transmission systems
may be found in "Miniaturized Implantable Power Transmission System for
Biomedical Wireless Applications", Ding,
Wireless Power Transfer, Oxford University Press, 2020, pp.1-9, which is
hereby incorporated herein in its entirety by
reference.
[00324] In some embodiments, an array of micro-coils may be used in an
inductive link receiver. In some such
embodiments, such receiving arrays may be less sensitive to lateral and/or
angular misalignment effects. In certain
embodiments, both sides of an inductance link may be tuned to a same resonant
frequency to increase power transfer
efficiency. Additional details regarding such micro-coils may be found in
"Multicoils-based Inductive Links Dedicated to
Power up Implantable Medical Devices: Modeling, Design, and Experimental
Results", Sawan, Springer Science, Biomed
Microdevices, 2009, 11:1059-1070, which is hereby incorporated herein in its
entirety by reference.
[00325] In some embodiments, a plurality of implanted coils may be used to
receive energy transcutaneously,
simultaneously, or at least substantially simultaneously, from a plurality of
external coils. In certain embodiments, such coil
Date Recue/Date Received 2022-12-30
44
systems may comprise feedback systems comprising RF receivers. In some
instances, the amount of power required to power
an implanted circuit may be divided into a number of portions such that each
coil may provide a certain fraction of the
required power. In some embodiments, a second circuit may also be provided,
which may comprise a control system and/or
voltage control circuit for maintaining a sufficient amount of power to the
second circuit. In some embodiments, first and
second coils may form a plurality of coil pairs. In some instances, each
receiving coil may be implanted beneath different
segments of tissue at different locations around the body as desired.
Additional details regarding power transmission systems
that may be useful in connection with various embodiments disclosed herein may
be found in U.S. Patent No. 6,058,330,
titled "Transcutaneous Energy Transfer Device", which is hereby incorporated
herein in its entirety by reference.
[00326] Some embodiments and implementations may incorporate various elements
as part of a system for transcutaneous
power transfer and/or communication via induction. The implant in such
embodiments may include one or more transmitting
coils, one or more of which may be located outside of the body, such as in a
charging/external device, and a receiving
component, which may be located subcutaneously, preferably on the implant. In
some embodiments, the transmitting and/or
receiving components of the system may comprise elements and/or features
configured to allow for variations in effective
coil area of the inductance coils. Examples of such elements/features can be
found in U.S. Patent No. 10,080,893 titled
"Varying the Effective Coil Area for an Inductive Transcutaneous Power Link",
which is hereby incorporated in its entirety
by reference.
[00327] Some embodiments may comprise a flux receiver and/or a flux
concentrator. Flux receivers are typically used in
conjunction with a receiving inductance coil. The receiving coil may, as
previously mentioned, be used for communication
and/or for power transfer. The implanted medical device may employ a receiving
coil disposed around a flux concentrator
located within the device. The flux concentrator may be used to concentrate
the near-field-energy through the receiving coil,
which may convert the near-field-energy into electrical energy. Examples of
suitable flux receivers and concentrators that
may be useful in connection with various embodiments disclosed herein can be
found in U.S. Patent No. 10,918,875 titled
"Implantable Medical Device with a Flux Concentrator and a Receiving Coil
Disposed about the Flux Concentrator", which
is hereby incorporated in its entirety by reference.
[00328] Some embodiments may comprise other features, such as varied
geometries for one or more of the inductance
coils. Some such embodiments may include coils wherein the coil is larger at a
first location than at a second. Other
embodiments may comprise a coil wherein the first and second locations are on
the same turn of the coil. Still other
embodiments may comprise a coil wherein the first location is on the first
turn and the second location is on the final turn.
Such inductance coil pairs may be used for transcutaneous power delivery or
communication with implanted medical
devices. Additional details and examples of such features can be found in U.S.
Patent Application Publication No.
2020/0395168 titled "Inductance Coil with Varied Geometry", which is hereby
incorporated in its entirety by reference.
[00329] In some instances, voltage and current may be induced in a deenergized
wire, which may run parallel to an
energized wire. Such induced voltage and current may be caused by electric-
field and magnetic-field induction. Additional
details regarding induction in parallel wires may be found in "Induced Voltage
and Current in Parallel Transmission Lines:
Causes and Concerns", Horton, 2008, IEEE Transactions on Power Delivery,
23(4): 2339-2346, which is hereby
incorporated herein in its entirety by reference.
[00330] Fig. 23 depicts a top view of an alternative compressible elongated
rectangular shaped implant 2301. Macro
positioning/instrument engaging hole s 2303 with surrounding optional
reinforced zones 2302, may be configured to receive
and/or engage an instrument, or a portion of an instrument, to facilitate
placement of the implant 2301 into a minimally
invasive and/or relatively (relative to the implant) small entrance incision.
Implant 2301 may also serve as a substrate for a
plurality of inductance coils 2311, which may be electrically coupled via
conductive wiring 2312. Each of these coils 2311
is shown as being formed into the same rectangular shape, but any number of
shapes may be used, which may be consistent
throughout the implant 2301 or may differ therewithin. Inductance coils linked
in series as shown in the figure may minimize
Date Recue/Date Received 2022-12-30
45
the deleterious effects of transferring energy transcutaneously from an
external energy source, possibly improving energy
transfer efficiency. Inductance coils 2311 may terminate in wiring 2314 and/or
an electrical port, which may be linked to
other electrical components 2315, such as a CPU. In some embodiments,
inductance coils, such as but not limited to
inductance coils 2311, may be used to power various elements on the implant,
such as LEDs, pumps, electrical field
generators, antennae, sensors, etc.
[00331] Some embodiments may comprise a voltage sensor 2305, which may be
helpful during charging once the implant
2301 is within a patient and therefore the various inductance coils 2311 in
the implant may not be visible to the practitioner.
By providing a voltage sensor 2305, a user may be able to move a transmitting
coil of an inductive charger (either one large
coil or an array of smaller coils similar to the receiving coils on the
implant 2301) about the region of the patient under
which the implant 2301 lies and view the voltage changes and thereby maximize
the charging voltage. In embodiments
having separate internal and external arrays of matching sizes, it may be
beneficial to correctly align the transmitting and
receiving coils. However, if the transmitting array is much larger than the
receiving array, then precisely aligning the arrays
may not be necessary as the inner portion of the transmitting array may
exhibit homogenous magnetic field-like
characteristics, therefore resulting in similar change in magnetic field
across the receiving array. In either case, having a
voltage sensor, which may be linked with a notifier, such as an audible alarm
or a dial/scale that is externally viewable, the
user may be able to maximize the efficiency of recharging a battery, which may
be part of the implant 2301.
[00332] In some embodiments, a plurality of transmitting coils may be
overlapped or stacked in order to overcome
inefficiencies due to misalignment of the transmitting and receiving wireless
charging inductance coils. Such designs may
generate a homogenous magnetic field across the entire transmitting array,
allowing more freedom of placement for the
receiving coil(s) while retaining high efficiency. Further details regarding
these features may be found in 'Geometrical
Design of a Scalable Overlapping Planar Spiral Coil Array to Generate a
Homogenous Magnetic Field', Jow, IEEE Trans
Magn, 2012; 49: 2933-2945, which is hereby incorporated in its entirety by
reference.
[00333] Secondary inductance coils, which may comprise inductance coils that
are, in some cases, stacked and/or layered
on top of one another on the implant rather than positioned in an array as
shown in FIG. 23, may also be used in some
embodiments. Such secondary inductance coils may, in addition to the primary
coil(s), in some embodiments be enclosed
within a housing of the implanted device in order to enhance power transfer to
greater depths. Such enhanced power transfer
may be achieved, for example, by multiple coils that are longitudinally
aligned and/or physically and electrically parallel,
thereby forming a secondary loop for a power delivery system rather than
having only a single loop. Such systems with two
or more receiving inductance coils can double the amount of turns collecting
magnetic flux. Additional details regarding
such secondary inductance coils may be found in U.S. Patent No. 7,191,007
titled "Spatially Decoupled Twin Secondary
Coils for Optimizing Transcutaneous Energy Transfer (TET) Power Transfer
Characteristics", which is hereby incorporated
in its entirety by reference.
[00334] Fig. 24a depicts a top view of an alternative compressible implant
2401 according to other embodiments. Implant
2401 again comprises a circular, flexible, mesh and compressible implant that
may be foldable for subcutaneous placement.
In some embodiments, the compressible mesh implant 2401 may be rollable and
therefore may be rolled into the
configuration shown in FIG. 24d. Implant 2401 is compressible by being
rollable and/or foldable. Implant 2401, whose
edge is depicted in the side view of Fig. 24d, when compressed, comprises 5
turns. Again, the number of rolls/folds/turns
may depend upon the inner diameter (internal space), implant thickness(es),
gaps between implant sheets/rolls,
superstructures, and/or surface irregularities/variances, etc. In alternative
embodiments, compressible implants may
comprise numbers of rolls/folds/turns ranging as previously described with
reference to Fig. 5. Fig. 24a depicts implant
2401 in its unrolled or otherwise uncompressed/native state. Unlike the
previous similar implants mentioned above, implant
2401 may be made up of a mesh lattice, which may comprise, for example, a
bioresorbable or non-bioresorbable polymer.
This may be more useful for delivery of drugs not requiring moisture, and may
also substantially increase the available
Date Recue/Date Received 2022-12-30
46
surface area of the implant. Such mesh implants may also be manufactured using
an additive manufacturing process. The
use of mesh implants that are sizeable may be beneficial to the overlying
tissues, for example the skin of the abdomen in a
10-20cm diameter mesh implant, because, if the mesh is sufficiently wide to
allow vascular ingrowth and communication
with the more superficial tissues through the implant, the superficial tissues
of the abdomen may experience better growth
conditions and blood supply rather than only being granted blood supply from
the relatively distant periphery of the implant.
If the mesh size is under lmm, it may be difficult for blood vessel ingrowth
to traverse from one side of the mesh to the
other. Therefore, one or more macro vascularization hole(s) 2477 exceeding lmm
(preferably at least several mm) in
diameter may be made even in a mesh to allow vascular ingrowth and/or vascular
crossing of the implant to benefit tissues
on the opposite side of the implant. The area around hole(s) 2477 may comprise
a ring or other shape of reinforcement 2478
in order to maintain the integrity of the implant. Areas of reinforcement for
implanted Kevlar mesh around a hole may be
beneficial to prevent ballistic penetration if hole placement were to weaken a
particular area. In contemplated embodiments,
peripheral placement of holes may not benefit the tissues as much as centrally
placed holes, as the tissues overlying the
center are farther from the periphery, thus implants may comprise central
holes. In other contemplated embodiments, such
holes for vascularization and biological cross communication may be present
throughout the implant in desired areas. In
contemplated embodiments of spiral coil implants, the spacing between spiral
arms may be altered in order to allow vascular
ingrowth into and across those areas.
[00335] Implantable mesh 2401 may contain drugs such as gentamicin or
methotrexate, suspended in hydrogels such as
PLA (polylactic acid). Also, the drugs niclosamide or IP6 (inositol phosphate)
may be mixed in PCL (polycaprolactone)
and/or graphene nanoplatelets in some embodiments. Biologic scaffolds may also
be used, which may include drugs such
as rhBMP-2 (recombinant bone morphogenetic protein-2) incorporated into PCL,
PLGA (poly lactic co-glycolic acid), or
Beta-TCP (tricalcium phosphate). Another example of a suitable biologic
scaffold is dexamethasone, which may be
embedded in Sr-MBG (strontium mesoporous bioactive glass). Bioceramics for
bone generation and infections may also be
used in some embodiments, and which may include VNC (vancomycin), rhBMP-2,
and/or heparin, and may be embedded
in materials such as brushite, unreacted alpha or beta-TCP, chitosan, and/or
HPMC. VNC and ceftazidime may also be
mixed into PLA cages and PLGA nanofibers. Other drugs and materials for
implantable patches, stents, meshes, scaffolds,
and/or bioceramics may be found in '3D Printed Drug Delivery and Testing
Systems a Passing Fad or the Future?', Lim,
Advanced Drug Delivery Reviews 132 (2018) p.139-168, 2018, which is hereby
incorporated in its entirety by reference. In
some embodiments, therapeutic agents may be discharged into the adjacent
vasculature to achieve a therapeutic result in the
(a) local tissues adjacent to the implant and/or (b) non-adjacent (distant)
tissues. A narcotic may be an example of a
therapeutic agents capable of non-adjacent (distant) tissue effects if the
discharging implant is located, for example, in the
subcutaneous tissues.
[00336] Drugs released by drug eluting stents may also be used in some
embodiments. Such drugs may include, for
example, immunosuppressants such as Sirolimus and Tacrolimus. Such drugs may
aid in counteracting neointimal
hyperplasia. Sirolimus-eluting-stents may aid in reducing incidents of
restenosis. Additional details regarding such drugs,
which again may be taken from the context of stents to the implants disclosed
herein, may be found in 'Molecular Basis of
Different Outcomes for Drug-Eluting Stents that Release Sirolimus or
Tacrolimus', Curr. Opin. Drug Discov. Devel.,
Giordano, 2010; 13: 159-68, which is hereby incorporated in its entirety by
reference.
[00337] The technology behind drug eluting stents may, in some embodiments, be
repurposed for use in connection with
one or more of the implants disclosed herein. For example, in some
embodiments, a mesh may be formed having materials
and/or structures similar to a stent. Such meshes may therefore comprise, for
example, various alloys/metals, such as cobalt
chromium or platinum chromium, which may allow thinner struts while retaining
high radial strength, radiopacity,
biocompatibility, and/or corrosion resistance. Lipophilic drugs, such as
paclitaxel may be linked to the mesh without the use
of a polymer in some embodiments. Further drugs that may be eluted from the
mesh may include, for example, everolimus,
Date Recue/Date Received 2022-12-30
47
zotarolimus, umirolimus, novolimus, amphilimus, and/or sirolimus. Polymers
used to bind drugs to stent-like meshes in an
implant may include, for example, vinylidene-fluoridehexafluoropropylene
copolymers and/or C 10-C19-
polyvinylpyrrolidone polymers. Biodegradable polymer coatings may also be
used, and which may comprise lactic and/or
glycolic acids. Such copolymers may include, for example, polylactic (PLLA,
PDLLA), polyglycolic (PGA), and/or
polylactic-co-glycolic (PLGA) copolymers. The aforementioned mesh materials
may, in some embodiments, be made to
have smooth, macroporous, microporous, and/or nanoporous surfaces. Such mesh
materials may also be filled with drugs,
resulting in release through laser-drilled holes. Such materials may also be
coated with biological agents such as CD34 to
enhance vessel healing in certain applications. Composites such as titanium
nitride oxide may also, or alternatively, be used
to accelerate endothelialization. Further information regarding the
aforementioned stent-like mesh materials may be found
in 'The Newest Generation of Drug-Eluting Stents and Beyond', Lee, European
Cardiology Review, 2018; 13: 54-9, which
is hereby incorporated in its entirety by reference.
[00338] Implantable devices, such as stents, may, in some embodiments,
comprise cells that produce and release therapeutic
agents. Such cells may be naked cells, encapsulated cells, or some mixture
thereof Such stents may comprise, for example,
subcutaneous ports, catheters, and reservoirs. In some instances, the implant
may be engineered using stent technology, such
as providing a framework for a stent in a mesh or other form more suitable for
the implants disclosed herein. Some such
embodiments may therefore be configured such that therapeutic agents are
released in response to changing physiological
conditions. In some embodiments, the reservoir may contain, for example, cells
or other therapeutic agents, and may
comprise, for example, a porous polymer, such as alginate. Further embodiments
may comprise reservoirs that may function
as immune-barriers, shielding therapeutic cells from the body's immune system
while allowing exchange of nutrients.
Additional details regarding stent materials and related therapeutic systems
that may be useful in connection with the
implants disclosed herein may be found in U.S. Patent No. 9,788,978, titled
"Implantable Systems and Stents Containing
Cells for Therapeutic Uses", which is hereby incorporated in its entirety by
reference.
[00339] In some embodiments, stent-like meshes may be configured to release
therapeutic cargo. In certain embodiments,
such implants may therefore comprise at least one first hydrophilic polymeric
material incorporating particles comprising
an outer layer of a second hydrophilic material, an inner layer comprising a
first hydrophobic material, and a core comprising
a hydrophobic therapeutic agent. In some such embodiments, the first and
second hydrophilic materials may be the same.
In some instances, the hydrophilic material may comprise polymers such as, for
example, polyvinyl alcohol (PVA), and/or
poly(L-lactide). In some other embodiments, the device may comprise at least
one first polymeric hydrophobic material
incorporating particles comprising an outer layer of a second hydrophobic
material, an inner layer comprising a first
hydrophilic material, and a core comprising a hydrophilic therapeutic agent.
In some embodiments, the first and second
hydrophobic materials may be the same. In some instances, the hydrophobic
polymeric material may comprise, for example,
copolymers of styrene and isobutylene, polyanhydrides, and/or the like.
Additional details regarding drug eluting stents,
which, again, may be used to create various drug-eluting implants suitable for
placement in the implant pockets disclosed
herein, may be found in U.S. Patent No. 8,119,153, titled "Stents with Drug
Eluting Coatings", which is hereby incorporated
in its entirety by reference.
[00340] In some embodiments, implanted mesh devices may comprise multiple
layers, some of which may be sensitive to
stimuli such as, for example, pH. In an embodiment, such a device may
comprise: a primary coextensive structural layer
that may be non-degradable; at least one interior coextensive pH sensitive
layer; at least one exterior coextensive pH
sensitive layer. In some instances, pH triggers may cause changes, such as,
for example, water solubility and/or degradation,
in properties of the pH sensitive layers. Additional details regarding such
mesh devices may be found in U.S. Patent
Application Publication No. 2019/0343991, titled "Multi-Layered Device", which
is hereby incorporated in its entirety by
reference.
[00341] In some embodiments, implanted meshes may comprise tubular members
having a plurality of openings. In some
Date Recue/Date Received 2022-12-30
48
instances, such devices may also comprise at least on elongated polymer strand
used for delivery of therapeutic agents.
Additional details regarding such mesh devices may be found in U.S. Patent
Application Publication No. 2004/0236415,
titled "Medical Devices Having Drug Releasing Polymer Reservoirs", which is
hereby incorporated in its entirety by
reference.
[00342] In some embodiments, implanted mesh devices may comprise demineralized
bone fibers mechanically entangled
into a biodegradable or permanent mesh. The mesh may further comprise
materials such as, for example, PLGA,
degradable/non-degradable polymers, PTFE, and the like. Additional details
regarding these additional mesh devices may
be found in U.S. Patent No. 10,813,763, titled "Implantable Mesh", which is
hereby incorporated in its entirety by reference.
[00343] In some embodiments, implantable meshes may be coated with
biodegradable agents. In some embodiments, such
agents may facilitate implanting of the mesh. In some instances, biodegradable
polymer coatings may comprise, for example,
temporary stiffening agents, biologically active agents, and/or drugs.
Additional details regarding such mesh implants may
be found in U.S. Patent No. 10,765,500, titled "Temporarily Stiffened Mesh
Prostheses", which is hereby incorporated in
its entirety by reference.
[00344] In some embodiments, implanted meshes may comprise coatings that may
contain bioactive materials which may
be eluted. In certain instances, sol-gel technology may be used to apply said
coatings. Such bioactive coatings may comprise,
for example, anti-inflammatory agents, anti-depressive agents, growth factor,
and the like. In some instances, various
bioactive agents may be combined, and/or the bioactive portions may comprise
two or more layers, each with adjustable
bioactive materials. Additional details regarding such coatings and mesh
implants may be found in U.S. Patent No.
10,285,968, titled "Drug Eluting Expandable Devices", which is hereby
incorporated in its entirety by reference.
[00345] In some embodiments, implanted mesh devices may comprise bioabsorbable
polymers. Such bioabsorbable
polymers may comprise, for example, polyhydroxyalkanoate, poly-L-lactic acid,
polyanhydride, and the like. Additional
details regarding such polymers may be found in U.S. Patent No. 9,980,800,
titled "Bioabsorbable Mesh for Surgical
Implants", which is hereby incorporated in its entirety by reference.
[00346] In some embodiments, implanted devices may be coated with rotational
spun materials that may be used to deliver
therapeutic agents. In some instances, drugs such as, for example, rapamycin,
paclitaxel, heparin, and the like may be
delivered in this manner. In certain embodiments, the rotational spun coating
may comprise, for example, PTFE, Kevlar,
polyethylene, chitosan, chitin, and the like. In certain instances, the
released therapeutic agent may be associated with the
rotational spun coating by methods of bonding such as, for example, covalent
and/or ionic bonding. Additional details
regarding such materials and coating methods may be found in U.S. Patent No.
9,198,999, titled "Drug-Eluting Rotational
Spun Coating and Methods of Use", which is hereby incorporated in its entirety
by reference.
[00347] In some embodiments, implanted meshes may be used in conjunction with
stimulation devices. Such stimulation
devices may comprise, for example, electrical neurostimulators. In some
embodiments, such meshes may comprise
incorporated electrically conductive elements. Such electrically conductive
elements may be used to electrically conduct the
modulated waveform emanating from the neurostimulator. Additional details
regarding such neurostimulation devices may
be found in U.S. Patent No. 8,751,003, titled "Conductive Mesh for
Neurostimulation", which is hereby incorporated in its
entirety by reference.
[00348] In some embodiments, polymeric porous films may be used to elute
bioactive agents. In some instances, factors
such as, for example, the polymer's composition, concentration, initial
molecular weight, surfactant, homogenization rate,
and the like may be used to alter the release profile of therapeutic cargo. In
certain embodiments, the porous film may
comprise polymers such as, for example, PDLGA. Additional information
regarding porous films may be found in U.S.
Patent No. 8,697,117, titled "Drug-Eluting Films", which is hereby
incorporated in its entirety by reference.
[00349] In some embodiments, meshes may be coated in biodegradable polymers
and formed into pouches for implantable
devices, such as, for example, cardiac rhythm management devices. Such mesh
pouches may be used to inhibit bacterial
Date Recue/Date Received 2022-12-30
49
growth, provide pain relief, inhibit scarring/fibrosis, permit tissue
ingrowth, and the like. In some instances, the
biodegradable polymer coating may comprise polymers such as, for example,
polylactic acid, polyglycolic acid,
polyethylene oxide, and the like. Additional details regarding such mesh
pouches may be found in U.S. Patent No. 8,591,531,
titled "Mesh Pouches for Implantable Medical Devices", which is hereby
incorporated in its entirety by reference.
[00350] In some embodiments, flexible mesh implants may be adapted for
repairing a tissue or a muscle wall defect. In
such mesh implants, mesh 'arms' extending outwards from a primary region may
be folded/bent over and fixed (via, for
example, glue or welding) to the primary region. In certain embodiments, the
preformed mesh may have a flat, two-
dimensional shape, which may be manipulated into a configuration comprising a
three-dimensional shape via
folding/bending. Additional details regarding such mesh implant may be found
in U.S. Patent No. 10,357,350, titled
"Surgical Implant", which is hereby incorporated in its entirety by reference.
[00351] In some embodiments, implanted mesh devices may be used to repair the
pelvic floor. Such meshes may comprise
implanted supportive slings adapted to anchor into patient tissue. In some
instances, applications may include, for example,
hernia, vaginal prolapse, and the like. Additional details regarding such mesh
implants may be found in U.S. Patent No.
10,251,738, titled "Pelvic Floor Repair System", which is hereby incorporated
in its entirety by reference.
[00352] In some embodiments, implanted devices may comprise three-dimensional
reticulated mesh structures. In some
instances, the layer-built components of said structures may comprise, for
example, Ti-6A1-4V or Co-26Cr-6Mo-0.2C
powders. In certain embodiments, the three-dimensional structure may comprise,
for example, a porous coating, a sintered
mesh array, and the like. In some instances, the structure may be configured
to release therapeutic agents, such as, for
example, cellular growth factors. Additional details regarding such structures
may be found in U.S. Patent No. 8,828,311,
titled "Reticulated Mesh Arrays and Dissimilar Array Monoliths by Additive
Layered Manufacturing Using Electron and
Laser Beam Melting", which is hereby incorporated in its entirety by
reference.
[00353] In some embodiments, implants may comprise fenestrated hollow shells
with biologic cores. In some instances,
designs may improve interface with surrounding tissue, aiding in processes
such as, for example, fixation to the surrounding
tissue. In certain embodiments, such devices may be used for functions such
as, for example, gene therapy, tissue
engineering, and growth factors. Additional details regarding such shells and
related processes may be found in U.S. Patent
Application Publication No. 2020/0015973, titled "Tissue Integration Design
for Seamless Implant Fixation", which is
hereby incorporated in its entirety by reference.
[00354] Implant 2401 lacks protruding tabs that may catch on tissue near the
entrance wound or occupy valuable diametric
dimensions reducing the ease of which the implant may pass a minimally
invasive entrance incision. However, implant 2401
may comprise internal and/or non-protruding tabs 2402, which may otherwise be
referred to herein as hole-defining and/or
structural reinforcement regions. One or more of internal tabs 2402 may define
one or more macro positioning/instrument
engaging holes 2403. Fig. 241) depicts a side view of unrolled or uncompressed
implant 2401 with edge 2404. Fig. 24c is a
top perspective view of implant 2401 also depicting hole 2403. Mesh implants
may be 3D printed and subject to lamination
such as previously discussed for other implants. Fig. 24d depicts a side view
of a rolled or revealing the edge of compressed
mesh implant 2401 that comprises 5 turns.
[00355] It is possible that implants may draw unwanted scarring or immune-
responses from the recipient. In contemplated
embodiments, meshes, implant envelopes, and the like may be impregnated with
fibrosis and/or other immune inhibiting
drugs may be used to treat scarification/keloids including steroids. For
example, triamcinolone acetonide (TAC), 5-
fluorouracil (5-FU), bleomycin (BLM), and verapamil (VER) may be used in some
such embodiments and implementations.
Some such drugs may have anti-inflammatory and antimitotic mechanisms thus
inhibiting growth of fibroblasts and reducing
endothelial budding and synthesis of procollagen and glycosaminoglycan. Such
medications may be bound, sometimes
releasably, to enveloping elements or to attached biodegradable elements such
as polylactic acid, poliglecaprone and the
like for slow release.
Date Recue/Date Received 2022-12-30
50
[00356] Fig. 25 depicts a top view of an alternative compressible implant 2501
according to other embodiments. Implant
2501 again comprises a circular, flexible, mesh and compressible implant that
may be foldable for subcutaneous placement.
Implant 2501 may be made up of similar materials as any of the other implants
disclosed herein, as previously mentioned.
However, in light of 3D printing of various medicines and other deposition
methods, implant 2501 may be partitioned via
sectors 2525 into various zones containing various concentrations of various
medicines and chemicals as may be needed.
Macro positioning/instrument engaging holes 2503 optionally surrounded by
reinforcement zones 2502 may be beneficial
for placement.
[00357] Holes 2503 may be also optionally surrounded by a detectable marker
2515, which may be beneficial for
determining placement or affixing the implant until the body's natural tissue
response restrains the implant. The marker may
comprise a denser material buried within (dashed lines shown here) the areas
around the hole(s) 2503. In some embodiments,
marker 2515 may comprise a metal to allow for detection by way of, for
example, an x-ray. Other dense materials useful as
a marker may be biodegradable or bioabsorbable, such as calcium bound in a
polymer and the like. Other dense materials
for use in markers 2515 may comprise nonbioabsorbables, such as certain
polymers and the like. Other contemplated
embodiments may merely rely on a difference in density, including an interface
between densities, to allow detection.
Knowing the location of a hole without direct visualization, a surgeon may
then affix the implant into proper position via a
transcutaneous suture that may later be removed once fixation is deemed
satisfactory. Having holes and/or markers located
at certain known zones on an implant may facilitate proper subsurface
orientation and/or unfolding. In some embodiments,
the marker(s) 2515 may comprise a peripheral target for use in detecting the
implant and/or marker and/or for use in
identifying a suitable location for a point of attachment, such as a suture.
In some embodiments, sectors 2525 may be defined
simply by virtue of the application of distinct drugs or other substances on
them. Alternatively, however, it is contemplated
that some embodiments may comprise sectors defined by physical barriers, which
may, for example, prevent drugs from
mixing with one another. Compressible implant 2501 may be divided into
plurality of compartments which may be
configured to hold a respective medication(s). In some contemplated
embodiments, the components of the partitioned area
may be configured individually to modulate the release of contained
therapeutic agents.
[00358] Fig. 26 depicts a top view of an alternative compressible implant 2601
according to other embodiments. Implant
2601 comprises a rectangular, flexible, mesh and compressible implant that may
be foldable/rollable for subcutaneous
placement. Implant 2601 may comprise macro positioning/instrument engaging
holes 2603 optionally surrounded by
reinforcement zones 2602 may be beneficial for placement, each of which is
placed in a respective corner region of the
implant 2601.
[00359] Fig. 27 depicts a top view of an alternative compressible implant 2701
according to other embodiments. Implant
2701 comprises a polygonal, flexible, mesh and compressible implant that may
be foldable/rollable for subcutaneous
placement. Implant 2701 may comprise macro positioning/instrument engaging
holes 2703 optionally surrounded by
reinforcement zones 2702 may be beneficial for placement. Reinforcement zones
2702 and their corresponding holes 2703
are shown at just two of the corners of the polygonal implant 2701, but may be
present at each of the corners, or elsewhere
(such as between the corners) in alternative embodiments.
[00360] Fig. 28 depicts a top view of an alternative compressible implant 2801
according to other embodiments. Implant
2801 comprises a rectangular, elongated, flexible, mesh and compressible
implant that may be foldable for subcutaneous
placement. Implant 2801 may comprise macro positioning/instrument engaging
holes 2803 optionally surrounded by
reinforcement zones 2802 may be beneficial for placement. A single
reinforcement zone 2802 and corresponding hole 2803
is shown at each opposing end of the elongated dimension of the implant 2801.
[00361] Fig. 29 depicts a top view of another implant 2901 that is similar to
implant 2201 except it is made from a mesh
material and comprises openings (as in macro positioning/instrument engaging
holes) 2903 formed within the mesh without
providing reinforcement regions. It is contemplated that these regions may not
be needed for some embodiments, depending
Date Recue/Date Received 2022-12-30
51
upon the material used for the implant. In addition, a large inductive coil
2929 is positioned within the implant 2901.
[00362] In some embodiments, one or more of the implants may comprise a
biocompatible coating, such as, for example,
PTFE. In some instances, PTFE coatings may be used to facilitate removal of
the implant as a pseudo-lubricant. Additional
details regarding PTFE coatings may be found in "Biocompatibility and
Durability of Teflon-Coated Platinum-Iridium
Wires Implanted in the Vitreous Cavity", Nishida, 2011, J. Artif. Organs,
PubMed, which is hereby incorporated herein in
its entirety by reference.
[00363] In some instances, Fibrin may be used as a sealant/adhesive in some
implants. Additional details regarding Fibrin
and its possible uses in various implants may be found in "Randomized Trial of
a Dry-Powder, Fibrin Sealant in Vascular
Procedures", Gupta, doi.org/10.1016/j.jvs.2015.05.038, PubMed, which is hereby
incorporated herein in its entirety by
reference.
[00364] In some embodiments, glues and/or adhesives may be used such as, for
example, hemostats, sealants, and the like,
which may be used with various implants for various purposes, including for
rigidifying a superstructure, for example. In a
preferred embodiment, an adhesive may have strong wet adhesion, high
stability, rapid curing/crosslinking, low toxicity,
and/or biodegradability. In some instances, fibrin glues may be used, which
may contain antifibrinolytic agents, such as
epsilon amino caproic acid. In certain embodiments, crosslinks may be formed
between the adhesive glycoproteins with
collagen and/or other proteins. Fibrin composition may be modulated to control
degradation time. In some embodiments,
gelatin-resorcinol-formaldehyde/glutaraldehyde (GRFG) may be used as glue. In
basic conditions, the resorcin-
formaldehyde may form a cross-linked polymer. Clinical use in human patients
may be limited by carcinogenic properties
of aldehydes, however, veterinary/animal use may be possible due to shorter
lifespans, making for less carcinogenic
expression. In some embodiments, gelatin-resorcin-based adhesives may be
crosslinked with water-soluble carbodiimide or
genipin instead of formaldehyde glutaraldehyde. In some instances, proteinoids
(such as RGDKANE) may be used to
improve cross-linking and/or bonding strength. In certain select embodiments,
cyanoacrylate glue may be used for adhesive
purposes. In some instances, the alkyl sidechains may be replaced with alkoxy
chains to improve the elasticity of the glue.
Clinical use in human patients may be limited by toxic properties of
cyanoacrylates, however, veterinary/animal use may be
possible. In some embodiments, adhesives may comprise, for example,
polysaccharide, polypeptides, and/or polymeric
adhesives. Groups such as, for example, amine, hydroxyl, and carboxylic acid
may adhere to amine groups on tissues via
covalent interaction. In a preferred embodiment, an adhesive may comprise a
gelatin due to its biodegradability and
biocompatibility. In some instances, hydrogels may be used as adhesives by,
for example, cross-linking aldehyde
functionalized alginate with amine-functionalized gelatin via, for example,
Schiff base reactions. Some embodiments of
adhesives may comprise, for example, vinylated proteins and/or
polysaccharides, which may adhere to tissues upon photo-
irradiation. In some instances, adhesives may also, or alternatively, be
configured for localized drug delivery. In some
embodiments, adhesives may be functionalized with phenolic and/or thiol groups
to promote tissue interaction. Certain
embodiments of tissue adhesives may employ techniques such as laser welding,
layer-by-layer assembly, and/or
temperature-dependent hardening. In other embodiments, adhesives may comprise
Poly(ethyleneglycol) (PEG)-based
hydrogels. To render PEG biodegradable, it may be modified with degradable
functionalities or be copolymerized with
degradable polymers. PEG may also be combined, in some instances, with
polysaccharides and/or protein-based adhesives.
Some medical adhesives may also be biomimetic. Such biomimetic tissue
adhesives may comprise, for example, mussel-
inspired adhesives, gecko-inspired adhesives, sandcastle worm-inspired tissue
adhesives, barnacle mimetic adhesives,
caddisfly-inspired adhesives; et al. Additional details regarding potentially
useful medical adhesives may be found in
"Degradable Adhesives for Surgery and Tissue Engineering", Bhagat,
BioMacromolecules, American Chemical Society,
3009-3039, 2017, which is hereby incorporated herein in its entirety by
reference.
[00365] Preferred methods and systems for wireless power transfer into the
body will avoid unwanted heating and potential
health concerns. Thus, some embodiments and implementations may include the
use of multiple flexible coils to avoid
Date Recue/Date Received 2022-12-30
52
performance loss through heating of the skin. They may also, in some
embodiments and implementations, include software
to optimize power delivery to avoid unwanted tissue heating. Additional
details that may be useful in this regard for various
embodiments disclosed herein may be found in 'A Breakthrough in Wireless
Charging for Implants', Earls, Medical
Technology, Issue 6, 2018, which is hereby incorporated in its entirety by
reference.
[00366] Implantable inductance coil designs may include those attached to
flexible PCBs. To avoid any potential health
risks due to alternating magnetic fields from the Tx (transmitting coil),
ferrite materials may be used on the top and bottom
of WPT (wireless power transfer) coils. The aforementioned information and
further details may be found in 'Design,
Simulation and Measurement of Flexible PCB Coils for Wearable Device Wireless
Power Transfer', Jeong, IEEE, 2018,
which is hereby incorporated in its entirety by reference.
[00367] Designs for various implantable Near-Field Inductive Coupling
inductance coils may optimize the tradeoff
between coil quality factors and coupling coefficient, to tailor specific
coils for various needs and high efficiency. An
example of such an optimized design along with methods for optimizing the
design for inductance charging coils and devices
may be found in 'Design, Test and Optimization of Inductive Coupled Coils for
Implantable Biomedical Devices', Zhao,
Journal of Low Power Electronics, Vol. 15, 76-86, 2019, which is hereby
incorporated in its entirety by reference.
[00368] Fig. 30 depicts a top view of still another implant 3001, which again
may comprise various reinforcement regions
3002 and/or macro positioning/instrument engaging holes 3003 for facilitating
coupling with a suitable instrument as
desired. In addition, implant 3001 comprises a battery 3030, which may be
useful for providing energy for actuation of a
drug delivery mechanism/system. Battery 3030 may also be configured to receive
energy from an inductance coil (not
shown) or the like, as desired, and as discussed in greater detail above.
[00369] In some instances, a thin battery may be positioned inside an
inductance coil. The device may be implanted in the
body; the battery may be used to power medical devices, and the coil may be
used to wirelessly charge the battery. Additional
information may be found in U.S. Patent No. 8,798,752, titled "Removable
Implantable Battery Positioned Inside Implant
Coil", which is hereby incorporated in its entirety by reference.
[00370] In some embodiments, implantable micro-generators may comprise
mechanisms for harnessing and converting
mechanical energy from natural body movement into electrical energy. In
certain embodiments, the general construction of
the micro-generator may resemble that of a winding mechanism for a mechanical
watch. Such generators may comprise, for
example, a rotating mass with an offset center of mass. Natural movement of
the body may cause the rotating mass to rotate.
The generator may convert this rotational kinetic energy of the spinning mass
into electrical energy for use by one or more
implants. In some instances, such micro-generators may be used to charge
capacitors or implantable batteries. The micro-
generator may also be used to power pacemakers, defibrillators, and the like.
Additional details regarding generators for
harnessing the energy of natural body movements, which may allow for
generation of energy for implants without use of
inductance coils and/or batteries (although batteries may still be useful to
store such energy) may be found in U.S. Patent
Application Publication No. 2005/0256549, titled "Micro-Generator Implant",
which is hereby incorporated in its entirety
by reference.
[00371] In some embodiments, power supplies may be implanted subcutaneously.
In some instances, the power supply
may comprise of one or more thin photovoltaic cells contained in a case formed
by lamination of plastic layers. The layers
may be thin and translucent in the area covering the cell so that the power
supply may be flexible. The power supply may
be used to power a variety of different implanted devices. Additional details
regarding such power supplies may be found
in U.S. Patent No. 6,961,619, titled "Subcutaneous Implantable Power Supply",
which is hereby incorporated in its entirety
by reference.
[00372] In some embodiments, medical devices may contain rechargeable lithium-
ion batteries. In some instances, the
battery may comprise a positive electrode including a current collector and
first and second active materials. The battery
may also comprise negative electrode with a current collector, a third active
material, and lithium in electrical contact with
Date Recue/Date Received 2022-12-30
53
the current collector of the negative electrode. In some embodiments, the
device may be used to provide therapeutic
treatment to patients. Additional details regarding such batteries and related
devices and methods may be found in U.S.
Patent No. 7,642,013, titled "Medical Device Having Lithium-Ion Battery",
which is hereby incorporated in its entirety by
reference.
[00373] In some embodiments, implanted batteries may be biodegradable. Upon
undergoing electrochemical oxidation, the
anode (comprising an inner and outer surface) material may result in a non-
toxic product; upon undergoing electrochemical
reduction, the cathode (comprising an inner and outer surface) material may
result in a non-toxic product. In a preferred
embodiment, the cathode should present larger standard reduction potential
than the anode. In some instances, the inner
surface of the cathode may be separated from the inner surface of the anode by
a permeable membrane in direct fluid contact
with the body's aqueous environment. In certain embodiments, one or more
biodegradable coatings may be disposed over
the outer surface of the cathode and a portion of the outer surface of the
anode. Additional details regarding such degradable
batteries may be found in U.S. Patent No. 9,362,571, titled "Degradable
Implantable Battery", which is hereby incorporated
in its entirety by reference.
[00374] In some embodiments, micro batteries may be biocompatible, self-
recharging, and/or biofueled. In some instances,
the micro battery may comprise bio-membranes to diffuse bio-fluids across an
anode and a cathode. In certain embodiments,
bio-membranes may comprise compartments for chemical storage and bio-fuel
storage. Biofluids to power the battery may
include, for example, glucose. In certain instances, bio-membranes may be
configured to allow diffusion of a bio-fluid across
an anode and a cathode to generate electron flow to charge the battery or to
provide a constant power supply. Additional
details regarding suitable micro batteries may be found in U.S. Patent No.
10,340,546, titled "Self-Rechargeable Bio-fueling
Micro Battery with a Glucose Burning Chamber", which is hereby incorporated in
its entirety by reference.
[00375] In some embodiments, high-powered batteries may be implanted for
medical use. In some instances, the battery
may comprise an input, output, numerous battery modules, each module
comprising numerous low voltage battery cells in
permanent parallel arrangements. In certain embodiments, a switch may be used
so that the battery modules may be charged
in parallel (for low charging voltage), and/or so that the battery modules may
discharge in series (for high output voltage).
In some instances, the power source may also be used to power implantable
defibrillators as an alternative to high voltage
capacitors. Additional details regarding such battery systems may be found in
U.S. Patent Application Publication No.
2006/0129192, titled "High-Energy Battery Power Source for Implantable Medical
Use", which is hereby incorporated in
its entirety by reference.
[00376] In other embodiments, high power implantable batteries may comprise a
first high-rate electrochemical cell and a
second high-rate electrochemical cell, which may be connected in parallel to a
low power control circuit and in series to a
high power output circuit. Implanted medical devices incorporating such
batteries may include, for example, hermetic
enclosures and circuits and resistive loads for power control. Additional
details regarding such batteries may be found in
U.S. Patent No. 7,209,784, titled "High Power Implantable Battery with
Improved Safety and Method of Manufacture",
which is hereby incorporated in its entirety by reference.
[00377] Components of the external transmitting component of a Wireless
Inductance Coupling Mechanism (WICM),
which may be used in various embodiments to provide power to the implant, may
include a power supply, an oscillator, and
a transmitter coil. Components of the receiving component of the WICM may
include the receiver coil, power rectifier, and
power stabilizer, resulting in an efficient and stable voltage to power a
device or charge a battery. The oscillator may generate
a high oscillating current, in order to have a strong alternating magnetic
field generated by the transmitting coil. The rectifier
may serve to rectify the high frequency voltage into a pulsating DC signal. A
capacitor may be used as a filter to smooth the
ripple DC current emanating from the rectifier. Further capacitors may be
wired as decoupling capacitors, which may be
configured for filtering high frequency noise at the output (the battery being
charged). Voltage regulators may also be used,
which may keep the voltage stable so circuits may have a constant charging
voltage. Regarding coil design, flat spiral coils
Date Recue/Date Received 2022-12-30
54
have higher efficiency with longer distance of transmission, and may therefore
be preferable for certain implants. Additional
details regarding such inductance coupled wireless charging may be found in
'Wireless Inductive Charging for Low Power
Devices', Macharia, 2017, which is incorporated herein in its entirety by
reference.
[00378] Fig. 31 depicts a top view of still another implant 3101 that is
similar to implant 3001 except it has a capacitor
3131 and defines a different shape (a pentagon). Macro positioning/instrument
engaging holes 3103 may again be provided.
[00379] Biodegradable capacitors may also be used in certain embodiments, in
which capacitors may be attached to an
implantable pad. Such implantable pads may comprise, for example, those with a
symmetrical stacked structure of one or
more of the following: PLA supporting substrate, PLA nanopillar arrays, zinc
oxide nanoporous layers, and PVA/PBS
hydrogel layers. The aforementioned information and further information may be
found in 'Fully Bioabsorbable Capacitor
as an Energy Storage Unit for Implantable Medical Electronics', Li, Advanced
Science, 2019, which is incorporated herein
in its entirety by reference.
[00380] Fig 32 depicts a side view of an implant 3201, which shows how various
elements may be stacked or otherwise
applied to a single implant. Thus, an inductance coil 3229 is shown coupled to
the implant 3201, along with a battery 3230,
which may be used to receive and store energy from the inductance coil 3229
and may therefore be electrically coupled with
inductance coil 3229. A capacitor 3231 may also be present in the assembly,
along with various other electrical components
as needed, such as a CPU 3232 and/or adjunctive circuitry 3233, which may, for
example, provide protection to CPU 3232
and superstructure 3219.
[00381] In some embodiments, implantable medical devices may include
rechargeable lithium-ion batteries. In some
instances, such batteries may comprise titanium anodes and circuitry for
battery charging and protection. Additional details
may be found in U.S. Patent No. 7,295,878, titled "Implantable Devices Using
Rechargeable Zero-Volt Technology
Lithium-Ion Batteries", which is hereby incorporated in its entirety by
reference.
[00382] In a preferred embodiment, skin-inspired electronics may be capable of
stretching, self-healing, and/or
biodegrading. In some instances, such devices may comprise stretchable
conductors (such as poly(3,4-ethyl-
enedioxythiophene) polystyrene sulfonate (PEDOT:PSS)), stretchable
semiconductors (such as poly(3-hexylthiophene)
copolymerized with amorphous polyethylene), stretchable dielectrics (such as
PDMS), stretchable sensors and displays, and
stretchable transistors. In some instances, material designs may be based on
intermolecular interactions such as, for example,
hydrogen bonding, metal-ligand coordination, pi-pi interactions, and/or
electronic interactions. In some embodiments, self-
healing matrices may be coupled with conducting fillers. Biodegradable
materials that may be used in electronics may
comprise, for example, silk, cellulose, gelatin, PLGA, and the like.
Additional details regarding such electronic devices may
be found in "Skin-Inspired Electronics: An Emerging Paradigm", Wang, Accounts
of Chemical Research, 2018: 51; 1033-
1045, which is hereby incorporated in its entirety by reference.
[00383] In order to protect the electronic components and circuitry from
bodily fluids, implant 3201 may be insulated by
biocompatible insulators, which may include polyimide and parylene-C.
Additional details regarding such implantable
insulators may be found in `Bio-Compatibility and Bio-Insulation of
Implantable Electrode Prosthesis Ameliorated by A-
174 Silane Primed Parylene-C Deposited Embedment', Lin, Micromachines, 2020,
which is incorporated herein in its
entirety by reference.
[00384] Further methods for insulating implant 3201 may comprise polymeric
materials, such as poly(V3D3)
(poly(trivinyltrimethylcyclotrisiloxane), which may be used as a permanent
electrical insulator. Such polymeric materials
may be deposited onto surfaces via methods such as initiated chemical vapor
deposition. Additional details regarding
poly(V3D3) may be found in 'Stable Biopassive Insulation Synthesized by
Initiated Chemical Vapor Deposition of
Poly(1,3,5-trivinyltrimethylcyclotrisiloxane)', O'Shaughnessy,
Biomacromolecules, 2007; 8: 2564-2570, which is hereby
incorporated in its entirety by reference.
[00385] For a permanent electrical implant, non-biodegradable insulators may
be preferred. Non-biodegradable polymers
Date Recue/Date Received 2022-12-30
55
such as silicones, poly(urethanes), poly(acrylates), or copolymers such as
poly(ethyelene vinyl acetate) may be used as non-
biodegradable electrical insulators for implantable electronics. Additional
details regarding such insulating polymers may
be found in 'Implantable Polymeric Drug Delivery Devices: Classification,
Manufacture, Materials, and Clinical
Applications', Stewart, MDPI, 2018; 10: 1379-1317, which is hereby
incorporated in its entirety by reference.
[00386] To power implant 3201, ultrathin batteries or capacitors may be used.
Such designs may include flexible batteries
attached to an implantable pad formed by nanoporous cellulose paper embedded
with aligned carbon nanotube electrodes
and electrolytes functioning as a cathode and a thin Li-metal layer as anode
with Al on both sides of the battery acting as
current collectors. Flexible capacitors attached to implantable pads may
include those formed by two layers of nanoporous
cellulose paper embedded with aligned carbon nanotube electrodes with an
electrolyte layer in between the cellulose paper
layers. The aforementioned information and further schematics may be found in
'Flexible Energy Storage Devices Based
on Nanocomposite Paper', Pushparaj, PNAS, 2007; 104: 13574-13577, which is
hereby incorporated in its entirety by
reference.
[00387] Rechargeable lithium cells may be used in certain embodiments, which
may, for example, include being used to
charge/power other implants (in addition to the implant within the implant
pocket itself, or as an alternative to that implant).
For example, lithium cells or other similar batteries may be used to power
implanted battery powered devices, such as
automatic implantable cardioverters/defibrillators. Implanted devices may
further comprise sensors and/or controllers to
monitor the charging state of the battery and/or accelerate the charging
process, which may occur via, for example, magnetic
induction. Further details regarding such cells may be found in U.S. Patent
No. 5,411,537 titled "Rechargeable Biomedical
Battery Powered Devices with Recharging and Control System Therefor", which is
hereby incorporated in its entirety by
reference.
[00388] In some embodiments, cardioverter-defibrillators may be implanted
subcutaneously. In some instances, such
devices may comprise, for example, a hermetically sealed housing with one or
more subcutaneous sensing and
cardioversion-defibrillation delivery leads. As another alternative
embodiment, two hermetically sealed housings may be
connected by a power/signal cable. In some embodiments, the housings may be
configured to match various rib structures.
Additional details regarding implantable cardioverter-defibrillating devices
may be found in U.S. Patent No. 7,684,864,
titled "Subcutaneous Cardioverter-Defibrillator", which is hereby incorporated
in its entirety by reference.
[00389] Fig. 33 depicts a bottom view of a circular, flexible, and
compressible implant 3301 with the addition of hollow,
fillable, circular shaped superstructure 3333 on one side. In some
embodiments, superstructure 3333 is circular in overall
shape and cross section and may be present only on one side of implant 3301,
which may be directed inward in a patient
when implanted. Implant 3301 may be compressible by being rollable and/or
foldable. Implant 3301 is shown in FIG. 33 in
its unrolled or otherwise uncompressed/native state. Implant superstructure
3333 is likewise compressible. Implant
superstructure 3333 may be hollow on the inside and/or may have an outer layer
comprising, in some embodiments, a
flexible plastic, organic polymer, biopolymer, or the like. Other embodiments
may comprise a polymeric external lamination
or containment to retain more dissolvable materials, such as hydrogels and the
like. Drugs, vitamins, or other chemicals,
including biologics, may also be bound, dissolved, or otherwise present in a
portion or all of the structure of implant
superstructure 3333 or elsewhere on implant 3301. Different regions and/or
portions of the superstructure may also have
different medications or chemicals printed or otherwise designed into them. In
addition, electronics, micro-pumps, and/or
printed circuit boards may be positioned in or on implant superstructure 3333
when properly protected. Injection port and/or
tubing 3334 may also be used to allow a surgeon or other user to inject fluids
for inflating superstructure 3333 and/or for
injecting drugs. Port 3334 may extend above the patient's skin or,
alternatively, may be positioned below the patient's skin
to allow for subcutaneous injection of such drugs and/or other fluids. In some
embodiments, port 3334 may have
radiographically, sonically, or electromagnetically identifiable material
positioned therein to allow injection needle filling
of the superstructure, for example, with medications such as for chemotherapy.
Date Recue/Date Received 2022-12-30
56
[00390] In some embodiments, superstructures may instead be positioned at
peripheral portion(s) of a foldable implant.
This may be somewhat similar to that shown for superstructures on individual
spiral implant arms as previously described
with reference to, for example in Figs. 67f, 67h, 67i, 67k, 67L, 67m, 68a,
68b, 68c, 68d, 68e.
[00391] Hydrogels may be used to fill superstructure 3333 in some embodiments.
Common hydrogels used for drug
delivery may include polyethylene glycol (PEG), which is inherently non-
biodegradable. In order to make non-
biodegradable hydrogels degradable, various degradable and reactive groups may
be added to hydrogels such as PEG to
make them biodegradable. Hydrogel chain lengths and multifunctionalities may
also be used to modulate degradation.
Degradable hydrogels may also be used for drug delivery while offering the
additional benefit of not requiring surgery for
removal after the drug has been delivered. Additional details regarding such
drug release characteristics and models may be
found in 'Predicting Drug Release from Degradable Hydrogels Using Fluorescence
Correlation Spectroscopy and
Mathematical Modeling', Sheth, Bioengineering and Biotechnology, 2019,
doi.org/10.3389/fbioe.2019.00410, which is
hereby incorporated in its entirety by reference. In some embodiments the
hydrogel may lack water and thus be a more
compact relatively dry, xerogel which may absorb water through a selectively
permeable membrane or other means to
become a hydrogel.
[00392] Fig. 34 depicts a lower view of a circular, flexible, and compressible
implant 3401 with the addition of hollow
fillable '+' shaped superstructure 3434 on one side. In some embodiments,
superstructure 3434 may be circular in cross
section following inflation. Injection port and tubing 3435 may also be used,
which may be in fluid communication with
superstructure 3434, as described above.
[00393] Micromechanical systems (MEMS) may be used in some embodiments in
order to provide control of release
kinetics to the patient or physician. Such MEMS may comprise micropumps,
microprobes, cantilevers, microneedles, shape
memory alloys, and/or microchips. Microchips may provide complex release
patterns while providing data telemetry.
Microchips may be categorized into solid state silicon chips or resorbable
polymeric chips. Microchips may comprise drug
delivering components such as reservoir arrays, batteries, microcontrollers,
processing units, and/or antennae. Titanium
coatings may be used in one or more biocompatible layers for microchips.
Reservoirs may be made to be individually
addressable or may use processes, such as electrothermal activation, to melt
the caps off of the reservoirs to selectively
deliver drugs from the implant. RF systems may be used to transfer power to
the chip, which rectifies the power into a DC
voltage. Pumps used to infuse drugs in connection with various embodiments
disclosed herein may comprise, for example,
infusion pumps, peristaltic pumps, osmotic pumps, and positive displacement
pumps. Power may be provided via RF
technology. Microvalves may be incorporated into the design of the implant
and/or superstructure and be selectively actuated
to control routing of drug formulations. Such microvalves may, for example,
comprise thermoresponsive materials, such as
hydrogels or other materials, such as paryelene, ionic polymer metal
composites, and/or piezoelectric materials. Spiral coils
or multilayer coils may be used to receive RF power. Thermopneumatic
micropumps may transfer heat generated from RF
transmission to the pump chamber, resulting in drug flow.
[00394] In some embodiments, drug eluting capsules may comprise a reservoir
and a split ring reservoir. When the external
radio frequency (RF) matches the resonant frequency of the split ring
reservoir, heat may be generated to melt the lid of the
capsule to release the drug. Microbots may also be used to deliver drugs.
Microbots may be controlled or powered by external
RF signals or external magnetic fields to propel themselves through blood
vessels. Furthermore, microbots may hold their
own power source or use the external RF or magnetic field for power or drug
release. Nanoparticles may also be used for
drug delivery or therapy. When exposed to external radio waves, nanoparticles
(such as those composed of Gold) may
generate heat for thermal ablation of cancerous cells, which may allow for
various implants disclosed herein to be used for
cancer treatments. The surfaces of nanoparticles may also be coated with
antibodies (such as cancer specific antibodies),
proteins, peptides, or even sugar residues to improve internalization within
the target cells. Cristalline silicon, quantum dots,
and platinum nanoparticles have shown high heat generation when exposed to RF
radiations. Nanoparticles may be infused
Date Recue/Date Received 2022-12-30
57
with sponge-like microspouters for precise repeated drug delivery. Such
reversibly deforming magnetic sponges may
comprise, for example, polydimethylsiloxane elastomers and ferromagnetic
carbonyl iron microparticles. Additional details,
including devices and methods for implantable wireless power transfer devices
that may be used in various embodiments
disclosed herein may be found in 'Radio Frequency Controlled Wireless Drug
Delivery Devices', Khan, Applied Physics
Reviews 6, 2019 (041301), which is hereby incorporated in its entirety by
reference.
[00395] In some instances, pharmaceutical agents may be delivered by implanted
actuating drug delivery devices. Some
embodiments may comprise, for example, a compressible dispensing chamber
situated in a first compartment, a
reciprocating plunger for dispensing doses, a compressible drug reservoir
chamber situated in a second compartment, a one-
way valve between the dispensing and the reservoir chambers, and/or a
compressible filler fluid chamber in communication
with the first two compartments. Various other elements, such as a control
board, motor driver, microprocessor, and/or
battery may also be provided. In certain embodiments, the device may be
refillable. Additional details regarding such drug
delivery systems may be found in U.S. Patent Application Publication No.
2014/0214010, titled "Drug Delivery Device with
Compressible Fluid Chambers", which is hereby incorporated in its entirety by
reference. Certain embodiments of suitable
drug delivery systems may comprise, for example, devices comprising dual-drug
configurations that may dispense each drug
independently. In such embodiments, the first and second drug chambers may
have a one-way valve into compartments
containing pistons and second compartments comprising followers in flow
communication with said pistons. Additional
details regarding such drug delivery systems may be found in U.S. Patent No.
9,381,299, titled "Implantable Drug Delivery
Devices", which is hereby incorporated in its entirety by reference.
[00396] In certain instances, pumps may be implanted subcutaneously to deliver
drugs to specific target sites via implanted
catheters. Types of subcutaneously implanted pumps may include, for example,
osmotic pumps, vapor pressure pumps,
electrolytic pumps, piezoelectric pumps, electrochemical pumps, effervescent
pumps, and the like. In certain embodiments,
drug delivery pumps may be implanted subcutaneously to release drugs into the
myocardial tissue via catheters. Additional
details regarding such pumps and drug delivery methods may be found in U.S.
Patent Application Publication No.
2003/0009145, titled "Delivery of Drugs from Sustained Release Devices
Implanted in Myocardial Tissue or in the
Pericardial Space", which is hereby incorporated in its entirety by reference.
[00397] Certain embodiments of implantable drug delivering devices may
comprise, for example, numerous reservoirs
located within a substrate, rupturable reservoir caps, and/or means for
accelerating the release of the reservoir contents.
Means for enhancing release of reservoir contents may include, for example,
shape memory materials, propellants to create
expanding products, flexible membranes, methods for enhancing diffusion, or
the like. In some embodiments, the reservoir
caps may be selectively disintegrated via methods such as, for example,
electric current, thermal ablation, oxidation, or the
like. Additional details regarding such drug delivery systems may be found in
U.S. Patent Application Publication No.
2005/0055014, titled "Methods for Accelerated Release of Material from a
Reservoir Device", which is hereby incorporated
in its entirety by reference.
[00398] In some embodiments, implantable drug delivery apparatuses may
comprise, for example, drug supply reservoirs
that may supply drugs into a delivery channel and actuators for delivering
said drugs. The drug reservoir may be coupled,
in certain embodiments, to the delivery channel via one or more drug supply
valves. In some instances, the drug delivery
channel(s) may be used to deliver drugs to various parts of the body. A first
actuator may be used to drive the drug through
the delivery channel and out of the outlet with a controlled degree of
dilution with a carrier fluid. In certain embodiments, a
second actuator may be used to cause drug flow in the delivery channel. In
some instances, the drug reservoir may be
pressurized. Additional details regarding such drug delivery systems may be
found in U.S. Patent No. 8,876,795, titled
"Drug Delivery Apparatus", which is hereby incorporated in its entirety by
reference.
[00399] In some instances, implanted drug delivery systems may comprise hollow
members that may define at least one
lumen for facilitating recirculating flow of a therapeutic fluid through the
lumen and/or a pump to control the flow rate of
Date Recue/Date Received 2022-12-30
58
the therapeutic fluid. In some embodiments, the therapeutic fluid may comprise
a bodily fluid and a drug. In certain instances,
recirculating fluid may be used to fill depleted volume within the device once
the drug is dispensed. A preferable
embodiment may comprise a device enabling recirculating drug delivery using a
cannula interface to a targeted internal
cavity of a patient. In some embodiments, the interface member may be
configured to draw bodily fluid from the location
where the drug is being delivered. Such systems may aid in, for example,
reducing net infusion rates without having to
reduce the pump's flow rate. Additional details regarding such drug delivery
methods may be found in U.S. Patent No.
7,867,193, titled "Drug Delivery Apparatus", which is hereby incorporated in
its entirety by reference.
[00400] In certain embodiments, drugs may be delivered by implanted
microminiature infusion devices. Such devices may
comprise, for example, a reservoir for therapeutic fluid, a driver, and/or one
or more electrodes which may be used to deliver
therapeutic electrical stimulation. In some instances, the driver may comprise
a pump, such as, for example, a diaphragmatic,
negative pressure or peristaltic pump. In some embodiments, the driver may be
actuated by electromagnetic means.
Additional details regarding such drug infusion devices may be found in U.S.
Patent No. 7,776,029, titled "Microminiature
Infusion Pump", which is hereby incorporated in its entirety by reference.
[00401] In some embodiments, implanted drug delivery devices may comprise
release mechanisms which may selectively
release therapeutic agents in response to external stimuli. In some instances,
such devices may comprise release mechanisms
sealingly engaged with a reservoir to release cargo. In some embodiments, the
release mechanism may comprise a diaphragm
membrane comprising a polymer matrix, which may be non-porous in a first
state; however, in response to external stimuli,
the matrix may transition to a second, substantially porous, or at least more
porous, state. In certain instances, the polymer
matrix may comprise, for example, a plurality of magnetic particles, which
upon application of a magnetic field, may cause
the diaphragm to transition to the second state. In some embodiments, the
membrane may be composed of electrospun
nanofibers comprising magnetic particles. In some instances, the device may
comprise a rotating membrane. In some such
embodiments, the rotating membrane may be affixed to a non-moveable membrane
in such a way that the non-moveable
membrane is between the rotating membrane and reservoir and/or may define at
least one hole or pore. The rotatable
membrane may be rotated such that when holes in the rotating and non-moveable
membranes align, therapeutic agents may
be released. In some embodiments, the release mechanism may comprise micro
channels connecting the reservoir to pores
in the membrane. In certain embodiments, such micro channels may comprise
valves allowing or restricting fluid flow.
Additional information regarding such drug delivery devices may be found in
U.S. Patent Application Publication No.
2012/0226265, titled "Remotely Controlled Drug Delivery Systems", which is
hereby incorporated in its entirety by
reference.
[00402] In some instances, devices may be used to regulate microfluidic flow.
Such devices may comprise, for example,
substrates defining fluid-conducting chambers, a flexible membrane sealing the
chamber, such that the flexible membrane
may be moved between two positions, one allowing more fluid flow than the
other, and a method (such as, for example,
electromagnetic mechanisms) disposed on the substrate to shift the membrane
between positions. Additional details
regarding such flow regulators may be found in U.S. Patent Application
Publication No. 2016/0003229, titled
"Electromagnetically-Actuated Microfluidic Flow Regulators and Related
Applications", which is hereby incorporated in
its entirety by reference.
[00403] In some embodiments, implantable devices may be configured for zero-
order drug release kinetics. Such devices
may comprise, for example, a housing formed from biocompatible materials. Said
housing may comprise a hollow core with
passages connecting the core to the exterior space, drugs loaded through a
first end, and/or a biocompatible seal on the
housing's first end. In some embodiments, the device may comprise multiple
compartments, enabling individual release
rates of therapeutic agents. The device may be used to deliver agents such as,
for example, drugs, proteins, genetic materials,
et al. In some instances, the device may be biodegradable. Additional details
regarding such drug delivery devices may be
found in U.S. Patent Application Publication No. 2018/0042549, titled "Methods
for Making Controlled Delivery Devices
Date Recue/Date Received 2022-12-30
59
Having Zero Order Kinetics", which is hereby incorporated in its entirety by
reference.
[00404] Fig. 35 depicts a lower view of a rectangular, flexible, and
compressible implant 3501 with the addition of hollow
fillable rectangular shaped superstructure 3535 on one side. In some
embodiments, superstructure 3535 may be circular in
cross section following inflation. Injection port and tubing 3536 may also be
used, and may be in fluid communication with
superstructure 3535.
[00405] Superstructure 3535 may, in some embodiments, contain magnetic
microdisks. Magnetic fields may be used to
control micro magnetic disks in order to damage target cell integrity, deliver
drugs, generate heat, and/or separate
tumor/cancer cells for early detection. Various types of magnetic disks may
include, for example, in-plane synthetic
antiferromagnetic (SAF) disks, perpendicular SAF disks, and vortex disks. In-
plane disks may have two ferromagnetic layers
separated via nonmagnetic spacer with magnetic moments in-plane in opposite
directions. Perpendicular disks may have
two ferromagnetic layers separated via nonmagnetic spacer with magnetic
moments out-of-plane pointing in opposite
directions. Magnetic disks may use mechanical force (from torque via external
magnetic field) to induce apoptosis in target
cells. Vortex disks may be comprised of Ni80Fe20 and be capped with two gold
layers (to insulate the body from adverse
effects). Such disks may be functionalized with antibodies matching antigens
on the membranes of targets cells to induce
apoptosis via torque and mechanical force. Magnetic disks may also be
endocytosed by target cells and accumulated into
lysosomes, which may be ruptured by the disks' torque. Magnetic disks may also
be used for drug and gene delivery.
Polymers such as thiolated chitosan may be assembled onto the surface of the
disks. Mechanical torque and force may then
be used to permeabilize the target cell membrane while simultaneously
delivering therapeutic material. Magnetic disks may
also be used for magnetic hyperthermia, the major heating mechanism being
hysteresis loss. Various additional details and
further information that may be useful in connection with the implants
disclosed herein may be found in "Disk-Shaped
Magnetic Particles for Cancer Therapy", Munoz, Applied Physics Review 7, 2020
(011306), which is hereby incorporated
in its entirety by reference.
[00406] Fig. 36 depicts a lower view of a rectangular, flexible, and
compressible implant 3601 with the addition of hollow
fillable '+' shaped superstructure 3636 on one side. In some embodiments,
superstructure 3636 may be circular in cross
section following inflation. Injection port and tubing 3637 may also be used,
and which may be in fluid communication with
superstructure 3636.
[00407] Drug delivery systems according to various embodiments disclosed
herein may include microparticles (which may
include biodegradable polymers, natural polymers), nanoparticles (which may
include biodegradable polymers, natural
polymers), micelles (which may include amphiphilic block copolymers), drug
conjugates (which may include hydrophilic
polymers, dendrimers), hydrogels and implants (which may include hydrophilic
polymers, biodegradable polymers, natural
polymers), or the like. Nanomaterials for drug delivery and theranostics may
include, for example, gold nanoparticles, silver
nanoparticles, iron oxide nanoparticles, carbon nanotubes, fluorescent
nanodiamonds, silica nanobeads, or the like.
Polymeric micelle nanoparticles may be created from the self-assembly of
amphiphilic block copolymers. Methods for
loading micelles with drugs may include, for example, solvent evaporation, co-
solvent evaporation, dialysis, flash
nanoprecipitation, and the like. Diblock copolymers used for micelles may
include Poly(L-lactide-block-acrylic acid) and
triblock copolymers may include Polylactide-block-poly(ethyleneglycop-block-
polylactide. Polymeric microsphere drug
carriers may be used to protect unstable drugs pre- and post-administration.
Microspheres may be used to release drugs over
time and prolong therapeutic effect. Microspheres may be comprised of
biodegradable polymers, such as poly(lactide-co-
glycolide) (PLGA). The surfaces of nanoparticles may be modified polyethylene
glycol to prolong in-vivo lifetime.
Polymers used in connection with various embodiments disclosed herein may also
be configured for resistance to
immunological response due to their lack of surface identifying proteins.
Microgels and nanogels may also be used in some
embodiments to encapsulate water-soluble, small molecule APIs that would
otherwise be difficult to encapsulate using
traditional biodegradable polymeric particles. Polymeric nanoparticles may be
prepared via methods such as
Date Recue/Date Received 2022-12-30
60
nanoprecipitation. Liposomes may also be used as drug delivery devices due to
their excellent biocompatibility while
nanoparticles possess excellent stability and drug carrying capacity. Lipid-
polymer hybrid nanoparticles (LPNs) may be
used to combine the advantageous properties of liposomes and nanoparticles.
Polymers that may be used in the cores of
LPNs may include PLGA, while lipids such as phosphatidylcholine may be used in
the shell of the LPN, along with
poly(ethylene glycol) (PEG) lipid conjugates. In some embodiments, LPNs may
also be engineered to be stimuli responsive,
responding to stimuli such as pH by using pH sensitive lipid coatings (such as
lipid-succinate-mPEG). LPNs may be
particularly useful to deliver drugs such as docetaxel, paclitaxel, curcumin,
and doxorubicin. Polysaccharides such as
chitosan may be used as drug delivering molecules and/or may be formulated
into drug delivering nanoparticles (by
mechanisms such as covalent crosslinking, ionic crosslinking, polyelectrolyte
complexation, and self-assembly of
hydrophobically modified polysaccharides, depending on desired structural
characteristics). Such natural polymers may
form bioadhesions which are advantageous as carriers because they can prolong
residence time, and therefore increase the
absorbance of loaded drugs. Depending on desired nanoparticle or nanomicelle
characteristics, natural polymers may be
modified prior to use with various implants disclosed herein. One such example
may be chitosan: amphiphilic chitosan may
be formed by grafting hydrophobic groups onto the amine functional groups.
Furthermore, the hydrophobic cores of certain
micelle carrier systems can improve drug solubility and stability by acting as
reservoirs for water-insoluble drugs.
Amphiphilic natural polymer-based micelles (such as those based on chitosan)
may be used to encapsulate drugs such as
ibuprofen and amphiphilic adriamycin for ultimate delivery in one or more of
the implants disclosed herein. Natural
polymer-based micelles may even encapsulate certain proteins, peptides, and
nucleic acids. Stimuli-responsive materials
may also be used to selectively deliver drugs as needed, which materials may
include thermo- and/or pH-sensitive materials
(thermal- and pH-sensitive materials are the most prevalent due to the
different thermal and pH conditions in various areas
of the body). Thermosensitive polymers may ideally exhibit transition
temperatures close to physiological temperatures.
Stimuli-responsive polymers may be formulated into stimuli responsive micelles
to deliver drugs such as doxorubicin to
cancer cells. The structures of such polymers may also be modified to coat
liposomes. Hydrogels may also, in some
embodiments, be coupled with nanometer-sized shape-changing structures to
release drugs. Swelling and de-swelling can
cause mechanical deformations that can be used to enable actuation in some
embodiments. Self-folding drug delivery
systems (DDS), such as theragrippers (DDS that have digits that may open and
close in response to external stimuli), may
be used for chemomechanical controlled drug release. Drugs such as mesalamine
and doxorubicin may be loaded into such
theragrippers. Hydrogels used for drug delivery may be functionalized with a
variety of groups such as methoxy, hydroxyl,
maleimide, thiol, and azide moieties. Hydrogels may also be used to create
biomatrices that may encapsulate various cell
types such as fibroblasts. Further drug/therapeutic cargo-delivery media that
may be useful in connection with various
embodiments may include collagen, poly(2-oxazoline), polyoxazolines, dendritic
polyester scaffolds, raft polymer carriers,
and/or linear branched polyethylenimines. Further details regarding drug and
therapeutic cargo delivery techniques that may
be useful for various embodiments may be found in 'Polymeric Drug Delivery
Techniques Translating Polymer Science for
Drug Delivery', Aldrich Materials Science (2015), which is hereby incorporated
in its entirety by reference.
[00408] Fig. 37a depicts a top view of a circular, spiral implant 3701 with
outer arm band terminus 3712 and inner arm
band terminus 3711 and space 3710 between the bands. Implant 3701 comprises 5
turns. In the depicted embodiment, space
3710 is similar in size as the corresponding width of each adjacent arm/band,
a pair of which defines the size of the space
3710. In some embodiments, space 3710 may therefore be the same, or at least
substantially the same, as this aforementioned
arm/band width. Of course, in other embodiments, space 3710 may be less (or
more) than this arm/band width. In fact, in
some embodiments, space 3710 may, in a resting configuration of implant 3701,
be zero or close to zero (see FIG. 69, for
example). However, in such embodiments, preferably the arms are sufficiently
flexible and separable to allow for temporary
separation of the arms to create sufficient space to facilitate installation
using, for example, one of the techniques described
herein through a minimally invasive entrance incision. Irrespective of whether
there is permanent space between the
Date Recue/Date Received 2022-12-30
61
adjacent bands/arm regions of a spiral implant or whether the implant is
sufficiently flexible to temporarily create such space
to allow for this installation, however, it should be understood that, as used
herein, the term "space"¨or the phrase "space
in between adjacent bands" of a spiral implant _________________________
should be considered to require the ability to utilize this space to insert
the
spiral implant through an entrance incision (preferably a minimally invasive
entrance incision) with just one arm/band
extending through the entrance incision at any given moment during an
installation procedure (as opposed to the entire
implant). Thus, it should be understood that the use of the aforementioned
"space" in this context, whether permanent or
temporary, should be considered to exclude any devices that have structures
that preclude use of this space for this purpose,
such as, for example, spiral-shaped inductance coils having a substrate, such
as a plate or other element, connecting each of
the various bands of the coil together, which, again, would preclude
installation in the aforementioned manner despite the
possible presence of "space" in some sense between the bands of the coil.
[00409] It should be understood that some embodiments comprising a spiral/coil
shape, or an at least substantially spiral
shape, may extend in a vertical direction (perpendicular to the space between
adjacent bands referenced above) and may
therefore, for example, form a cone shape. Thus, there may be "space" between
each adjacent band in the same plane or, in
some embodiments, there may be space between each adjacent band in a vertical
direction such that the entire coil does not
reside in the same plane, either instead of or in addition to the lateral
"space" mentioned above. In some embodiments, an
implant may be configured for positioning within a soft tissue implant pocket
as in the description of Figs. 47.
[00410] In some embodiments, spiral implant 3701 may be circular in overall
shape and rectangular in cross section. As
described below, however, various other shapes may be used in alternative
embodiments. Spiral implant 3701 may be rigid
or, if preferred, more flexible. In some embodiments, the spiral implant 3701
may be compressible by being rollable and/or
foldable. In some embodiments, spiral implant 3701 may comprise a metal,
ceramic, cermet, glass, flexible plastic, organic
polymer, biopolymer, or the like. Other embodiments may comprise a polymeric
external lamination or containment to
retain more dissolvable materials such as hydrogels and the like. Drugs,
vitamins, or other chemicals, including biologics,
may also be bound, dissolved, or otherwise present in a portion or all of the
structure of spiral implant 3701 and/or elements
contained therein. In some embodiments, therapeutic agents may be discharged
into the adjacent vasculature to achieve a
therapeutic result in the (a) local tissues adjacent to the implant and/or (b)
non-adjacent (distant) tissues. A narcotic may be
an example of a therapeutic agents capable of non-adjacent (distant) tissue
effects if the discharging implant is located, for
example, in the subcutaneous tissues.
[00411] Spiral implant 3701 may, in some embodiments, comprise pores 3791, for
example, nanoscale agents responsive
to stimuli. Such nanoscale agents may respond to stimuli such as light,
magnetic fields, ultrasound, radio frequency, and x-
ray, which may allow for selective actuation from outside of the
user/patient's body. Magnetic fields may be used for
magnetoporation and magnetic field drug targeting. Electric current or voltage
may be used for electroporation and
iontophoresis. Ultrasound may be used for sonodynamic therapy and
sonoporation. Pulsed light may be used for
optoporation and drug release. Temperatures may be influenced for
thermoporation and hyperthermia. Such temperature
changes may be induced for example, by electricity (via, for example, a thin-
film resistor), by ultrasound, or by radiation,
such as microwave or infrared radiation. Hyperthermia may be induced via
magnetic particles or near infra-red light coupled
with gold nanorods. Various hybrids of magnetic nanoparticles may be used to
eradicate tumors such as breast, liver, colon,
and more, via magnetic fluid hyperthermia. Various light-triggered functions
could be implemented in a nanodevice, such
as light-induced cancer nanotheranostics, which normally respond to UV,
visible, and near infra-red light. Photosensitizers
responsive to UV, visible, or NIR light may include inorganic or organic
photosensitizers, such as, for example zinc
phthalocyanine, zinc oxide, quantum dots, and the like. NIR light can trigger
nanoparticles, such as gold nanorods,
polypyrrole, and others for photothermal therapy. Due to the low penetration
depth of light, optical fibers inserted through
surgery or endoscopy may aid in delivering light deeper into the body. Further
information regarding such possible nanoscale
agents and related materials and devices may be found in 'Physically
stimulated nanotheranostics for next generation cancer
Date Recue/Date Received 2022-12-30
62
therapy: focus on magnetic and light stimulations', Thorat, Applied Physics
Reviews 6, 2019 (041306), which is hereby
incorporated in its entirety by reference.
[00412] Different regions and/or portions of spiral implant 3701 may also have
different medications or chemicals printed
or otherwise designed into them. In addition, electronics, micro-pumps, and/or
printed circuit boards may be present in the
spiral implant 3701 when properly protected. Radiographically, sonically,
and/or electromagnetically identifiable material
may also be present in implant 3701 to aid in locating and/or manipulating the
implant. Spiral implants may be inserted by
rotating/winding the implant into a minimally invasive entrance wound, as will
be discussed and depicted later in greater
detail. Spiral implants may also lend themselves to carrying electronics, such
as inductance coils, thin film batteries, printed
circuit boards as well as chemicals, medicines, and/or biopolymers.
[00413] In some embodiments, spiral implants, such as implant 3701, may
measure at least 2 cm in diameter (measured
along the implant's footprint from one outer edge of an outer band to the
opposite outer edge of the outer band). In some
such embodiments, spiral implants may measure at least 5 cm in diameter, and
in some cases may measure at least 10 cm in
diameter, or in some such embodiments at least 20 cm in diameter. As depicted
in Fig. 37a, spiral implant 3701 comprises
turns. Spiral implants may comprise numbers of turns ranging from 1 to 100.1n
some embodiments, spiral implants may
comprise a range of numbers of turns chosen from the group of: 2-3 turns, 3-5
turns, 5-7 turns, 7-10 turns, 10-15 turns, 15-
20 turns, 20-50 turns, and 50-100 turns. In further embodiments, spiral
implants may comprise a range of numbers of turns
chosen from the group of: 2-30 turns, 3-25 turns 4-15 turns, and 5-10 turns.
Spiral implants may comprise diameters ranging
from lOmm to 50cm. In further embodiments, spiral implants may comprise a
range of diameters chosen from the group of:
1-3cm, 3-5cm, 5-7cm, 7-10cm, 10-15cm, 15-20cm, and 20-50 cm. In further
embodiments, spiral implants may comprise a
range of diameters chosen from the group of: 1-30cm, 2-20cm, 3-15cm, and 5-
10cm. Spiral implants may comprise an
overall arm/branch length (of a spiral arm) ranging from 35mm to 5m. In
further embodiments, spiral implants may comprise
a range of overall lengths of their spiral arms chosen from the group of: 3.5-
10cm, 10-20cm, 20-50cm, 50-100cm, 100-
250cm, and 250-500cm. In further embodiments, spiral implants may comprise a
range of overall lengths of their spiral
arms from the group of: 3.5-200cm, 4-100cm, 20-80cm, and 30-75cm.
[00414] Fig. 37b is a side view of implant 3701 also depicting outer arm band
terminus 3712, which, as discussed below,
may comprise an opening to allow for access to the interior of implant 3701 or
may be solid.
[00415] Fig. 37c is a top perspective view of implant 3701 also depicting
outer arm band terminus 3712.
[00416] Fig. 37d depicts a cross-sectional view of spiral implant 3701 taken
from Fig. 37a along the line and arrow depicted
therein. The cross-sectional view of spiral implant 3701 depicts
superstructure 3719 positioned on the upper surface of the
implant. Of course, in alternative embodiments, the superstructure 3719 may be
positioned on any other side and/or portion
of the implant. Spiral implant 3701 may also comprise temperature sensor
3719t, which may protrude from another location
on implant 3701. The depicted embodiment also comprises various
layers/elements, including a metallic inductance coil
3721, battery 3722 (thin film in this embodiment), printed circuit board 3723,
one or more additional inductance coils 3721a,
capacitor 3726, data storage 3727, lab-on-a-chip 3729, antenna 3792, ancillary
electronics 3724, such as a heating element,
thin film resistors, etc., and polymeric protective inner sheath 3725i, which
may be positioned adjacent to protective outer
sheath 3725o. As also shown in this figure, a hollow space may be created
between inner and outer sheaths 3725i/3725o,
which may be used to contain a fluid and/or gel, for example, which may serve
as a protective sheath/seal, a superstructure,
and/or a location for drug containment and/or delivery. In some embodiments,
microfluidic channels (not shown) may bring
patient serum/blood/tissue fluid located outside of the protected
encasement/wrapper in contact with lab-on-a-chip for
analysis(es). In further contemplated embodiments, temperature sensors may be
placed in many locations on the inside
and/or outside of spiral implant 3701 or any of the other implants disclosed
herein. Temperature sensors located on the
outside may, in some embodiments, be configured to send temperature data to a
CPU, which may be programmed with a set
temperature threshold such as, for example, 45 C, to possibly shut down or
reduce external wireless inductance coil charging
Date Recue/Date Received 2022-12-30
63
to protect delicate adjacent tissue. Once external temperatures return to a
preset safe threshold, for example 42 C, wireless
charging may recommence. Temperature sensors placed internally in the spirals
may have preset thresholds to alter the
charging parameters to protect one or more of the aforementioned internal
elements of the spiral coil 3701. Some
contemplated embodiments may comprise multiple internal antennas.
[00417] Silk nanoribbons (SNR), konjac glucomannan (KGM), and chromium or
aurum may be used to prepare
biodegradable wires for use in some embodiments. A vacuum filtration process
may be used to combine SNR and KGM
into a thin film. Chromium or Aurum may be evaporated onto the composite film
as electrodes. Further details regarding
such processes may be found in 'Natural Polymer-Based Bioabsorbable Conducting
Wires for Implantable Bioelectronic
Devices', Niu, Journal of Materials Chemistry A, 2020, DOI: 10.1039/d0ta09701b
which is hereby incorporated in its
entirety by reference.
[00418] Implantable wireless drug eluting devices may, in some embodiments,
employ a wirelessly induced current to
electrochemically accelerate the dissolution of a metal gate sealing a drug
reservoir, leading to drug release. For example,
polybutanedithiol 1,3,5-trially1-1,3,5-triazine-2,4,6(111,311,511)-trione
penteonic anhydride (PBTPA) may be used as a
substrate and reservoir for the drug in question. Current may be delivered to
the device via inductive wireless charging for
immediate actuation or, alternatively, the energy may be stored in a capacitor
for subsequent actuation at a desired time.
Electrodes of Mg may comprise the gates in some embodiments. The harvester may
generate an overpotential bias, which
leads to accelerated electrochemical corrosion of the Mg electrodes via
Faradic reaction enabled by the surrounding biofluid.
Given the irreversible nature of the reaction, the device may only be of
single use in some embodiments. Additional details
regarding such possible applications may be found in `Wirelessly controlled,
bioresorbable drug delivery device with active
valves that exploit electrochemically triggered crevice corrosion', Koo,
Health and Medicine, 2020, Vol. 6 No. 35, which is
hereby incorporated in its entirety by reference.
[00419] In some embodiments, additional elements, such as electronic elements,
may be coupled to the coil to make the
coil more useful as a standalone implant, or an implant configured to
standalone as a power supply to another, secondary
implant. In some such embodiments, use of a unitary coil, as shown in Fig.
80a, may eliminate the need for an auxiliary
implant altogether. In contemplated embodiments, a unitary coil may therefore
be coupled with other implants, such as
implants to which the unitary coil is providing energy, without the use of an
auxiliary implant to aid the unitary coil in doing
so. It is also contemplated, however, that some coil embodiments may have
some, but not all, of the components that may
be provided on an auxiliary implant and may therefore be considered a "hybrid"
coil implant.
[00420] Fig. 38 depicts a perspective view of a circular, spiral implant 3801
with circular cross section and a solid (as
opposed to hollow) center terminating in outer arm band terminus 3812.
[00421] Fig. 39 depicts a perspective view of another circular, spiral implant
3901 with circular cross section. However,
unlike spiral implant 3801, spiral implant 3901 comprises a hollow center
terminating in outer arm band terminus 3912.
Injection port and/or tubing 3934 may also be used to allow a surgeon or other
user to inject fluids for inflating a
superstructure hidden within implant 3901 and/or for injecting drugs. Port
3934 may extend above the patient's skin or,
alternatively, may be positioned below the patient's skin to allow for
subcutaneous injection of such drugs and/or other
fluids. In some embodiments, port 3934 may have radiographically, sonically,
or electromagnetically identifiable material
positioned therein to allow injection needle filling of the superstructure,
for example, with medications, such as for
chemotherapy. Fig. 40 depicts a perspective view of still another circular,
spiral implant 4001 with circular cross section. In
this embodiment, the center of implant 4001 is hollow again and terminates in
outer arm band terminus 4012. However,
unlike spiral implant 3901, spiral implant 4001 comprises an internal
guidewire 4014 for rigidity to facilitate implantation
or the like. In alternative embodiments, such as likely smaller spiral
implants, guidewire 4014 may be removable, which
may allow for retraction and introduction of other elements and/or materials,
such as gels, drugs, electronics, etc.
[00422] Fig. 41 depicts a top view of a rectangular, spiral implant 4101 which
may be both rectangular in shape in plan
Date Recue/Date Received 2022-12-30
64
view, as shown in the figure, and in some embodiments, may also be rectangular
in cross section. Implant 4101 comprises
4 turns. Alternatively, the cross-sectional shape may be circular, oval, or
other suitable shapes in other embodiments
including but not limited to geometric or 3 dimensional. In some embodiments,
additional elements, such as electronic
elements, may be coupled to the coil to make the coil more useful as a
standalone implant, or an implant configured to
standalone as a power supply to another, secondary implant. In some such
embodiments, use of a unitary coil, as shown in
Fig. 80a, may eliminate the need for an auxiliary implant altogether. In
contemplated embodiments, a unitary coil may
therefore be coupled with other implants, such as implants to which the
unitary coil is providing energy, without the use of
an auxiliary implant to aid the unitary coil in doing so. It is also
contemplated, however, that some coil embodiments may
have some, but not all, of the components that may be provided on an auxiliary
implant and may therefore be considered a
"hybrid" coil implant.
[00423] Fig. 42a depicts a top view of a pentagonal/polygonal, spiral implant
4201, which may be rectangular in cross
section with outer arm band terminus 4201a. Implant 4201 comprises 8 turns. In
further contemplated embodiments, the
cross section may be a non-rectangular shape. As should be apparent from
considering the shape of this implant, it is
contemplated that spiral implants may be formed into any suitable shape as
desired, preferably in a manner that allows for
winding/rotation of the implant into a minimally invasive entrance incision
one band/arm at a time, as discussed herein. As
shown in Fig. 69, as the space between adjacent arms approaches zero, the
possibilities for shapes either formed by spiral
arms or cut into a spiral are virtually limitless. For example, in some
contemplated embodiments, possible suitable shapes
may include: cartoon character, flower, sailor, or anchor. As per the
description for Fig. 37, a similar variety of turns may
comprise contemplated spiral implant embodiments.
[00424] Fig. 42b depicts an enlarged top view of outer arm band terminus 4201a
with a bulbous reduced catching tissue
passage facilitator 4201b with opening/port 4201c which may be configured to
accommodate electronic coupling and/or
fluid delivery/extraction. For example, tissue passage facilitator 42016 may
comprise a smooth cap and/or bulb configured
to both facilitate passage of the terminus 4201a through the entrance wound
and to provide a smoother tip to prevent terminus
4201a from catching on tissue as the implant 4201 is rotated and advanced into
the body/pocket. Port 4201c may comprise
an electrical port electrically coupled to another element of the implant or
an accessory device, implant, and/or element of a
system, such as the auxiliary implant 5408 shown in Fig. 54a, which will be
discussed in greater detail below.
[00425] Fig. 43 is an enlarged view of an oval cross section of a spiral band
43016 located between spiral band 4301a and
spiral band 4301c. Spiral band 43016 is shown passing through and being
compressed by an entrance wound 250. In this
embodiment, the implant comprises flaps 4301f, which may be flexible and
partially or fully fold/wrap around spiral band
4301b, which may allow the flaps to bend, fold, compress, or otherwise fit
into the minimally invasive entrance wound 250
with a lower profile and unfold/decompress once inside the body, as shown in
the other two arms/bands 4301a and 4301c.
In the configuration shown in Fig. 43, band 4301a is inside the patient, as it
has already passed through the entrance wound
250, whereas band 4301c has yet to pass through the entrance wound 250 and is
therefore wholly outside of the patient. The
procedure by which this implant is inserted into the patient will be described
below in greater detail.
[00426] In some embodiments, the flaps 4301f may allow a flexible inductance
coil 4319 to be positioned not only within
the central portion of spiral band 4301b but also may extend within the flaps
4301f themselves. Flaps 4301f can unfold like
the solar panels on a satellite once in the body to present a greater surface
area for various purposes. For example, when an
inductance coil 4319 is positioned, either partially or wholly, therein, this
may provide increased surface area for an inductive
charger. Increased surface area may also be beneficial for medicine/drug
release in alternative embodiments. Thus, for
example, in some embodiments, flaps 4301f may be fluidly coupled with the
center/main body of the spiral implant and may
be configured to recoil/unfold to the configurations of the inner and outer
bands of the implant, 4301a and 4301c,
respectively, by virtue of the fluid pressure contained therein.
[00427] Fig. 44 depicts an implant 4401 in which the bands are rectangular in
cross section resembling linguine, and which
Date Recue/Date Received 2022-12-30
65
may be spaghetti-like following implantation, such as similar to the
configuration shown in FIG. 44. In alternative
embodiments, the cross-sectional shape may instead be circular more like
spaghetti or other shapes as desired. Once
implanted spaghetti-like implants may be relatively planar/flattened (x,y
dimensions much greater than thickness z
dimension) and/or take on a 'tertiary' 3-dimensional shape (wherein x,y,z
dimensions are within less than one order of
magnitude of each other) for example if placed in the peritoneal cavity. In
some embodiments, such an implant may be used
to fill subcutaneous, muscular, and/or other outwardly visible defects from
trauma or cancer and/or be multifunctional by
carrying monitoring electronics for a cancer recurrence or anti-cancer
therapy. In some embodiments, such shapes may be
useful when implanted into anatomical locations such as the thoracic cavity or
abdomen, for example, in or around the
omental areas.
[00428] Fig. 45a is a side view of a portion of a flexible implant 4501,
which, in turn, may contain electronics 4511, and
which may, again, be spaghetti-like during and/or after implantation if
desired. Electronics 4511 may comprise inductance
coils, batteries, printed circuit boards, thin film resistive heaters, and the
like. In some embodiments, the implant 4501 may
resemble a tapeworm. Optional guide wire 4512, shown here as extending in a
straight line, may facilitate implantation
and/or be removable from implant 4501. Optional guide wire 4512 may comprise,
for example, a metal or other material
configured for placement within the implant, such as, for example, a naturally
conformed stainless, spring steel coil may be
used to introduce a soft, highly flexible implant into a tissue pocket and,
upon removal, leave the implant in a desired coil
shape imparted by the shape of the guide wire. In some embodiments, a shape
memory material may be used to form guide
wire 4512, such as a shape-memory alloy or shape-memory polymer. This may
allow for implants of a wide variety of
shapes, such as elongate implants, to be inserted through a minimally-invasive
entrance wound, and resume any shape within
the body, or remain in an elongated configuration, as desired.
[00429] To power such spaghetti-like implants, flexible, cable-like batteries
may be used in some embodiments. Flexible
implantable battery designs may include, for example, cable-type lithium ion
batteries. Such batteries may comprise several
Cu anode strands (coated with Ni-Sn) in a hollow helical shape, using a
modified PET separator membrane wound around
with an Al coil, surrounded by a LiCo02 tubular cathode, the entirety of which
may be insulated. The aforementioned
information and further schematic may be found in 'Cable-Type Flexible Lithium
Ion Battery Based on Hollow Multi-Helix
Electrodes', Kwon, Advanced Materials, 2012, which is hereby incorporated in
its entirety by reference.
[00430] Fig. 45b is a side view of a rigid hollow cannula/trocar 4515, which
may facilitate subcutaneous, intraperitoneal,
or intrathoracic implantation of a flexible spaghetti-like implant. In other
implementations, the cannula/trocar may have
some degree of flexibility or see use in other organ systems/cavities.
[00431] Fig. 45c is a side view of a plunger 4520 that may be used to drive an
implant, such as a flexible and/or spaghetti-
like implant through a rigid hollow cannula/trocar into its target resting
site. The plunger system may have plunger piston
4525 to drive the implant through the cannula when a force is applied by a
surgeon to plunger top 4530.
[00432] Fig. 46a is a side view of a flexible and/or spaghetti-like implant
system 4600 which may be somewhat reminiscent
of a segmented tapeworm. Implant system 4600 may comprise enlarged
segmentation pod 4671 with connecting segments
4672, which may comprise tubes, for example, through which may pass various
elements as desired, such as flexible
electronics 4673, including, for example, inductance coils, wiring, printed
circuit boards, fiber-optics, and the like. The
segmentation pods 4671 may, in some embodiments, be removable and addable to
allow the implant to be modular and/or
customizable. One or more of the segmentation pods 4671 may, for example,
comprise/contain one or more micro-
pumps/motors 4674, Printed Circuit Board 4675, sensors 4676, fluidic tubing
4678, fluidic tubing 4679, which may be
configured to deliver fluids in the opposite direction of tubing 4678, and/or
storage bays 4677, which may house drugs,
fluids, powders, etc. In further contemplated embodiments, a wrapper 4670 may
be placed overlying the exterior of pods
4671 and/or outside of connection segments 4672, which may facilitate sliding
the implant into an incision and past tissues
and/or may provide protection and/or a fluid seal to protect the components of
the various pods 4671. In some embodiments,
Date Recue/Date Received 2022-12-30
66
wrapper 4670 may comprise a shrink wrap or may otherwise be adherent to one or
more of the pods 4671, in which case the
wrapper 4670 may pinch/extend into the space overlying one or more of segments
4672 between the pods. Although wrapper
4670 is shown open at both ends, which is intended to convey the notion that
any number of additional pods 4671 may be
added to the implant at either end, it should be understood that it would
typically be closed before implantation.
[00433] Fig. 46b depicts an embodiment that facilitates the aforementioned
modularity. More particularly, a first pod
4671a is shown being coupled with a second pod 467 lb using a releasable male
connector 4680a configured to fit within a
female connector 46806. In this manner, pods can be obtained/added to the
assembly as needed. For example, a pharmacist
may add drugs to a pod specifically tailored for a particular patient and then
the pod may be snapped or otherwise coupled
to the chain by coupling it with an adjacent pod. It should also be understood
that pods may be selectively coupleable with
any of the other implants and/or implant components disclosed herein. For
example, an implantable inductance coil may be
configured with a connector configured to couple to a pod to allow for
selective addition of a power source. The reference
to spaghetti is to indicate that what may start as an organized implant, such
as an implant wound around a spool, once
inserted into the body may assume a relatively random appearance, similar to
that of a long spaghetti noodle dropped at
random. Areas where spaghetti-like implants may be helpful may include, for
example, intra-abdominal, intra-thoracic, or
other body cavities, where an assumption of filling a natural void/crevasse
with conformable materials is possible. In a
subcutaneous layer, it is possible that a spaghetti-like implant may be useful
in an area where tissue is missing from previous
trauma or a natural space of a breast, scrotum, or axilla.
[00434] Figs. 47a-e depict a method for placing the outer portion/terminus
47010 of a spiral implant into a subcutaneous
and/or soft tissue implant pocket comprised of two pocket portions outlined in
dashed lines in Fig. 47a, namely, an implant
pocket portion 4711, which may be similar to the pockets previously described,
and an implant delivery pocket portion 4712,
which is formed below the minimally invasive entrance incision 4710 and
opposite the minimally invasive entrance incision
relative to the implant pocket portion 4711 in these figures. Implant 4701
comprises 5 turns. In alternative embodiments,
spiral implants may comprise numbers of turns ranging as previously described
with reference to Fig. 37. As described in
greater detail below, implant delivery pocket portion 4711, which is
semicircular in the depicted embodiment, due to the
shape of the implant 4701, but may be formed of other shapes in alternative
methods, is a temporary pocket that is only used
during implantation of implant 4701. By contrast, implant pocket portion 4711
is configured to fully and, in some cases
permanently, receive the full implant 4701.
[00435] Fig. 47a depicts the right side of a human torso in which a
epidermal/dermal entrance incision 4710 has been made,
typically with a scalpel, to create a relatively minimal entrance wound into
the subcutaneous/fatty layer below in the
inguinal/hypogastric area to create an implant pocket via minimally invasive
dissection instrument, such as shown in Figs.
1 and 2. In some implementations, the pocket location is anywhere on the body
that a dissection can practically be made in
non-bony, non-cartilaginous tissues.
[00436] Fig. 47b depicts the dashed outline of a implant delivery pocket
portion 4712 and a connected polygonal implant
pocket 4711 (which may be shaped otherwise in other embodiments) in the
subcutaneous layer with minimally invasive
entrance wound 4710 lying roughly in-between their intersection/abutment. A
spiral implant 4701 is resting pre-placement,
as shown in Fig. 47b, on the outside of the skin in which it may eventually be
placed almost directly below. Once the spiral
implant 4701 is picked up by the surgeon, preferably with sterile technique,
the outer portion 47010 of spiral implant 4701
is made to fit through entrance wound 4710 in a rotating direction 4714.
[00437] Wires/wiring elements may be coupled to inner coil terminus 4701i
and/or outer coil terminus 4701o, which may
be left in place as the coil is rotated or otherwise positioned within an
implant pocket, such as implant pocket 4711. These
wires/elements, which are preferably durable and flexible, may remain passing
through incision 4710 and, if sufficiently
flexible and dynamically connected may rotate with the coil as it turns and is
repositioned from outside of the body to within
an implant pocket through a minimally invasive entrance incision, as discussed
throughout this disclosure.
Date Recue/Date Received 2022-12-30
67
[00438] Fig. 47c depicts the dashed outline of an implant delivery pocket
portion 4712 and a connected implant pocket
portion 4711 in the subcutaneous layer with minimally invasive entrance wound
4710. Spiral implant 4701 has been rotated
several turns now in the direction of arrow 4714 adjacent the outer
end/portion of the implant 47010 and thus much of the
implant 4701 is depicted in dashed lines indicating that this portion is in
the subcutaneous layer below the outer dermal
layers of the skin. It is to be noted that the inner terminal end 4701i of the
coil and the adjacent portion of the implant 4701
is the region now left for the surgeon to advance and twist as it lies
external to entrance wound 4710. Also, much of the
implant 4701 has, at the point of the procedure depicted in Fig. 47c, migrated
away from the implant pocket portion 4712
and into the implant delivery pocket portion 4711 by virtue of rotational
insertion and the shape. Thus, it should be apparent
that, if the external terminus 47010 is inserted first, as the implant 4701 is
advanced into the body, the implant 4701 will
naturally move towards the implant pocket portion 4711.
[00439] Fig. 47d depicts a subsequent stage of the process at which point the
implant 4701 has been fully inserted below
the patient/user's skin in the subcutaneous layer. Spiral implant 4701 is now
depicted by completely dashed lines and is thus
appreciated to be entirely hidden from view below the surface of the skin. The
implant 4701 has likely migrated as far as it
may go into the implant delivery pocket portion 4712 by virtue of rotational
insertion and the shape. The surgeon may then
advance the implant 4701 into the implant pocket portion 4711, as shown in
Fig. 47e. In some implementations, this may
be done via finger pressure on the outer skin by palpation and finger
pressure, preferably using the feel of the edge implant
4701 at location 4715 in the direction of the arrow 4716 in Fig. 47d. By
pressing the surgeon's finger against the edge of the
implant 4701 and pushing in the direction of arrow 4716, akin to kneading
dough, the surgeon can migrate the implant 4701
away from the entrance incision more toward and into the implant pocket
portion 4711. In some contemplated
implementations an instrument or suture may be used to place/move the implant.
In further contemplated embodiments,
increasing the flexibility and/or third dimensionality of a spiral implant may
allow for an increased number of possible
locations of minimally invasive entrance incision sites about the area of an
implant pocket portion from which to insert an
implant and/or a reduced need for area-size of an implant delivery pocket
portion.
[00440] Fig. 47e depicts implant 4701 wholly within implant pocket portion
4711 in the subcutaneous layer. The entrance
wound may now be sewn shut unless there are more ancillary parts to connect or
deliver through the entrance wound, such
as a wire, tube, or the like, which may be used to connect the implant with a
source of energy, access to drugs, or the like.
[00441] In alternative implementations for placing a spiral implant into a
subcutaneous implant pocket, the inner
portion/terminus 4701i may instead be inserted/passed through the minimally
invasive entrance incision 4710 before the
outer portion/terminus 47010 and rotated/spun in the direction of the inner
portion/terminus 4701i into pocket 4711 with
little or none of the implant requiring semicircular implant pocket 4712 for
placement, especially if implant 4701 is flexible.
Thus there may be no need for semicircular implant pocket 4712 if this
alternative method is used. A possible disadvantage
of placing a spiral implant where the inner portion/terminus 4701i may be
inserted/pass first is that the inner terminus, which
moves the least during implantation rotation (as it is the center of a circle)
will pass farther into the implant pocket toward
the end of the procedure, thus making placement of a fixation suture via the
inner terminus 4701i a bit more difficult.
[00442] In some embodiments, an implant may be configured for positioning
within a soft tissue implant pocket (or such
as an implant pocket below the surface of the skin but not within bone,
preferably within the dermis, subcutaneous tissues,
muscle, and/or fascia). The implant may comprise an arm extending in a spiral
shape from an outer terminus at a periphery
of the implant to an inner terminus adjacent to a center of the implant. the
arm may define a plurality of adjacent bands.
The implant may be configured to define a space between adjacent bands and/or
comprise a flexible material configured to
allow for temporary creation of space between adjacent bands so as to
facilitate insertion of the implant through a minimally
invasive entrance incision. Preferably, the implant may be configured to at
least substantially maintain the spiral shape both
before and after implantation within the implant pocket through a minimally
invasive entrance incision. In some such
embodiments, the implant may further be configured to at least substantially
maintain the spiral shape during implantation
Date Recue/Date Received 2022-12-30
68
within the implant pocket through the minimally invasive entrance incision.
[00443] Implants are foreign bodies, and with the trauma accompanying implant
pocket formation, seroma formation may
occur; thus, a temporary drain, for example 2-3mm diameter tubing, may be sewn
into the entrance wound as a
countermeasure.
[00444] Faraday's law states that the EMF induced by a change in magnetic flux
depends on the change in flux A, time At,
and number of turns of coils. Thus the number of turns shown in the diagram
and/or the apparent spacing may not be
representative of the optimal choices for a given use.
[00445] Figs. 48a-48L depict various alternative embodiments of respective
spiral implants 4801a-4801L having various
alternative configurations. Implant 4801a comprises a flat implant viewed from
the side. Implant 48016 comprises a spiral
circular implant viewed in cross-section, which may comprise, for example, one
band of a spiral implant. Implant 4801c
comprises an encasement 4802c, which may comprise one or more layers. Implant
4801d also comprises an
encasement/outer layer 4802d. Implant 4801e comprises multiple
laminates/layers, namely an inner layer 4802e and an outer
layer 4803e. Similarly, implant 4801f comprises an inner encasement 4802f and
an outer encasement 4803f. Implant 4801g
comprises a flat implant having a full encasement 4802g. Implant 4801h
comprises a rectangular-shaped implant in cross-
section (again, this may be but one arm/branch of a spiral implant in some
embodiments). Implant 4801i comprises a
flattened implant comprising an internal mesh. Implant 4801j comprises a full
encasement 4802j. Implant 4801k comprises
a cross-sectionally oval-shaped bladder-like implant having a corresponding
oval-shaped encasement 4802k. Implant 4801L
comprises two encasements, namely, an inner encasement 4802L and an outer
encasement 4803L. In some contemplated
embodiments, part or all of an implant or encasement may be
bioabsorbable/biodegradable. However, in other contemplated
embodiments, part or all of an implant may not be bioabsorbable/biodegradable;
in some of those contemplated
embodiments, all or part of the implant may be coated with
polytetrafluoroethylene (PTFE) or other inert/biocompatible
substances/elements. A coating with such a material and/or the like may make
surgical extraction through a relatively small
entrance wound more feasible, especially for instruments such as those shown
in Figs. 9a-b. In some contemplated
embodiments of spiral/coil and/or mesh type implants, such a coating may be
beneficial to facilitate removal and/or minimize
tissue interaction.
[00446] Fig. 49 depicts a human patient after having undergone a surgical
procedure using a lysing tip, such as a lysing tip
having beads and adjacent recesses for delivery of energy therefrom, to form
one or more implant pockets, each having one
or more dimensions substantially greater than those of the incision
4904a/49046/4904c used to create the respective pocket
4905a/49056/4905c. Each of the implant pockets 4905a/49056/4905c has a
respective implant 4901/4902/4903 contained
therein. In the depicted example, each of the implant pockets
4905a/49056/4905c contains a respective implant
4901/4902/4903 comprising a subcutaneous tattoo.
[00447] Each of the subcutaneous tattoos 4901/4902/4903 shown in FIG. 49 is an
illuminated tattoo comprising light
sources, such as LEDs, mLEDs, or OLEDs. Thus, implant 4901 comprises a heart-
shaped LED subcutaneous tattoo implant,
which is positioned within a subcutaneous implant pocket 4905a formed in the
chest area above the patient's heart organ.
Implant 4902 comprises a cross-shaped LED subcutaneous tattoo implant, which
is positioned within an implant pocket
4905b formed in a central region of the patient's abdomen. Implant 4903
comprises a miniature heart-shaped LED
subcutaneous tattoo implant, which is positioned within yet another implant
pocket 4905c formed adjacent to the patient's
groin region.
[00448] An external device, such as a smartphone or an external wearable
device, such as a watch or other armband 4998,
in some embodiments, may be used to detect the heartrate of the patient.
Armband 4998 may therefore comprise a heartrate
sensor 4998c and a wireless transmitter or transceiver 4998t, which may allow
for sending of signals containing the heartrate
to a smartphone 4999 via transceiver 4999t and/or to an internal receiver or
transceiver that may be part of one or more
implants, or auxiliary implants. In this manner, a user may be able to link an
internal tattoo, such as implant 4901, with the
Date Recue/Date Received 2022-12-30
69
user's heartrate such that the illumination provided by the implant 4901
matches up with the user's heartbeat. To accomplish
this feature, one or more other implants or implant components may be
provided, such as an inductance coil 4914 and/or an
energy storage source, such as a battery 4907 or supercapacitor, which may be
positioned on the implant 4901 or in a
connected auxiliary implant. A wireless receiver or transceiver 4908 may be
positioned on one or more of the implants, such
as implant 4901, and may be configured to receive signals from the heartrate
sensor 4998c, either directly from the armband
4998 or indirectly through smartphone 4999, which may be programmed to allow a
user to, for example, change the colors,
patterns, etc. of the illumination provided by the implant 4901, along with,
or as an alternative to, linking the pattern to the
wearer/user's heartrate.
[00449] In some embodiments, thin film encapsulation may be used to
encapsulate OLED devices. Methods to perform
thin film encapsulation may include, for example, atomic layer deposition
(ALD). In some embodiments, A1203 may be
used as an atomic layer deposed barrier layer. In some instances, 03-based
A1203 may be used as it may exhibit better
barrier properties than H20-based A1203. It may be preferred to use 03 as an
ALD reactor, but H20 may be used in some
instances. In other embodiments, nanolaminates such as, for example,
A1203/Ti02, may be prepared by ALD. In some
embodiments, barrier structures may comprise hybrid materials with embedded
polymers in a laminated structure to combine
high barrier properties with high flexibility. Some embodiments may comprise
an A1203/Hf02 nanolaminate barrier with
an inserted layer of SiNx to help alleviate barrier stress. In some
embodiments, OLED devices may benefit from additional
heat sink systems. In some such embodiments, ultrathin heat conducting films
with high flexibility, ductility, and/or
transparency may therefore be used to encapsulate OLED devices. Such barrier
layers may simply comprise Ag or
A1203/Ag/A1203 structures to improve anti-reflection effect. In a certain
embodiment, a barrier layer may comprise an
A1203/Ag/A1203/S-H nanocomposite/A1203 structure. An organic nanocomposite
layer may be inserted to improve
flexibility. Additional details regarding such encapsulation methods and
materials may be found in "Thin Film Encapsulation
for the Organic Light-Emitting Diodes Display via Atomic Layer Deposition",
Li, Journal of Materials Research, 2019,
DOI: 10.1557/jmr.2019.331, which is hereby incorporated herein in its entirety
by reference.
[00450] In some embodiments, LED devices may be used for light-emitting
sutures, implanted sheets (i.e. LED tattoos),
optical sensors, catheters, phototherapy, and the like. In some instances,
contacts, interconnections, and/or structural bridges
may be printed onto a temporary substrate, which may comprise, for example,
PMMA, before being transferred to and
integrated on elastomeric sheets, which may comprise, for example,
poly(dimethylsiloxane) (PDMS). PDMS may be
preferred as it is a soft, elastomeric, biocompatible material. In a preferred
embodiment, arrays of mLEDs may be connected
by serpentine-shaped ribbons which may serve as electrical interconnects or
structural bridges. Such serpentine structures
may absorb some or most of the applied strain. In some embodiments, LED
devices may comprise multilayer stacks or LED
arrays to overcome possibly low LED density within a single array. Integration
of numerous arrays may be accomplished
with PDMS coatings, which may serve as interlayer dielectrics, encapsulants,
and/or adhesives. Such PDMS coatings may,
in some embodiments, be as thin as 300 micrometers thick, resulting in four-
layer LED system with a thickness of up to
¨1.3mm. In some embodiments, LED devices may be connected in series to allow
full control over the entire array. In some
instances, an mLED array may be placed on a thin sheet of polyethylene
terephthalate film coated with an adhesive epoxy
layer, and encapsulated on both sides with PDMS. Thin ceramic-insulated gold
wires may be used to connect metal pads
around the edges of the array to external power sources. Additional details
regarding suitable LED devices may be found in
"Waterproof AlInGaP Optoelectronics on Stretchable Substrates with
Applications in Biomedicine and Robotics", Kim,
Nature Meterials, 2010, DOI: 10.1038/NMAT2879, which is hereby incorporated
herein in its entirety by reference.
[00451] In some embodiments, stretchable LED arrays may be used in fluid
composition sensors, proximity sensors, and/or
light emitting sutures. In some embodiments, such LED devices may comprise
waterproof protecting elements, thereby
permitting interaction of the device with biological environments. In some
embodiments, such devices may comprise
flexible and/or stretchable electronic circuits, which may comprise inorganic
semiconductor elements, controllers in
Date Recue/Date Received 2022-12-30
70
electrical communication with said circuit, and/or a flexible substrate, which
may comprise materials such as PDMS, and/or
an encapsulation barrier layer which may comprise an elastomer material. In a
certain embodiment, the LED device may
comprise a suture, which may comprise biocompatible, bioinert materials, or a
combination thereof In certain embodiments,
the suture may be bioresorbable, comprising materials such as, for example,
PLA, PLGA, and the like. In some instances,
such materials may comprise, for example, polyglycolic acid, polylactic acid,
polypropylene, polyester, nylon, and the like.
In some embodiments, the device may comprise a barrier layer having a
microstructured external surface providing a
plurality of features, such as, for example, channels, pores, openings, and
the like, exposed to the biological environment.
In some embodiments, such features may be patterned using replica molding
and/or nano-imprint lithography techniques.
In some embodiments, the implanted LED device may be used to provide
phototherapy to a target tissue. In some
embodiments, the device may be in electrical communication with a controller
which may, for example, provide a
current/voltage to the circuit. In some embodiments, electrical interconnects
with the controller may be used, which may
comprise wire bonded interconnects, ribbon cables, lithographically patterned
conductors, and the like. In some
embodiments, LED arrays may comprise, for example, AlInGaP LEDs, GaN LEDs,
stacked inorganic LEDs, inorganic
LEDs, and the like. In some embodiments, each LED may be individually
addressable. In some embodiments, LED arrays
may be stacked, in which a stacked LED element may emit green, red, and/or
blue light. In some embodiments, the LED
array may generate electromagnetic radiation, which may be used for tissue
actuation, detection, and/or transmission through
a plasmonic crystal or the like. In some instances, the LED array layers may
be configured in a laterally offset position such
that the LEDs in each layer do not reside on top of each other. In some
embodiments, the device may employ an island
bridge structure, in which bridges connecting device islands may be wavy,
buckled, serpentine, and/or meandering. In certain
embodiments, the LED device may be in optical communication with a plasmonic
crystal, which may be used to transmit
or receive /electromagnetic radiation. Additional details regarding such
structures and materials for LEDs may be found in
U.S. Patent Application Publication No. 2018/0359850, titled "Waterproof
Stretchable Optoelectronics", which is hereby
incorporated herein in its entirety by reference.
[00452] In some embodiments, flexible and/or stretchable electronic displays
may be implanted in the body. Such
implantable electronics may comprise, for example, a flexible and/or
stretchable substrate, a stretchable and/or flexible
circuit supported by the substrate, a barrier layer encapsulating at least a
portion of the circuit, and/or substrate. In some
embodiments, the flexible/stretchable substrate may comprise polymers,
rubber/silicone materials, biocompatible/bioinert
materials, gas-permeable elastomeric sheets, and the like. In certain
embodiments, the circuit may comprise any combination
of, for example, electrodes, transistors, inducers, LEDs, LED arrays,
capacitors, sensors, actuators, inductors, controllers,
and the like. Other embodiments may comprise circuits comprising nanoribbons,
micromembranes, and/or nanomembranes,
which may comprise, for example, metallic structures, crystalline structures,
or any hybrid thereof. In some instances, the
circuit may comprise island and bridge structures. In some embodiments, the
barrier layer may comprise, for example,
polymers (organic/inorganic), elastomers, biopolymers, biocompatible/bioinert
materials, and the like. Some examples of
barrier compositions may include, for example, acrylate polymers, siloxane
polymers, cyanoacrylates, and the like. The
barrier layer may be used, in some embodiments, for functions such as, for
example, electronic, thermal, and/or optical
insulation from the biological environment. Such implanted electronics may
also comprise a multilayer geometry. For
example, the substrate, circuit, and barrier layer may comprise stacked
layers, potentially with intermediate layers. In some
embodiments, the barrier may be structured to comprise optically
transmissive/opaque regions, and/or regions permeable to
select molecules. In other embodiments, the barrier may comprise, for example,
multilayer structures and/or
nano/microstructured features. In certain embodiments, actuating elements may
include, for example, electrode elements,
electromagnetic radiation-emitting elements, LEDs, lasers, and the like.
Additional details regarding such electronic devices
may be found in U.S. Patent Application Publication No. 2020/0315488, titled
"Flexible and Stretchable Electronic Systems
for Epidermal Electronics", which is hereby incorporated in its entirety by
reference.
Date Recue/Date Received 2022-12-30
71
[00453] In some instances, implanted devices may be configured to use light or
other electromagnetic radiation for
therapeutic purposes. Such implanted devices may comprise, for example, an
antenna, circuitry, supercapacitors, light
sources (which may be assembled into an array), and/or fiber optic light
guides (to guide light to the target tissue). In certain
embodiments, the device may receive energy via transcutaneous wireless
transmission from an external coil, which may
charge a supercapacitor, which may, in turn, provide power to the light
sources. In a preferred embodiment, the device may
use light to target light-sensitive proteins, triggering a change within the
targeted tissue. In certain embodiments, the device
may be remotely powered and/or employ wireless communication. In some
instances, the device may be controlled via
onboard computer or external data telemetry. In some embodiments, the light
sources may comprise, for example, LEDs or
lasers. Additional details regarding such light therapy devices and methods
may be found in U.S. Patent Application
Publication No. 2014/0324138, titled "Wirelessly-Powered Illumination of
Biological Tissue", which is hereby incorporated
in its entirety by reference.
[00454] A peeling reduction layer may be used in some embodiments, for
example, to reduce potential peeling of an OLED
panel. The OLED device may comprise, for example, a substrate (comprising
opening and non-opening regions), OLEDs
disposed on the substrate, a bank layer on a non-opening region, and a peeling
reduction layer having a reverse-tapered
shape disposed in the non-opening area. Additional details regarding OLED
devices with peeling reduction layers may be
found in U.S. Patent No. 9,570,524, titled "Flexible Organic Light Emitting
Diode Display Panel", which is hereby
incorporated in its entirety by reference.
[00455] In some embodiments, LEDs may comprise a layered stack, which may
comprise, for example, a p-type layer, an
n-type layer, and a p/n junction therebetween. In certain instances, a p-
electrode may be disposed on a first side of the
substrate in contact with the p-type layer on an exposed surface and an n-
electrode on a first side of the substrate in contact
with a surface of an n+ sub-layer of the n-type layer. Additional details
regarding such LEDs may be found in U.S. Patent
No. 8,502,192 titled "LED with Uniform Current Spreading and Method of
Fabrication", which is hereby incorporated in
its entirety by reference.
[00456] In some embodiments, LED chips may comprise a plurality of sub-LEDs
mounted on a submount. In some
instances, sub-LEDs may be serially interconnected such that the voltage
necessary to drive the sub-LEDs depends on the
number of sub-LEDs and the junction voltage of the sub-LEDs. Additional
details regarding such LED devices may be
found in U.S. Patent No. 8,530,921, titled "High Voltage Low Current Surface
Emitting LED", which is hereby incorporated
in its entirety by reference.
[00457] Some embodiments may comprise implanted LED devices configured for
cell stimulation. In some instances, gene
transfer (via methods such as, for example, a virus) may be used to induce
expression of photosensitive bio-molecular
proteins. Such proteins may comprise, for example, photosensitive proteins
that bind to target cells. In other embodiments,
the device may be used to stimulate electrically-excitable cells, such as, for
example, neurons. Additional details regarding
such devices may be found in U.S. Patent Application Publication No.
2008/0085265, titled "System for Optical Stimulation
of Target Cells", which is hereby incorporated in its entirety by reference.
[00458] In some instances, LED devices may be used to stimulate target cells
along an elongated light-delivery passageway.
Such devices, in some embodiments, may be used to delivery light to light-
responsive proteins adjacent to activated light
sources along the elongated light-delivery structure. Such cells may comprise,
for example, neurons, which may be
genetically altered to express proteins such as, for example, ChR2, rendering
the neurons responsive to light. Additional
details regarding such light-stimulation devices and techniques may be found
in U.S. Patent No. 10,426,970, titled
"Implantable Optical Stimulators", which is hereby incorporated in its
entirety by reference.
[00459] In some embodiments, LED devices may be flexible. Such devices may
comprise, for example, a flexible LED
module in which LEDs are disposed in an array on a flexible circuit board, a
protective sheet covering the LEDs, a heat
conduction sheet under the flexible LED module, and/or a heat radiation sheet
under the heat conduction sheet. Additional
Date Recue/Date Received 2022-12-30
72
details regarding such flexible LED devices may be found in U.S. Patent No.
10,107,488, titled "Flexible LED Substrate
Device", which is hereby incorporated in its entirety by reference.
[00460] In some embodiments, OLED displays may be flexible. Such devices may
comprise, for example, multi-layer
encapsulation films with a metal layer on or within a bending portion of the
film. Such multi-layer encapsulation films may
include, for example, at least a first inorganic layer, an organic layer, and
a second inorganic layer. The metal layer may be
formed and placed such that it reduces the stress generated and prevents
cracks from forming within the encapsulation film
due to bending. Additional details regarding such flexible OLED devices may be
found in U.S. Patent No. 10,326,109, titled
"Flexible Organic Light Emitting Diode Display Device", which is hereby
incorporated in its entirety by reference.
[00461] In some embodiments, organic LEDs may be used as part of and/or in
connection with various implants disclosed
herein. Such LEDs may be implemented into circuits by linking the anode to the
positive terminal side of a battery preferably
contained on the implant and linking the cathode of the OLED to the negative
battery terminal side. In circuits with OLEDs,
current limiting resistors may be useful as well, as too much current can
cause burn-out. Other OLED properties worthy of
consideration may include forward voltage drop, maximum recommended current,
and luminosity.
[00462] Micro LED (mLED) devices may be used in some embodiments, such as
embodiments involving illuminated
internal tattoos. Such devices may comprise, for example, two-dimensional
arrays of parallel-addressed InGaN blue micro-
LEDs. InGaN or GaN LEDs may offer new approaches to allow more light to be
released from LEDs by increasing surface
area via etching of microdisks. LED wafers may be grown of sapphire substrates
while employing GaN buffer layers, Si-
doped GaN layers, InGaN/GaN multi-quantum wells for emission. 5i02 layers may
be used as insulation layers before Ti
or Al are used for the n-contact and Ni or Au are used for the p-contact.
Sloped sidewalls may be employed to allow
individual elements to be easily interconnected in parallel via metallization.
Although LEDs, mLEDs, or the like may be
preferred, any light sources, including incandescent light sources, may be
used in various embodiments. Further details
regarding GaN-based mLEDs may be found in 'Efficient GaN-based Micro-LED
Arrays', Choi, 2003, Mat. Res. Soc. Symp.
Proc. Vol. 743, Materials Research Society, which is hereby incorporated in
its entirety by reference.
[00463] Microdisplays (mD) may be comprise, in some embodiments, GaN-based
mLEDs of green and blue with
transparent epitaxial and insulating sapphire substrates. Red mLEDs may
comprise, for example, AlGaInP, which may be
grown on opaque and/or conductive GaAs substrates. AlGaInP epilayers may also
be used for certain applications, in which
epilayers may, for example, be bound to double polished sapphire substrates
via, for example, wafer-bonding followed by
removal of the absorbing GaAs substrate. In order to improve performance of
red mLEDs, the epilayer of the mLEDs may
be transferred to a sapphire substrate via wafer bonding in some embodiments
and implementations. Luminescence of such
mLEDs may be dependent on current; as distance from the p-contact increases,
resistance increases, leading to a decrease
in brightness. Thus, the amount of current delivered to the mLEDs may be
adjusted by the user, such as via a wireless
communication technology, such as Bluetooth , to allow the user to adjust the
lighting and/or display of the underlying
implant. Further details regarding mLEDs and microdisplays that may be useful
in connection with one of more of the
embodiments disclosed herein, such as AlGaInP-based red mLEDs, may be found in
'Fabrication and Study on Red Light
Micro-LED Displays, Homg, 2018, IEEE 2168-6734 (c), which is hereby
incorporated in its entirety by reference.
[00464] mLED displays may, in some embodiments, be based on inorganic GaN-
based LEDs. mLED displays may offer
advantages such as high resolution, high brightness, flexibility,
durability/reliability, low power consumption, and fast
response time. The growth technique, transfer printing technique, and/or color
conversion technique may be used to yield a
full-color mLED display, which may comprise and/or be part of various implants
disclosed herein. mLEDs may include, for
example, nanowire LEDs, multicolor quantum well (QW) mLEDs, and nanoring LEDs.
QW mLEDs may be integrated with
complementary metal-oxide-semiconductors (CMOS) for certain uses. Transfer
printing techniques for assembly and
processing of mLED displays may include, for example, the pick-and-place
process (which may utilize
polydimethylsiloxane stamps (PDMS)), laser selective-release, electrostatic
pick-up transfer, electromagnetic pick-up
Date Recue/Date Received 2022-12-30
73
transfer, and/or fluidic transfer. Color conversion may be achieved via one or
more of the following methods: using UV
mLED arrays to excite organic fluorescent materials; and combining quantum
dots and inkjet printing technique with UV
mLED arrays. Color conversion may be achieved with materials such as colloidal
CdSe/ZnS nanocrystals combined with
self-aligned curing methods to limit the material to the top of designated UV
mLEDs. Donor substrates for mLEDs may
include Si, SiC, sapphire substrates, and others. To form a top-emission mLED,
epitaxial growth of mLED may be performed
on the substrate by, for example, metal-organic chemical vapor deposition
(MOCVD). In some embodiments, the epitaxial
structure may consist of a doped GaN buffer layer, a n-GaN layer, an InGaN/GaN
multiple QW region, and a p-GaN layer.
An indium tin oxide (ITO) film, which may be formed via electron beam
evaporation of magnetron supporting, may be
fabricated on the surface of the p-GaN layer. The epitaxial wafer may then be
mesa-etched by, for example, inductively
coupled plasma and thermally annealed to form a p-type ohmic contact of p-GaN.
Plasma-enhanced chemical vapor
deposition may be used to deposit a 5i02 passivation layer for certain
embodiments. Sputtering may be used to deposit a
Ti/Au layer on the ITO layer to form a p-pad. Substrate removal may be useful
in connection with full-color displays.
Removal methods may include, for example, the laser lift-off technique (which
only works with UV-transparent substrates,
such as sapphire substrates), and the chemical substrate removal method (which
may only be viable with Si substrate).
Nanostructure pixels for full-color mLED displays may be precisely fabricated
through high-resolution photolithography.
Selective-area growth techniques (SAG) may allow precise control over the
growth of InGaN/GaN nanowires. Nanowire
(ensemble InGaN/GaN or single) diameter may be increased to yield color
emissions shifting from blue to red. Core-shell
nanowires composed of, for example, lateral and longitudinal QWs may have
color modulation due to changes in bias
voltages, shifting from red to blue as voltage increases. Again, this
introduces the possibility of modulating the voltage of
the LEDs/display to selectively adjust one or more aspects and/or parameters
of the implant. Nanoring LED fabrication via
monolithic epitaxial growth may also be used to yield full-color mLED
displays. Color conversion may be utilized in some
embodiments to change the colors of monochrome mLEDs. Red and green lights may
be obtained by exciting red and green
quantum dots or phosphors with blue/UV mLEDs. AJ printing methods for color
conversion may be coupled with photoresist
molds to reduce optical crosstalk and improve color purity. Geometric color
converters may also be employed to improve
contrast and purity of mLED colors. The liquid-capillary force transferring
technique may be used in the process of color
conversion. Further details regarding mLED technology and mLED displays that
may be useful in connection with one or
more of the implants disclosed herein may be found in 'Growth, Transfer
Printing and Colour Conversion Techniques
Towards Full-Colour Micro-LED Display', Zhou, 2020, JPQE, 100263, which is
hereby incorporated in its entirety by
reference.
[00465] mLEDs may also employ color filters in some embodiments to change the
color of monochromatic mLEDs to
encompass the RGB spectrum. Furthermore, mLED displays may utilize flexible
substrates to allow for flexible displays,
which may be particularly useful due to the nature of the implants disclosed
herein in preferred embodiments. Variations in
luminance may occur and thus require correction to yield uniform brightness
across the display. Further details surrounding
such mLED displays may be found in 'Progress in MicroLED Fabrication and
Quality: Closing the Commercialization Gap',
Corning, 2021, Radiant Vision Systems, radiantvisionsy stems.com/blog/progress-
microled-fabrication-and-quality-closing-
commercialization-gap, which is hereby incorporated in its entirety by
reference.
[00466] mLED arrays may constitute direct-view mLED displays or mLED
microdisplays. Direct-view mLED displays
may, for example, comprise mLEDs fabricated with small pixel pitches,
separated into individual dice, and transferred to an
active-matrix backplane using methods such as the pick-and-place technique.
The larger expansion may allow for high
luminescence displays. The large unoccupied space between individual LEDs may
allow for interconnection electronics and
larger current distribution for passive-matrix display development and
integration and also permits active-matrix approaches
for large-areas. Resulting large (3-70in) direct-view mLED displays may show
improved luminescence coupled with
improved color gamut. Secondary substrates for direct-view mLED displays may
include glass or flexible substrates. Active-
Date Recue/Date Received 2022-12-30
74
matrix formats may be formulated by transferring mLEDs to secondary substrates
with, for example, indium gallium zinc
oxide and/or low-temperature polysilicon transistors. mLED microdisplays may
use semiconductor integration to combine
small pixel-pitch mLEDs with transistor back plates, which may be integrated
with optical systems. Due to the small pixel-
pitch for micro displays, the scaling of mLEDs may benefit from full
integration at the wafer-fabrication level, resulting in
active-matrix schemes as passive-matrix schemes may be unable to achieve
brightness or resolution for displays under 2in.
Methods for semiconductor integration may include pixel-to-transistor bonding,
chip-level mLED pixel-to-CMOS-transistor
bonding, LED epitaxial transfer to silicon CMOS, and/or integration with thin-
film transistors. Micro-tube technology may
aid in the bonding process in chip-level bonding. Transistors may be
fabricated from polycrystalline silicon to yield a high-
performance low-temperature transistor from which necessary circuits may be
formed. Colors may be generated via, for
example, one or more of the following methods: combining three mLED
microdisplays; integration of phosphor materials;
and stacking of red, green, and blue epitaxial layers. Parabolic mLED
structure may be used for light collimation and light
extraction (analogous to InfiniLEDO's mLED technology). Further information on
mLED displays may be found in 'Micro-
LED Technologies and Applications', Lee, Frontline Technology, 2016, which is
hereby incorporated in its entirety by
reference.
[00467] In some embodiments, micro LED (mLED) displays for use in implants may
be assembled using micro-printing
technology. In some instances, mLED devices may be prepared on a native
substrate and be printed onto a display substrate,
which may be, for example, flexible and/or transparent. Such methods may allow
for the formation of mLEDs under
conditions that may not be suitable for the display substrate. Certain
embodiments may comprise display substrates
comprising, for example, plastic, polymers, resins, sapphire, and the like.
Some embodiments may comprise displays with
sparsely distributed mLEDs and/or integrated functions such as embedded
memory, micro-sensors (such as light sensors),
power harvesting devices, antennae, and the like. In some instances,
additional mLEDs of different colors, such as yellow,
cyan, or slightly different RGB emitters, may be used to broaden the color
gamut. Additional details regarding such displays
may be found in U.S. Patent Application Publication No. 2015/0372051, titled
"Micro Assembled LED Displays and
Lighting Elements", which is hereby incorporated in its entirety by reference.
[00468] Processes such as bonding and laser lift off may be used to transfer
mLEDs from the working substrate onto the
carrier substrate, which may, for example comprise flexible and/or
biocompatible materials. It may be preferable for certain
applications that the carrier substrate comprises at least two layers, which
may include a carrier layer and flexible polymer
layers. Such a carrier substrate may allow singulated LED structures to be
embedded within a flexible environment, which
may be particularly useful for some of the implants disclosed herein. Certain
embodiments may comprise, for example,
GaN-based mLED matrices on flexible substrates, suitable for implanting within
the body. Additional details regarding such
methodologies and systems may be found in U.S. Patent No. 10,276,631, titled
"Method for Producing a Micro-LED Martix,
Micro-LED Matrix and Use of a Micro-LED Matrix", which is hereby incorporated
in its entirety by reference.
[00469] Certain embodiments of flexible mLED devices may comprise, for
example, a flexible substrate, upper insulating
film, lower insulating film, a thin metal layer between the upper and lower
insulating films, a plurality of mLED chips
arrayed on the top surface of the flexible substrate, and/or a light-
transmitting resin on the top surface of the flexible substrate
to cover the top and side surfaces of the mLED chips. In some embodiments, the
flexible substrate may comprise a reflective
layer, such as a white reflective layer, which may be in contact with the
light-transmitting resin. Further details regarding
such mLED displays may be found in U.S. Patent Application Publication No.
2021/0265328, titled "Flexible Lighting
Device and Display Panel Using Micro LED Chips", which is hereby incorporated
in its entirety by reference.
[00470] In some instances, mLED devices may include, for example, those in
which CMOS (complementary metal-oxide-
semiconductor) cells may be arranged in a mLED driving substrate backplane and
a mLED panel which may be flip-chip
bonded onto the driving substrate. In certain embodiments of the mLED panel,
mLED pixels may be electrically connected
with the CMOS cells, in which mLED pixels may be formed by etching a first
surface of an emission structure along a pixel
Date Recue/Date Received 2022-12-30
75
region, and separators may be formed on a second surface in between locations
of mLED pixels. Additional information
regarding such mLED displays may be found in U.S. Patent No. 10,636,349,
titled "Micro LED Display Device and Method
of Fabricating the Same", which is hereby incorporated in its entirety by
reference.
[00471] Reflective pixels in or beneath a display viewing area may be used in
certain embodiments such as, for example,
a reflective display with a mLED front light. Some embodiments may include a
display comprising a layer of reflective
pixels beneath a viewing area, and a layer, which may be, for example, a
transparent layer, which may be positioned on or
over the reflective display viewing area. In some instances, the layer
(transparent in this example) may comprise a plurality
of mLEDs oriented to emit light toward the reflective display viewing area, a
plurality of conductors electrically connected
to the mLEDs, and/or a controller for mLED function. Additional details
regarding such reflective displays may be found
in U.S. Patent No. 10,133,426, titled "Display with Micro-LED Front Light",
which is hereby incorporated in its entirety by
reference.
[00472] In some instances, mLED devices may comprise a receiving substrate and
a mLED. In certain embodiments, the
mLED may constitute first and second semiconductor layers, a current
controlling layer, reflective layers, and/or one or
more electrodes. The first and second type semiconductors may be joined. The
current controlling layer may be joined with
the semiconductor layers, and may comprise at least one opening therein. The
reflective layer may be electrically coupled
with the first type semiconductor layer. The first electrode may be positioned
on the receiving-substrate layer-facing side of
the reflective layer, acting as an adhesive bonding system with the receiving
substrate. Additional details regarding such
mLED devices may be found in U.S. Patent No. 10,297,719, titled "Micro-Light
Emitting Diode (Micro-LED) Device",
which is hereby incorporated in its entirety by reference.
[00473] Some embodiments of mLED devices may constitute mLEDs comprising, for
example, a micro p-n diode and a
metallization layer between the p-n diode and a bonding layer. In some
instances, a conformal dielectric barrier may span
the sidewalls of the p-n diode. In some embodiments, the bottom surface of the
p-n diode may be wider than the top surface
of the p-n diode, which may be accomplished by, for example, providing tapered
sidewalls. In other embodiments, the top
surface of the p-n diode may be wider than the bottom surface of the p-n
diode, or of the same width as the bottom layer. In
other embodiments, the bottom surface of the p-n diode may be wider than the
top surface of the metallization layer. Once
formed, the mLED structure and arrays may be transferred from a native
substrate to a receiving substrate. In certain
embodiments, the receiving substrate may comprise, for example, a lighting
substrate, a substrate with devices such as
transistors or integrated circuits, and/or substrates with metal
redistribution lines. Additional details regarding such mLED
devices may be found in U.S. Patent No. 10,297,712, titled "Micro LED
Display", which is hereby incorporated in its entirety
by reference.
[00474] The subcutaneous tattoos 4901/4902/4903 shown in FIG. 49 may also
comprise organic LED devices in some
embodiments, such as organic Polymer LEDs (PLEDs), which may be as thin as 3
micrometers or less. Such PLEDs may
be manufactured, for example, on ultrathin parylene films while using
transparent electrodes from indium tin oxide (ITO).
A protective passivation layer (which may comprise of 5 alternating layers of
SiON and Parylene) may be inserted into the
display film to improve durability and half-life of the PLED. The
aforementioned PLED system may, in some embodiments
and implementations, be used in conjunction with organic photodetectors (OPD)
to yield ultrathin sensors, such as reflective
pulse oximeters. Such organic optical devices may also be made flexible and
stretchable by using rubber substrates and
laminating in prestretched acrylic tape-silicone rubber sheets. Further
information regarding such PLEDs may be found in
`Ultraflexible Organic Photonic Skin', Yokota, 2016,
advantages.sciencemag.org, which is hereby incorporated in its
entirety by reference.
[00475] Organic LEDs are often extremely sensitive to water vapor and oxygen
exposure. Thin Film Encapsulation (TFE)
methods may therefore be employed for encapsulating implantable OLED devices
into a biocompatible implant. In order to
minimize risk of damaging the OLEDs, films may need to be applied at lower
temperatures, which may lead to defects.
Date Recue/Date Received 2022-12-30
76
Multilayer films with alternating stacks may be used if desired such that
defects in each individual layer do not span the
whole thickness of the encapsulation. One layer of the alternating stack in
some cases may be composed of TPD (TPD-N,
N'-diphenyl-N, N'-bis-3-methylphenyl [1, 1'-bipheny]-4, 4'-diamine, while
another layer may be composed of a
synthesized material XP (2.2.6. 5, 5'-(4, 4 '-(2,6-di- tert-buty lanthracene-
9, 10-diy1)bi s(4, 1-pheny lene))6 is(2 -(4-hexy 1pheny1)-
1, 3, 4-oxadiazole). Vacuum thermal deposition may be used in some embodiments
to form the alternating stack for
encapsulation. Further details may be found in 'New Organic Thin-Film
Encapsulation for Organic Light Emitting Diodes',
Grover, Scientific Research, 2011; 1: 23-28, which is hereby incorporated in
its entirety by reference.
[00476] Some implantable LEDs may comprise biocompatible polymers, such as
poly(dimethylsiloxane) (PDMS), to
create a mesh-like array of LEDs. Polymers such as PDMS may make the array
flexible and/or stretchable. Further
information regarding such implantable LEDs may be found in 'Flexible LEDs For
Implanting Under the Skin', Edwards,
2010, which is hereby incorporated in its entirety by reference.
[00477] Additional embodiments may involve and/or comprise encapsulation
materials for OLED devices to prevent
damage from external sources. In some embodiments, thin film barriers may be
ideal, as thin film barriers provide the OLED
with flexible capabilities. Such barriers may include, for example,
alternating layers of A1203 and polymerized hexane. On
top of such thin film barriers, biocompatible layers may be placed to protect
the receiving organism. Further information
regarding encapsulation for OLED devices may be found in 'Review of
Organic/Inorganic Thin Film Encapsulation by
Atomic Layer Deposition for a Flexible OLED Display', Lee, The Minerals,
Metals, and Materials Society, 2018, which is
hereby incorporated in its entirety by reference.
[00478] OLED devices may also be fabricated in such a way that they do not
require being attached to a substrate. Some
such OLEDs may be sandwiched between 2 hybrid TFE (thin film encapsulation)
layers (one composed of Al2O3/ZrO2
nanolaminates and the other Parylene-C). Such substrateless encapsulation may
make the OLED flexible and water-resistant.
Further information on substrateless OLED devices may be found in 'A
Substrateless, Flexible, and Water-Resistant Organic
Light Emitting Diode', Keum, Nature Communications, 2020; 11:6250, which is
hereby incorporated in its entirety by
reference.
[00479] Each of the implant pockets may be formed and sized to specifically
accommodate a particular implant. Thus, the
implant pocket 49056 containing the cross is largest to accommodate the
largest of the depicted tattoo implants and the
implant pocket 4905c containing the miniature heart is smallest to accommodate
the smallest of the depicted tattoo implants.
However, each of the implant pockets, along with each of the respective
implants 4901/4902/4903, is substantially larger
than the incision made in order to form the pocket. More particularly, each
incision has a length that is substantially smaller
than the -width" or largest dimension of the implant pocket parallel to the
incision.
[00480] In preferred embodiments and implementations, the length of each
incision 4904a/49046/4904c may be between
about 5 mm and about 25 mm. In some such embodiments and implementations, the
length of the incision
4904a/49046/4904c may be between about 12 mm and about 18 mm. Thus, the
procedures described herein can all be
considered minimally invasive and should lead to little scarring. However, the
size of the implant and implant pocket can
be much larger, due to the techniques and inventive structures and features
described herein.
[00481] For example, in some embodiments and implementations, the size of the
implant pocket may therefore have a
maximum dimension that is more than three times the length of the entrance
incision. In some such embodiments and
implementations, the size of the implant pocket may therefore have a maximum
dimension that is more than four times the
length of the entrance incision. In some such embodiments and implementations,
the size of the implant pocket may therefore
have a maximum dimension that is more than five times the length of the
entrance incision.
[00482] In some embodiments and implementations, the size of the implant
pocket may have a maximum dimension in a
direction parallel, or at least substantially parallel, to a direction of the
incision, that is more than three, four, or five times
the length of the entrance incision.
Date Recue/Date Received 2022-12-30
77
[00483] In some embodiments and implementations, the implant pocket may have a
minimum dimension of at least three,
four, or five times the length of the entrance incision.
[00484] In some embodiments, the implant itself may be configured to be
substantially reduced in size to allow for insertion
through the entrance incision and then expanded once past the entrance
incision and is within the implant pocket. This
reduction and expansion in size may be accomplished, for example, by
compressing, rolling, and/or folding the implant, as
previously discussed.
[00485] In some preferred embodiments and implementations, the maximal
dimension of the uncompressed implant in
height, width, and/or any measurable dimension _________________________ after
implantation may be at least four times the maximal, cross-sectional
dimension of the implant in its compressed/deployment configuration. In some
such embodiments and implementations, the
maximal dimension of the uncompressed implant __________________________ in
height, width, and/or any measurable dimension after implantation
may be at least seven times the maximal, cross-sectional dimension of the
implant in its compressed/deployment
configuration. In some such embodiments and implementations, the maximal
dimension of the uncompressed implant in
height, width, and/or any measurable dimension _________________________ after
implantation may be at least ten times the maximal, cross-sectional
dimension of the implant in its compressed/deployment configuration.
[00486] In some embodiments and implementations, the implant in its deployed
or uncompressed (uncompressed should
be considered to encompass any implant in a state prior to its having been
rolled, folded, or otherwise compressed or after
it has been unrolled, unfolded, or otherwise decompressed; in the case of an
inflatable implant, uncompressed should be
considered to encompass the implant in its final, fully inflated
configuration) configuration has a minimum cross-sectional
dimension that is more than three, four, or five times the minimum cross-
sectional dimension of the implant in its compressed
or delivery configuration so that it can be inserted through the
aforementioned, minimally invasive entrance incision.
[00487] In some embodiments and implementations, the subcutaneous tattoo
implants may be programmable and/or
wirelessly rechargeable. For example, a user may be able to change the color
of the light emitted by the LEDs, turn them on
or off, and/or make them flash, possibly in a desired pattern of flashing. In
addition, as discussed in greater detail below, the
implants may comprise induction coils and/or circuits to allow for wireless
recharging.
[00488] Fig. 50 depicts another human patient having other subcutaneous,
compressible implants positioned in respective
implant pockets. More particularly, a light sheet 5001 is positioned within a
subcutaneous implant pocket 5005a behind a
traditional, ink tattoo 5003. This may allow a user to selectively illuminate
a tattoo. Light sheet 5001 may, in some
embodiments, comprise a flexible, compressible sheet comprising light sources,
such as LEDs, mLEDs, or OLEDs. Again,
implant pocket 5005a is much "larger" (as described previously) than the
entrance incision 5004 used to allow a lysing tip
to enter the subcutaneous region of the body and to create the implant pocket
5005a. Similarly, light sheet 5001 is, in its
deployed and/or uncompressed state, much "larger" than it is in its compressed
state and much larger than the length of the
entrance incision 5004. In further contemplated embodiments illuminable
compressible implants may comprise a light sheet
with at least one chosen from the group of: a macro-vascularization hole, a
macro-positioning/instrument engaging hole, a
reinforcement tab, a mesh reinforcement, a structural reinforcement region and
a superstructure.
[00489] Another subcutaneous, compressible implant is shown at 5002. Implant
5002 may comprise a screen, such as an
LED screen, that may be used to display an image or video, for example. Again,
implant 5002 is positioned within an implant
pocket 5005b, as previously described, and may be deployed in a compressed
state, such as a rolled state, and then unrolled
or otherwise decompressed once inserted through the entrance incision and
positioned within the implant pocket. In the
depicted embodiment, due to the nature of the lysing tip and the techniques
involved in creating the implant pocket, the
same entrance incision 5004 may be used to create both implant pockets
5005a/5005b. Indeed, as shown in FIG. 50, implant
pocket 5005a may be formed by extending a tissue dissector towards the left
from incision 5004 and implant pocket 5005b
may be formed by extending the tissue dissector towards the right from
incision 5004, in both cases preferably with a back
and forth motion that progressively widens the respective pocket.
Date Recue/Date Received 2022-12-30
78
[00490] Fig. 51a depicts a plan view of the implant 5101 in its
deployed/uncompressed state. Fig. 51b depicts a side view
of implant 5101 in its deployed/uncompressed state. FIG. 51c depicts a side
view of implant 5101 in its compressed state,
which, as previously mentioned, is the state within which implant 5101 may be
inserted through an entrance incision. In the
depicted embodiment, compressing implant 5101 comprises rolling implant 5101,
as shown in Fig. 51c comprises 2 1/2 turns.
Again, the number of rolls/folds/turns may depend upon the inner diameter
(internal space), implant thickness(es), gaps
between implant sheets/rolls, superstructures, and/or surface
irregularities/variances, etc. In alternative embodiments, rolled
compressible implants may comprise a range of numbers of turns from 1 to 100.
In further embodiments, rolled compressible
implants may comprise a range of numbers of turns chosen from the group of: 2-
3 turns, 3-5 turns, 5-7 turns, 7-10 turns, 10-
15 turns, 15-20 turns, 20-30 turns, 30-40 turns, 40-50 turns, 50-75 turns, and
75-100 turns. In further embodiments, rolled
implants may comprise a range of numbers of turns chosen from the group of: 2-
10 turns, 3-8 turns 4-7 turns, and 4-5 turns.
[00491] The distance w1 shown in Fig. 51a is the width or diameter of the
implant. Similarly, the distance Li is the length
of the implant. In the case of a circular implant, distances W 1 and Li are
the same. However, this may not be the case in,
for example, a rectangular implant. Distance dl is the cross-sectional
diameter of the implant following compression (rolling
in the case of the depicted embodiment) to prepare for insertion into a
patient. Although dl is a diameter in the case of a
rolled implant forming a circular shape in cross section, this need not be the
case in all contemplated embodiments. Thus, it
should be understood that, for example, in the case of implants that are
folded, dl may be a corner to corner diagonal
distance. DI should therefore be considered the maximal cross-sectional
dimension of the implant in its compressed
configuration (and therefore the dimension that must be minimized in order to
minimize the size of the entrance wound.
[00492] Fig. 52a depicts a plan view of the implant 5202 in its
deployed/uncompressed state. Fig. 52b depicts a side view
of implant 5202 in its deployed/uncompressed state. FIG. 52c depicts a side
view of implant 5202 in its compressed state,
which, as previously mentioned, is the state within which implant 5202 may be
inserted through an entrance incision. As
with implant 5201, implant 5202 is rolled in its compressed state. However, as
discussed elsewhere in this disclosure,
alternative embodiments are contemplated in which implants may be compressed
in other ways, such as by folding them,
deflating them, or the like.
[00493] Similar distances are shown in Figs. 52a-52c. Thus, distance w2 is the
width of rectangular-shaped implant 5202
prior to compression and w3 is the maximal distance of the implant in this
configuration from this view. Similarly, L2 is the
length of the implant, which may differ from w2 for non-square, rectangular
implants, and d2 is the maximal cross-sectional
dimension in the compressed configuration.
[00494] Fig. 53a depicts another example of a compressible, subcutaneous
implant 5300. Implant 5300 comprises a light
screen or sheet 5301, as previously mentioned, which may be configured to
display images and/or videos. Implant 5300 may
be useful, for example, as an internal tattoo, including the embodiments shown
in Figs. 49 and 50 described above. Implant
5300 may also be useful in connection with more therapeutic embodiments, such
as implants used to deliver light therapy.
Further details regarding such light treatments can be found in "Formation of
Lumirubin During Light Therapy in Adults,"
Journal of Biological Sciences 4 (3):357-360 (2004), which is incorporated
herein in its entirety by reference. Implant 5300
may further comprise an antenna 5302 to allow for receipt of electromagnetic
signals, which may be used to transmit data
for use in displaying images on screen 5301. A CPU 5303 may also be provided,
which may allow for processing of signals
received via antenna 5302. A flexible battery 5304 may also be provided. For
charging of flexible battery 5304, a wireless
charging system may be provided, such as the wireless inductance assembly 5305
shown in FIG. 53a. Preferably, each of
the elements of implant 5300 is either flexible and/or compressible, or is
small enough on its own to fit within a minimally
invasive entrance incision with other elements of implant 5300 compressed
about it.
[00495] Fig. 53b is a side elevation view of implant 5300 illustrating how
each of the elements may be coupled to screen
5301. As shown in Fig. 53c, preferably, each of the elements of implant 5300,
including screen 5301, is sealed within a
container or envelope 5306, which is preferably both waterproof and
biocompatible. Examples of suitable materials for
Date Recue/Date Received 2022-12-30
79
container 5306 include polyethylene, parylene-C, polyimide, and the like.
[00496] In some embodiments, a sensor 5303s may be provided, which in some
embodiments may be used to detect the
user's heartrate by, for example, electrical methods similar to
electrocardiography, pulse oximetric methods, and/or
acoustic/vibrational methods, wherein the vibration of a pulse may be detected
by sensor 5303s. This may be useful, for
example, to display outwardly the pulse rate. This may be displayed by, for
example, matching the light display on the
implant with the heartrate, or having the light display pulse at a rate that
is a multiple, or fraction, of the wearer's current
heartrate. In other embodiments, sensor 5303s may comprise a pressure sensor,
which may allow, for example, a user to
actuate and/or change the light element(s) of the implant, such as actuating
the lights of an internal tattoo, changing the color
of the tattoo, changing the display properties of the lights (pulsing, for
example), or actuating therapeutic lights, by applying
pressure to a selected portion of the implant.
[00497] Implant 5300 may further comprise a wireless transceiver 5307, such as
a Bluetooth transceiver, which may
allow for actuation of one or more features of the device wirelessly from, for
example, a smartphone or the like.
[00498] Fig. 54a depicts another compressible implant system 5400 comprising
implant 5401 and auxiliary implant 5408,
which may be electrically coupled to implant 5401 via wire 5407. Providing an
auxiliary implant 5408 may allow for certain
components, such as sensitive electrical components, to be placed within a
separate implant, which may be more protective
of such components, such as being within a waterproof/sealed container, for
example.
[00499] Implant 5401 may be similar to one or more of the implants previously
discussed and may therefore comprise an
inductance coil 5405, an antenna 5402a, and a laminate/wrapper 5406. The
components contained within auxiliary implant
5408 may comprise an antenna 54026, which may be provided instead of antenna
5402a or in addition to antenna 5402a, a
CPU 5403, and a battery 5404. A seal, such as a wrapper, may be used to
contain all of the elements of auxiliary implant
5408 therein. During implantation, the auxiliary implant 5408 may simply be
inserted through the same entrance incision as
the compressed implant 5401, either before or after implant 5401.
[00500] Fig. 54b depicts implant 5401 in its uncompressed configuration from
the side, which shows inductance coil 5405
extending from one side of the implant 5401.
[00501] Fig. 54c depicts a full system comprising implant 5401 and auxiliary
implant 5408. This figure also shows the use
of a laminate/wrapper 5406, which may extend about the entirety of implant
5401.
[00502] Fig. 55a depicts a human patient's abdomen having subcutaneous,
compressible mesh implants 5501 positioned in
respective subcutaneous and/or soft tissue implant pockets 5505R and 5505L,
wherein the dashed lines emanating from
minimally invasive entrance incision 5504 indicate the edges of the
undermined/tissue-dissected areas of the pockets. More
particularly, each of the two, separate mesh implants 5501 shown in this
figure are positioned within a respective implant
pocket 5505R/5505L, each of which is delineated by the dashed lines and may be
created by such methods as previously
shown in Fig. 2. Again, implant pockets 5505R and 5505L are much "larger" (as
described previously) than the entrance
incision 5504 used to allow a lysing tip to enter the subcutaneous region of
the body and to create the implant pockets.
Similarly, mesh implants 5501 are in their deployed and/or uncompressed state,
much "larger" than they are in their
compressed state and much larger than the length and/or size of the entrance
incision 5504. Macro positioning/instrument
engaging holes 5503 may aid in implant placement as previously discussed. In
some embodiments/implementations, mesh
implant 5501 may be Kevlar or Kevlar-like soldier/spy protective meshes
comprising, for example, para-aramid synthetic
fiber & fiber-PMMA (polymethylmethacrylate (Acrylic)) composites wherein the
aramid is biocompatible. In contemplated
implementations, a secondary coat of biocompatible plastic coating may be
applied to the mesh, which coating may contain,
in some cases, an antibiotic and/or antiseptic that may be released on impact
to prevent/reduce infection, such as upon impact
with a sufficient force and/or pressure and/or upon impact with a penetrating
object, such as a bullet or other ballistic object
or knife. In some embodiments/implementations, such as those configured for
abdominal hernia repair, the mesh implant
5501 may be Kevlar or expanded polytetrafluoroethylene (ePTFE) & POL ¨
Collagen, for example, to reinforce the
Date Recue/Date Received 2022-12-30
80
abdominal wall against pressures on underlying weak tissues related to
hernias.
[00503] Fig. 55b depicts a side view of a mesh implant 5501 with optional mesh
implant peripheral folds 5501f which may
aid in mitigating a penetrating wound, for example, if the mesh is an
antiballistic, such as Kevlar, by catching a bullet at an
edge rather than allowing edge slippage.
[00504] Fig. 55c depicts a side view of a mesh implant 5501 with optional zone
of overlap 5501o, which may be secured
by binding element 55016, such as a staple, suture, grommet, rivet, or the
like. Overlap 55010 and binding element(s) 55016
may aid in mitigating a penetrating wound if the mesh is an antiballistic,
such as Kevlar, by doubling the thickness at what
otherwise would have been an edge with a direct weakened area/space to the
underlying structures below.
[00505] Fig. 56a depicts a soldier who resembles a gingerbread man having
multiple subcutaneous, compressible mesh
implants 5601 positioned in implant pockets 5605 wherein the dashed lines
emanating from minimally invasive entrance
incisions 5604 indicate the edges of the undermined/tissue-dissected areas of
the pockets. More particularly, mesh implants
5601 are positioned within the implant pockets 5605, as previously discussed.
Again, the implant pockets are much larger
in one or more (in some cases, all) peripheral edge dimensions than the
entrance incision 5604 measures along one or more,
or all, such corresponding dimensions. It is noteworthy that multiple implant
pockets 5605 may share a single minimally
invasive entrance incision 5604. In some embodiments/implementations, mesh
implant 5601 may be may be anti-
ballistic/penetration resistant such as Kevlar or Kevlar-like soldier/spy
protective meshes comprising, for example, para-
aramid synthetic fiber & fiber-PMMA (polymethylmethacry late (Acrylic)
composites wherein the aramid is a biocompatible
material. Area 5601e may comprise electronic elements including, but not
limited to, inductance coil, antenna, CPU/printed
circuit board and sensors to receive power, and antennas to transmit status of
soldier and sensors/wiring in mesh to determine
compromise and relay data to allow remedy from onboard or remote CPU. In some
embodiments, meshes may comprise
sensors, wires, and/or fiberoptics to determine mesh integrity and/or soldier
status. Although only one of the implants
depicted in Fig. 56a comprises the aforementioned electrical component region
5601e, it should be understood that this
region may be present on each of the implants if desired. In some embodiments,
one or more implants, such as implant 5607,
may be laminated (with or without mesh), and may comprise, for example,
graphene In some embodiments, an outer
laminate may comprise PTFE for biocompatibility and to facilitate removal if
necessary. Further embodiments may
comprise peripheral placement holes and/or macro vascularization holes, as
previously discussed.
[00506] In some embodiments, a foldable anti-ballistic protective mesh implant
may comprise at least one chosen from the
group of: an antenna, a PCB, a folded end, an inductance coil, a capacitor, an
antibiotic drug, an inotropic agent (including
but not limited to dobutamine, dopamine & milrinone), a vasopressor (including
but not limited to adrenergic drugs,
phenylephrine, epinephrine, norepinephrine. ephedrine, pseudoephedrine, &
vasopressin), a battery, a macro-vascularization
hole, a macro-positioning/instrument engaging hole, a reinforced tab, a mesh
reinforcement, and a superstructure. In further
embodiments, a foldable anti-ballistic protective mesh implant may be
communicatively coupled with at least one of a heart
rate sensor and/or blood pressure sensor similar to items 6698, 6697 described
in Fig. 66.
[00507] In some embodiments, stacked graphene sheets may be used as a
ballistic resistance layer. In some instances,
individual graphene sheets may comprise one-atom-thick layers of carbon atoms
arranged in a honeycomb structure. Given
the extremely thin nature of each graphene layer, many graphene layers may be
stacked to improve ballistic resistant
properties. Additional details regarding such graphene armor may be found in
`Graphene Body Armor: Twice the Stopping
Power of Kevlar, at a Fraction of the Weight', Anthony, extremetech.com, 2014,
which is incorporated herein by reference
in its entirety.
[00508] In some embodiments, it may be preferable to only stack two single-
atom thick sheets of graphene. Such
configurations may result in a diamene (a stack of 2 sheets of graphene) that
may harden into a diamond-like consistency
upon impact. In the absence of mechanical pressure, diamene may retain a
degree of flexibility; however, when subject to
sudden mechanical pressure, diamene may temporarily harden. It may be
preferable to stack only two single-atom-thick
Date Recue/Date Received 2022-12-30
81
graphene layers, as the aforementioned properties are only observed in
diamene. Additional details regarding the
aforementioned diamene structure may be found in "This Ultra-Thin Material Can
Stop Bullets by Hardening Like a
Diamond', Ratner, Hard Science, Big Think, 2017, which is also incorporated
herein by reference in its entirety.
[00509] In some embodiments, ballistic resistant articles may comprise hybrid
materials comprising different fabric
sections. In a preferred embodiment, such an article may comprise 3 layers of
fabric arranged into a gradient wherein the
outermost, strike-facing sections of the article have the highest tenacity. In
some embodiments, each layer may comprise a
fibrous layer comprising one or more fibrous plies. The second fibrous
material may comprise a lower tenacity than the first
material, and the third fibrous material may comprise a tenacity lower than
the second material. The first, second, and third
fibrous materials may be bonded together to form a consolidated composite
article. In some embodiments, the third fibrous
material may comprise nylon fibers, polyester fibers, polypropylene fibers,
polyolefin fibers, or a combination thereof In
some embodiments, the first fibrous material may comprise high molecular
weight polyethylene fibers, the second fibrous
material may comprise high molecular weight polyethylene fibers and/or aramid
fibers, and the third fibrous material may
comprise nylon fibers. In other embodiments, the first fibrous material may
comprise a woven aramid fabric, the second
fibrous material may comprise a non-woven aramid fabric, and the third fibrous
material may comprise nylon fibers. In
some instances, the first fibrous material may comprise a non-woven fabric of
unidirectionally oriented fibers, the second
fibrous material may comprise a non-woven fabric of unidirectionally oriented
fibers, and the third fibrous material may
comprise a non-woven fabric of unidirectionally oriented fibers, a woven
fabric, a knitted fabric, and/or a felt. In some
embodiments, the ballistic resistant composite may comprise a non-fibrous
isotropic polymer layer attached to the third
fibrous material such that the first, second, and third layers along with the
fibrous isotropic polymer are bonded together to
form a consolidated composite. Additional details regarding the disclosed
ballistic resistant article may be found in U.S.
Patent Application Publication 2019/0016089, titled "Materials Gradient within
Armor for Balancing the Ballistic
Performance", which is hereby incorporated herein in its entirety by
reference.
[00510] In some embodiments, Kevlar may be used as a ballistic resistant
article. Such articles may comprise stacked
Kevlar layers in a 90/45/90 orientation relative to each other. It may be
desirable to have 6 to 7 multiples of 3 layers (in a
90/45/90 configuration) of 200 GSM Kevlar (18-21 total layers) to effectively
stop ballistic projectiles. It may be observed
that it may require twice as many layers of Kevlar as the amount damaged to
stop a ballistic projectile. Additional details
regarding Kevlar body armor and bullet-proofing capabilities of Kevlar may be
found in "Experimental Study of Bullet-
Proofing Capabilities of Kevlar, of Different Weights and Number of Layers,
with 9mm Projectiles", Stopforth, Science
Direct, Defense Technology, 2018, which is hereby incorporated in its entirety
by reference.
[00511] Fig.56b depicts two implants 5601 that are positioned within a shared
subcutaneous pocket and overlap with one
another to an extent, as indicated by the overlapping region 5601o. This may
be useful for certain applications. For example,
a single larger implant may be effectively created from a plurality of smaller
implants that may be inserted separately and
will likely end up fusing together with the patient's tissue. This may present
an option for more safely and/or efficiently
reconstructing a larger implant within the body.
[00512] Fig. 57a depicts a human patient's abdomen having subcutaneous,
compressible implants 5701 positioned in
respective subcutaneous and/or soft tissue implant pockets 5705R and 5705L,
wherein the dashed lines emanating from a
single minimally invasive entrance incision 5704. Again, the outer dashed
lines indicate the edges of the undermined/tissue-
dissected areas of the pockets 5705R/5705L. Implant pockets 5705R and 5705L
may be relatively elongated to accommodate
elongated implants. In this embodiment, the bulk of the implant may be
bioresorbable with RFID chips 5707 placed in
random patterns so as to make them numerous and less predictable in location
for an unwanted party to remove.
[00513] Fig. 57b depicts a top view of an implant 5701 containing RFID chips
5707 placed in less predictable patterns.
Again, once the implant 5701 has been resorbed in the body, each of the RFID
chips 5707 will be positioned at, preferably,
random locations throughout the body such that removal of one chip, or
multiple chips, is likely to result in retaining at least
Date Recue/Date Received 2022-12-30
82
one or more chips absent knowledge of the location of all of the chips. For
example, human traffickers and the like may find
one RFID chip and be able to remove it to inhibit locating/identifying a
victim, but having multiple RFID chips implanted,
preferably at random locations, may be very difficult and/or cost-prohibitive
i.e., may require a surgeon, antibiotics, X-
rays, specialized micro-metal detectors, etc. In preferred embodiments, RFID
chips 5707 are each configured as plates or
plate-like elements having flat upper and lower surfaces that are parallel, or
at least substantially parallel, to each other.
[00514] Moreover, even if removal of a randomly positioned plurality of chips
were attempted, risks of missing even one
(which is all it takes to set off an alarm) would be present. Further,
infection and tell-tale scarring from removal of such a
plurality of chips may alert others e.g., doctors or police¨of RFID
removal, thwarting human trafficking.
[00515] Radio frequency identification chips may be used in certain
embodiments, which may, for example, be used as
devices to track and/or monitor patient health. For example, the RFID device
may be active or passive, with low power,
long-range transceivers for location and movement tracking. The RFID circuit
may be multi-functional in some
embodiments. For example, the RFID circuit may comprise a circuit inductively
coupled with devices, such as temperature
sensors, which may be used to assess patient health. The tracking device may
also, or alternatively, comprise a
microcontroller, radio transceiver, antennae, and/or power sources. Further
details regarding suitable RFID devices for use
in connection with various embodiments disclosed herein may be found in U.S.
Patent No. 11,141,062 titled "System and
Method for Animal Location Tracking and Health Monitoring Using Long Range
RFID and Temperature Monitoring,"
which is hereby incorporated in its entirety by reference.
[00516] Certain RFID embodiments may comprise, for example, a ferromagnetic
mass disposed near a coil and a resonator
circuit coupled to said coil, which may be configured to resonate upon
receiving current from the coil. An antenna may be
coupled to the resonator circuit. In some embodiments, the device may contain
a modulator coupled to the resonator circuit
to modulate output. The ferromagnetic mass may slide in and out of the coil
naturally with bodily movement, which may
induce voltage in the coil, thereby providing power to the circuit, in some
cases without need for an external power source
at all. Further details which may be useful in connection with various
embodiments disclosed herein may be found in U.S.
Patent Application Publication No. 2015/0129664 titled "Implantable RFID Tag",
which is hereby incorporated in its
entirety by reference.
[00517] In certain embodiments, RFID chips may contain power stores which may
be recharged in the presence of
electromagnetic fields, such as electromagnetic fields generated by
transceiver units. The power stores may comprise, for
example, capacitors or batteries. The transponder unit may communicate via
numerous frequencies, thereby improving real-
time performance, identification, and/or compatibility. The transponder unit
may further comprise transmission units,
memory, and/or power circuitry. In some instances, the transponder unit may be
coupled to one or more antennae. Some
embodiments may comprise RFID devices wrapped to seal the device from
surroundings. Further details regarding RFID
chips and systems may be found in U.S. Patent Application Publication No.
2011/0169610 titled "Radio Frequency Animal
Tracking System", which is hereby incorporated in its entirety by reference.
[00518] Some embodiments may comprise implantable RFID transceivers used for
identification and tagging of medical
devices, such as medical devices incorporated into the implants disclosed
herein or medical devices communicatively
coupled with such implants. Some embodiments may comprise tagging devices and
related components, such as tagging
devices with manufacturing, implant information, and/or patient identification
information. For example, such RFID tags
may be coupled with implanted defibrillators, pulse generators, and/or stents.
In some instances, the RFID module may be
integrated into the medical device for identification, data storage, and/or
communication purposes. Additional details
regarding such RFID implants may be found in U.S. Patent No. 7,429,920, titled
"Radio Frequency Identification and
Tagging for Implantable Medical Devices and Medics Device Systems", which is
hereby incorporated in its entirety by
reference.
[00519] Some embodiments and implementations may comprise RFID chips for use
with active implantable medical
Date Recue/Date Received 2022-12-30
83
devices (AIMD). Such systems may comprise, for example, an interrogator and/or
a hermetically sealed RFID device
comprising a substrate, RFID chip, and antenna. In some instances, the RFID
device may be used to store data such as
patient information, manufacturing information, serial numbers, and the like.
Further details may be found in U.S. Patent
No. 7,916,013 titled "RFID Detection and Identification System for Implantable
Medical Devices,", which is hereby
incorporated in its entirety by reference.
[00520] Fig. 58a depicts a minimally invasive electro-dissection device with a
2-bead tip 5804 according to some
embodiments having two beads protruding distally from a shaft 5805 and handle
5806. Tip 5804 comprises a beaded
structure that may be positioned at the distal end of a shaft. The
device/system may further comprise an implant expelling
cannula 5820, which may be fixedly or releasably attached (or may be entirely
separate in other embodiments) to shaft 5805
and may comprise an implant expelling plunger 5821.
[00521] Fig. 58b depicts a human torso after having undergone comparative
bilateral surgical procedures. On the patient's
right side (the left side of the figure), a lysing tip, such as a lysing tip
having beads and adjacent recesses for delivery of
energy therefrom (for example in Fig. 58a), was used to form implant pockets
5803R and 5803L, with one or more
dimensions substantially greater than that of the entrance incision 5850
(about 5mm, for example) used to begin to create
the pocket. The outward arrows depict the initial forward paths of the
dissection device radiating along the axis of the shaft
5805 away from the entrance incision 5850; the device shown may also be
configured to dissect in a rearward direction.
However, for space considerations, rearward arrows are not shown. Implant
pocket 5803L in Fig. 58b results from a human
patient's abdomen having received subcutaneous, expellable implants 5801
deposited on either forward or rearward passage
of the implant expelling cannula 5820. In this embodiment, expellable implants
5801 comprise RFID chips. In other
contemplated embodiments expellable implants may comprise electronics or
medicines or clusters of biologic materials,
such as stem cells.
[00522] Although the implant pockets 5803L and 5803R are shown as having been
formed with multiple strokes from
instrument 5804, it should be understood that, in alternative implementations,
a single stroke may be used. Thus, unlike
most of the embodiments disclosed herein, implants 5801 need not be
compressible and therefore need not be larger, or at
least substantially larger, than the entrance incision 5850. Thus, a single
stroke of instrument 5805 may be used to both
create the path or paths into which the implants 5801 are inserted and to
insert the implants. The pockets may therefore
consist of a single stroke, or of multiple strokes that may be connected to
form a larger, continuous pocket as shown in Fig.
58b or multiple pockets each defined by a single stroke emanating from the
entrance incision 5850. To further illustrate, in
another alternative implementation, a first stroke in a first direction may,
if the backstroke is followed in the same path, form
a first pocket defined by the first stroke alone, and a second stroke may
extend at an angle relative to the first stroke, such
as an angle of up to or even exceeding 90 degrees for example, so that the
implants 5801 contained in the respective single-
stroke pockets may be separated from one another by whatever distance may be
desired. Unlike implants 5707, implants
5801 may be configured in a cylindrical or at least substantially cylindrical
shape, or another shape unlike implants 5707 in
that such a shape may lack opposing, flat surfaces that are parallel to one
another.
[00523] Fig. 58c depicts a side view of an alternative embodiment of an
implant expelling cannula 5820s that is configured
to expel implants from a side opening 5820os rather than through the distal
end of the device. As with the instrument depicted
in Fig. 58a, this instrument may further comprise an implant expelling plunger
5821c, which is shown advancing each of a
series of the expellable implants 5801, each comprising RFID chips 5801rf
through opening 5820os after each expelled
implant is redirected off the cannula axis by angular diversion 5820a, which
may comprise, for example, a ramp structure.
The device shown in Fig. 58c is shown without a coupled tissue dissecting
instrument, although, as those of ordinary skill
in the art will appreciate, this device could easily be mounted on or
otherwise coupled together with such an instrument if
desired.
[00524] Fig. 58d depicts a more detailed side view of a of implant expelling
cannula 5820 fixedly or releasably attached to
Date Recue/Date Received 2022-12-30
84
shaft 5805, again also depicting implant expelling plunger 5821, pushing each
of a series of the expellable implants 5801
comprising RFID chips out through frontal/distal shaft opening 5820of.
[00525] Fig. 59a depicts a human torso after having undergone comparative
bilateral surgical procedures whereupon
minimally invasive stem cell incubator implant rectangular strips 5901 were
placed in implant pockets 5903R and 5903L,
with one or more dimensions substantially greater than that of the entrance
incision 5950 (about 5mm, for example) used to
begin to create the pocket. Minimally invasive stem cell incubator implant
rectangular strips 5901 may comprise, for
example, an implant payload bay 5901p comprising living biologic cell clusters
(such as stem cells), which may be
ensconced within implant protective pouch 59016, which may comprise smooth
laminates, meshes, and/or semipermeable
membranes as well as possible nutrients, hormones, biologics, medicines,
antibiotics that may support the proper survival
of the stem cells. A mesh may be preferred to encourage blood vessel growth
into the cells contained therein. Hormones
may be added to the mesh in some embodiments to further encourage such growth,
such as, for example, proliferin, prolactin,
growth hormone and placental lactogen. In order to recover the growing stem
cells by surgical extraction, it may be
preferable that such strip and/or pouch materials be non-biodegradable and non-
bioresorbable so the item is intact for
removal. However, it is conceivable that bioresorbable materials may be used
in alternative embodiments and
implementations. It is possible that by tissue matching donors and recipients
stem cell surrogates may incubate cell clusters
for other patients. The surrogate may also be non-human in some cases, such as
a genetically modified pig the immune
system of which will not damage or otherwise negatively affect the foreign
stem cells. Macro positioning/instrument
engaging holes 5901h may facilitate placement and/or manipulation and/or
fixation.
[00526] As mentioned above, prolactin, growth hormone, placental lactogen,
proliferin, and proliferin-related protein share
structural similarities and biological activities, including angiogenesis, and
therefore it may be useful to incorporate one or
more of these proteins/substances, or other known angiogenesis-promoting
substances, into one of the more of the implants
disclosed herein. Such substances may act both as circulating hormones and as
paracrine/autocrine factors to either stimulate
or inhibit various stages of the formation and remodeling of new blood
vessels, including endothelial cell proliferation,
migration, protease production and apoptosis. Such opposing actions can reside
in similar but independent molecules, as is
the case of proliferin and proliferin-related protein, which stimulate and
inhibit angiogenesis respectively. The potential to
exert opposing effects on angiogenesis can also reside within the same
molecule as the parent protein can promote
angiogenesis (i.e. prolactin, growth hormone and placental lactogen), but,
after proteolytic processing, the resulting peptide
fragment acquires anti-angiogenic properties (i.e. 16 kDa prolactin, 16 kDa
growth hormone and 16 kDa placental lactogen).
Thus, it may be possible to use both angiogenesis-promoting substances and
angiogenesis-inhibiting substances in an
implant to, for example, promote vessel and/or tissue growth on a lower
surface/side of the implant where therapeutic agents
may be released and inhibit vessel and/or tissue growth on the upper side of
the implant. Angiogenesis-inhibiting substances,
such as 16kDa prolactin, 16 kDa growth hormone, and/or 16 kDa placental
lactogen, or any other known angiogenesis-
inhibiting substances, may be selectively applied to certain areas of an
implant that are desired to be free from blood vessel
and/or tissue formation. Additional details regarding both angiogenesis
promoting and angiogenesis inhibiting substances
that may be incorporated into various implants disclosed herein can be found
in "Roles Of Prolactin And Related Members
Of The Prolactin/Growth Hormone/Placental Lactogen Family In Angiogenesis,"
Corbacho A, Martinez G, Clapp C, Journal
of Endocrinology (2002) 173, 219-238, which is incorporated herein by
reference in its entirety.
[00527] In some instances, meshes, such as scaffolds, may be used to aid in
tissue engineering. In a preferred embodiment,
such scaffolds may be used for retention and deliverance of cells and
biochemical factors for cell adhesion and migration.
Such scaffolds may also be used, in some embodiments, for templates to, for
example, guide tissue development. In certain
embodiments, materials such as, for example, natural biomaterials, ceramics,
synthetic biomaterials, and/or biomimetic
natural polymers may be used for implantable scaffolds. In some instances,
natural biopolymers may comprise, for example,
proteins, polysaccharides, and the like. In some instances, synthetic polymers
may comprise PLA, PGA, PLGA, and the
Date Recue/Date Received 2022-12-30
85
like. In some embodiments, ceramics may be used as scaffolds, which ceramics
may comprise, for example, hydroxyapatite,
tricalcium phosphate, alumina, and the like. In some instances, scaffold
properties such as, for example, biomaterial,
biodegradability, incorporated ECM variants, porosity, shape, and the like,
may be varied as desired according to the
application of the implant(s). In certain embodiments, scaffolds may comprise,
for example, hydrogel scaffolds, fibrous
scaffolds, microsphere scaffolds, bioceramic scaffolds, mesoporous bioactive
glass scaffolds, and the like. In some
embodiments, a 3D cell culture system may be used to create an artificial
environment, aiding in processes such as, for
example, cell differentiation and morphogenesis. Additional details regarding
such scaffolds may be found in "Scaffolds
from Biomaterials: Advantages and Limitations in Bone and Tissue Engineering",
Alaribe, Biologia; 353-367, 2016, which
is hereby incorporated in its entirety by reference.
[00528] Fig. 59b depicts a side view of minimally invasive stem cell incubator
implant strip 5901, wherein implant payload
bays 5901p are ensconced within individual implant protective pouches 590 lb.
As shown in this figure, bays 5901p and/or
pouches 59016 may be positioned on either or both sides of the implant/strip
5901.
[00529] Fig. 59c depicts a side view of an alternative embodiment of a
minimally invasive stem cell incubator implant
5901C wherein implant payload bays 5901p, along with their corresponding
contents (stem cells, for example) are
sandwiched within implant laminate layers 5901L1 and 5901L2.
[00530] Fig. 60a depicts the right side of a torso of a human patient having a
rectangular compressible subcutaneous
electronic neuro stimulative (SQENS) implant system 6000 positioned in a
respective subcutaneous and/or soft tissue
implant pocket 6005 made via minimally invasive entrance incision 6010. More
particularly, a SQENS implant 6001 is
positioned within an implant pocket 6005, one or both of which may be similar
to any of the other implants and/or implant
pockets previously mentioned. Implant pocket 6005 may be made by methods
described elsewhere within this application,
including Figs. 1 & 57. In some implementations, the series of SQENS implants
may be oriented along the dermatomal,
sclerotomal, myotomal, and/or nerve map areas. Implant 6001 may, in some
embodiments, comprise a flexible, compressible
sheet, or stack of sheets of electronics. Again, implant pocket 6005 is much
"larger" (as described previously) than the
entrance incision 6004 used to allow a lysing tip to enter the subcutaneous
region of the body and to create the implant
pocket 6005. Similarly, implant 6001 is, in its deployed and/or uncompressed
state, much "larger" than it is in its compressed
state and much larger than the length of the entrance incision 6004.
[00531] Implant system 6000 may further comprise an antenna 6007 to allow for
receipt of electromagnetic signals, which
may be used to transmit data to CPU/printed-circuit-board 6003 for use in
activating peripherally based terminal electrodes
6012 and optional non-peripherally based terminal electrodes 6011 using energy
derived from battery 6004 and inductance
coil 6014. Peripheral terminal electrodes 6012 may, as shown on the figure,
only be positioned partially on the implant 6001
itself, whereas the non-peripheral terminal electrodes 6011 may be wholly
positioned on the implant 6001. An external
transmitter may be adjusted by the patient or healthcare personnel to transmit
signals to internal antenna 6007 that, in turn,
may provide instructions to CPU 6003 to coordinate electrical output of
electrodes 6011 and/or 6012. These external signals
may, for example, be generated and/or received from a smartphone or other
wireless communication device 6099. Battery
6004 may also be flexible. A wireless charging system may be provided, such as
the wireless inductance assembly 6014
may charge flexible battery 6004. Preferably, each of the elements of implant
6001 is either flexible and/or compressible,
or is small enough on its own to fit within a minimally invasive entrance
incision with other elements of implant 6001
compressed about it.
[00532] Fig. 60b is a side elevation view of implant 6001 of system 6000
illustrating how each of the elements may be
coupled on implant 6001; however, in other embodiments, orientations and
locations may vary. In some embodiments, each
of the elements of implant 6001, possibly with the exception of terminal
electrodes 6011 and 6012, may be sealed within a
container or envelope, which is preferably both waterproof and biocompatible.
Examples of suitable materials for said
container include polyethylene, polyurethane, polypropylene, and the like. In
some embodiments, various coatings, such as
Date Recue/Date Received 2022-12-30
86
polymer coatings, may also, or alternatively, be used.
[00533] As shown in Fig. 60b, in some embodiments, a superstructure 6001s may
also be provided. Preferably, such
superstructure(s) are flexible and/or expandable. Such superstructure(s) may
be located on the underside of the elements
depicted in fig. 60b, and may aid in fully unfolding/uncompressing the implant
6001, maintaining the shape and/or location
of the implant 6001 as it nestles in the subcutaneous layers below. In some
embodiments, superstructure 6001s may comprise
biocompatible polymers that are selectively permeable. In some embodiments,
superstructure 6001s is hollow, end-sealed,
and/or may comprise a xerogel, which may expand as water passes through the
selectively permeable polymers into the
inside of the superstructure 6001s causing it to rigidify to varying degrees.
This may be beneficial to reduce unwanted
folding and/or migration.
[00534] Fig. 60c depicts a top plan view of the implant 6001 in its
deployed/uncompressed state. Externally detectable
macro positioning/instrument engaging holes 6023 (as described previously) may
aid in the positioning of implant system
6000. In alternative embodiments, holes 6023 are not externally detectable.
One or more printed circuit boards 6003 and/or
CPUs, ancillary electronics 6024, including but not limited to a heart rate
sensor and oxygen saturation monitor, may also
be provided. During an episode of pain or discomfort, a patient's heart rate
may elevate. An ancillary electronic heart rate
sensor 6024 option may therefore detect an elevated heart rate, which may be
used by the SQENS to signal/stimulate nerves
upon detecting, for example, a threshold heart rate and/or a threshold
increase in heart rate over a given period. In this
manner, if pain is reduced by the implant 6001, the heart rate should lessen
and cause the stimulation to cease. Internal or
external programming may, in some embodiments, determine a preset heart rate
diminution, which if not achieved by a
programmable time threshold/limit, would cease the SQENS unit firing as
another health cause may be the origin of the
particular elevated heat rate sampling. In further embodiments, a SQENS
implant may be communicatively coupled with at
least one of a heart rate sensor and/or blood pressure sensor similar to items
6698, 6697 described in Fig. 66.
[00535] For comparative purposes, Percutaneous Electrical Nerve Stimulation
(PENS), goes even deeper than
Transcutaneous Electrical Nerve Stimulation (TENS, surface electrodes)
although both have in common, small wires
attached to a battery-powered electrical stimulator, PENS has needle
electrodes deliver current closer to the nerves or the
muscles beneath the skin, in the hopes of bypassing upper nerves and thus
causing less skin transmission pain. PENS
typically involves insertion of an acupuncture-like needle which probes into
the soft tissues or muscles to electrically
stimulate nerve fibers in the sclerotomal, myotomal, or dermatomal
distribution corresponding to the patient's pain
symptoms. However, needle insertion and even slight movements cause pain in
PENS. Thus, outside of the implant
procedure, SQENS may offer both conveniences of less needling and skin
transmission pain.
[00536] Fig. 60d depicts a top plan breakaway view of an alternative implant
in its deployed/uncompressed state. Also
shown are peripherally based terminal electrodes 6012a-d and optional non-
peripherally based terminal electrodes 6011a-c
which each may be electrically coupled, directly or indirectly, to a CPU, such
as CPU 6003 in Fig. 60c. If the electrodes are
on independent circuits to the CPU then each may be programmed to fire at
random or independently in a preprogrammed
pattern so as to provide a differing stimulus pattern to the subject/recipient
over time. This may provide an improved ability
to avoid pain by changing, either randomly or based upon a preconfigured
pattern, for example, the actuation of each of the
various electrodes. Psychological and neurological studies have shown that a
stimulus' effect may diminish based upon
unchanging repetition over time (recipient's nervous system becomes jaded to a
repetitive unchanging/boring stimulus).
Thus preprogrammed or randomized or changing programmable stimuli may serve to
enhance the effect of SQENS.
Electrodes output may be individually addressed in terms of amplitude,
frequency, and/or activation in order to achieve
multiple stimuli.
[00537] A multiplicity of stacked inductance coils may increase the power
transfer as well as increase of mutual inductance
between coupled coils.
Reference: 'Achieve High Power Density with Stacked Inductor 25.08.2021,
https://www.electronicdesign.com'
Date Recue/Date Received 2022-12-30
87
[00538] In some embodiments, electrodes may be injected into the body using
one or more of the techniques and/or in one
or more of the implants disclosed herein. In a preferred embodiment, such
electrodes may comprise an in-body curing
polymer and metal composite. In some instances, such electrodes may be used in
conjunction with neural stimulating
devices. In certain embodiments, injected electrodes may comprise silicone-
metal-particle composites. In some
embodiments, the composite may comprise silicone elastomers and metallic
silver flakes. Additional details regarding such
injectable electrodes may be found in "An Injectable Neural Stimulation
Electrode Made from an In-Body Curing
Polymer/Metal Composite", Trevathan, Advanced Healthcare Materials, 2019, DOI:
10.1002/adhm.201900892, which is
hereby incorporated herein in its entirety by reference.
[00539] Fig. 61a depicts the right side of a torso of a human patient having a
spiral subcutaneous electronic neuro
stimulative (SSENS) implant system 6100 having a plurality of implants each
preferably positioned in a respective
subcutaneous and/or soft tissue implant pocket made via minimally invasive
entrance incision 6110. In this embodiment, a
series of 3 SSENS spiral implants 6101a, 6101b, 6101c are positioned within
respective implant pockets. More particularly,
spiral implant 6101c (shown in dashed lines to indicate it has already been
implanted below the skin) is positioned within
an implant pocket 6122. Implant pocket 6122 may be made by methods described
elsewhere within this application,
including Figs. 47a-e. In some implementations, the series of SSENS implants
may be oriented along the dermatomal,
sclerotomal, or myotomal, or nerve map areas. Spiral implants may be installed
in minimally invasive entrance wounds by
methods including those described in Figs. 47a-e. More particularly, spiral
implants 6101a & 6101b are shown without
dashed lines to indicate they are being positioned before surgery above the
prepped (with chlorhexidine and/or iodine)
surgical site for the surgeon to assess optimal implant location, spacing and
entrance wound distance for each implant prior
to pocket formation or skin marking.
[00540] Fig. 61b shown as top view of a single 3 turn SSENS implant 6101 with
outer terminal end 61010 and electrodes
dispersed along one or more sides of the faces or sides of the spiral with
outer arm band terminus 61010 and inner arm band
terminus 6101i and space 6188 between adjacent bands. Implant 6101 comprises 3
turns. Spacing 6188 may be helpful for
a variety of purposes, such as improving the ease with which spiral implants
can be surgically implanted through a minimally
invasive entrance incision. Spacing 6188 between adjacent bands of a spiral
implant may also provide potential benefits to
the implant following implantation, such as providing increased surface area
for drug delivery or other purposes, and/or for
providing features that project, either permanently or selectively, into this
space 6188, for various purposes. In alternative
embodiments, spiral implants may comprise numbers of turns ranging as
previously described with reference to Fig. 37.
[00541] In some embodiments, spiral implant 6101 is circular in overall shape
from a top plan view, as shown in Fig. 61b,
and rectangular in cross section. As described below, however, various other
shapes may be used in alternative embodiments
as desired. Spiral implant 6101 may be rigid or, if preferred, more flexible.
In some embodiments, the spiral implant 6101
may be compressible by being rollable and/or foldable. In some embodiments,
spiral implant 6101 may comprise a metal,
ceramic, cermet, glass, flexible plastic, organic polymer, biopolymer, or the
like. Other embodiments may comprise a
polymeric external lamination or containment to retain more dissolvable
materials such as hydrogels and the like. Drugs,
vitamins, or other chemicals, including biologics, may also be bound,
dissolved, or otherwise present in a portion or all of
the structure of spiral implant 6101 and/or elements contained therein. Also
shown are terminal electrodes 6111a-f which
each may be hooked in series or parallel or independently directly or
indirectly to CPU 6103pb, as shown in Fig. 61c. If the
electrodes are on independent circuits to the CPU then each may be programmed
to fire at random or independently in a
preprogrammed pattern so as to provide a differing stimulus pattern to the
subject/recipient over time. Psychological and
neurological studies have shown that a stimulus' effect may diminish based
upon unchanging repetition over time
(recipient's nervous system becomes jaded to a repetitive unchanging/boring
stimulus). Thus preprogrammed or randomized
or changing programmable stimuli may serve to enhance the effect of SSENS.
Electrodes output may be individually
addressed in terms of amplitude, frequency, and/or activation in order to
achieve multiple stimuli.
Date Recue/Date Received 2022-12-30
88
[00542] Fig. 61c is an enlarged view of a cross section at the location
demarcated by the line intersecting the arrow in Fig.
6 lb near outer arm band terminus 61010 of one possible embodiment, wherein
various layers/elements are depicted therein,
including a metallic inductance coil 6114, battery 6104 (thin film in this
embodiment), printed circuit board 6103pb (in some
embodiments printed circuit board 6103pb is a CPU), antenna 61026, ancillary
electronics 6124, such as a heart rate sensor
or oxygen saturation monitor, which may be positioned adjacent to protective
outer sheath 6117. In other contemplated
embodiments, additional metallic inductance coils 6114a may be stacked to
enhance the capabilities of the implant. During
an episode of pain or discomfort, a patient's heart rate may elevate. An
ancillary electronic heart rate sensor 6124 option
may detect elevated heart rate causing in the SSENS to signal/stimulate nerves
whereupon if pain is reduced the heart rate
should lessen. Internal or external programming may determine a preset heart
rate diminution, which if not achieved by a
programmable time threshold/limit, would cease the SSENS unit firing as
another health cause may be the origin of the
particular elevated heat rate sampling. Some contemplated embodiments may
comprise multiple internal antennas. An
external transmitter may be adjusted by the patient or healthcare personnel to
transmit signals to internal antenna 61026 that,
in turn, may provide instructions to printed circuit board 6103pb to
coordinate electrical output of electrodes terminal
electrodes 6111a-f. These external signals may, for example, be generated
and/or received from a smartphone or other
wireless communication device 6199. In further embodiments, a SSENS implant
may be communicatively coupled with at
least one of a heart rate sensor and/or blood pressure sensor similar to items
6698, 6697 described in Fig. 66.
[00543] Each of the elements of implant 6101, except for terminal electrodes
6111 & 6112, may be sealed within a container
or envelope (protective outer sheath 6117), which is preferably both
waterproof and biocompatible. Examples of suitable
materials for said container include polyethylene, polyurethane,
polypropylene, and the like. Again, a superstructure 6101s,
which is preferably flexible and/or expandable, may aid in fully
unfolding/uncompressing the implant and/or maintaining
the shape and location of the implant as it nestles in the subcutaneous layers
below. In some embodiments, superstructure
6101s may comprise biocompatible polymers that are selectively permeable. In
some embodiments, superstructure 6101s
may be hollow, end-sealed and/or may comprise an expansive/expansile material,
such a xerogel, which expands as water
passes through the selectively permeable polymers into the inside of the
flexible expandable superstructure 6101s causing
expansive/expansile material to engorge in a limited space and thus relatively
rigidify to varying degrees. This may be
beneficial to reduce unwanted implant folding and/or migration.
[00544] Inductance coil/'group of stacked coils' may be present as per the
coil cross section depicted in Fig. 37d.
[00545] A multiplicity of stacked inductance coils may increase the power
transfer as well as increase of mutual inductance
between coupled coils.
Reference: 'Achieve High Power Density with Stacked Inductor 25.08.2021,
https://www.electronicdesign.com'
[00546] To deliver proper alignment the maximal energy transfer per
orientation of coil groups may be, in some
embodiments, assessed by an internal or external CPU with a signaling when
optimal alignment is approaching or departing,
or made or lost. In some embodiments, the rate of maximal energy transfer may
determine optimal position/orientation.
[00547] As per Fig. 37d, a temperature sensor such as 3719t may be present in
implant 6101, which temperature sensor
may be configured to detect tissue temperatures external to the coil and/or
wrapper so that hardware and /or software in the
system can alert the user/external coil to increase or decrease energy
transmission as the case may be. In some embodiments,
one or more threshold temperatures may be established, such as a shutoff
temperature, which may be, for example, 45
degrees C, which may result in termination of energy delivery until the
temperature returns to a second threshold
temperature, such as 40 degrees C, at which point the energy delivery may
resume.
[00548] In some embodiments, additional elements, such as electronic elements,
may be coupled to the coil to make the
coil more useful as a standalone implant, or an implant configured to
standalone as a power supply to another, secondary
implant. In some such embodiments, use of a unitary coil, as shown in Fig.
80a, may eliminate the need for an auxiliary
implant altogether. In contemplated embodiments, a unitary coil may therefore
be coupled with other implants, such as
Date Recue/Date Received 2022-12-30
89
implants to which the unitary coil is providing energy, without the use of an
auxiliary implant to aid the unitary coil in doing
so. It is also contemplated, however, that some coil embodiments may have
some, but not all, of the components that may
be provided on an auxiliary implant, and may therefore be considered a
"hybrid" coil implant.
[00549] Fig. 62a depicts the right side of a torso of a human patient having a
flexible strand/string subcutaneous electronic
neuro stimulative (FSQENS) implant system 6200 comprising implants positioned
in respective implant pockets preferably
made via minimally invasive entrance incision 6210. More particularly, implant
system 6200 comprises a FSQENS flexible
strand/string implant 6201, which may be positioned within a subcutaneous
and/or soft tissue implant pocket 6205c
comprising a canal that may be made by trocar, probe and/or beaded dissector
as shown later. Inductance coil 6214 (with or
without additional electronics attached) and auxiliary implant 6208 may be
deposited in various implant pockets made
similarly to others described by methods described elsewhere within this
application, including Figs. 1 & 57. In some
implementations, the FSQENS implant may be oriented along the dermatomal,
sclerotomal, or myotomal, or nerve map
areas. Flexible strand/string implant 6201 may, in some embodiments, comprise
a flexible tube or strand of electronics.
[00550] As used herein, a "flexible electronic string/strand" implant is a
linear implant comprising one or more end
effectors/receptors. In some such embodiments, the length of the flexible
electronic string/strand implant exceeds the
maximal width of the implant by a factor of at least 25. In some such
embodiments, the length of the flexible electronic
string/strand implant exceeds the maximal width of the implant by a factor of
at least 50. As used herein, an "end
effectors/receptor" is any terminus for the discharge or receipt of energy
within the body including: light, heat, electrical,
chemical, vibrational or electromagnetic energy.
[00551] Implant system 6200 may further comprise auxiliary implant 6208
elements previously similarly described in Fig.
54 a-c including but not limited to an antenna 62026 to allow for receipt of
electromagnetic signals, which may be used to
transmit data to CPU/printed-circuit-board 6203 for use in activating
peripherally based terminal electrodes 6211, 6211a-g
using energy derived from battery 6204, wiring 6215i, and inductance coil
6214. An external transmitter may be adjusted
by the patient or healthcare personnel to transmit signals to internal antenna
62026 that in turn directs CPU 6203 to
coordinate electrical output of electrodes 6211a-g. In some embodiments, the
battery 6204 may also be flexible and/or
installed within or along inductance coil 6214. A wireless charging system may
be provided, such as the wireless inductance
assembly 6214 may charge the battery 6204. Preferably, each of the elements of
implant system 6200 is either flexible and/or
compressible, or is small enough on its own to fit within a minimally invasive
entrance incision 6210 with other elements
of implant 6200 moved into their optimal positions in separate tissue pockets,
such as enlarged tissue pocket 6205, which
contains inductance coil 6214 in the depicted embodiment. Auxiliary implant
6208 may allow for certain components, such
as sensitive electrical components, to be placed within a separate implant,
which may be more protective of such
components, such as being within a waterproof/sealed container, for example. A
seal, such as a wrapper, may be used to
contain all of the elements of auxiliary implant 6208 therein. An external
transmitter may be adjusted by the patient or
healthcare personnel to transmit signals to internal antenna 62026 that, in
turn, may provide instructions to CPU/printed-
circuit-board 6203 to coordinate output. These external signals may, for
example, be generated and/or received from a
smartphone or other wireless communication device 6299
[00552] In some embodiments, additional elements, such as electronic elements,
may be coupled to the coil to make the
coil more useful as a standalone implant, or an implant configured to
standalone as a power supply to another, secondary
implant. In some such embodiments, use of a unitary coil, as shown in Fig.
80a, may eliminate the need for an auxiliary
implant altogether. In contemplated embodiments, a unitary coil may therefore
be coupled with other implants, such as
implants to which the unitary coil is providing energy, without the use of an
auxiliary implant to aid the unitary coil in doing
so. It is also contemplated, however, that some coil embodiments may have
some, but not all, of the components that may
be provided on an auxiliary implant, and may therefore be considered a
"hybrid" coil implant.
[00553] Fig. 62b is a side elevation view of FSQENS flexible strand/string
implant 6201 illustrating how each of the
Date Recue/Date Received 2022-12-30
90
elements may be coupled on strand 6201; however, in other embodiments
orientations & locations may vary. Not shown in
Fig. 62b, is that preferably, each of the elements of implant 6201, except for
terminal electrodes 6211, is sealed within a
container or envelope, which is preferably both waterproof and biocompatible.
Examples of suitable materials for said
container include polyethylene, polyurethane, polypropylene, and the like. A
wire 6215o may be used to couple the auxiliary
implant 6208 with one or more (preferably all) of the various electrodes 6211a-
g of the string implant 6201.
[00554] During an episode of pain or discomfort, a patient's heart rate may
elevate. An ancillary electronic heart rate sensor
6224 option may detect elevated heart rate, causing in the FSQENS to
signal/stimulate nerves whereupon if pain is reduced
the heart rate should lessen. Internal or external programming may determine a
preset heart rate diminution, which if not
achieved by a programmable time threshold/limit, would cease the SQENS unit
firing as another health cause may be the
origin of the particular elevated heat rate sampling. Also shown are terminal
electrodes 6211a-g which each may be
electrically coupled, directly or indirectly, to a CPU 6203 and/or other
suitable electrical circuitry. In further embodiments,
a FSQENS implant may be communicatively coupled with at least one of a heart
rate sensor and/or blood pressure sensor
similar to items 6698, 6697 described in Fig. 66.
[00555] Fig. 62c is an enlarged transparency view of Fig. 62b depicting an
embodiment of a wiring scheme for various
terminal electrodes 6211a-e along a flexible strand/string subcutaneous
electronic neuro stimulative (FSQENS) implant
6201. In this embodiment, electrodes 6211a-e are all wired independently (for
example, on wires such as 6211aw, which is
coupled with electrode 6211a) of each other, thus allowing for different
programmable control for each. In other
contemplated embodiments the wiring may be in series, parallel or another form
of independent wiring or a combination
thereof Firing may vary in terms of amplitude and time of firing and on-off
cycle. Again, this may be random, controllable
by the user, or both (selectively random or specific, as selected by the
patient). If the electrodes are on independent circuits
to the CPU then each may be programmed to fire at random or independently in a
preprogrammed pattern so as to provide
a differing stimulus pattern to the subject/recipient over time. Psychological
and neurological studies have shown that a
stimulus' effect may diminish based upon unchanging repetition over time
(recipient's nervous system becomes jaded to a
repetitive unchanging/boring stimulus). Thus preprogrammed or randomized or
changing programmable stimuli may serve
to enhance the effect of FSQENS. Electrodes output may be individually
addressed in terms of amplitude, frequency, and/or
activation in order to achieve multiple stimuli. The triangles used to
represent the electrodes in Figs. 62a-c are by no means
restrictive or indicative of electrode shape. For example, in Figs. 62b & 62c,
internal wiring 6211aw is connected to a
peripheral/circumferential electrode 6211a that may have several potential
benefits. For example, providing a band-
like/circumferential electrode may allow for a more widely distributed signal
that may be less prone to missing a particular
target nerve or other tissue region. However, it may be desirable for certain
applications to form such an electrode such that
it extends only partially about the periphery of the string and/or tube-like
implant 6201. For example, it may be desirable to
avoid the increased points of termination, such as corners, which may result
from an incomplete circumferential electrode.
It should be understood, however, that such points of termination may be
preferred for certain applications, particularly
since it may be desirable to vary the location, strength, and/or other
parameters of the signal for certain applications, such
as FSQENS applications.
[00556] Although electrode 6211a is shown projecting slightly from the
peripheral wall of the implant 6201 in Fig. 62c, it
should also be understood that it may be desirable to have the electrode flush
with this exterior wall, which may be a hollow
or solid tube, for example, instead, which may allow the implant to slide more
easily through, for example, a trocar, adjacent
tissues, and/or the entrance wound. The cross-sectional shape of implant 6201
may vary as desired, such as from circular to
oval to strap-like to polygonal in various contemplated embodiments.
[00557] Inductance coil/'group of stacked coils' may be present as per the
coil cross section depicted in Fig. 37d.
[00558] A multiplicity of stacked inductance coils may increase the power
transfer as well as increase of mutual inductance
between coupled coils.
Reference: 'Achieve High Power Density with Stacked Inductor 25.08.2021,
Date Recue/Date Received 2022-12-30
91
https://www.electronicdesign.com'
[00559] To deliver proper alignment the maximal energy transfer per
orientation of coil groups may be, in some
embodiments, assessed by an internal or external CPU with a signaling when
optimal alignment is approaching or departing,
or made or lost.
[00560] As per Fig. 37d, a temperature sensor such as 3719t may be configured
to detect tissue temperatures external to
the coil and/or wrapper so that hardware and/or software in the system can
alert the user/external coil to increase or decrease
energy transmission as the case may be. In some embodiments, one or more
threshold temperatures may be established,
such as a shutoff temperature, which may be, for example, 45 degrees C, which
may result in termination of energy delivery
until the temperature returns to a second threshold temperature, such as 40
degrees C, at which point the energy delivery
may resume.
[00561] Fig. 63a depicts the right side of a torso of a human patient having a
flexible strand/string subcutaneous implant
6301 positioned in a respective implant pockets comprising elongated canals
made adjacent minimally invasive entrance
incisions 6310a-c. More particularly, implant system 6300 comprises a flexible
strand/string implant 6301, which may be
positioned within a canal that may be made by trocar, probe and/or beaded
dissector as previously described.
[00562] Although most implant pockets described in this disclosure are shown
as having been formed with multiple strokes
from instrument 5804, in trocar/cannula implementations, a single stroke may
be used. Thus, unlike most of the embodiments
disclosed herein, implant 6301 need not be compressible and therefore need not
be larger, or at least substantially larger,
than the entrance incisions 6310a-c. Thus, a single stroke of trocars/cannulas
6331 and 6332 may be used to both create the
path or paths into which the implant 6301 will come to rest.
[00563] Implant 6301 may be fed into the initial trocar/cannula 6331 prior to
body insertion to extend no further than the
internal ramp 6331r. The initial trocar/cannula 6331 is inserted through
initial incision 6310a, usually in the subcutaneous
tissues, in a vector directed toward a second entrance incision 63106 for an
optional second trocar/ cannula 6332. The second
entrance incision 63106 for a second trocar/ cannula 6332 may become the exit
incision for the initial trocar/cannula 6331.
Alternatively, the initial trocar/cannula 6331 may be backed out of initial
incision 6310a once the opening 633 lo has allowed
for passage of the cargo of implant 6301 therein. The proximal end of the
implant 6301p may continue to be fed into the
initial entrance wound until the desired length and placement is achieved.
After sufficient amount/length of the implant has
been fed into the second trocar/ cannula 6332, the second trocar/ cannula 6332
may be forced into second entrance incision
63106 along a vector 6333v headed toward an optional third entrance incision
6310c whereupon the process may be repeated
except that the cannulas can no longer be conveniently backed out over the
implant after the initial incision 6310a. In this
manner, a string-like implant of any length may be implanted into any region
of the body along any lines, whether straight
or curved, as desired.
[00564] Fig. 63b depicts an upper plan view of an upright beveled relatively
sharp tipped trocar 6331c with pointed tip
6331p.
[00565] Fig. 63c depicts a plan view rotated 90 degrees on its axis of the
same trocar 6331c as in Fig. 63b with shaft
opening/hole 6331h and pointed tip 6331p.
[00566] Fig. 63d depicts an upper plan view of an upright beveled relatively
blunt spatula tipped trocar 6331d with blunt
spatula tip 633 lb.
[00567] Fig. 63e depicts a plan view rotated 90 degrees on its axis of the
same trocar 6331d as in Fig. 63d with shaft
opening 63310 and blunt spatula tip 633 lb.
[00568] Fig. 63f depicts another alternative trocar 6331f, which may be
similar to the trocars previously discussed and
depicted aside from the shape of the trocar shaft, which may be curved. In
some embodiments, the shaft may be
permanently/rigidly curved or, alternatively, may be flexible to allow for
obtaining a variety of curvatures within the
constraints of the material. An opening/aperture 6331a and tip 6331t, which
may be blunt or pointed, may also be present.
Date Recue/Date Received 2022-12-30
92
[00569] Fig. 63g depicts a side view of an implant expelling cannula 633 lb
that is configured to, and is shown, expelling
a string-like implant 6301 from a side opening 6331o. This figure also depicts
a ramp 6331r, which may be configured to
divert or redirect the implant 6301 out of opening 6331o.
[00570] Fig. 64a depicts the front side of a torso of a human patient having
one or more compressible subcutaneous
electronic muscle stimulative (SQEMS) implants, which may be part of a system
6400, each of which may be positioned in
one or more respective implant pockets, such as pockets 6405R & 6405L,
preferably made via minimally invasive entrance
incision 6410. In the depicted embodiment, a single minimally invasive
entrance incision 6410 is used to form both implant
pockets 6405R/6405L. However, if the proximity of the pockets is not
sufficient, or for other reasons, a separate entrance
incision may be used for each implant pocket if desired. It is noteworthy, for
the layperson's understanding, that the electric
stimulation needed to contract significant and deepest portions of muscle is
carried via a muscular nerve that is electrically
stimulated carrying the depolarization to the smallest nerve branches deep
within the muscle leading to contraction.
Stimulating only surface muscle cells may produce a more limited effect. Thus,
an efficacious electronic muscle stimulative
apparatus intends to stimulate/depolarize a muscle's nerves to contract a
target muscle.
[00571] More particularly, a SQEMS implant 6401 is positioned within a
subcutaneous and/or soft tissue implant pocket
6405R, one or both of which may be similar to any of the other implants and/or
implant pockets previously mentioned.
Implant pocket 6405R may be made by methods described elsewhere within this
application, including Figs. 1 & 57. In
some implementations, one or more of the SQEMS implants may be oriented along
the location of the rectus abdominis
muscle or other abdominal muscles, or any other muscle group in alternative
embodiments or implementations as desired.
Implant 6401 may, in some embodiments, comprise a flexible, compressible
sheet, or stack of sheets, of electronics. Again,
implant pocket(s) 6405R and 6405L are preferably much "larger" (as described
previously) than the entrance incision(s)
6410 used to allow a lysing tip to enter the subcutaneous region of the body
and to create the implant pocket(s) 6405R/6405L.
Similarly, implant 6401 is, preferably, in its deployed and/or uncompressed
state, much "larger" than it is in its compressed
state and much larger than the length of the entrance incision(s) 6410. The
contralateral implant (not dashed to indicate it is
resting above surgically prepped skin for planning purposes) illustrates
various components of the implant. The
dissection/implant pocket may differ for muscle stimulation because the muscle
lies below the deepest part of the skin's
subcutaneous fat layer in an investing fascia. Therefore, implant configured
for muscle stimulation may be placed deeper,
such as in the lower layer of the fat that is adjacent to the muscle or
directly upon the muscle and/or its adjacent fascia to
excite the muscle tissue from a more proximate location. It may also be
preferable for such embodiments to face the
electrodes on the underside of the implant.
[00572] Implant(s) 6401 of system 6400 may further comprise an antenna 6407,
as previously described, to allow for receipt
and/or transmission of electromagnetic signals, which may be used to transmit
data to CPU/printed-circuit-board 6403 or
another suitable electrical components for use in activating peripherally
based terminal electrodes 6412 and optional non-
peripherally based terminal electrodes 6411 using, for example, energy derived
from battery 6404 and/or inductance coil
6414, as also previously described. Peripheral terminal electrodes 6412 may,
as shown on the figure, only be positioned
partially on the implant 6401 itself, whereas the non-peripheral terminal
electrodes 6411 may be wholly positioned on the
implant 6401. An external transmitter may be adjusted by the patient or
healthcare personnel to transmit signals to internal
antenna 6407 that, in turn, may provide instructions to CPU 6403 to coordinate
electrical output of electrodes 6411 and/or
6412. These external signals may, for example, be generated and/or received
from a smartphone or other wireless
communication device 6499. Battery 6404 may also be flexible. A wireless
charging system may be provided, such as the
wireless inductance assembly 6414, which may be used to charge flexible
battery 6404 and/or provide more direct energy
transfer, such as to a capacitor. Preferably, each of the elements of implant
6401 is either flexible and/or compressible or is
small enough on its own to fit within a minimally invasive entrance incision
with other elements of implant 6401 compressed
about it.
Date Recue/Date Received 2022-12-30
93
[00573] In some embodiments, one or more myoelectric sensors 6425 may also be
provided. Such sensor(s) 6425 may be
used to sense when muscle tissue is becoming fatigued, which may be used to
adjust and/or terminate stimulation of the
muscle to prevent damage to the tissue or simply provide a threshold for
cessation of stimulation. In some embodiments, the
user may be allowed to adjust this threshold according to, for example, a
desired "workout" intensity or current mood.
[00574] Some embodiments may further comprise one or more externally
detectable macro positioning/instrument
engaging holes 6423 (as described previously), which may aid in the
positioning of implant system 6400 during installation.
In alternative embodiments, placement holes 6423 need not be externally
detectable, or need not be present at all. One or
more printed circuit boards/CPUs 6403 and/or ancillary electronics 6424 may
also be provided as needed, including but not
limited to a heart rate sensor, oxygen saturation monitor, and the like.
[00575] As a more specific example, during an episode of pain or discomfort, a
patient's heart rate may elevate. An ancillary
electronic heart rate sensor 6424 option may therefore detect an elevated
heart rate, which may be used to by the SQEMS
to cease or reduce further stimulation of nerves upon detecting, for example,
a threshold heart rate and/or a threshold increase
in heart rate over a given period. In this manner, if pain is being caused by
implant 6401, the implant 6401 may be configured
to reduce or terminate stimulation of muscle to reduce or eliminate the pain
and/or avoid tissue damage. As previously
discussed for nerve stimulation, various terminal electrodes may be
electrically coupled, directly or indirectly, to a CPU,
such as CPU 6403. If the electrodes are on independent circuits to the CPU
then each may be programmed to fire at random
or independently in a preprogrammed pattern so as to provide a differing
stimulus pattern to the subject/recipient over time.
This may provide an improved ability to reduce pain or muscle fatigue by
changing, either randomly or based upon a
preconfigured pattern, for example, the actuation of each of the various
electrodes. Allowing one portion of a muscle to
relax whilst a different portion is activated may enhance the effect whilst
allowing more comfort for the patient. Thus
preprogrammed or randomized or changing programmable output may serve to
enhance the effect of SQEMS. Electrodes
output may be individually addressed in terms of amplitude, frequency, and/or
activation in order to achieve multiple varying
outputs. This effect may be enhanced, or alternatively achieved, by use of
multiple implants. For example, in the depicted
embodiment, the implant on the right may be configured to intermittently cease
stimulation as the implant on the left fires,
and vice versa. This may be accomplished as an alternative to firing multiple
electrodes on a single implant intermittently,
or randomly, or may be done in addition to independently firing multiple
electrodes on a single implant. In further
embodiments, a SQEMS implant may be communicatively coupled with at least one
of a heart rate sensor and/or blood
pressure sensor similar to items 6698, 6697 described in Fig. 66.
[00576] Fig. 641) is a bottom plan view of implant 6401 of system 6400
illustrating how each of the elements may be
coupled on implant 6401; however, in other embodiments, orientations and
locations may vary. In some embodiments, each
of the elements of implant 6400, possibly with the exception of terminal
electrodes 6411 and 6412, may be sealed within a
container or envelope, which is preferably both waterproof and biocompatible.
In some embodiments, one or more of the
electrodes may be exposed, such as by protruding through openings formed in
the container/envelope. Examples of suitable
materials for said container may include polyethylene, polyurethane,
polypropylene, and the like. In some embodiments,
various coatings, such as polymer coatings, may also, or alternatively, be
used.
[00577] Fig. 64c depicts a front view of an abdominal tension detecting belt
6451 that may be optionally used in conjunction
with implant 6401. Abdominal tension detecting belt 6451 may comprise antenna
6457, tension sensor 6458, CPU 6454,
and battery 6453. Belt 6451 may be communicatively coupled with one or more
implants 6401. For example, upon detecting
a threshold tension, a signal may be generated to fire one or more electrodes
of the one or more implants 6401. This may be
used as a training tool to, for example, voluntarily or involuntarily train a
user to avoid having the abdomen/stomach project
outwardly to an undesired degree and/or avoid poor posture. For example, if
the user has poor posture, the abdomen may be
projecting outward, which may cause the sensor to reach a threshold tension.
This threshold may cause firing of one or more
electrodes, the sensation/pain of which may cause the user to suck or withdraw
the abdomen inwardly to avoid the sensation,
Date Recue/Date Received 2022-12-30
94
which may be used to train better posture over time.
[00578] Inductance coil/'group of stacked coils' may be present as per the
coil cross section depicted in Fig. 37d.
[00579] A multiplicity of stacked inductance coils may increase the power
transfer as well as increase of mutual inductance
between coupled coils.
Reference: 'Achieve High Power Density with Stacked Inductor 25.08.2021,
https://www.electronicdesign.com'
[00580] To deliver proper alignment the maximal energy transfer per
orientation of coil groups may be, in some
embodiments, assessed by an internal or external CPU with a signaling when
optimal alignment is approaching or departing,
or made or lost.
[00581] As per Fig. 37d, a temperature sensor such as 3719t may be configured
to detect tissue temperatures external to
the coil and/or wrapper so that hardware and/or software in the system can
alert the user/external coil to increase or decrease
energy transmission as the case may be. In some embodiments, one or more
threshold temperatures may be established,
such as a shutoff temperature, which may be, for example, 45 degrees C, which
may result in termination of energy delivery
until the temperature returns to a second threshold temperature, such as 40
degrees C, at which point the energy delivery
may resume.
[00582] Fig. 65a depicts the front side of a torso of a human patient having a
plurality of spiral subcutaneous electronic
muscular stimulative (SSEMS) implants 6501a-6501g, which may be part of a
SSEMS system 6500. Implant 6501 comprises
3 turns. In alternative embodiments, spiral implants may comprise numbers of
turns ranging as previously described with
reference to Fig. 37. Each of the implants 6501a-6501g is preferably
positioned in a respective subcutaneous and/or soft
tissue implant pocket made via minimally invasive entrance incisions
6510a,b,n. As shown in this figure, a plurality of
implants may be positioned in some pockets, whereas other pockets may contain
only a single implant (i.e., implant 6501g
in implant pocket 6522c). Of course, this may vary in other embodiments as
desired. As previously mentioned, a single
entrance incision may be used to form each of the implant pockets or,
alternatively, a separate entrance incision may be used
for each implant pocket, or for a subset of the implant pockets. In the
depicted embodiment, however, a single entrance
incision 6510a is used to form implant pockets 6522a and 65226, whereas a
separate incision 65106 is used to form the
lower implant pocket 6522c. A circular/oval incision 6510n is also depicted as
an optional alternative, whereby the incision
may be hidden within the navel. Thus, the incision may be formed anywhere
within the navel represented by this closed
loop. In this embodiment, a series of 7 SSEMS spiral implants 6501a-g are
positioned within respective implant pockets.
More particularly, spiral implant 6501g (shown in dashed lines to indicate it
has already been implanted below the skin) is
positioned within an implant pocket 6522c. Implant pockets 6522a-c may be made
by methods described elsewhere within
this application, including Figs. 47a-e. In some implementations, the series
of SSEMS implants may be oriented along
desired portions of the rectus abdominis muscle. Spiral implants may be
installed in minimally invasive entrance wounds
by methods including those described in Figs. 47a-e. Spiral implant 6501g is
shown in dashed lines to indicate it has already
been implanted subcutaneously in pocket 6522c. More particularly, spiral
implants 6501a-f are shown without dashed lines
to indicate they are being positioned before surgery above the prepped (with
chlorhexidine and/or iodine) surgical site for
the surgeon to assess optimal implant location, spacing, and entrance wound
distance for each implant prior to pocket
formation or skin marking. As previously described, a portable electronic
device, such as smartphone 6599, may be part of
system 6500, and therefore may be communicatively coupled with one or more of
the implants. In further embodiments, a
SSEMS implant may be communicatively coupled with at least one of a heart rate
sensor and/or blood pressure sensor
similar to items 6698, 6697 described in Fig. 66.
[00583] Fig. 65b depicts a plan view of a single 3 turn SSEMS implant 6501
with outer terminal end 65010 and electrodes
dispersed along one or more sides of the faces or sides of the spiral with
outer arm band terminus 65010 and inner arm band
terminus 6501i and space 6588 between adjacent bands. Spacing 6588 may be
helpful for a variety of purposes, such as
improving the ease with which spiral implants can be surgically implanted
through a minimally invasive entrance incision.
Date Recue/Date Received 2022-12-30
95
Spacing 6588 between adjacent bands of a spiral implant may also provide
potential benefits to the implant following
implantation, such as providing increased surface area for drug delivery or
other purposes, and/or for providing features that
project, either permanently or selectively, into this space 6588, for various
purposes.
[00584] In some embodiments, spiral implant 6501 is circular in overall shape
from a top plan view, as shown in Fig. 65b,
and/or oval in cross section, as shown in Fig. 65c. As described below,
however, various other shapes may be used in
alternative embodiments as desired. Spiral implant 6501 may be rigid or, if
preferred, more flexible. In some embodiments,
the spiral implant 6501 may be compressible by being rollable and/or foldable.
However, due to the nature of the novel
spiral structure and implantation techniques described herein, the implant
6501 may be non-compressible and/or non-
foldable in some embodiments. In some embodiments, spiral implant 6501 may
comprise a metal, ceramic, cermet, glass,
flexible plastic, organic polymer, biopolymer, or the like. Other embodiments
may comprise a polymeric external lamination
or containment to retain more dissolvable materials such as hydrogels and the
like. Drugs, vitamins, or other chemicals,
including biologics, may also be bound, dissolved, or otherwise present in a
portion or all of the structure of spiral implant
6501 and/or elements contained therein. Also shown are terminal electrodes
6511a-f which each may be electrically coupled,
in some cases independently, directly or indirectly, to CPU 6503pb, as shown
in Fig. 65c. If the electrodes are on independent
circuits to the CPU then each may be programmed to fire at random or
independently in a preprogrammed pattern so as to
provide a differing stimulus pattern to the subject/recipient over time. Thus,
preprogrammed or randomized or changing
programmable stimuli may serve to enhance the effect of SSEMS. Electrode
output may be individually addressed in terms
of amplitude, frequency, and/or activation in order to achieve multiple
stimuli.
[00585] Fig. 65c is an enlarged view of a cross section at the location
demarcated by the line intersecting the arrow in Fig.
65b near outer arm band terminus 65010 of one possible embodiment, wherein
various layers/elements are depicted therein,
including a metallic inductance coil 6514, antenna 65026, battery 6504 (thin
film in this embodiment), printed circuit board
6503pb (in some embodiments, printed circuit board 6503pb may comprise a CPU),
and ancillary electronics 6524, such as
a heart rate sensor, oxygen saturation monitor, or the like, any of which may
be positioned adjacent to protective outer sheath
6517. In other contemplated embodiments, additional metallic inductance coils
6514a and 6514b may be stacked to enhance
the power generation capabilities of the implant. Some contemplated
embodiments may comprise multiple internal antennas.
[00586] In some embodiments, additional elements, such as electronic elements,
may be coupled to the coil to make the
coil more useful as a standalone implant, or an implant configured to
standalone as a power supply to another, secondary
implant. In some such embodiments, use of a unitary coil, as shown in Fig.
80a, may eliminate the need for an auxiliary
implant altogether. In contemplated embodiments, a unitary coil may therefore
be coupled with other implants, such as
implants to which the unitary coil is providing energy, without the use of an
auxiliary implant to aid the unitary coil in doing
so. It is also contemplated, however, that some coil embodiments may have
some, but not all, of the components that may
be provided on an auxiliary implant and may therefore be considered a "hybrid"
coil implant.
[00587] As previously mentioned, a myoelectric sensor 6525 may be provided in
some embodiments, which may be used
to provide feedback to the electrodes regarding the fatigue of the muscles
being stimulated.
[00588] In some embodiments, each of the elements of implant 6501, with the
possible exception of terminal electrodes
6511, may be sealed within a container or envelope (protective outer sheath
6517), which is preferably both waterproof and
biocompatible. Examples of suitable materials for said container may include
polyethylene, polyurethane, polypropylene,
and the like. In addition, the depicted embodiment further comprises an
implant superstructure 6501s. For purposes of this
disclosure, an "implant superstructure" should be considered to encompass any
structure that is formed upon and/or as an
extension to an implant to add rigidity to the implant in its uncompressed
form. Some implant superstructures may be
inflatable with a liquid or another fluid, which may allow for selectively
adding such rigidity, while others may be configured
to provide such rigidity automatically, such as upon unfolding or otherwise
decompressing the implant. Preferably, implant
superstructures are flexible and/or expandable, which may aid in fully
unfolding/uncompressing the implant and/or
Date Recue/Date Received 2022-12-30
96
maintaining the shape and location of the implant as it nestles in the
subcutaneous layers below. In some embodiments,
superstructure 6501s may comprise biocompatible polymers that are selectively
permeable. In some embodiments,
superstructure 6501s may be hollow, end-sealed, and/or may comprise an
expansive/expansile material, such a xerogel,
which may be configured to expand as water or another liquid, such as body
fluids, pass through the selectively permeable
polymers into the inside of the flexible expandable superstructure 6501s,
thereby causing an expansive/expansile material
to engorge in a limited space and thus relatively rigidify to varying degrees.
This may be beneficial to reduce unwanted
implant folding and/or migration. Although superstructure 6501s is shown
positioned within a lumen of the spiral implant
6501, it should be understood that similar superstructures may be formed at
other locations as desired according to the type
of implant, application, and desired rigidity modification. Thus, in some
embodiments, the superstructure may be formed
on an exterior surface of a spiral implant, which may provide the rigidity
necessary to maintain the spiral shape in some
cases.
[00589] Inductance coil/'group of stacked coils' may be present as per the
coil cross section depicted in Fig. 37d.
[00590] A multiplicity of stacked inductance coils may increase the power
transfer as well as increase of mutual inductance
between coupled coils.
Reference: 'Achieve High Power Density with Stacked Inductor 25.08.2021,
https://www.electronicdesign.com'
[00591] To deliver proper alignment the maximal energy transfer per
orientation of coil groups may be, in some
embodiments, assessed by an internal or external CPU with a signaling when
optimal alignment is approaching or departing,
or made or lost.
[00592] As per Fig. 37d, a temperature sensor such as 3719t may be configured
to detect tissue temperatures external to
the coil and/or wrapper so that hardware and/or software in the system can
alert the user/external coil to increase or decrease
energy transmission as the case may be. In some embodiments, one or more
threshold temperatures may be established,
such as a shutoff temperature, which may be, for example, 45 degrees C, which
may result in termination of energy delivery
until the temperature returns to a second threshold temperature, such as 40
degrees C, at which point the energy delivery
may resume.
[00593] Fig. 66a depicts a front side of a torso of a human patient having a
flexible strand/string subcutaneous electronic
muscular stimulative (FSQEMS) implant 6601, which may be part of a system
6600. Implant 6601 may be positioned in a
respective subcutaneous and/or soft tissue implant pocket preferably made via
a minimally invasive entrance incision 6610.
More particularly, implant system 6600 comprises a FSQEMS flexible
strand/string implant 6601, which may be positioned
within an implant pocket that in this embodiment may comprise a canal rather
than an enlarged pocket configured to receive
an expandable implant. Pocket/canal 6605c may be made by, for example, a
trocar, probe and/or beaded dissector, as
previously discussed. System 6600 may further comprise inductance coil spiral
implant 6614 that comprises 3 turns (with
or without additional electronics attached) and/or auxiliary implant 6608,
which may be deposited in various enlarged, non-
canal implant pockets, such as pocket 6605, which may be made similarly to
other methods described elsewhere within this
disclosure, including Figs. 1 & 57. In some embodiments and implementations,
the FSQEMS string implant 6601 may be
oriented along the location of the rectus abdominis muscle or other abdominal
muscles, or any other muscle group as desired.
Flexible strand/string implant 6601 may, in some embodiments, comprise a
flexible tube and/or strand of electronics. The
contralateral implant (not dashed to indicate it is resting above surgically
prepped skin for planning purposes) illustrates
various possible components of the implant. The dissection/implant
pocket/canal for string implants may differ for muscle
stimulation in that the muscle lies below the deepest part of the skin's
subcutaneous fat layer in an investing fascia. Therefore,
implants configured for muscle stimulation may be placed deeper, such as in
the lower layer of the fat that is adjacent to the
muscle or directly upon the muscle and/or its adjacent fascia to excite the
muscle tissue from a more proximate location. It
may also be preferable for such embodiments to face the electrodes on the
underside of the implant. An external transmitter
may be adjusted by the patient or healthcare personnel to transmit signals to
internal antenna 66026 that, in turn, may provide
Date Recue/Date Received 2022-12-30
97
instructions to CPU/printed-circuit-board 6603 to coordinate electrical output
of electrodes 6611. These external signals
may, for example, be generated and/or received from a smartphone or other
wireless communication device 6699. In
alternative embodiments, spiral implants may comprise numbers of turns ranging
as previously described with reference to
Fig. 37.
[00594] As best illustrated in Fig. 66b, implant system 6600 may further
comprise auxiliary implant 6608, various possible
elements of which may be as described in Figs. 54 a-c, including but not
limited to an antenna 66026 to allow for sending
and/or receipt of electromagnetic signals, which may be used to transmit data
to CPU/printed-circuit-board 6603 for use in
activating peripherally based terminal electrodes 6611a-f using energy derived
from battery 6604 and/or inductance coil
6614, and wiring 6615i/6615o. Auxiliary implant 6608 may also comprise a
capacitor 6626 and/or a lab-on-a-chip 6629. A
lab-on-a-chip may be beneficial for, for example, diabetics to assess blood
glucose levels pre, post, and/or during muscular
activity. In some embodiments, microfluidic channels (not shown) may bring
patient serum/blood/tissue fluid located outside
of the protected encasement/wrapper in contact with lab-on-a-chip for
analysis(es). An external transmitter may be adjusted
by the patient or healthcare personnel to transmit signals to internal antenna
66026 that in turn, may direct CPU 6603 to
coordinate electrical output of electrodes 6611a-f, which, again, may be
actuated independently or together. In some
embodiments, the battery 6604 may also be flexible and/or installed within or
along inductance coil 6614. A wireless
charging system may be provided, such as a wireless inductance assembly, which
may be used to charge the battery 6604.
Preferably, each of the elements of implant system 6600 is flexible and/or
compressible or is small enough on its own to fit
within a minimally invasive entrance incision 6610 with other elements of
implant 6600 moved into their optimal positions
in separate tissue pockets. Auxiliary implant 6608 may allow for certain
components, such as sensitive electrical
components, to be placed within a separate implant, which may be more
protective of such components, such as being within
a waterproof/sealed container, for example. A seal, such as a wrapper, may be
used to contain all of the elements of auxiliary
implant 6608 therein.
[00595] In some embodiments, additional elements, such as electronic elements,
may be coupled to the coil to make the
coil more useful as a standalone implant, or an implant configured to
standalone as a power supply to another, secondary
implant. In some such embodiments, use of a unitary coil, as shown in Fig.
80a, may eliminate the need for an auxiliary
implant altogether. As mentioned later, a unitary coil may also comprise a lab-
on-a-chip. A lab-on-a-chip may be beneficial
for, for example, diabetics to assess blood glucose levels pre, post, and/or
during muscular activity. Thus, glucose may be
modulated by implant driven electrical muscular stimulation. In some
embodiments, microfluidic channels (not shown)
may bring patient serum/blood/tissue fluid located outside of the protected
encasement/wrapper in contact with lab-on-a-
chip for analysis(es). In contemplated embodiments, a unitary coil may
therefore be coupled with other implants, such as
implants to which the unitary coil is providing energy, without the use of an
auxiliary implant to aid the unitary coil in doing
so. It is also contemplated, however, that some coil embodiments may have
some, but not all, of the components that may
be provided on an auxiliary implant, and may therefore be considered a
"hybrid" coil implant.
[00596] In some embodiments, one or more myoelectric sensors 6625 may also be
provided. Such sensor(s) 6625 may be
used to sense when muscle tissue is becoming fatigued, which may be used to
adjust and/or terminate stimulation of the
muscle to prevent damage to the tissue or simply provide a threshold for
cessation of stimulation. In some embodiments, the
user may be allowed to adjust this threshold according to, for example, a
desired "workout" intensity or current mood.
[00597] As a more specific example, during an episode of pain or discomfort, a
patient's heart rate may elevate. An ancillary
electronic heart rate sensor 6624 option may therefore detect an elevated
heart rate, which may be used to by the FSQEMS
to cease or reduce further stimulation of muscles upon detecting, for example,
a threshold heart rate and/or a threshold
increase in heart rate over a given period. In this manner, if pain is being
caused by the implant 6601, the implant 6601 may
be configured to reduce or terminate stimulation of muscle to reduce or
eliminate the pain and/or avoid tissue damage. As
previously discussed for nerve stimulation, various terminal electrodes may be
electrically coupled, directly or indirectly, to
Date Recue/Date Received 2022-12-30
98
a CPU, such as CPU 6603. If the electrodes are on independent circuits to the
CPU then each may be programmed to fire at
random or independently in a preprogrammed pattern so as to provide a
differing stimulus pattern to the subject/recipient
over time. This may provide an improved ability to reduce pain or muscle
fatigue by changing, either randomly or based
upon a preconfigured pattern, for example, the actuation of each of the
various electrodes. Allowing one portion of a muscle
to relax whilst a different portion is activated may enhance the effect whilst
allowing more comfort for the patient. Thus
preprogrammed or randomized or changing programmable output may serve to
enhance the effect of FSQEMS. Electrode
output may be individually addressed in terms of amplitude, frequency, and/or
activation in order to achieve multiple varying
outputs. This effect may be enhanced, or alternatively achieved, by use of
multiple implants. For example, in the depicted
embodiment, the implant on the right may be configured to intermittently cease
stimulation as the implant on the left fires,
and vice versa. This may be accomplished as an alternative to firing multiple
electrodes on a single implant intermittently,
or randomly, or may be done in addition to independently firing multiple
electrodes on a single implant. In further
embodiments, a FSQEMS implant may be communicatively coupled with at least one
of a heart rate sensor 6698 and/or
blood pressure sensor 6697 to prevent undesirable electrostimulative stress.
Additional details regarding such blood pressure
sensor and/or heart rate sensor devices may be found in "Subcutaneous Blood
Pressure Monitoring with An Implantable
Optical Sensor", Theodor, Biomed Microdevices, Vol. 5:811-820, 2013, &
"Implantable loop recorder: A heart monitoring
Device," Mayo Clinic, https://www.mayoclinic.org/tests-procedures/implantable-
loop-recorder/pyc-20384986, 2022 which
are hereby incorporated herein in their entirety by reference.
[00598] Fig. 66b is a side elevation view of FSQEMS flexible strand/string
implant 6601 illustrating how each of the
elements may be coupled on strand 6601; however, in other embodiments,
orientations & locations may vary. In some
embodiments, each of the elements of implant 6601, with the possible exception
of the electrodes 6611a-f, may be sealed
within a container or envelope, which is preferably both waterproof and
biocompatible. Examples of suitable materials for
said container include polyethylene, polyurethane, polypropylene, and the
like. A wire 6615o may be used to couple the
auxiliary implant 6608 with one or more (preferably all) of the various
electrodes 6611a-f of the string implant 6601.
[00599] Fig. 66c is an enlarged transparency view of Fig. 66b depicting an
embodiment of a wiring scheme for various
terminal electrodes 6611a-e along a flexible strand/string subcutaneous
electronic muscle stimulative (FSQEMS) implant
6601. In this embodiment, electrodes 6611a-e are all wired independently (for
example, on wires such as 6611aw, which is
coupled with electrode 6611a) of each other, thus allowing for different
programmable control for each. In other
contemplated embodiments, the wiring may be in series, parallel or another
form of independent wiring or a combination
thereof Firing may vary in terms of amplitude, time of firing, and/or on-off
cycle. Again, this may be random, controllable
by the user, or both (selectively random or specific, as selected by the
patient). If the electrodes are on independent circuits
to the CPU, then each may be programmed to fire at random intervals or
independently in a preprogrammed pattern so as to
provide a differing stimulation pattern to the subject/recipient over time.
Thus preprogrammed or randomized or changing
programmable stimuli may serve to enhance the effect of F SQEMS. Electrode
output may be individually addressed in terms
of amplitude, frequency, and/or activation in order to achieve multiple
stimuli. The triangles used to represent the electrodes
in Figs. 66a-c are by no means restrictive or indicative of electrode shape.
In Figs. 66b & 66c, internal wiring 6611aw may
be connected to a peripheral/circumferential electrode 6611a, which may have
several potential benefits. For example,
providing a band-like/circumferential electrode may allow for a more widely
distributed signal that may be less prone to
missing a particular target nerve or other tissue region. However, it may be
desirable for certain applications to form such
an electrode such that it extends only partially about the periphery of the
string and/or tube-like implant 6601. For example,
it may be desirable to avoid the increased points of termination, such as
corners, which may result from an incomplete
circumferential electrode. It should be understood, however, that such points
of termination may be preferred for certain
applications, particularly since it may be desirable to vary the location,
strength, and/or other parameters of the signal for
certain applications, such as FSQEMS applications.
Date Recue/Date Received 2022-12-30
99
[00600] Although electrode 6611a is shown projecting slightly from the
peripheral wall of the implant 6601 in Fig. 66c, it
should also be understood that it may be desirable instead to have the
electrode flush with this exterior wall, which may be
a hollow or solid tube, for example, which may allow the implant to slide more
easily through, for example, a trocar, adjacent
tissues, and/or the entrance wound. As well, a flush match between these
elements may reduce the chance of tissue
trauma/shear between an implant with a hard protrusion and a tissue structure
such as a blood vessel or nerve. The cross-
sectional shape of the implant 6601 may vary as desired, such as from circular
to oval to strap-like to polygonal in various
contemplated embodiments.
[00601] The implant system 6600 may also comprise, as in Fig. 64c, an
abdominal tension detecting belt that may be
optionally used in conjunction with implant 6601. This may be used as a
training tool to, for example, voluntarily or
involuntarily train a user to avoid having the abdomen/stomach project
outwardly to an undesired degree and/or avoid poor
posture. For example, if the user has poor posture, the abdomen may be
projecting outward, which may cause the sensor to
reach a threshold tension. This threshold may cause firing of one or more
electrodes, the sensation/pain of which may cause
the user to suck or withdraw the abdomen inwardly to avoid the sensation,
which may be used to train better posture over
time.
[00602] Implant system 6600 may be particularly useful in connection with
treatment of patients who have been immobile
or bedridden for prolonged periods. For example, use of system 6600 in
treatment of stroke or other trauma victims may
tone muscle and/or help metabolize sugars. In addition, similar to the manner
in which EMS (Electrical Muscle Stimulation)
and PEMs (percutaneous electrical muscle stimulation) may aid type 2 diabetics
by lowering postprandial glucose (Diabetes
Res. Clin. Pract. 2012 June; 96(3):306-12), in some alternative
implementations, an embodiment of an FSQEMS system
may be used for such treatment, but without the painful needles of PEMs.
Although FSQEMS is shown here associated with
the rectus abdominis musculature, it may be appreciated that use with many
other voluntary muscle groups may be practical.
[00603] Inductance coil/'group of stacked coils' may be present as per the
coil cross section depicted in Fig. 37d.
[00604] A multiplicity of stacked inductance coils may increase the power
transfer as well as increase of mutual inductance
between coupled coils.
Reference: 'Achieve High Power Density with Stacked Inductor 25.08.2021,
https://www.electronicdesign.com'
[00605] To deliver proper alignment the maximal energy transfer per
orientation of coil groups may be, in some
embodiments, assessed by an internal or external CPU with a signaling when
optimal alignment is approaching or departing,
or made or lost.
[00606] As per Fig. 37d, a temperature sensor such as 3719t may be configured
to detect tissue temperatures external to
the coil and/or wrapper so that hardware and/or software in the system can
alert the user/external coil to increase or decrease
energy transmission as the case may be. In some embodiments, one or more
threshold temperatures may be established,
such as a shutoff temperature, which may be, for example, 45 degrees C, which
may result in termination of energy delivery
until the temperature returns to a second threshold temperature, such as 40
degrees C, at which point the energy delivery
may resume.
[00607] In some embodiments, lab-on-a-chip devices may be incorporated into
one or more of the implants disclosed
herein, which devices may comprise microfluidic chips. In some embodiments,
microfluidic chips may comprise channel
systems connected to liquid reservoirs by, for example, tubing systems. In
some embodiments, sensors, detectors, optical
components, and the like may be integrated on-chip. In some instances,
miniaturization technology and/or reduction of
reaction volume may decrease the absolute amount of analytes, allowing for the
analysis of small compounds out of a
flowing bulk sample. In some embodiments, fluorescence analysis may allow for
real time measurements due to its high
temporal resolution and sensitivity. Such microchips may be used for
applications such as, for example, enzymatic assays,
photo-induced protein conversion, analysis of DNA, and the like. In some
embodiments, merging channel geometries may
be used to regulate the concentrations of reagents. Additionally, in some
instances, temperature may also be regulated. In
Date Recue/Date Received 2022-12-30
100
some embodiments, such chips may comprise continuous flow microreactors, which
may facilitate multi-step reactions,
allowing for the combination of multiple reaction steps and on-line analysis.
In some embodiments, such chips may be used
for high throughput screening and/or cell sorting. In some embodiments, chips
may be constructed to detect and/or sort DNA
fragments and/or bacterial cells, preferably with high throughput rates.
Combining appropriate biological assays with high-
sensitivity detection techniques may facilitate the identification and
isolation of targeted cells and/or molecules. In some
embodiments, small liquid volumes may be generated such that the supply of
reagents may be regulated in precise reactions,
such as protein crystallization or molecular evolution. In some instances,
said volumes may be formed by aqueous droplets
in a carrier medium. In some embodiments, chips may be used for microfluidic
cell treatment, as reaction volumes may
approach volumes analogous to those found in cells, allowing for manipulation
of objects of cellular size in a controlled
environment. Additional details regarding such lab-on-a-chip devices may be
found in "Lab-on-a-chip: Microfluidics in
Drug Discovery", Dittrich, Nature, Vol. 5,210-218, 2006, which is hereby
incorporated herein in its entirety by reference.
[00608] Fig. 67a depicts an embodiment of a spiral implant 6701 comprising a
plurality of LEDs 6711 interspersed
throughout the implant 6701, such as LEDs, OLEDs, and/or mLEDs, each of which
may be positioned inside the lumen of
the spiral implant 6701 or on an outer surface thereof Spiral implant 6701
comprises an inner terminus 6701i and an outer
terminus 6701o, and may comprise space 6788 between each pair of adjacent
spiral arms. Implant 6701 comprises 3 turns.
In alternative embodiments, spiral implants may comprise numbers of turns
ranging as previously described with reference
to Fig. 37. The embodiment depicted by Fig. 67a may be useful for illuminating
a preexisting ink tattoo through the skin
surface. Other uses may include implantation for mood improvement, as
previously discussed. Some
implementations may include uses for illumination of overlying traditional
tattoos from an illuminated subcutaneous
implantable spiral which may optionally be controllable from an external
device. Other implementations may include
illuminated subcutaneous implantable spirals themselves are the implantable
tattoo art which may optionally be controllable
from an external device; a combination of these uses may be possible. Any of
the LEDs or other light sources shown or
discussed as being used on a compressible implant may be used on a spiral/non-
compressible implant in various
contemplated embodiments. Other implementations may include those outside of
an organism's body such as an
inductive/wireless/cordless charged decoration, ornament, toy, etc.
[00609] Further implementations may include uses for treating bilirubin or
chemicals derived therefrom in liver disease,
cancer, or other disease states. LEDs or other light sources shown or
discussed as being used on a compressible implant may
be used on a spiral/non-compressible implant in various contemplated
embodiments and may be therapeutic. For example,
phototherapy may produce specific changes in bile acid metabolism and may
reduce itching in liver disease patients by
altering the cutaneous bile acid pool. Additional details may be found in
'Effects Of Phototherapy On Hepatic Function In
Human Alcoholic Cirrhosis', Knodell, Gastroenterology, 70: 1112, 1976 which is
hereby incorporated in its entirety by
reference. Phototherapy results in transformation of bilirubin to more water-
soluble isomers. Effective bilirubin altering
wavelengths in vitro (i.e., leading to greater than 25% photoisomer) were in
the blue spectrum from approximately 390 to
470 nm. Green light (530 nm) was not only ineffective for production of
photoisomer, but may reverse the reaction. The
results indicate that clinically useful phototherapy units should include the
blue portion of the visible spectrum, with
increasing effectiveness by eliminating of green light. Additional details may
be found in 'Phototherapy For Neonatal
Jaundice: Optimal Wavelengths Of Light', Ennever, J Pediatr, 103: 295, 1983
which is hereby incorporated in its entirety
by reference. Thus, blue LED light may reduce bilirubin in liver disease
patients.
[00610] In some embodiments, additional elements, such as electronic elements,
may be coupled to the coil to make the
coil more useful as a standalone implant, or an implant configured to
standalone as a power supply to another, secondary
implant. In some such embodiments, use of a unitary coil, as shown in Fig.
80a, may eliminate the need for an auxiliary
implant altogether. In contemplated embodiments, a unitary coil may therefore
be coupled with other implants, such as
implants to which the unitary coil is providing energy, without the use of an
auxiliary implant to aid the unitary coil in doing
Date Recue/Date Received 2022-12-30
101
so. It is also contemplated, however, that some coil embodiments may have
some, but not all, of the components that may
be provided on an auxiliary implant, and may therefore be considered a
"hybrid" coil implant.
[00611] In some embodiments, the coil/spiral implant may comprise an arm
extending along at least 2 complete turns to
form the spiral shape. In some such embodiments, the coil/spiral implant may
comprise an arm extending along at least 10
complete turns to form the spiral shape. In some such embodiments, the
coil/spiral implant may comprise an arm extending
along at least 15 complete turns to form the spiral shape. In some such
embodiments, the coil/spiral implant may comprise
an arm extending along at least 20 complete turns to form the spiral shape. In
some such embodiments, the coil/spiral implant
may comprise an arm extending along at least 25 complete turns to form the
spiral shape. The spiral implant of Fig. 67a
comprises 3 turns. In alternative embodiments, spiral implants may comprise
numbers of turns ranging as previously
described with reference to Fig. 37.
[00612] Fig. 67b depicts a cross-sectional view of an embodiment of a spiral
implant with rectangular cross-section 6701re
taken from Fig. 67a as demarcated by the line and arrow.
[00613] Fig. 67c depicts a cross-sectional view of another embodiment of a
spiral implant 670 HL with a relatively flat
cross-sectional shape.
[00614] Fig. 67d depicts a cross-sectional view of still another embodiment of
a spiral implant 670 by having an oval
cross-sectional shape.
[00615] Fig. 67e depicts a cross-sectional view of yet another embodiment of a
spiral implant 6701pe with a pentagonal
cross-sectional shape. In further anticipated embodiments, the cross-sectional
shapes may be any geometric shape, including,
but not limited to polygons.
[00616] Fig. 67f is a side view of another alternative embodiment of a portion
of a spiral implant 6701if showing the inner
terminus, which comprises an open loop end or handle 6750f projecting
therefrom. Loop 6750f may facilitate the placement
of, for example, a fixating suture or a guide suture by a surgeon. In the case
of a spiral implant, as the implant pockets are
often slightly larger than the size of the implant, if a surgeon wishes to
limit the mobility of the implant before the body
seals it in place, a suture may be helpful.
[00617] Fig. 67g is a side view of another alternative embodiment of a spiral
implant 6701ig showing the inner terminus
of the implant, which inner terminus comprises a notch 6750g, which may
facilitate the placement of a suture or other similar
structure that may be coupled with the implant to facilitate affixing the
implant at a desired location within an implant
pocket. For example, in some implementations, the implant pocket may be
significantly larger than the implant and the
implant may therefore be prone to shifting within the pocket. In order to
maintain the implant at a desired location, such as
directly under an ink tattoo, a surgeon may wrap a suture about the notch
6750g and couple the suture to the skin at that
location to prevent the implant from shifting. Notch 6750g may also, or
alternatively, be used to facilitate movement of the
implant by, for example, allowing a surgeon to pull the implant with the
suture similar to a tether.
[00618] Fig. 67h depicts a cross-sectional view of another example of a spiral
implant 6701h. Implant 6701h is similar to
the spiral implant of Fig. 67b, but further comprises a superstructure 6751h,
which may extend along the entire length of the
implant 6701h or, alternatively, just a portion thereof, to provide added
structure to the implant 6701h. Superstructure 6751h
may, in some embodiments, be adhered to one side and/or surface of the spiral
implant 6701h and, although shown as a
semicircle in the figure, may comprise any shape as desired.
[00619] Fig. 67i depicts a cross-sectional view of a similar spiral implant
6701ii also having a superstructure 6751i, but in
this case the superstructure 6751i is positioned within a lumen of the implant
rather than coupled to an outer surface thereof
In contemplated embodiments, superstructures that are cross sectionally
circular may be a variety of other shapes, including
ovals and/or polygons.
[00620] Fig. 67j depicts a cross-sectional view of another similar spiral
implant 6701j comprising a fully contained
superstructure 6751j positioned in a lumen thereof. However, in this
embodiment, the superstructure 6751j is sandwiched
Date Recue/Date Received 2022-12-30
102
between various other elements of the implant, such as battery 6704 and
inductance coil 6714. It should be understood,
however, that the superstructure may be coupled to and/or sandwiched between
any other elements of the assembly,
including other functional elements, or alternatively, elements the sole
purpose of which may be to couple the superstructure
67511 to the implant, such as laminate and/or adhesive layers, for example.
[00621] Fig. 67k depicts a cross-sectional view of another spiral implant
6701k comprising an externally attached
superstructure 6751k, which, as shown in the figure, may be coupled to an
outer side/surface of the implant. In some
embodiments, a superstructure may be segmented and/or discontinuous and/or may
comprise at least one selected from the
group of: a battery, an inductance coil, a capacitor, a data storage element,
an EMI suppression element, and an antenna as
in the description for Fig. 19b.
[00622] Fig. 67L depicts a cross-sectional view of still another spiral
implant 6701L comprising a fully contained
semicircular superstructure 675 IL.
[00623] Fig. 67m depicts a cross-sectional view of yet another spiral implant
6701m comprising an externally coupled
superstructure 6751m. Implant 6701m differs from implant 6701h in that the
superstructure is coupled to an opposite side
(inner vs. outer, for example) of the implant relative to implant 6701h.
[00624] Fig. 67n depicts a cross-sectional view of a spiral implant 6701n
comprising a superstructure 6751n positioned on
the upper and lower surfaces of the implant. Of course, in alternative
embodiments, the superstructure 6751n may only be
positioned on the top, or only the bottom, of the implant.
[00625] Fig. 68a depicts a top plan view of an embodiment of a compressible
implant 6801, which may comprise a
semisolid implant, and which further comprises a peripheral superstructure 685
lb. Implant 6801 further comprises macro
positioning/instrument engaging holes 6803 and reinforcement areas 6802.
[00626] As shown in Figs. 686-68e, each of which is a cross-sectional view of
a possible iteration of the general
embodiment of Fig. 68a, superstructures 68516-6851e, which are variations of
the superstructure 685 lb shown in Fig. 68a,
may either extend along the outer peripheral edge of implants 6801, 6801c,
6801d, as shown in Figs. 68b, 68c, and 68d, or
may extend inside the implant 6801e (e.g., between upper and lower surfaces
thereof) to define or be adjacent to the
peripheral edge of the implant, as shown in Fig. 68e.
[00627] Any of the aforementioned superstructures, such as superstructures
68516-6851e, may comprise, for example, a
bladder-like structure that may be inflatable in some embodiments. Similarly,
in some embodiments, the implant itself may
comprise a bladder-like structure, as shown in Fig. 68c, which depicts an
implant 6801c having a central space peripherally
bound at opposing ends by superstructure 6851c. Such bladder-like implants
may, in some embodiments and
implementations, be configured with electronic control, an energy source,
and/or pumping/drug delivery systems to infuse
drugs/chemicals directly into the blood supply of a target tissue such as, for
example, chemotherapy into a cancer.
Superstructures, such as but not limited to superstructures 68516-6851e, may
also be configured to reduce or eliminate
potentially problematic edges and/or relatively sharp points, which, as
discussed above, may result in inflammation and/or
other problems. Thus, preferred embodiments may be specifically configured
solely, or at least primarily, with smooth
and/or softened edges, surfaces, and/or points to reduce or eliminate these
issues.
[00628] Fig. 69 depicts a spiral implant 6900 comprising spiral arms 6901a
having little to no space between each adjacent
pair of spiral arms 6901a, as indicated at 6988. Implant 6900 comprises 4
turns. This type of shape may be manufactured,
for example, by simply cutting a spiral out of a planar substrate with no
space in between arms. For this type of spiral to be
implanted in a relatively easy manner, however, the material of the implant
may be sufficiently flexible so that the spirals
created by cutting may be bent/flexed away from each other in order to fit
through the preferably minimally invasive entrance
wound, as shown by the techniques previously disclosed. As per Fig. 47, this
spiral implant 6900 may be rotated into an
incision from either the inner or outer terminus. It is contemplated that such
spiral implants may be formed into any suitable
shape as desired, preferably in a manner that allows for winding/rotation of
the implant into a minimally invasive entrance
Date Recue/Date Received 2022-12-30
103
incision one band/arm at a time, as discussed herein. As the space between
adjacent arms approaches zero, many possibilities
for shapes either formed by spiral arms or cut into a spiral exist. For
example, again, in some contemplated embodiments,
possible shapes may include: cartoon character, flower, sailor, or anchor. The
spiral implant of Fig. 69 comprises 4 turns.
In alternative embodiments, spiral implants may comprise numbers of turns
ranging as previously described with reference
to Fig. 37.
[00629] Inductance coil/'group of stacked coils' may be present as per the
coil cross section depicted in Fig. 37d.
[00630] A multiplicity of stacked inductance coils may increase the power
transfer as well as increase of mutual inductance
between coupled coils.
Reference: 'Achieve High Power Density with Stacked Inductor 25.08.2021,
https://www.electronicdesign.com'
[00631] To deliver proper alignment the maximal energy transfer per
orientation of coil groups may be, in some
embodiments, assessed by an internal or external CPU with a signaling when
optimal alignment is approaching or departing,
or made or lost.
[00632] As per Fig. 37d, a temperature sensor such as 3719t may be configured
to detect tissue temperatures external to
the coil and/or wrapper so that hardware and/or software in the system can
alert the user/external coil to increase or decrease
energy transmission as the case may be. In some embodiments, one or more
threshold temperatures may be established,
such as a shutoff temperature, which may be, for example, 45 degrees C, which
may result in termination of energy delivery
until the temperature returns to a second threshold temperature, such as 40
degrees C, at which point the energy delivery
may resume.
[00633] Fig. 70a depicts a front view of a torso, especially the lower abdomen
and genital region, of a human patient having
a flexible strand/string electronic genital stimulative (FSEGS) implant system
7000 comprising one or more implants
positioned in respective implant pockets preferably made via one or more
minimally invasive entrance incisions 7010. More
particularly, implant system 7000 comprises a FSEGS flexible strand/string
implant 7001, which may be positioned within
a subcutaneous and/or soft tissue implant pocket 7005c, which may comprise a
canal that may be made by a trocar, probe,
and/or beaded dissector as shown previously. System 7000 may further comprise
connecting wires 7015i, inductance coil
7014 (with or without additional electronics attached) and/or auxiliary
implant 7008, each of which may be deposited in
various subcutaneous and/or soft tissue implant pockets, either their own
individual implant pockets or an implant pocket
shared with another implant of the system, which may be made similarly to
others described by methods described elsewhere
within this application, including Figs. 1 & 57. In some implementations, the
primary FSEGS implant 7001 of system 7000
may be oriented in or about the clitoral or crus clitoral tissues, or in or
adjacent to the penis. Flexible strand/string implant
7001 may, in some embodiments, comprise a flexible tube or strand of
electronics.
[00634] In some embodiments, inductance coils may be replaced by other power
generating and/or yielding devices, such
as, thermoelectric generators, flexible piezoelectric energy harvesters,
capacitive coupling transmission, magnetodynamic
coupling transmission, microwave power transmission, and the like, depending
on the subject patient and safety guidelines.
[00635] It may be beneficial to have not only electrode stimulation of the
nerve supply to the genitalia, but a simultaneous
or rhythmic interrupted stimulation of the genital tissues themselves by, for
example, vibrational mechanical means, such
as piezoelectric means 7071a. In further contemplated embodiments, the
piezoelectric generator/actuator/means 7071a may
be replaced with, for example, miniaturized eccentric rotating mass motors,
linear resonant actuators, solenoids, and the like.
[00636] As best depicted in Fig. 70b, implant system 7000 may further comprise
auxiliary implant 7008, which may
comprise any of the elements previously described in Figs. 54 a-c, including
but not limited to an antenna 70026 to allow
for receipt of electromagnetic signals, which may be used to transmit data to
CPU/printed-circuit-board 7003 for use in
activating peripherally based terminal electrodes 7011a-e using energy derived
from battery 7004 and/or inductance coil
7014. An external transmitter may be adjusted by the patient or healthcare
personnel to transmit signals to internal antenna
70026 that in turn directs CPU 7003 to coordinate electrical output of
electrodes 7011a-e. In some embodiments, the battery
Date Recue/Date Received 2022-12-30
104
7004 may also be flexible and/or installed within or along inductance coil
7014. A wireless charging system may be
provided, as previously described, and which may be configured to wirelessly
charge the battery 7004 via inductance coil
7014. Preferably, each of the elements of implant system 7000 is either
flexible and/or compressible, or is small enough on
its own to fit within a minimally invasive entrance incision 7010 with other
elements of implant 7000 moved into their
optimal positions in separate tissue pockets, such as pocket 7005, which
contains inductance coil 7014 in the depicted
embodiment. Auxiliary implant 7008 may allow for certain components, such as
sensitive electrical components, to be
placed within a separate implant, which may be more protective of such
components, such as being within a
waterproof/sealed container, for example. A seal, such as a wrapper, may be
used to contain all of the elements of auxiliary
implant 7008 therein.
[00637] In further contemplated embodiments, the implant system may comprise
an auxiliary implant with any element
including, but not limited to, those mentioned for the auxiliary implant
described in Fig. 66, for example, CPU(s)/printed-
circuit-board(s), battery(ies), memory/data storage element(s), antenna(e),
capacitor(s), electronic heart rate sensor(s), lab-
on-a-chip element(s). In other contemplated embodiments, either coils or
auxiliary implants may comprise pulse oximetry
elements. Although some auxiliary implants shown in the figures are
cylindrical in shape, in further contemplated
embodiments they may comprise a variety of shapes including, but not limited
to, ovoids, polygonal prisms, pads, pillow-
like, purse-like, with or without various cavities or convexities.
[00638] The electrode termini may be positioned and configured to stimulate in
and/or adjacent to the genitalia (e.g., the
clitoris or penis), in some cases along with and its associated tissues, such
as branches of the pudendal nerve. For example,
some implementations may involve stimulation of the dorsal nerve of the
clitoris and labial nerves or the dorsal nerve of the
penis, the genital femoral nerve, and/or other nerve branches that may be
supplied by the sacral plexus, for example, or any
other nerve capable of sexual stimulation.
[00639] An external transmitter may be adjusted by the patient or healthcare
personnel to transmit signals to internal
antenna 7007 that, in turn, may provide instructions remotely to CPU 7003 to
coordinate electrical output of electrodes
7011a-e. These external signals may, for example, be generated and/or received
from a smartphone or other wireless
communication device 7099. The smartphone/wireless communication device may
comprise a CPU and software capable
of interpreting and/or sending signals to and from the implantable CPU 7003.
The external CPU and/or the internal CPU
may contain programming sequences that will elicit the electrode firing in
predetermined patterns that may be desirably
stimulative. For example, sexual stimulations that occur in a wave-like
pattern wherein a distal set of electrodes fires and
then turns off and the next set of more proximal electrodes fires and then
turns off and then the next set of even more
proximal electrodes fires and then turns off, may be more pleasurable in some
subjects than if all the electrodes fire at once.
[00640] In some embodiments, devices may be implanted to stimulate the
clitoris in patients possessing vaginas. Some
systems may include, for example, devices implanted near the dorsal nerves of
the clitoris. In some instances, signal
generators may be activated on command to generate energy pulses and stimulate
the dorsal nerves. Such pulses may be
generated in a controlled manner via stored programs and internal sensors,
and/or may be dynamically controlled by an
external device. In some instances, generated energy may include ultrasonic
energy, electrical energy, chemical energy, and
the like. Further details regarding such clitoral stimulation devices may be
found in U.S. Patent Application Publication No.
2009/0259095, titled "System and Method for Treatment of Hypo-Orgasmia and
Anorgasmia", which is hereby incorporated
herein in its entirety by reference.
[00641] Certain embodiments may comprise systems to aid in achieving the
enlarged state of female erectile tissue. In some
instances, a device may be implanted within the female erectile tissue, such
that, upon activation, fluid may be pumped from
a subcutaneous reservoir into the device, enlarging the device, which may aid
in achieving enlarged state of female erectile
tissue. Some embodiments may comprise devices that may be controlled or
recharged via external devices. Such systems
may be used to aid in achieving female orgasm. Additional details regarding
such systems may be found in U.S. Patent No.
Date Recue/Date Received 2022-12-30
105
10,568,804, titled "System, an Apparatus, and a Method for Treating a Sexual
Dysfunctional Female Patient", and U.S.
Patent Application Publication No. 2020/0390643, titled "System, an Apparatus,
and a Method for Treating a Sexual
Dysfunctional Female Patient", both of which are hereby incorporated herein in
their entireties by reference.
[00642] Some embodiments may include systems comprising distributed implanted
devices that may selectively stimulate
different nerves, which may, in some cases, provide aid to patients with
sexual and urinary activity disorders. In some
instances, a master controller may communicate with each stimulating device,
preferably wirelessly, to transmit control
commands. The master controller device and/or individual stimulators may be
configured to respond to signals created from
sensing devices in some embodiments. Examples of stimulation may include
electrical stimulation of selected devices at
selected intervals to achieve various phases of sexual arousal. Further
details regarding such implants and systems may be
found in U.S. Patent Application Publication No. 2006/0020297, titled
"Neurostimulation System with Distributed
Stimulators", which is hereby incorporated herein in its entirety by
reference.
[00643] Implantable vaginal stimulators may be used in certain embodiments to
enhance sexual response to stimuli. In
some instances, an implantable system may comprise an operation device for
control over the stimulating device.
Movement/vibration of the stimulating device may be configured to be generated
by, for example, an electromagnetic device,
an electric motor, or the like. Furthermore, the system may comprise, in some
embodiments, an implantable switch/wireless
remote control for manual control and/or one or more sensors configured for
detecting physical parameters for automatic
control. Further details regarding such devices and systems may be found in
U.S. Patent No. 9,107,796, titled "Apparatus,
System and Operation Method for the Treatment of Female Sexual Dysfunction",
which is hereby incorporated herein in its
entirety by reference.
[00644] Some embodiments of a system for enhanced female arousal may comprise
an implant and/or system configured
for restricting blood flow exiting the erectile tissue. Such systems may, in
some embodiments, utilize a two-stage restriction
of blood flow exiting a patient's erectile tissue, such as an initial
stimulation of an erectile tissue to cause contraction and
initially reduce blood flow leaving the erectile tissue, which may be coupled
with additional gentle constriction of blood
flow leaving the erectile tissue to further aid in the erectile tissues'
engorgement with blood. Additional details regarding
such devices and systems may be found in U.S. Patent No. 8,795,153, titled
"Method for Treating Female Sexual
Dysfunction", which is hereby incorporated herein in its entirety by
reference.
[00645] In some instances, electrical stimulators may be implanted within the
body using the techniques and/or on the
implants disclosed herein. In some embodiments, such electrical stimulators
may comprise inductance coils, which may be
used for purposes such as, for example, wireless data and power transmission.
Additional details regarding such electrical
stimulators may be found in "Implantable Functional Electrical Stimulation
with Inductive Power and Data Transmission
System", Lee, 2007, doi.org/10.12701/YUJM.2007.24.2.97, which is incorporated
herein by reference in its entirety.
[00646] In some embodiments, implanted stimulators may comprise external
casings comprising a first metal portion and
a second portion, which may comprise a plastic/polymer portion. Some
embodiments may comprise inductance coils
embedded within the polymer/plastic portion of the casing. Additional details
regarding such casings may be found in U.S.
Patent No. 7,376,466, titled "Casings for Implantable Stimulators and Methods
of Making the Same", which is hereby
incorporated herein in its entirety by reference.
[00647] Implanted lead connectors may be used, in some embodiments, to
interconnect multiple devices and/or channel
electrical signals between said devices and/or target organs. Some embodiments
may comprise lead connectors comprising,
for example, first and second ports configured to each receive signals
suitable for tissue stimulation and a third port
configured to connect to an organ. Additional details regarding such lead
connectors may be found in U.S. Patent No.
8,706,230, titled "Implantable Lead Connector", which is hereby incorporated
herein in its entirety by reference.
[00648] In some embodiments, electrical stimulation systems may comprise
implantable control modules. Such modules
may comprise, for example, a housing comprising an electronic subassembly, an
antenna, and/or a plurality of connectors.
Date Recue/Date Received 2022-12-30
106
Some embodiments may comprise, for example, a control module, a connector
receptacle, and/or leads including a plurality
of electrodes on a distal end and a plurality of contacts on the proximal end.
In some embodiments, a proximal end of the
lead may be positioned in a connecter electrically coupled via, for example
lead spring contacts to a control module.
Additional details regarding such control modules may be found in U.S. Patent
No. 7,803,021, titled "Implantable Electrical
Stimulation Systems with Leaf Spring Connective Contacts and Methods of Making
and Using", and in U.S. Patent No.
8,983608, titled "Lead Connector for an Implantable Electric Stimulation
System and Methods of Making and Using", both
of which are hereby incorporated herein in their entireties by reference.
[00649] Some electrical stimulation devices involve the use of passive
electrical conductors that may extend from
subcutaneous tissue to the target tissue. Such devices may comprise, for
example, superficial electrodes positioned in the
upper lower subcutaneous electrodes forming a pick-up end, which preferably
has a sufficient surface area to allow a
sufficient portion of the current to flow from the surface electrodes through
the fat and to the pick-up electrodes. In some
embodiments, such devices may have functions such as, for example,
blocking/activating neural impulses and/or stimulating
a target tissue. Additional details regarding such methods and devices for
electrical stimulation may be found in U.S. Patent
No. 9,072,886, titled "Method of Routing Electrical Current to Bodily Tissues
via Implanted Passive Conductors", which is
hereby incorporated herein in its entirety by reference.
[00650] In some embodiments, implanted electrical stimulation devices may be
configured to deliver electrical stimulation
therapy by using, for example, controlled current pulses to emulate controlled
voltage pulses. In some instances, the current
and/or voltage levels may be modulated. Some devices may be configured as
controlled-current and/or controlled-voltage
devices, preferably being configured to deliver current or voltage on a
selective basis to electrodes implanted within the
patient. Additional details regarding such stimulation devices may be found in
U.S. Patent No. 9,259,578, titled "Electrical
Stimulator with Voltage Mode Emulation Using Regulated Current", which is
hereby incorporated herein in its entirety by
reference.
[00651] In some embodiments, implantable stimulator devices may comprise
arrays of electrodes used, for example, to
stimulate muscles and nerves. In some instances, the stimulator may comprise
at least one array of electrodes that may serve
as inputs and/or outputs. Some embodiments of the stimulator may comprise, for
example, an integrated circuit to control
the stimulator, a memory chip, a power source, and/or a transceiver. In
certain embodiments, each element may be wrapped
in a bio-compatible encasement and be connected with flexible wiring. In
certain instances, the electrodes may comprise a
flexible array of electrical contacts, which may be dynamically selected.
Certain embodiments may also comprise sensors
to detect physiological conditions. Additional details regarding such
stimulators may be found in U.S. Patent Application
Publication No. 2020/0406030, titled "Implantable Electrical Stimulator",
which is hereby incorporated herein in its entirety
by reference.
[00652] In some embodiments, miniature implantable stimulators may be used to
produce unidirectionally propagating
action potentials. Some configurations may comprise, for example,
microstimulators arresting action potentials travelling in
one direction along large and/or small nerves. Such devices may comprise, for
example, electrodes for applying stimulating
current; electrical/mechanical components hermetically encapsulated in
biocompatible materials; an electrical coil for
receiving energy and/or transmitting information; and/or means for storing
electrical energy. In certain embodiments, such
microstimulators may be configured to operate independently or in cooperation
with other implanted devices. Additional
details regarding such microstimulators may be found in U.S. Patent No.
9,823,394, titled "Implantable Microstimulators
and Methods for Unidirectional Propagation of Action Potentials", which is
hereby incorporated herein in its entirety by
reference.
[00653] Some embodiments comprising electrical stimulators may comprise
electrodes including a porous substrate
comprising bio-compatible materials, which may be configured to mimic
extracellular matrix embedding. Such substrates
may have an adjustable pore size configured to control tissue in growth. Such
electrodes may, in some embodiments, be
Date Recue/Date Received 2022-12-30
107
coupled with a pulse generator to generate an electric field around a target
tissue. Additional details regarding the disclosed
stimulation device may be found in U.S. Patent No. 10,780,275, titled
"Implantable Neuro-Stimulation Device", which is
hereby incorporated herein in its entirety by reference.
[00654] In some instances, electrical stimulation may be delivered in current-
based waveforms via implanted electrodes.
Such devices may support selective control of stimulation, which may occur,
for example, via a combination of two or more
electrodes coupled to regulated current paths and/or at least one electrode
coupled to an unregulated current path. In some
instances, an unregulated current may balance current that would otherwise be
unbalanced between regulated current paths.
Additional details regarding such stimulators may be found in U.S. Patent No.
9,987,493, titled "Medical Devices and
Methods for Delivery of Current-Based Electrical Stimulation Therapy", which
is hereby incorporated herein in its entirety
by reference.
[00655] Some implanted neurostimulating devices may favor very thin electrodes
and backings that may be conformable
to an arciform area of the body; however, implants under pressure may be
subject to migration and, if not sufficiently
rigidified during a relatively large time period of tissue fibrosis and
'healing-in,' small, very flexible implants may be
susceptible to folding, flipping, and/or unwanted migration. Unwanted
migration of a sharp edge of a piece of electronics,
even on a plastic backing, adjacent a delicate nerve or even a thick blood
vessel, can cause inflammation leading to pain in
the nerve or weakening of the blood vessel wall, which may lead to rupture.
Additional details regarding such implants may
be found in U.S. Patent No. 10,653,888, titled "Wireless Neurostimulators",
and U.S. Patent Application Publication No.
2020/0254266, titled "Wireless Neurostimulators," which is incorporated herein
by reference in its entirety. It is also noted
that, in this reference, Fig. 13 provides an indication of how small the
implant may be, which in some instances may restrict
some function.
[00656] With current technology, alternative embodiments/implementations may
allow the smartphone or other wireless
communication device 7099 to display video or image sites of pornography in a
pattern or quality that may be synchronized
with sexual stimulation output from system 7000. Further contemplated
embodiments/implementations may allow for the
synchronization of sound and sexual stimulation in system 7000. For example,
in some embodiments and implementations,
particular scenes from a movie may be linked to system 7000 in a manner such
that stimulation is generated automatically
upon starting a particular scene. Similarly, particular portions of a scene
may result in increased or decreased stimulation to
allow for synchronization of particular portions of the scene, rather than the
entire scene itself, to system 7000.
[00657] It is noteworthy that what now is considered an external smartphone or
other wireless communication device 7099
may, in some embodiments, be internalized by, for example, removing the screen
and/or traditional protective components
and implanting the battery, CPU, antenna, and other necessary electronics
using methods such as those described herein.
Therefore, it is to be understood that system 7000 may also comprise this type
of traditionally external device into an
internalized location with internalized function. These parts may be not
limited to those discussed, but may also include, for
example, eye glasses/corrective lenses that are communicative with the system
as well as hearing aids or implantable hearing
devices. Eventually, the so called `Metaverse' may become highly miniaturized,
but until that time, many devices may
require amounts of power and wireless charging that necessitate relatively
large space and/or surface areas that may be
accommodated by the devices and methods described herein, examples of which
are discussed below.
[00658] In some embodiments, additional elements, such as electronic elements,
may be coupled to the coil to make the
coil more useful as a standalone implant, or an implant configured to
standalone as a power supply to another, secondary
implant. In some such embodiments, use of a unitary coil, as shown in Fig.
80a, may eliminate the need for an auxiliary
implant altogether. In contemplated embodiments, a unitary coil may therefore
be coupled with other implants, such as
implants to which the unitary coil is providing energy, without the use of an
auxiliary implant to aid the unitary coil in doing
so. It is also contemplated, however, that some coil embodiments may have
some, but not all, of the components that may
be provided on an auxiliary implant, and may therefore be considered a
"hybrid" coil implant.
Date Recue/Date Received 2022-12-30
108
[00659] Fig. 70b is a side elevation view of FSEGS flexible strand/string
implant 7001 illustrating how each of the elements
may be coupled on strand implant 7001; however, in other embodiments,
orientations and/or locations may vary. In some
embodiments, one or more, or each, of the elements of implant 7001, with the
possible exception of terminal electrodes
7011a-e, may be sealed within a container or envelope, which is preferably
both waterproof and biocompatible. Examples
of suitable materials for said container include polyethylene, polyurethane,
polypropylene, and the like. A wire 7015o may
be used to couple the auxiliary implant 7008 with one or more (preferably all)
of the various electrodes 7011a-e of the string
implant 7001. In some embodiments, string implant 7001 may also comprise
piezoelectric elements 7071a-e. Said
piezoelectric elements may also comprise flexible piezoelectrics comprising,
for example, PbZr0.52Ti0.4803, LiNb03,
LiTa03, PZT/PVDF composites, and/or the like. In further contemplated
embodiments, string implant 7001 may further
comprise LEDs 708 la-c, such as LED/OLED/mLEDs, which may further pleasure the
patient or the patient's partner by
providing programmable illumination.
[00660] In some embodiments, piezoelectric energy harvesters may be based on
polyimide (P1)/Bi,La)Fe03-PbTiO3(BLF-
PT)0-3 composites. Such piezoelectric energy harvesters may be flexible,
lightweight, and/or free-standing. Additional
details regarding such piezoelectrics may be found in "Flexible Piezoelectric
Energy Harvester/Sensor with High Voltage
Output over Wide Temperature Range", Sun, Nanoenergy, 2019,
doi.org/10.1016/j.nanoen.2019.04.055, which is hereby
incorporated herein in its entirety by reference.
[00661] In some embodiments, piezoelectric energy harvesters may comprise a
sandwich structure comprising, for
example, PVDF film filled with FeTiNb06 (FIN) semiconductor particles, one or
more intermediate layers, and/or pure
PVDF films as upper and lower barriers. Such piezoelectrics may be prepared by
hot pressing technology, and in some
instances, may be flexible. Additional details regarding such piezoelectric
devices may be found in "Flexible Piezoelectric
Energy Harvester with Extremely High Power Generation Capability by Sandwich
Structure Design Strategy", Fu, Applied
Math & Interfaces, 2020, DOI: 10.1021/acsami.9621201, which is hereby
incorporated herein in its entirety by reference.
[00662] In some embodiments, piezoelectric devices may comprise all-inorganic
compounds, such as, for example,
Pb(Zr0.52Ti0.48)03. In certain instances, such piezoelectrics may be flexible.
In certain embodiments, such piezoelectrics
may be based on two-dimensional mica substrates via a sol-gel method.
Additional details may be found in "All-Inorganic
Flexible Piezoelectric Energy Harvester Enabled by Two-Dimensional Mica",
Wang, Nanoenergy, 2017,
doi.org/10.1016/j.nanoen.2017.11.037, which is hereby incorporated herein in
its entirety by reference.
[00663] In some embodiments, piezoelectric devices may comprise multimaterial
piezoelectric fibers. In some instances,
such piezoelectric devices may be shaped like hollow cylinders. Such devices
may comprise, for example, poly(vinylidene
difluoride-trifluoroethylene) shells, which may also comprise carbon-loaded
poly(carbonate)/indium electrodes and/or
poly(carbonate) cladding. In some embodiments, piezoelectric devices may
comprise perovskite, having a general formula
of ABX3. Examples may comprise materials such as LaA103, NaW03, and the like.
In a preferred embodiment, a
piezoelectric device may have high-electromechanical coupling properties while
exhibiting low dielectric loss. Suitable
materials for such uses may include, for example, PbMg1/3Nb2/303-PbTiO3,
PbZn1/3Nb2/303-PbTiO3, and the like. In
some embodiments, piezoelectric crystals may also be used, due to their high
piezoelectric performance. Additional details
regarding piezoelectric devices may be found in "Developments of Immobilized
Surface Modified Piezoelectric Crystal
Biosensors for Advanced Applications", Pramanik, International Journal of
Electrochemical Science, 2013,
researchgate.net/publication/258052187, which is hereby incorporated herein in
its entirety by reference.
[00664] During sexual arousal or stimulation, a patient's heart rate may
change. An ancillary electronic heart rate sensor
7024 option may therefore be configured to detect heart rate, whereupon a
preprogrammed FSEGS may signal a desired
change in stimulation or stimulation pattern. As a safety precaution, internal
or external programming may determine a
preset heart rate, the reaching of which may cease the FSEGS unit firing. An
ancillary pulse oximeter 7025 may also be
coordinated with a stimulation pattern. In some contemplated embodiments more
distant heart rate sensor 7098 and/or blood
Date Recue/Date Received 2022-12-30
109
pressure sensor 7097 may be communicatively connected to the unit to prevent
undesirable electrostimulative stress.
Additional details regarding such blood pressure sensor and/or heart rate
sensor devices may be found in "Subcutaneous
Blood Pressure Monitoring with An Implantable Optical Sensor", Theodor, Biomed
Microdevices, Vol. 5:811-820, 2013,
& "Implantable loop recorder: A heart monitoring Device," Mayo Clinic,
https://www.mayoclinic.org/tests-
procedures/implantable-loop-recorder/pyc-20384986, 2022 which are hereby
incorporated herein in their entirety by
reference.
[00665] Terminal electrodes 7011a-e and/or piezoelectric elements 707 la-c may
be electrically coupled, directly or
indirectly, to a CPU 7003 and/or other suitable electrical circuitry.
Additionally, the firing of the LEDs 7081a-c may be
programmable.
[00666] Fig. 70c is an enlarged transparency view of Fig. 70b depicting an
embodiment of a wiring scheme for various
terminal electrodes 7011a-e along a flexible strand/string electronic genital
stimulative (FSEGS) implant 7001. In this
embodiment, electrodes 7011a-e are all wired independently (for example, on
wires such as 701 law, which is coupled with
electrode 7011a) of each other, thus allowing for different programmable
control for each. In this embodiment, piezoelectrics
707 la-c may also be wired independently of each other, thus allowing for
different programmable control for each. In other
contemplated embodiments, the wiring may be in series, parallel or another
form of independent wiring or a combination
thereof Firing may vary in terms of amplitude and time of firing and on-off
cycle. Again, this may be random, controllable
by the user, or both (selectively random or specific, as selected by the
patient). If the electrodes are on independent circuits
to the CPU then each may be programmed to fire at random or independently in a
preprogrammed pattern so as to provide
a differing stimulus pattern to the subject/recipient over time. Psychological
and neurological studies have shown that a
stimulus' effect may diminish based upon unchanging repetition over time
(recipient's nervous system becomes jaded to a
repetitive unchanging/boring stimulus). Thus, preprogrammed or randomized or
changing programmable stimuli may serve
to enhance the effect of FSEGS. Electrode output may be individually addressed
in terms of amplitude, frequency, and/or
activation in order to achieve multiple stimuli. The triangles used to
represent the electrodes in Figs. 70b-c are by no means
restrictive or indicative of electrode shape. For example, in Figs. 70b and
70c, internal wiring 7011aw is connected to a
peripheral/circumferential electrode 7011a that may have several potential
benefits. For example, providing a band-
like/circumferential electrode may allow for a more widely distributed signal
that may be less prone to missing a particular
target nerve or other tissue region. However, it may be desirable for certain
applications to form such an electrode such that
it extends only partially about the periphery of the string and/or tube-like
implant 7001. For example, it may be desirable to
avoid the increased points of termination, such as corners, which may result
from an incomplete circumferential electrode.
It should be understood, however, that such points of termination may be
preferred for certain applications, particularly
since it may be desirable to vary the location, strength, and/or other
parameters of the signal for certain applications, such
as FSEGS applications.
[00667] Although electrode 7011a is shown projecting slightly from the
peripheral wall of the implant 7001 in Fig. 70c, it
should also be understood that it may be desirable instead to have the
electrode flush with this exterior wall, which may be
a hollow or solid tube, for example, which may allow the implant to slide more
easily through, for example, a trocar, adjacent
tissues, and/or the entrance wound. The cross-sectional shape of the implant
7001 may vary as desired, such as from circular
to oval to strap-like to polygonal in various contemplated embodiments.
[00668] Figs. 70d-70g depict various implantation sites that may be
particularly desirable for use in connection with the
FSEGS systems disclosed herein. For example, Fig. 70d depicts a string implant
7001 extending into the clitoris within a
soft tissue implant pocket 7005c. In preferred embodiments and
implementations, the implant 7001 may extend directly into
the glans 7069g, as shown in Fig. 70d. Alternatively, or additionally,
implants may extend into the crux 7069c of the clitoris,
as shown in Fig. 70e, which depicts the results of an implementation involving
a first implant 7001a extending into the shaft
and/or glans 7069g of the clitoris, a second implant 70016 extending into a
first side/wing of the crux 7069c, and a third
Date Recue/Date Received 2022-12-30
110
implant 7001c extending into a second side/wing of the crux 7069c. Although
not shown in this figure, it should be
understood that each implant may extend within a respective implant pocket,
which may comprise an implant canal, as
needed.
[00669] Figs. 70f and 70g depict FSEGS implants positioned within male
genitalia. More particularly, Fig. 70f depicts an
implant 7001 positioned within a soft tissue implant pocket 7005c extending
down the shaft of a patient's penis 7096s and
at least partially into the glans 7096g of the penis 7096s. Similarly, Fig.
70g depicts the results of an alternative
implementation in which two implants 7001 have been positioned within the
penis 7096s side by side. Again, implant
pockets are not shown in this figure but it should be understood that they may
be present.
[00670] Inductance coil/'group of stacked coils' may be present as per the
coil cross section depicted in Fig. 37d.
[00671] A multiplicity of stacked inductance coils may increase the power
transfer as well as increase of mutual inductance
between coupled coils.
Reference: 'Achieve High Power Density with Stacked Inductor 25.08.2021,
https://www.electronicdesign.com'
[00672] To deliver proper alignment the maximal energy transfer per
orientation of coil groups may be, in some
embodiments, assessed by an internal or external CPU with a signaling when
optimal alignment is approaching or departing,
or made or lost.
[00673] As per Fig. 37d, a temperature sensor such as 3719t may be configured
to detect tissue temperatures external to
the coil and/or wrapper so that hardware and/or software in the system can
alert the user/external coil to increase or decrease
energy transmission as the case may be. In some embodiments, one or more
threshold temperatures may be established,
such as a shutoff temperature, which may be, for example, 45 degrees C, which
may result in termination of energy delivery
until the temperature returns to a second threshold temperature, such as 40
degrees C, at which point the energy delivery
may resume.
[00674] Fig. 71a depicts an example of a sensory-processing-feedback-system
7100 comprising, in the depicted
embodiment, a flexible strand/string electronic implant (FSEI). System 7100
comprises one or more implants positioned in
respective implant pockets preferably made via one or more minimally invasive
entrance incisions 7110. More particularly,
implant system 7100 comprises flexible strand/string implant(s) (FSEI) 7101,
which may be positioned within an elongated
implant pocket(s) 7105c comprising a canal that may be made by a trocar, probe
and/or beaded dissector as shown
previously. System 7100 may further comprise inductance coil 7114 (with or
without additional electronics attached) and/or
auxiliary implant 7108, each of which may be deposited in various subcutaneous
and/or soft tissue implant pockets 7105,
their own individual implant pockets, or an implant pocket shared with another
implant of the system, which may be made
similarly to others described by methods described elsewhere within this
application, including Figs. 1 & 57. Inductance
coil 7114 may be connected to auxiliary implant 7108 by an incoming wire
7115i, and auxiliary implant 7108 may be
connected to the FSEI 7101 by outgoing wires 71150. In some embodiments and
implementations, the primary FSEI implant
7101 of system 7100 may be oriented in, about, or toward a target zone of a
distant/distal auxiliary implant 7141 that may
be placed in the subcutaneous tissues and/or soft tissue of the upper body, or
another remote location on the body relative
to the entrance incision and/or other implants of the system 7100. The
distant/distal auxiliary implant(s) 7141 may comprise,
for example, a wireless communication device/antenna 7141a and/or a
transcutaneous sound receiver 7141s, such as a
subcutaneously implanted microphone.
[00675] Flexible strand/string implant 7101 may, in some embodiments, comprise
a flexible tube or strand of electronics,
wires, and/or fiber optics. In some embodiments, inductance coils may be
replaced by other power generating and/or yielding
devices, such as, thermoelectric generators, flexible piezoelectric energy
harvesters, capacitive coupling transmission,
magnetodynamic coupling transmission, microwave power transmission, and the
like, depending on the subject patient and
safety guidelines. In some implementations, fiber optics may transfer data
and/or energy.
[00676] In some embodiments, thermoelectric generators may comprise, for
example, SiGe, CoSb3, Bi2Te3, PbTe, and the
Date Recue/Date Received 2022-12-30
111
like. In certain embodiments, materials such as Bi2Te3 may be mixed with
nanomaterials to reduce the lattice thermal
conductivity. In some instances, such thermoelectric generators may be
flexible. Such thermoelectric generators may
comprise, for example, polymers, such as polyaniline, which exhibits good
thermoelectric properties. In certain instances,
thermoelectric properties may be enhanced by incorporating conductive
additives such as, for example, carbon nanotubes
with Au nanoparticles. In some embodiments, a TEG may be fabricated from a
hybrid material comprising granulated carbon
nanotubes granulated into p/n-type bismuth telluride, which may be distributed
within a flexible material, such as
polydimethylsiloxane. In certain embodiments, TEGs may be cylindrical, or even
thin-film, in some cases a few micrometers
thick. TEGs may be cooled via active/passive cooling methods. In a preferred
embodiment, multi-stage TEGs may be used
to generate higher power compared to a single TEG for a given temperature
gradient. To enhance biocompatibility, TEGs
may be coated in a biocompatible membrane. Additional details regarding
thermoelectric generators may be found in "The
Design of a Thermoelectric Generator and Its Medical Applications", Kumar,
MDPI, 2019, DOI: 10.3390/designs3020022,
which is hereby incorporated herein in its entirety by reference.
[00677] In some embodiments, thermoelectric generators may comprise DC-DC
rectifiers in order to yield a
current/potential, which may be used to charge a battery.
[00678] In some embodiments, the orientation of the top electrodes of a
thermoelectric generator module may be oriented
in a way which may increase unidirectional flexibility. In a preferred
embodiment, all of the top electrodes may be integrated
in parallel to increase flexibility. In some instances, small thermoelectric
semiconductor chips may be mounted on a substrate
at a high packaging density, realizing efficient power recovery while
maintaining stable adhesion and flexibility. Additional
details regarding such electrodes may be found in "Flexible Thermoelectric
Generator Module: A Silver Bullet to Fix Waste
Energy Issues", Osaka University, 2018, from phys.org/news/2018-12-flexible-
thermoelectric-module-silver-bullet.html,
which is hereby incorporated herein in its entirety by reference.
[00679] In some embodiments, thermoelectric generators may comprise
polydimethylsiloxane substrates and/or
thermocouples. PDMS may provide flexibility and low thermal conductivity to
the TEG. A lower thermal conductivity may
aid in reducing losses in the heat flowing through thermocouples. Additional
details regarding implantable thermoelectric
devices may be found in "Human Body Heat Energy Harvesting Using Flexible
Thermoelectric Generator for Autonomous
Microsystems", Kim, Materials Science, 2012, which is hereby incorporated
herein in its entirety by reference.
[00680] In some embodiments, electrostatic generators may be used to produce
energy via electrostatic induction. Such
devices may convert mechanical vibration into electrical energy by moving part
of the transducer relative to an electric field.
In some embodiments, kinetic generators based on electrostatic transducers may
comprise variable capacitors. In some
embodiments, magnetic induction generators may be used to produce electricity.
Such devices may induce flux changes by,
for example, rotating a circuit along an axis, thereby changing the surface
associated with magnetic flux. Such devices may
comprise, for example, eccentric masses, permanent magnet rings, and/or planar
coils. In some embodiments, thermo-
electric harvesters may be used to produce electricity. Such devices may
comprise thermocouples, which may be electrically
connected in series with high thermal resistance while being thermally
connected in parallel. Such devices may use
differences in temperature to produce power. In some embodiments,
environmental energy harvesting may be used to power
implanted devices. In some such embodiments, one such harvesting method may
comprise a capacitive coupling link, which
may involve two parallel plates acting as capacitors. The first plate may be
outside the body while the second plate in
implanted within the body. Such capacitive coupling devices may be used to
transfer data and/or power. In some instances,
piezoelectric devices may be used to convert mechanical motion/strain into
electrical energy. Additional details regarding
such energy harvesting methods may be found in "Energy Harvesting for the
Implantable Biomedical Devices: Issues and
Challenges", Hannan, BioMedical Engineering Online, 2014, 13:79, which is
hereby incorporated herein in its entirety by
reference.
[00681] In some embodiments, batteries, such as, for example, lithium-based
batteries, may be used to power implanted
Date Recue/Date Received 2022-12-30
112
devices. In certain instances, bio-fuel cells may be used to generate
electrical power. Bio-fuel cells may generate power
from sources such as, for example, glucose and/or amylum from within the body.
In certain embodiments, thermoelectric
generators may be used to generate power by exploiting the difference in
temperatures around the body. In some instances,
transcutaneous power transmission via inductive coupling may be used to
charge/power implanted devices. In certain
embodiments, kinetic energy from the body's movement may be converted into
electrical energy. Additional details
regarding such powering methods may be found in "Power Approaches for
Implantable Medical Devices", Amar, Sensors,
2015; 15: 28889-28914, which is hereby incorporated herein in its entirety by
reference.
[00682] System 7100 also may comprise smart glasses 7142, capable of
transmitting optical information to and from the
wearer. System 7100 may also comprise acoustic implant 7143, which may be
positioned, for example, within the ear and/or
within the adjacent tissues. The purpose for having implant 7141 positioned
relatively distant from the inductance coil and/or
other associated electronics/implants relative to implants previously
discussed is that the lower abdomen is an area that is
usually clothed and may have sufficient subcutaneous and/or soft tissue in
which to contain, cushion, and/or hide a relatively
larger implant. In addition, the tissue in this region of the body is
relatively inert, thereby possibly reducing the risk of
electromagnetic carcinogenesis. Thus, ongoing visual signals, which may
currently be transmitted by Bluetooth or another
wireless communication protocol, may not penetrate through the skin at various
postural angles, and placing an auxiliary
implant 7141 may reduce the distance and energies necessary to transmit
signals from eyeglasses or hearing aids/speakers,
thus improving the quality of the signals. In some contemplated embodiments,
inductance coil 7114, when not receiving
transmitted wireless energy, may also be configured to act as a transmitting
and/or receiving antenna. In some embodiments
and implementations, the incision, or one of the incisions, may be made in the
region of the patient's navel 7110n.
[00683] In some embodiments, additional elements, such as electronic elements,
may be coupled to the coil to make the
coil more useful as a standalone implant, or an implant configured to
standalone as a power supply to another, secondary
implant. In some such embodiments, use of a unitary coil, as shown in Fig.
80a, may eliminate the need for an auxiliary
implant altogether. In contemplated embodiments, a unitary coil may therefore
be coupled with other implants, such as
implants to which the unitary coil is providing energy, without the use of an
auxiliary implant to aid the unitary coil in doing
so. It is also contemplated, however, that some coil embodiments may have
some, but not all, of the components that may
be provided on an auxiliary implant, and may therefore be considered a
"hybrid" coil implant.
[00684] As depicted the perspective view of Fig. 71b, implant system 7100 may
further comprise auxiliary implant 7108,
which may comprise any of the elements previously described in Figs. 54 a-c,
including but not limited to an antenna 71026
to allow for receipt of electromagnetic signals, which may be used to transmit
data to CPU/printed-circuit-board 7103. An
external transmitter may be adjusted by the patient or healthcare personnel to
transmit signals to internal antenna 71026 that,
in turn, directs CPU 7103 to coordinate electrical output of wiring contained
in implant 7101. In some embodiments, the
battery 7104 may also be flexible and/or installed within or along inductance
coil 7114. A wireless charging system may be
provided, as previously described, which may be configured to wirelessly
charge the battery 7104 via inductance coil 7114.
Preferably, one or more of the elements of implant system 7100 is either
flexible and/or compressible, or is small enough
on its own to fit within a minimally invasive entrance incision 7110 with
other elements of implant 7100 moved into their
optimal positions in separate tissue pockets, such as pocket 7105, which
contains inductance coil 7114 in the depicted
embodiment. However, some components, such as the string-like implant 7101,
need not be compressible. Similarly, in
some embodiments, the inductance coil 7114 may be rigid but may, due to the
techniques for insertion of spiral implants
disclosed herein, be inserted into a larger implant pocket, as previously
discussed. Auxiliary implant 7108 may allow for
certain components, such as sensitive electrical components, to be placed
within a separate implant, which may be more
protective of such components, such as being within a waterproof/sealed
container, for example. A seal, such as a wrapper,
may be used to contain all of the elements of auxiliary implant 7108 therein.
Auxiliary implant 7108 may further comprise,
for example, a memory/data storage element 7125.
Date Recue/Date Received 2022-12-30
113
[00685] In further contemplated embodiments, the implant system may comprise
an auxiliary implant with any element
including, but not limited to, those mentioned for the auxiliary implant
described in Fig. 66, for example, CPU(s)/printed-
circuit-board(s), battery(ies), memory/data storage element(s), antenna(e),
capacitor(s), electronic heart rate sensor(s), lab-
on-a-chip element(s). In other contemplated embodiments, either coils or
auxiliary implants may comprise pulse oximetry
elements. Although some auxiliary implants shown in the figures are
cylindrical in shape, in further contemplated
embodiments they may comprise a variety of shapes including, but not limited
to, ovoids, polygonal prisms, pads, pillow-
like, purse-like, with or without various cavities or convexities.
[00686] As previously mentioned, in some embodiments, system 7100 may further
comprise and/or be a replacement for
various other functional elements such as, for example, eyeglasses/corrective
lenses that are communicative with the system,
hearing aids, and/or implantable hearing devices. In some embodiments, antenna
7141a may be configured to communicate
with various sensory feedback elements of the system 7100, such as eyeglasses
7142 and/or hearing aid 7143.
[00687] Fig. 71c is a side perspective view of auxiliary implant 7141, which
may be positioned at the terminus of the
FSEI(s) 7101. In this embodiment, auxiliary implant 7141 may comprise antenna
7141a and transcutaneous audio receiver
7141s. In some embodiments, two separate implants 7141 may be provided to, for
example, decrease the distance that signals
must travel to and/or from the various sensory devices, such as glasses 7142
and/or hearing aids/speakers 7143.
[00688] In some embodiments, inductance coils may be replaced by other power
generating and/or yielding devices, such
as, thermoelectric generators, flexible piezoelectric energy harvesters,
capacitive coupling transmission, magnetodynamic
coupling transmission, microwave power transmission, and the like, depending
on the subject patient and safety guidelines.
[00689] Inductance coil/'group of stacked coils' may be present as per the
coil cross section depicted in Fig. 37d.
[00690] A multiplicity of stacked inductance coils may increase the power
transfer as well as increase of mutual inductance
between coupled coils.
Reference: 'Achieve High Power Density with Stacked Inductor 25.08.2021,
https://www.electronicdesign.com'
[00691] To deliver proper alignment the maximal energy transfer per
orientation of coil groups may be, in some
embodiments, assessed by an internal or external CPU with a signaling when
optimal alignment is approaching or departing,
or made or lost.
[00692] As per Fig. 37d, a temperature sensor such as 3719t may be configured
to detect tissue temperatures external to
the coil and/or wrapper so that hardware and/or software in the system can
alert the user/external coil to increase or decrease
energy transmission as the case may be. In some embodiments, one or more
threshold temperatures may be established,
such as a shutoff temperature, which may be, for example, 45 degrees C, which
may result in termination of energy delivery
until the temperature returns to a second threshold temperature, such as 40
degrees C, at which point the energy delivery
may resume.
[00693] Fig. 72a depicts an example of a Subcutaneous Electrocardiogram
(ECG=EKG) system 7200 comprising, in the
depicted embodiment, a flexible strand/string electronic (FSEI-EKG) implant of
Subcutaneous Electrocardiogram Leads
720 la-c. System 7200 comprises one or more implants positioned in respective
implant pockets 7205, preferably made via
one or more minimally invasive entrance incisions 7210. More particularly,
implant system 7200 comprises an FSEI-EKG
implant 7201 comprising three leads, namely, leads 7201a, 7201b and 7201c,
which may be positioned within an elongated
subcutaneous and/or soft tissue implant pocket 7205c comprising a canal that
may be made by trocar, probe and/or beaded
dissector as shown previously. In some embodiments, of course, more or fewer
than three leads may be used. Similarly,
although in a preferred embodiment, each of the leads may be packaged together
in a single implant; in alternative
embodiments, each lead may comprise a separate implant. System 7200 may
further comprise inductance coil 7214 (with
or without additional electronics attached) and/or auxiliary implant 7208,
each of which may be deposited in various implant
pockets 7205, their own individual implant pockets, or an implant pocket
shared with another implant of the system, which
may be made similarly to others described by methods described elsewhere
within this application, including Figs. 1 & 57.
Date Recue/Date Received 2022-12-30
114
Inductance coil 7214 may be connected to auxiliary implant 7208 by an incoming
wire or wires 7215i, and auxiliary implant
7208 may be connected to the FSEI-EKG 720 la-c by an outgoing wire or wires
72150. The Subcutaneous Electrocardiogram
Leads 7201a, 7201b and 7201c of flexible strand/string electronic (FSEI-EKG)
implant 7201 may each terminate in a
respective lead terminals 7221a, 7221b and 7221c on heart 7220.
[00694] Although traditional external, skin-attached ECGs typically refer to a
12-lead ECG, it commonly uses only 10
electrodes. Certain electrodes are part of two pairs and thus provide two
leads. However, it is contemplated that fewer leads
may be used for subcutaneous implants. Thus, for example, using the embodiment
depicted in Fig. 72a and variations thereof,
a three-lead subcutaneous ECG may be used to provide sufficient data for
pacing or defibrillation. In some embodiments,
subcutaneous implantable cardiac defibrillators (S-ICD) sometimes utilize
electrograms recorded between one or two
sensing electrodes and the pulse generator for ventricular sensing. Additional
details regarding electrode requirements may
be found in 'How many patients fulfil the surface electrocardiogram criteria
for subcutaneous implantable cardioverter-
defibrillator implantation?', Randles DA, EP Europace, Volume 16: 1015-1021,
2014, which is hereby incorporated in its
entirety by reference.
[00695] Flexible strand/string implant 7201 may, in some embodiments, comprise
a flexible tube or strand of electronics,
wires, and/or fiber optics. In some embodiments, inductance coils may be
replaced by other power generating and/or yielding
devices, such as, thermoelectric generators, flexible piezoelectric energy
harvesters, capacitive coupling transmission,
magnetodynamic coupling transmission, microwave power transmission, and the
like, depending on the subject patient and
safety guidelines. The purpose for having the inductance coil and/or other
associated electronics/implants in the
subcutaneous fat of the lower abdomen is an area that is usually clothed and
may have sufficient subcutaneous tissue in
which to contain, cushion, and/or hide a relatively larger implant. In
addition, the tissue in this region of the body is relatively
inert, thereby possibly reducing the risk of electromagnetic carcinogenesis.
In some contemplated embodiments, inductance
coil 7214, when not receiving transmitted wireless energy, may also be
configured to act as a transmitting and/or receiving
antenna. In some embodiments and implementations, the incision, or one of the
incisions, may be made in the region of the
patient's navel 7210n.
[00696] In some embodiments, additional elements, such as electronic elements,
may be coupled to the coil to make the
coil more useful as a standalone implant, or an implant configured to
standalone as a power supply to another, secondary
implant. In some such embodiments, use of a unitary coil, as shown in Fig.
80a, may eliminate the need for an auxiliary
implant altogether. In contemplated embodiments, a unitary coil may therefore
be coupled with other implants, such as
implants to which the unitary coil is providing energy, without the use of an
auxiliary implant to aid the unitary coil in doing
so. It is also contemplated, however, that some coil embodiments may have
some, but not all, of the components that may
be provided on an auxiliary implant, and may therefore be considered a
"hybrid" coil implant.
[00697] Fig. 72b is a perspective view of auxiliary implant 7208, which may
comprise any of the elements previously
described in Figs. 54 a-c, including but not limited to an antenna 72026 to
allow for receipt of electromagnetic signals, which
may be used to transmit data to CPU/printed-circuit-board 7203. An external
transmitter may be adjusted by the patient or
healthcare personnel to transmit signals to internal antenna 72026 that, in
turn, directs CPU 7203 to coordinate electrical
output of wiring contained in implant 7201. In some embodiments, the battery
7204 may also be flexible and/or installed
within or along inductance coil 7214. A wireless charging system may be
provided, as previously described, and which may
be configured to wirelessly charge the battery 7204 via inductance coil 7214.
Although in the depicted embodiment, each
of the implants of system 7200 may, due to their nature and/or the unique
structures and/or implantation techniques disclosed
herein, need not be compressible, it is contemplated that, in some
embodiments, one or more of the elements of implant
system 7200 is either flexible and/or compressible, or is small enough on its
own to fit within a minimally invasive entrance
incision 7210 with other elements of implant 7200 moved into their optimal
positions in separate tissue pockets, such as
pocket 7205, which contains inductance coil 7214 in the depicted embodiment.
However, again, some components, such as
Date Recue/Date Received 2022-12-30
115
the string-like implant 7201, need not be compressible. Similarly, in some
embodiments, the inductance coil 7214 may be
rigid but may, due to the techniques for insertion of spiral implants
disclosed herein, be inserted into a larger implant pocket,
as previously discussed. Auxiliary implant 7208 may allow for certain
components, such as sensitive electrical components,
to be placed within a separate implant, which may be more protective of such
components, such as being within a
waterproof/sealed container, for example. A seal, such as a wrapper, may be
used to contain all of the elements of auxiliary
implant 7208 therein. Auxiliary implant 7208 may further comprise, for
example, a memory/data storage element 7225.
[00698] Fig. 72c depicts an alternative embodiment of a component of a
Subcutaneous Electrocardiogram (ECG=EKG)
system that, in some embodiments, may be configured to be coupled with the
distal end of implant 7201 or may be configured
to replace implant 7201. In the depicted embodiment, this component or sub-
system comprises a dendritic and preferably
resiliently flexible subcutaneous and/or soft-tissue implant, which may be
configured to be positioned in a subcutaneous
and/or soft tissue implant pocket 7910c preferably made via a minimally
invasive entrance incision 7210c. This dendritic
subcutaneous implant comprises branches 7231c that may extend at various
angles relative to the implant axis, in this case
terminating with electrodes 7241c in locations approximating a desired 5 lead
EKG. In preferred embodiments, each of the
branches/leads may be preconfigured in a particular shape/configuration, which
in some cases may be specifically designed
for a particular patient, which may vary/depend on the patient's size and/or
heart. In some such embodiments, the
leads/branches may be resiliently flexible, such that the implant comprising
the leads may be delivered in a compressed
configuration through a minimally invasive entrance incision and then may be
configured to automatically be decompressed,
once delivered into an implant pocket, into its original shape with each of
the branches/leads extending in
desired/preconfigured directions and/or in desired/preconfigured distances
that may be most useful for a particular patient
(or a category of patients, such as "children aged X-Y" or "adults having a
relatively normal heart size", for example). Thus,
the leads of an EKG implant, which may comprise an implant configured to be
coupled with a string implant coupled with
a spiral implant/inductance coil or may be coupled directly with a spiral
implant/inductance coil, may be configured with a
plurality of leads in a configuration targeting a particular patient/heart
configuration or may be configured to target a range
of patients/heart configurations The depicted alternative embodiment further
comprises distal and proximal end positioning
holes/rings 7251, one or more inductance coils 7214c, which may be configured
for receiving external wireless energy
and/or signal reception/transmission, preferably along with a battery and/or
PCB/CPU 7204c. Element 7204c may comprise
a separate piece of the system that may be electrically coupled with the
dendritic/EKG implant or, alternatively, may be part
of the dendritic implant, such as positioned on/in and/or otherwise coupled
with the trunk of the dendritic/EKG implant.
The system may further comprise an external antenna 7202c and/or PCB/CPU
7204d, which may be incorporated into a
cellphone or watch or wearable electronic or the like may communicate in
delayed or real time the EKG to a health
professional or Al for assessment. It is contemplated, in alternative
embodiments, one or more of the branches 7231c may
comprise circumferential electrodes which may be positioned to encircle or
otherwise extend about a portion of one or more
of the various branches 7231c, as previously described in connection with
other embodiments. Further embodiments may
comprise other numbers of branches and/or leads, such as, for example, between
3 and 12 branches/leads. In contemplated
embodiments, holes/rings 7251 may comprise a luminescent material, such as
phosphorescent, chemiluminescent,
bioluminescent, and/or radioluminescent material, to assist a surgeon in
identifying implant location to facilitate implant
placement/fixation via suturing with external lighting dimmed transiently.
This feature may, of course, be applied to and/or
used with any of the other embodiments disclosed herein to facilitate stable
positioning of an implant in a desired location,
preferably within an implant pocket. In further embodiments and
implementations, the implant's branch size and location
may be custom designed/fitted for differing patient scenarios such as
cardiomegaly, vertical heart, etc. via, for example, 3-
D printing guide by a chest x-ray, ultrasound, or other technique, such as
MR1. In further implementations, the implant may
temporarily be encased in a removable sheath to accompany the implant a
sufficient distance through the entrance incision
and to compress the branches into a manageable shape for insertion/passage.
Date Recue/Date Received 2022-12-30
116
[00699] In further contemplated embodiments, the implant system may comprise
an auxiliary implant with any element
including, but not limited to, those mentioned for the auxiliary implant
described in Fig. 66, for example, CPU(s)/printed-
circuit-board(s), battery(ies), memory/data storage element(s), antenna(e),
capacitor(s), electronic heart rate sensor(s), lab-
on-a-chip element(s). In other contemplated embodiments, either coils or
auxiliary implants may comprise pulse oximetry
elements. Although some auxiliary implants shown in the figures are
cylindrical in shape, in further contemplated
embodiments they may comprise a variety of shapes including, but not limited
to, ovoids, polygonal prisms, pads, pillow-
like, purse-like, with or without various cavities or convexities.
[00700] In some embodiments, inductance coil 7214 may be replaced by other
similar devices, such as In some
embodiments, inductance coils may be replaced by other power generating and/or
yielding devices, such as, thermoelectric
generators, flexible piezoelectric energy harvesters, capacitive coupling
transmission, magnetodynamic coupling
transmission, microwave power transmission, and the like, depending on the
subject patient and safety guidelines.
[00701] Inductance coil/'group of stacked coils' may be present as per the
coil cross section depicted in Fig. 37d.
[00702] A multiplicity of stacked inductance coils may increase the power
transfer as well as increase of mutual inductance
between coupled coils.
Reference: 'Achieve High Power Density with Stacked Inductor 25.08.2021,
https://www.electronicdesign.com'
[00703] To deliver proper alignment the maximal energy transfer per
orientation of coil groups may be, in some
embodiments, assessed by an internal or external CPU with a signaling when
optimal alignment is approaching or departing,
or made or lost.
[00704] As per Fig. 37d, a temperature sensor such as 3719t may be configured
to detect tissue temperatures external to
the coil and/or wrapper so that hardware and/or software in the system can
alert the user/external coil to increase or decrease
energy transmission as the case may be. In some embodiments, one or more
threshold temperatures may be established,
such as a shutoff temperature, which may be, for example, 45 degrees C, which
may result in termination of energy delivery
until the temperature returns to a second threshold temperature, such as 40
degrees C, at which point the energy delivery
may resume.
[00705] Fig. 73a depicts an example of a Subcutaneous Power Delivery System
7300, which may be used, for example, to
provide power for an Implantable Cardiac Pacemaker. In the depicted
embodiment, system 7300 comprises a flexible
strand/string electronic (FSEI) implant 7301. System 7300 may further comprise
one or more other implants positioned in
respective implant pockets, preferably made via one or more minimally invasive
entrance incisions 7310. As shown in this
figure, the entrance incision 7310 used to make subcutaneous and/or soft
tissue implant pocket 7305a is at an arbitrary angle
relative to the pocket, which illustrates that the devices and techniques
disclosed herein may allow for creation of an implant
pocket directed in any direction a full 360 degrees from the angle of the
incision as desired. More particularly, implant
system 7300 comprises an FSEI implant 7301, which may be positioned within an
elongated subcutaneous and/or soft tissue
implant pocket 7305c comprising a canal that may be made by trocar, probe
and/or beaded dissector as shown previously.
System 7300 may further comprise inductance coil 7314a (with or without
additional electronics attached) and/or auxiliary
implant 7308, each of which may be deposited in various subcutaneous and/or
soft tissue implant pockets 7305a/7305c,
either their own individual implant pockets or an implant pocket shared with
another implant of the system, which may be
made similarly to others described by methods described elsewhere within this
application, including Figs. 1 & 57.
Inductance coil 7314a may be connected to auxiliary implant 7308 by an
incoming wire(s) 7315i, and auxiliary implant
7308 may be connected to the FSEI 7301 by outgoing wire(s) 7315o. The flexible
strand/string electronic (FSEI) 7301
terminate in a second inductance coil 7314b which may also, in some
embodiments, be configured to function as an antenna
as well. Inductance coil 7314b may be positioned in a second implant pocket
7305b. Inductance coil 7314b may be
configured and positioned to emit wireless energy to a third inductance coil
7314c, which may be part of an
implantable/implanted cardiac pacemaker 7321, which may be placed on a cardiac
vein of heart 7320. It should be
Date Recue/Date Received 2022-12-30
117
understood that, in some embodiments, pacemaker 7321 may therefore be
considered part of a different system that is simply
powered by system 7300. Alternatively, however, it is contemplated that
pacemaker 7321 may be considered part of system
7300 in some embodiments.
[00706] Flexible strand/string implant 7301 may, in some embodiments, comprise
a flexible tube or strand of electronics,
wires, and/or fiber optics. The purpose for having the inductance coil and/or
other associated electronics/implants in the
subcutaneous fat of the lower abdomen is an area that is usually clothed and
may have sufficient subcutaneous tissue in
which to contain, cushion, and/or hide a relatively larger implant. In
addition, the tissue in this region of the body is relatively
inert, thereby possibly reducing the risk of electromagnetic carcinogenesis.
In some contemplated embodiments, inductance
coil 7314a, when not receiving transmitted wireless energy, may also be
configured to act as a transmitting and/or receiving
antenna. In some embodiments and implementations, the incision, or one of the
incisions, may be made in the region of the
patient's navel 7310n.
[00707] As depicted the perspective view of Fig. 73b, implant system 7300 may
further comprise auxiliary implant 7308,
which may comprise any of the elements previously described in Figs. 54 a-c,
including but not limited to an antenna 73026
to allow for receipt of electromagnetic signals, which may be used to transmit
data to and/or receive data from CPU/printed-
circuit-board 7303. An external transmitter may be adjusted by the patient or
healthcare personnel to transmit signals to
internal antenna 73026 that, in turn, directs CPU 7303 to coordinate
electrical output of wiring contained in implant 7301.
In some embodiments, the battery 7304 may also be flexible and/or installed
within or along inductance coil 7314. A wireless
charging system may be provided, as previously described, and which may be
configured to wirelessly charge the battery
7304 via inductance coil 7314a. Optionally, one or more of the elements of
implant system 7300 is either flexible and/or
compressible, or is small enough on its own to fit within a minimally invasive
entrance incision 7310 with other elements
of implant 7300 moved into their optimal positions in separate tissue pockets.
However, some components, such as the
string-like implant 7301, need not be compressible. Similarly, in some
embodiments, the inductance coils may be rigid but
may, due to the techniques for insertion of spiral implants disclosed herein,
be inserted into a larger implant pocket, as
previously discussed. Auxiliary implant 7308, which may be compressible to
allow it to fit within the preferably minimally
invasive entrance incision 7310, may allow for certain components, such as
sensitive electrical components, to be placed
within a separate implant, which may be more protective of such components,
such as being within a waterproof/sealed
container, for example. A seal, such as a wrapper, may be used to contain all
of the elements of auxiliary implant 7308
therein. Auxiliary implant 7308 may further comprise, for example, a
memory/data storage element 7325.
[00708] In further contemplated embodiments, the implant system may comprise
an auxiliary implant with any element
including, but not limited to, those mentioned for the auxiliary implant
described in Fig. 66, for example, CPU(s)/printed-
circuit-board(s), battery(ies), memory/data storage element(s), antenna(e),
capacitor(s), electronic heart rate sensor(s), lab-
on-a-chip element(s). In other contemplated embodiments, either coils or
auxiliary implants may comprise pulse oximetry
elements. Although some auxiliary implants shown in the figures are
cylindrical in shape, in further contemplated
embodiments they may comprise a variety of shapes including, but not limited
to, ovoids, polygonal prisms, pads, pillow-
like, purse-like, with or without various cavities or convexities.
[00709] Cardiac devices usable in connection with one or more embodiments may
comprise a pulse generator, which may
be implanted in, for example, a prepectoral subcutaneous pocket, along with a
number of transvenous leads. Each lead may
be attached proximally to the can and fixated distally to the endocardial
aspect of the heart. Implantation of the lead may
require venous puncture, with the subclavian, axillary and cephalic veins
frequently used. Device implantation, however, is
often associated with infection, hematoma, inadvertent arterial puncture,
pneumothorax, hemothorax and cardiac
tamponade. Late complications associated with transvenous systems include lead
fracture, lead displacement, venous
obstruction and infective endocarditis. Additional details regarding devices
and methods that may be useful in connection
with various energy delivery embodiments disclosed herein in the context of
pacemakers and/or defibrillators may be founds
Date Recue/Date Received 2022-12-30
118
in 'Update On Leadless Cardiac Devices For General Physicians', Wiles BM, Clin
Med (Lond) 17: 33-36, 2017, which is
hereby incorporated in its entirety by reference.
[00710] Some embodiments disclosed herein may be particularly useful in
connection with some existing wireless/leadless
devices, which may be configured for implantation external to the cardiac
chambers to avoid high intra-cardiac pressure
gradients, while enabling intravascular deployment of the device to the
anterior cardiac vein. Various embodiments herein
may be configured to improve upon these systems by providing a more convenient
and/or less invasive method for powering
such devices. The devices and methods disclosed herein may also allow for
increasing the amount of electrical energy that
can be generated and/or delivered to various cardiac implants, such as
pacemakers, ECG implants, and/or defibrillators.
Additional details regarding such cardiac devices can be found in "Inductively
Powered Wireless Pacing Via A Miniature
Pacemaker And Remote Stimulation Control System". Abiri P. Sci Rep. 7: 6180,
2017
ncbi.nlm.nih.gov/pmc/articles/PMC5522478/, which is incorporated herein in its
entirety by reference.
[00711] Inductance coil/'group of stacked coils' may be present as per the
coil cross section depicted in Fig. 37d.
[00712] A multiplicity of stacked inductance coils may increase the power
transfer as well as increase of mutual inductance
between coupled coils.
Reference: 'Achieve High Power Density with Stacked Inductor 25.08.2021,
https://www.electronicdesign.com'
[00713] To deliver proper alignment the maximal energy transfer per
orientation of coil groups may be, in some
embodiments, assessed by an internal or external CPU with a signaling when
optimal alignment is approaching or departing,
or made or lost.
[00714] As per Fig. 37d, a temperature sensor such as 3719t may be configured
to detect tissue temperatures external to
the coil and/or wrapper so that hardware and/or software in the system can
alert the user/external coil to increase or decrease
energy transmission as the case may be. In some embodiments, one or more
threshold temperatures may be established,
such as a shutoff temperature, which may be, for example, 45 degrees C, which
may result in termination of energy delivery
until the temperature returns to a second threshold temperature, such as 40
degrees C, at which point the energy delivery
may resume.
[00715] In some embodiments, inductance coil 7314 may be replaced by other
similar devices, such as, in some
implementations, the wireless charging of the inductance coil 7314 may be
replaced by, for example, thermoelectric
generators, flexible piezoelectric energy harvesters, capacitive coupling
transmission, magnetodynamic coupling
transmission, microwave power transmission, and the like, depending on the
subject patient and safety guidelines. It is
anticipated that some embodiments of these devices may be configured in a
spiral shape similar to that of inductance coils
already discussed and thus benefit form similar minimally invasive
implantation techniques.
[00716] Fig. 73c is a side elevation view of another embodiment of a powering
system 7300 that may be used to provide
electrical energy to any of the various implants and/or systems disclosed
herein. System 7300 depicts an almost fully
implanted thermoelectric spiral implant 7314t (shown in dashed lines to
indicate its presence below the skin) which was
repositioned into a patient's implant pocket 7305t through incision 7310t,
which may, in some implementations, be done in
a manner similar to that depicted in Figs. 47a-e. Thermoelectric spiral
implant 7314t comprises 2 turns. However, when the
hairpin (180 degree curved) central inner coil 73180 of implant 7314t is
reached, the surgeon may merely reverse the
direction of rotation to maintain insertion into the patient. As previously
discussed in connection with Fig. 47b, wires/wiring
elements may, in some embodiments, be coupled to the inner and/or outer coil
termini, which may be left in place as the
coil is repositioned into place within the subcutaneous and/or soft tissue
implant pocket 7305t. The wires/wiring elements
may remain passing through incision 73101 and, if sufficiently flexible and
dynamically connected, may rotate with the
implant 7314t as it turns and is repositioned from outside of the body to
within implant pocket 7305t through minimally
invasive entrance incision 73101. In some embodiments, additional elements,
such as electronic elements, may be coupled
to the coil to make the coil more useful as a standalone implant, or an
implant configured to standalone as a power supply
Date Recue/Date Received 2022-12-30
119
to another, secondary implant. In some such embodiments, use of a unitary
coil, as shown in Fig. 80a, may eliminate the
need for an auxiliary implant altogether. In contemplated embodiments, a
unitary coil may therefore be coupled with other
implants, such as implants to which the unitary coil is providing energy,
without the use of an auxiliary implant to aid the
unitary coil in doing so. It is also contemplated, however, that some coil
embodiments may have some, but not all, of the
components that may be provided on an auxiliary implant, and may therefore be
considered a "hybrid" coil implant. In
further contemplated embodiments, thermoelectric spiral implants may power the
range of other electronics comprising
those described in Fig. 80 unitary coil that may otherwise comprise a spiral
shaped inductance coil. In alternative
embodiments, spiral implants may comprise numbers of turns ranging as
previously described with reference to Fig. 37.
[00717] Fig. 74a depicts an example of a Subcutaneous Power Delivery System
and a Subcutaneous Implantable
Cardioverter Defibrillator (SICD) system 7400 comprising, in the depicted
embodiment, a flexible strand/string electronic
implant (FSEI) 7401 that terminates in a Subcutaneous Implantable Cardioverter
Defibrillator (SICD). System 7400
comprises one or more implants positioned in respective implant pockets, each
of which is preferably made via one or more
minimally invasive entrance incisions 7410. More particularly, implant system
7400 comprises an FSEI implant 7401, which
may be positioned within an elongated subcutaneous and/or soft tissue implant
pocket 7405c comprising a subcutaneous
and/or soft tissue canal that may be made a by trocar, probe and/or beaded
dissector, as shown and discussed previously.
System 7400 may further comprise inductance coil 7414 (with or without
additional electronics attached) and/or auxiliary
implant 7408, each of which may be deposited in various subcutaneous and/or
soft tissue implant pockets 7405, either their
own individual implant pockets or an implant pocket shared with another
implant of the system, which may be made
similarly to others described by methods described elsewhere within this
application, including Figs. 1 & 57. Inductance
coil 7414 may be connected to auxiliary implant 7408 by an incoming wire or
wires 7415i and auxiliary implant 7408 may
be connected to the FSEI 7401 by one or more outgoing wires 7415o.
[00718] Flexible strand/string implant 7401 may, in some embodiments, comprise
a flexible tube or strand of electronics,
wires, and/or fiber optics. The purpose for having the inductance coil and/or
other associated electronics/implants in the
subcutaneous fat of the lower abdomen, as it is an area that is usually
clothed and may have sufficient subcutaneous tissue
in which to contain, cushion, and/or hide a relatively larger implant. In
addition, the tissue in this region of the body is
relatively inert, thereby possibly reducing the risk of electromagnetic
carcinogenesis. In some contemplated embodiments,
inductance coil 7414, when not receiving transmitted wireless energy, may also
be configured to act as a transmitting and/or
receiving antenna. In some embodiments and implementations, the incision, or
one of the incisions, may be made in the
region of the patient's navel 7410n.
[00719] As depicted in the perspective view of Fig. 741), implant system 7400
may further comprise auxiliary implant 7408,
which may comprise any of the elements previously described in Figs. 54 a-c,
including, but not limited to an antenna 74026
to allow for receipt of electromagnetic signals, which may be used to transmit
data to CPU/printed-circuit-board 7403. An
external transmitter may be adjusted by the patient or healthcare personnel to
transmit signals to internal antenna 74026 that
may, in turn, direct CPU 7403 to coordinate electrical output of wiring
contained in implant 7401. In some embodiments,
the battery 7404 may also be flexible and/or installed within or along
inductance coil 7414. A wireless charging system may
be provided, as previously described, and may be configured to wirelessly
charge the battery 7404 via inductance coil 7414.
Preferably, one or more of the elements of implant system 7400 is either
flexible and/or compressible, or is small enough
on its own to fit within a minimally invasive entrance incision 7410 with
other elements of implant 7400 moved into their
optimal positions in separate tissue pockets, such as pocket 7405, which
contains inductance coil 7414 in the depicted
embodiment. However, some components, such as the string-like implant 7401
and/or the coil 7414, need not be
compressible. Similarly, in some embodiments, the inductance coil 7414 may be
rigid but may, due to the techniques for
insertion of spiral implants disclosed herein, be inserted into a larger
implant pocket, as previously discussed. Auxiliary
implant 7408 may allow for certain components, such as sensitive electrical
components, to be placed within a separate
Date Recue/Date Received 2022-12-30
120
implant, which may be more protective of such components, such as being within
a waterproof/sealed container, for example.
A seal, such as a wrapper, may be used to contain all of the elements of
auxiliary implant 7408 therein. Auxiliary implant
7408 may further comprise, for example, a memory/data storage element 7425.
[00720] In further contemplated embodiments, the implant system may comprise
an auxiliary implant with any element
including, but not limited to, those mentioned for the auxiliary implant
described in Fig. 66, for example, CPU(s)/printed-
circuit-board(s), battery(ies), memory/data storage element(s), antenna(e),
capacitor(s), electronic heart rate sensor(s), lab-
on-a-chip element(s). In other contemplated embodiments, either coils or
auxiliary implants may comprise pulse oximetry
elements. Although some auxiliary implants shown in the figures are
cylindrical in shape, in further contemplated
embodiments they may comprise a variety of shapes including, but not limited
to, ovoids, polygonal prisms, pads, pillow-
like, purse-like, with or without various cavities or convexities.
[00721] In the depicted embodiment, part of implant 7401 may be insulated,
such as portion 7401i, and another portion
may be non-insulated or bare, such as portion 7401c, which may need to be
exposed to deliver sufficient energy to serve as
a defibrillator.
[00722] Cardiac devices traditionally comprise two components: a pulse
generator (also known as a `can'), most commonly
implanted in a prepectoral subcutaneous pocket, and one or more transvenous
leads. Each lead is attached proximally to the
can and fixated distally to the endocardial aspect of the heart. Implantation
of the lead, however, typically requires venous
punctures, with the subclavian, axillary and cephalic veins frequently used.
Such device implantation is often associated
with infection, hematoma, inadvertent arterial puncture, pneumothorax,
hemothorax, and cardiac tamponade. Late
complications associated with transvenous systems include lead fracture, lead
displacement, venous obstruction, infective
endocarditis, or the like. Subcutaneously implantable cardioverter
defibrillators (S-ICD), by contrast, typically require
greater defibrillation energy (80 Joules, for example) than a transvenous
implantable cardioverter defibrillator (TV-ICD)
(35 Joules, for example). These higher energy requirements result in longer
charge times and necessitate a larger and heavier
can. The S-ICD in also may have extremely limited pacing capabilities.
Subcutaneous pacing is similar to transcutaneous
pacing in that it is significantly uncomfortable for the patient and is
associated with mechanical capture of skeletal muscle.
Additional details regarding implantable defibrillators that may be useful in
connection with various systems and methods
disclosed herein can be found in 'Update On Leadless Cardiac Devices For
General Physicians', Wiles BM, Clin. Med.
(Lond) 17: 33-36, 2017, which is incorporated herein by reference in its
entirety.
[00723] Although only a single lead/implant 7401 is shown in the depicted
embodiment, it should be understood that other
embodiments may have multiple leads and/or multiple implants (in some
embodiments, a single implant may comprise
multiple leads and in others each lead may be part of a separate implant). For
example, some embodiments may additionally,
or alternatively, be configured to serve as an EKG. Thus, it is contemplated
that some embodiments may be coupled with
another system, such as the system depicted in FIGS. 72a-72c, which may allow
for coupling of these features in a single
system.
[00724] In some embodiments, inductance coils may be replaced by other power
generating and/or yielding devices, such
as, for example, thermoelectric generators, flexible piezoelectric energy
harvesters, capacitive coupling transmission,
magnetodynamic coupling transmission, microwave power transmission, and the
like, depending on the subject patient and
safety guidelines.
[00725] Inductance coil/'group of stacked coils' may be present as per the
coil cross section depicted in Fig. 37d.
[00726] A multiplicity of stacked inductance coils may increase the power
transfer as well as increase of mutual inductance
between coupled coils.
Reference: 'Achieve High Power Density with Stacked Inductor 25.08.2021,
https://www.electronicdesign.com'
[00727] To deliver proper alignment the maximal energy transfer per
orientation of coil groups may be, in some
embodiments, assessed by an internal or external CPU with a signaling when
optimal alignment is approaching or departing,
Date Recue/Date Received 2022-12-30
121
or made or lost.
[00728] As per Fig. 37d, a temperature sensor such as 37191 may be configured
to detect tissue temperatures external to
the coil and/or wrapper so that hardware and/or software in the system can
alert the user/external coil to increase or decrease
energy transmission as the case may be. In some embodiments, one or more
threshold temperatures may be established,
such as a shutoff temperature, which may be, for example, 45 degrees C, which
may result in termination of energy delivery
until the temperature returns to a second threshold temperature, such as 40
degrees C, at which point the energy delivery
may resume.
[00729] In some embodiments, additional elements, such as electronic elements,
may be coupled to the coil to make the
coil more useful as a standalone implant, or an implant configured to
standalone as a power supply to another, secondary
implant. In some such embodiments, use of a unitary coil, as shown in Fig.
80a, may eliminate the need for an auxiliary
implant altogether. In contemplated embodiments, a unitary coil may therefore
be coupled with other implants, such as
implants to which the unitary coil is providing energy, without the use of an
auxiliary implant to aid the unitary coil in doing
so. It is also contemplated, however, that some coil embodiments may have
some, but not all, of the components that may
be provided on an auxiliary implant, and may therefore be considered a
"hybrid" coil implant.
[00730] Fig. 75a depicts frontal side view of an example of a Subcutaneous
Power Delivery System 7500, which may be
used, for example, to provide power for a variety of implantable devices. In
the depicted embodiment, system 7500
comprises a flexible strand/string electronic implant (FSEI) 7501. System 7500
may further comprise one or more other
implants positioned in respective implant pockets, preferably made via one or
more minimally invasive entrance incisions
7510. As shown in this figure, the entrance incision 7510 used to make
subcutaneous and/or soft tissue implant pocket 7505a
is at an arbitrary angle relative to the pocket, which illustrates that the
devices and techniques disclosed herein may allow
for creation of an implant pocket directed in any direction a full 360 degrees
from the angle of the incision as desired.
Implant system 7500 comprises one or more FSEI implants 7501, each of which
may be positioned within an elongated
implant pocket 7505c comprising a canal that may be made by a trocar, probe
and/or beaded dissector as shown previously.
System 7500 may further comprise spiral implant inductance coils or groups of
stacked coils 7514a (with or without
additional electronics attached) and/or auxiliary implant 7508, each of which
may be deposited in various subcutaneous
and/or soft tissue implant pockets 7505a/7505c, either their own individual
implant pockets, or an implant pocket shared
with another implant of the system, which may be made similarly to others
described by methods described elsewhere within
this application, including Figs. 1 & 57. Inductance coil 7514a may be
connected to auxiliary implant 7508 by one or more
incoming wires 7515i, and auxiliary implant 7508 may be connected to the FSEI
7501 by one or more outgoing wires 75150.
The flexible strand/string electronic (FSEI) 7501 may be coupled with a second
spiral implant inductance coil 7514x and
antenna 7502x. In some embodiments, inductance coil 7514x, be configured to
function as an antenna as well. In alternative
embodiments, spiral implants may comprise numbers of turns ranging as
previously described with reference to Fig. 37.
[00731] Inductance coil 7514x may be positioned in a second subcutaneous
and/or soft tissue implant pocket, preferably at
a location adjacent to another spiral implant 75x, which may be located at
various positions about the body as desired, and
as represented by the examples of Figs. 75c-75g, each of which represents a
possible specific implant for generic implant
75x of Fig. 75a. Inductance coil 7514x may be configured and positioned to
emit wireless energy to a third inductance coil
7524c-g, which may be part of a selection of implantable/implanted devices
denoted by the starred black box 75x seen above
the depicted patient's left shoulder. The 'x' may denote the various
configurations c through g. Box 75x may represent
various implantable surgical systems/devices which may be placed in/around a
variety of organs/locations depicted, but not
limited to those shown in Figs. 75c-g, typically at a deeper or otherwise less
accessible location. Thus, the elements of
system 7500 may be preferably positioned more superficially and/or more
accessible relative to the various possible implants
denoted by box 75x, or more specifically by the examples of Figs. 75c-g. It
should be understood that, in some embodiments,
the selection of implantable/implanted systems/devices in Figs. 75c-g may
therefore be considered part of a different system
Date Recue/Date Received 2022-12-30
122
that is simply powered by system 7500. Alternatively, however, it is
contemplated that the selection of
implantable/implanted systems/devices in Figs. 75c-g may be considered part of
system 7500 in some embodiments.
Antenna 7502x may communicate with one or more of the selection of
implantable/implanted devices.
[00732] The system of body cavity or organ 'leapfrog' with multiple inductance
coils may be of benefit in that suggested
electric wiring/fiber optic transmission may be placed into and/or through the
subcutaneous fat where the fatty cushion and
relatively low reactance may be of benefit; this also may avoid long-standing
wires passing into/through/between critical
cavities/anatomical barriers. Power transmission via wire is more efficient
than wireless currently but there may be benefit
to wirelessly crossing critical anatomy to power a small power efficient
device or battery. In some embodiments and
implementations, magnetic alignment may be helpful to avoid misalignment
between the external power delivery coil and/or
the first internal power receiving coil, which may stop or reduce power
transmission to a critical device. In contemplated
embodiments, a CPU or other programmable device within or external to the
system may assess the maximum/peak power
levels being transmitted and/or received between wireless pairs or groups and
then alert those involved in the immediate
surgical, convalescent, and/or postoperative positioning of the devices as to
whether optimal alignment is being maintained.
[00733] Flexible strand/string implant 7501 may, in some embodiments, comprise
a flexible tube or strand of electronics,
wires, and/or fiber optics. It may be beneficial to place an inductance coil
and/or other associated electronics/implants in the
subcutaneous fat and/or soft-tissue of the lower abdomen, as it is an area
that is usually clothed and may have sufficient
subcutaneous tissue in which to contain, cushion, and/or hide a relatively
larger implant. In addition, the tissue in this region
of the body is relatively inert, thereby possibly reducing the risk of
electromagnetic carcinogenesis. In some contemplated
embodiments, inductance coils, when not receiving transmitted wireless energy,
may also be configured to act as a
transmitting and/or receiving antenna. In some embodiments and
implementations, the incision, or one of the incisions, may
be made in the region of the patient's navel 7510n.
[00734] As depicted the perspective view of Fig. 75b, implant system 7500 may
further comprise auxiliary implant 7508,
which may comprise CPU/printed-circuit-board 7503, battery 7504, memory/data
storage element 7525, antenna 75026,
capacitor 7526, electronic heart rate sensor 7024, and lab-on-a-chip 7527.
Auxiliary implant 7508 may also comprise any
of the elements previously described in Figs. 54 a-c, including but not
limited to an antenna 75026 to allow for receipt of
electromagnetic signals, which may be used to transmit data to and/or receive
data from CPU/printed-circuit-board 7503.
An external transmitter may be adjusted by the patient or healthcare personnel
to transmit signals to internal antenna 75026
that, in turn, directs CPU 7503 to coordinate electrical output of wiring
contained in implant 7501. In some embodiments,
the battery 7504 may also be flexible and/or installed within or along
inductance coil 7514a. A wireless charging system
may be provided, as previously described, which may be configured to
wirelessly charge the battery 7504 via inductance
coil 7514a. Optionally, one or more of the elements of implant system 7500 is
either flexible and/or compressible or is small
enough on its own to fit within a minimally invasive entrance incision 7510
with other elements of implant system 7500
moved into their optimal positions in separate tissue pockets. However, some
components, such as the string-like implant
7501, need not be compressible. Similarly, in some embodiments, inductance
coils may be rigid but may, due to the
techniques for insertion of spiral implants disclosed herein, be inserted into
a larger implant pocket, as previously discussed.
Auxiliary implant 7508, which may be compressible to allow it to fit within
the preferably minimally invasive entrance
incision 7510, may allow for certain components, such as sensitive electrical
components, to be placed within a separate
implant, which may be more protective of such components, such as being within
a waterproof/sealed container, for example.
A seal, such as a wrapper, may be used to contain all of the elements of
auxiliary implant 7508 therein. Auxiliary implant
7508 may further comprise, for example, a memory/data storage element 7525.
[00735] In further contemplated embodiments, the implant system may comprise
an auxiliary implant with any element
including, but not limited to, those mentioned for the auxiliary implant
described in Fig. 66, for example, CPU(s)/printed-
circuit-board(s), battery(ies), memory/data storage element(s), antenna(e),
capacitor(s), electronic heart rate sensor(s), lab-
Date Recue/Date Received 2022-12-30
123
on-a-chip element(s). In other contemplated embodiments, either coils or
auxiliary implants may comprise pulse oximetry
elements. Although some auxiliary implants shown in the figures are
cylindrical in shape, in further contemplated
embodiments they may comprise a variety of shapes including, but not limited
to, ovoids, polygonal prisms, pads, pillow-
like, purse-like, with or without various cavities or convexities.
[00736] In some embodiments, inductance coils may be replaced by other power
generating and/or yielding devices, such
as thermoelectric generators, flexible piezoelectric energy harvesters,
capacitive coupling transmission, magnetodynamic
coupling transmission, microwave power transmission, and the like, depending
on the subject patient and safety guidelines.
[00737] Fig. 75c depicts a side view of an example of a wirelessly powered
gastric/stomach implant 7524c, which may
comprise an inductance coil, along with a more superficial inductance coil
7514c positioned within a subcutaneous and/or
soft tissue implant pocket 7521c. Implant 7524c may, for example, comprise
electrodes implanted into the nearby stomach
7520c and/or smooth muscle in the gastric antrum. Implant 7524c may be
configured to be wirelessly powered by implant
coil 7514c located in the relatively nearby implant pocket 7521c (not visible
through the surface skin and thus depicted in
dashed lines) in subcutaneous fat 7523c. Implant 7514c may, in turn, be
powered by the electrical output of wiring contained
in implant 7501 from implanted coil(s) 7514a, which, again, may be positioned
in implant pocket 7505a, which may be in
a position that allows for use of a larger inductance coil generating more
electrical power/energy than the remote coil 7514c.
An example of an implant that system 7500 may be configured to power is the
Exilis TM gastric electrical stimulation (GES)
system manufactured be Medtronic.
[00738] Fig. 75d depicts a side view of an example of a wirelessly powered
foot drop/leg motor nerve implant 7524d,
which may comprise an inductance coil and may comprise electrodes implanted
onto a nearby motor nerve, such as the
common peroneal nerve 7520d which may, in some cases, ameliorate foot drop.
Implant 7524d may be configured to be
wirelessly powered by system 7500. More particularly, implant 7514d may
directly power implant 7524d and may itself
receive energy from implanted coil(s) 7514a. Implant 7514d may be positioned
in a more proximate and/or adjacent implant
pocket 7521d, preferably in subcutaneous fat 7523d. Implant 7514d may be, in
turn, powered by the electrical output of
wiring contained in implant 7501 via coil(s) 7514a. An example of an implant
that system 7500 may be configured to power
in this context is the ActiGait, which is a product of nstim Services GmbH +
Neurodan A/S. However, other similar devices
are manufactured by Arthrex, Bioness, Finetech Medical, Ottobock, Stryker, and
Wright Medical.
[00739] Fig. 75e depicts a side view of an example of a wirelessly powered
drug/chemical pump implant 7524e. Implant
7524e may comprise, for example, an insulin releasing or other drug releasing,
such as an opioid-releasing or Narcan-
releasing, pump comprising electrodes implanted into a pump
motor/magnetic/hydraulic drive system 7520e. Implant 7524e
may be wirelessly powered by implant 7514e, which may comprise an inductance
coil and/or may be positioned in a more
proximate and/or adjacent implant pocket 7521e, preferably in subcutaneous fat
7523e. Implant 7514e may be, in turn
powered by the electrical output of wiring contained in implant 7501 via
coil(s) 7514a.
[00740] Fig. 75f depicts a side view of an example of a wirelessly powered
brain/nervous system implant 7524f, which
may comprise electrodes implanted into the nervous tissue of the brain 7520f.
Implant 7524f may be wirelessly powered by
implant 7514f, which may be positioned in a more proximate and/or adjacent
implant pocket 7521f, preferably in
subcutaneous fat and/or galea aponeurotica 7523f. Implant 7514f may be, in
turn, powered by the electrical output of wiring
contained in implant 7501 via coil(s) 7514a. Examples of suitable deep brain
stimulation implants for this purpose are
manufactured by, for example, Abbott, Medtronic, and Boston Scientific.
[00741] Fig. 75g depicts a side view of an example of a wirelessly powered
ear/internal-stimulator portion of a cochlear
implant 7524g, which may comprise electrodes implanted into the nearby cochlea
7520g. Implant 7524g may be wirelessly
powered by implant 7514g, which may be positioned in a more proximate and/or
adjacent implant pocket 7521g, preferably
in subcutaneous fat 7523g. Implant 7514g may be, in turn, powered by the
electrical output of wiring contained in implant
7501 via coil(s) 7514a. In some contemplated embodiments, it may be possible
that, in some patients, the traditional external
Date Recue/Date Received 2022-12-30
124
components of the cochlear implant, which normally comprise an external
microphone and speech processor worn behind
the ear and which convert soundwaves into an electric signal, may be
substituted for by similar hardware/software located
in, for example, auxiliary implant 7508, wherein a nearby or overlying
transcutaneous microphone may provide some sound
data/signal to be processes and relayed via implants 7501 and 7514g to the
more traditional internal receiver¨stimulator
components of the cochlear implant, which may convert the signals into rapid
electrical impulses distributed to multiple
electrodes on the implant electrode array that stimulates spiral ganglion
cells along the cochlear canals causing auditory
nerve excitement for brain processing. Examples of cochlear implants that may
be useful for this purpose include those
manufactured by Cochlear Corp, Advanced Bionics Corp, and Med-El Corp.
[00742] Inductance coil/'group of stacked coils' may be present as per the
coil cross section depicted in Fig. 37d.
[00743] In addition to the depicted electronic medical devices other medical
devices, for example, tissue heaters, tissue
illuminators, tissue irradiators, electrical bone growth stimulators, etc.,
may be powered by such an energy transfer system
as discussed for Fig. 75.
[00744] A multiplicity of stacked inductance coils may increase the power
transfer as well as increase of mutual inductance
between coupled coils.
Reference: 'Achieve High Power Density with Stacked Inductor 25.08.2021,
https://www.electronicdesign.com'
[00745] To deliver proper alignment the maximal energy transfer per
orientation of coil groups may be, in some
embodiments, assessed by an internal or external CPU with a signaling when
optimal alignment is approaching or departing,
or made or lost.
[00746] As per Fig. 37d, a temperature sensor such as 3719t may be configured
to detect tissue temperatures external to
the coil and/or wrapper so that hardware and/or software in the system can
alert the user/external coil to increase or decrease
energy transmission as the case may be. In some embodiments, one or more
threshold temperatures may be established,
such as a shutoff temperature, which may be, for example, 45 degrees C, which
may result in termination of energy delivery
until the temperature returns to a second threshold temperature, such as 40
degrees C, at which point the energy delivery
may resume.
[00747] In some embodiments, additional elements, such as electronic elements,
may be coupled to the coil to make the
coil more useful as a standalone implant, or an implant configured to
standalone as a power supply to another, secondary
implant. In some such embodiments, use of a unitary coil, as shown in Fig.
80a, may eliminate the need for an auxiliary
implant altogether. In contemplated embodiments, a unitary coil may therefore
be coupled with other implants, such as
implants to which the unitary coil is providing energy, without the use of an
auxiliary implant to aid the unitary coil in doing
so. It is also contemplated, however, that some coil embodiments may have
some, but not all, of the components that may
be provided on an auxiliary implant, and may therefore be considered a
"hybrid" coil implant.
[00748] Fig. 76a depicts frontal side view of an example of a Subcutaneous
Power Delivery System 7600, which may be
used, for example, to provide power to implantable motor units. In the
depicted embodiment, system 7600 comprises a
flexible strand/string electronic implant (FSEI) 7601. System 7600 may further
comprise one or more other implants
positioned in respective implant pockets, preferably made via one or more
minimally invasive entrance incision(s) 7610a.
As shown in this figure, the initial entrance incision 7610a used to make
subcutaneous and/or soft tissue implant pocket
7605a is at an arbitrary angle relative to the pocket, which illustrates that
the devices and techniques disclosed herein may
allow for creation of an implant pocket directed in any direction a full 360
degrees from the angle of the incision as desired.
Implant system 7600 comprises an FSEI implant 7601 comprising multiple
sections extending at relatively large angles
relative to one another to allow the implant 7601 to extend up to the shoulder
and then down the arm. Implant 7601 may
therefore be positioned within multiple implant pockets that are adjacent to
one another, as shown in the figure. Both the
initial implant pocket 7605b and the secondary implant pocket 7605c, which may
be made using another entrance incision
76106 positioned at or adjacent to the distal end of pocket 7605b. Implant
pockets 7605b and 7605c may comprise a canal
Date Recue/Date Received 2022-12-30
125
that may be made by trocar, probe and/or beaded dissector as shown previously.
System 7600 may further comprise one or
more inductance coils, including inductance coil(s) 7614a. As depicted in Fig.
76a, spiral implant 7614a comprises 3 turns.
In alternative embodiments, spiral implants may have/comprise numbers of turns
ranging as previously described in Fig. 37.
System 7600 may further comprise an auxiliary implant 7608, as previously
discussed. Again, each of these various implants
may be deposited in various implant pockets 7605a/76056/7605c, either their
own individual implant pockets or an implant
pocket shared with another implant of the system, which may be made similarly
to others by methods described elsewhere
within this application, including Figs. 1 & 57. Inductance coil 7614a may be
connected to auxiliary implant 7608 by
incoming wire(s) 7615i, and auxiliary implant 7608 may be connected to the
FSEI 7601 by outgoing wire(s) 7615o. The
flexible strand/string electronic (FSEI) 7601 may be coupled to one or more
motor drives, such as motor drives 7621 and/or
7623, to mimic or aid the musculoskeletal system, the muscles of which
typically work in opposing pairs across a joint. It
should be understood that, in some embodiments, selection of
implantable/implanted motor drive systems/devices
7621/7623 may therefore be considered part of a different system that is
simply powered by system 7600. Alternatively,
however, it is contemplated that selection of implantable/implanted motor
drive systems/devices 7621/7623 may be
considered part of system 7600 in some embodiments.
[00749] Flexible strand/string implant 7601 may, in some embodiments, comprise
a flexible tube or strand of electronics,
wires, and/or fiber optics. It may be beneficial to place an inductance coil
and/or other associated electronics/implants in the
subcutaneous fat and/or soft-tissue of the lower abdomen, as it is an area
that is usually clothed and may have sufficient
subcutaneous tissue in which to contain, cushion, and/or hide a relatively
larger implant. In addition, the tissue in this region
of the body is relatively inert, thereby possibly reducing the risk of
electromagnetic carcinogenesis. In some contemplated
embodiments, inductance coil 7614a, when not receiving transmitted wireless
energy, may also be configured to act as a
transmitting and/or receiving antenna. In some embodiments and
implementations, the incision, or one of the incisions, may
be made in the region of the patient's navel 7610n.
[00750] As depicted the perspective view of Fig. 76b, implant system 7600 may
further comprise auxiliary implant 7608,
which may comprise CPU/printed-circuit-board 7603, battery 7604, memory/data
storage element 7625, antennas 76026.
Auxiliary implant 7608 may also comprise any of the elements previously
described in Figs. 54 a-c, including but not limited
to an antenna 76026 to allow for receipt of electromagnetic signals, which may
be used to transmit data to and/or receive
data from CPU/printed-circuit-board 7603. An external transmitter may be
adjusted by the patient or healthcare personnel
to transmit signals to internal antenna 76026 that, in turn, directs CPU 7603
to coordinate electrical output of wiring
contained in implant 7601. In some embodiments, the battery 7604 may also be
flexible and/or installed within or along
inductance coil 7614a. A wireless charging system may be provided, as
previously described, which may be configured to
wirelessly charge the battery 7604 via inductance coil(s) 7614a. Optionally,
one or more of the elements of implant system
7600 is either flexible and/or compressible, or is small enough on its own to
fit within a minimally invasive entrance incision
7610a with other elements of implant 7600 moved into their optimal positions
in separate tissue pockets. However, some
components, such as the string-like implant 7601, need not be compressible.
Similarly, in some embodiments, the inductance
coil(s) 7614a may be rigid but may, due to the techniques for insertion of
spiral implants disclosed herein, be inserted into
a larger implant pocket, as previously discussed. Auxiliary implant 7608,
which may be compressible to allow it to fit within
the preferably minimally invasive entrance incision 7610a, may allow for
certain components, such as sensitive electrical
components, to be placed within a separate implant, which may be more
protective of such components, such as being within
a waterproof/sealed container, for example. A seal, such as a wrapper, may be
used to contain all of the elements of auxiliary
implant 7608 therein. Auxiliary implant 7608 may further comprise, for
example, a memory/data storage element 7625.
[00751] In further contemplated embodiments, the implant system may comprise
an auxiliary implant with any element
including, but not limited to, those mentioned for the auxiliary implant
described in Fig. 66, for example, CPU(s)/printed-
circuit-board(s), battery(ies), memory/data storage element(s), antenna(e),
capacitor(s), electronic heart rate sensor(s), lab-
Date Recue/Date Received 2022-12-30
126
on-a-chip element(s). In other contemplated embodiments, either coils or
auxiliary implants may comprise pulse oximetry
elements. Although some auxiliary implants shown in the figures are
cylindrical in shape, in further contemplated
embodiments they may comprise a variety of shapes including, but not limited
to, ovoids, polygonal prisms, pads, pillow-
like, purse-like, with or without various cavities or convexities.
[00752] In some embodiments, motor drives for the musculoskeletal system may
comprise, for example, hydraulic and/or
magnetic movement systems and the like. As natural muscles work in opposing
pairs across a joint, a synthetic muscle,
similar to motorized robotics, may create work across a moveable interface,
which in the depicted embodiment is the lower
arm 7620 (ulna) across the finger joints, with ulnar attachment by natural or
synthetic tendon 7629 and proximal motor
portion 7621 drawing together (or repelling to reset) distal motor portion
7623 which is, in turn, attached to a ventral portion
of a phalanx by natural or synthetic tendon 7624. These surgeries may occur
separately or in concert with surgery to create
pockets 7605a, 7605b, & 7605c and implant the depicted elements.
[00753] The motor(s) or other elements may derive their respective
instructions and/or power from implant 7601, which
reaches the arm via incisions 7610a and 76106, and terminates near incision
7610c as discussed previously in Fig. 63 and
the like.
[00754] Ultimately, energy may be wirelessly fed into coil(s) 7614a via an
external coil and the system may store and feed
energy to motor(s)/groups as needed.
[00755] In some embodiments, prosthetic devices may use sensored brushless
motors for actuation. Such sensored
brushless motors may comprise brushless motors, field oriented control
systems, rotary encoders, and gearboxes. In certain
embodiments, the rotary encoder may comprise a tunneling magnetoresistance
sensor. In some instances, each motor may
be individually actuatable. Additional details regarding the disclosed
prosthetic device may be found in US Patent
Publication Application No. 2020/0306059, titled "System and Method for a
Prosthetic Hand Having Sensored Brushless
Motors", which is hereby incorporated in its entirety by reference.
[00756] In some embodiments, powered prosthetic devices (such as prosthetic
thighs), may use computer controlled
actuators to rotate the prosthetic thigh. In a preferred embodiment, a
computer-controlled actuator may be configured to
rotate the prosthetic thigh along a sagittal plane relative to the socket. In
certain embodiments, the actuator may increase
stiffness of the joint if the foot is in contact with the ground and may
decrease stiffness if the foot is in not in contact with
the ground. Additional details regarding the disclosed prosthetic device may
be found in US Patent Publication Application
No. 2013/0261766, titled "Powered Prosthetic Hip Joint", which is hereby
incorporated in its entirety by reference.
[00757] In some instances, actuators may be used to augment joint function.
Such actuators may involve, for example,
energizing a transverse flux motor to apply torque to a joint. In some
instances, the motor may be directly couple to a low-
reduction ratio transmission system, which is connected to an elastic element
that is connected to the joint to supply torque,
equilibrium, and/or impedance to a joint. Additional details regarding the
disclosed actuating joint may be found in US
Patent No.10143570, titled "Biomimetic Joint Actuators", which is hereby
incorporated in its entirety by reference.
[00758] In some instances, powered ankle-foot prostheses may be used to
increase amputees' metabolic walking economy.
Such devices may comprise, for example, a controller including an
electromyographic processing unit, which may be
coupled to an electromyographic sensor, which may be coupled to a plurality of
servo controllers, which may link the
controllable powered actuators and the controller. In some instances, the
servo controllers may comprise torque controllers,
impedance controllers, and/or position controllers. In some embodiments,
unidirectional springs may be configured in
parallel with the controllable actuators. Additional details regarding the
disclosed ankle joint may be found in US Patent No.
10137011, titled "Powered Ankle-Foot Prosthesis", which is hereby incorporated
in its entirety by reference.
[00759] In some embodiments, knee prostheses may comprise agonist-antagonist
arrangements of two series-elastic
actuators in parallel, a knee joint, and a controller for independently
energizing the actuators. In a preferred embodiment,
the first rotary actuator may be connected to a first linear ball screw, which
may be linked to the mechanical knee joint via
Date Recue/Date Received 2022-12-30
127
a link which may comprise a first ball-nut threadably engaged with the first
linear screw. In such an embodiment, the second
rotary actuator may be connected to a second linear ball screw, which may be
linked to the mechanical knee joint via a link
which may comprise a second ball-nut threadably engaged with the second linear
screw. Upon actuation of the rotary
actuator, the linear screw rotates, causing the link to move along the linear
screw causing rotation of the joint. Additional
details regarding the disclosed knee joint may be found in US Patent No.
9149370, titled "Powered Artificial Knee with
Agonist-Antagonist Actuation", which is hereby incorporated in its entirety by
reference.
[00760] In some instances, prosthetic legs may comprise electronically
controlled, power generating knee joints. In certain
instances, the knee may either be passive, or it may be active, assisting or
completely controlling gait. In either active/passive
mode, the knee may still generate electrical energy. In certain embodiments,
the prosthetic leg may comprise an electronic
control system for overall operation of the leg, and storage devices for
excessively generated electrical energy. Additional
details regarding the disclosed prosthetic leg may be found in US Patent No.
7485152, titled "Prosthetic Leg Having
Electronically Controlled Prosthetic Knee with Regenerative Braking Feature",
which is hereby incorporated in its entirety
by reference.
[00761] Agonist-antagonist actuators may be used for artificial joints in
artificial limbs, which may be used in, for example,
orthotic, prosthetic, or exoskeletal applications. In some embodiments, a
flexion actuator may include a series combination
of a first active element and a first elastic element; an extension actuator
may comprise a second active element and a second
elastic element. In some embodiments, series elasticity may be used for
mechanical power amplification. Additional details
regarding the disclosed joint may be found in US Patent No. 8870967, titled
"Artificial Joints Using Agonist-Antagonist
Actuators", which is hereby incorporated in its entirety by reference.
[00762] In some embodiments, prosthetic leg devices may comprise powered knee
and ankle joints with motor units for
delivering power to each joint. Such prosthetics may comprise, for example,
sensors for measuring real-time inputs and
controllers for controlling movement. The control system may comprise, for
example, a processor, memory for storing
instructions, and means for generating control signals for each powered joint.
Additional details regarding the disclosed
prosthetic device may be found in US Patent No. 8652218, titled "Powered Leg
Prosthesis and Control Methodologies for
Obtaining Near Normal Gait", which is hereby incorporated in its entirety by
reference.
[00763] In some embodiments, implanted devices may comprise motors. Such
motors may be, for example, coreless.
Eliminating the ferromagnetic core may offer, in some instances, reduced mass,
lower electrical time constant, high power
efficiency, low noise, et al. Additionally, core-free motors may lead to
longer battery life and more rapid cycling. In a
preferred embodiment, a permanent magnet motor may comprise high energy
density, increased oxidation resistance, and
stable magnetization curves. In some instances, sintered ceramic bearings may
provide more precision when compared to
traditional motors. For internal applications, it may be preferred, in some
embodiments, to use hydrodynamic or magnetic
bearings due to their longer lifespans. Additional details regarding the
disclosed motors may be found in 'Electric Motors
for Medical and Clinical Applications', Gieras, 2008,
researchgate.net/publication/245024769, which is hereby incorporated
in its entirety by reference.
[00764] Inductance coil/'group of stacked coils' may be present as per the
coil cross section depicted in Fig. 37d.
[00765] A multiplicity of stacked inductance coils may increase the power
transfer as well as increase of mutual inductance
between coupled coils.
Reference: 'Achieve High Power Density with Stacked Inductor 25.08.2021,
https://www.electronicdesign.com'
[00766] To deliver proper alignment the maximal energy transfer per
orientation of coil groups may be, in some
embodiments, assessed by an internal or external CPU with a signaling when
optimal alignment is approaching or departing,
or made or lost.
[00767] As per Fig. 37d, a temperature sensor such as 3719t may be configured
to detect tissue temperatures external to
the coil and/or wrapper so that hardware and/or software in the system can
alert the user/external coil to increase or decrease
Date Recue/Date Received 2022-12-30
128
energy transmission as the case may be. In some embodiments, one or more
threshold temperatures may be established,
such as a shutoff temperature, which may be, for example, 45 degrees C, which
may result in termination of energy delivery
until the temperature returns to a second threshold temperature, such as 40
degrees C, at which point the energy delivery
may resume.
[00768] In some embodiments, additional elements, such as electronic elements,
may be coupled to the coil to make the
coil more useful as a standalone implant, or an implant configured to
standalone as a power supply to another, secondary
implant. In some such embodiments, use of a unitary coil, as shown in Fig.
80a, may eliminate the need for an auxiliary
implant altogether. In contemplated embodiments, a unitary coil may therefore
be coupled with other implants, such as
implants to which the unitary coil is providing energy, without the use of an
auxiliary implant to aid the unitary coil in doing
so. It is also contemplated, however, that some coil embodiments may have
some, but not all, of the components that may
be provided on an auxiliary implant, and may therefore be considered a
"hybrid" coil implant.
[00769] Fig. 77 depicts a top plan partially transparent view of a flexible
tissue implant facilitating system (FTIFS) 7700
and devices comprising an instrument comprising blunt introducing tip 7709,
dilator 7708, clockwise screw threads 7711
positioned on a tapering portion of dilator 7708. Tip 7709 is coupled to a
distal portion of shaft 7714. Clockwise rolled
implant 7704 is in rolled up into a compressed configuration and has been
inserted in tissue pocket 7705, which is depicted
in dashed lines indicating these elements lie below the skin surface adjacent
minimally invasive entrance wound/incision
7710. The depicted as internal portion of a suture 7751i was previously
affixed to implant macro positioning/instrument
engaging hole 7703 when the implant was outside of body (preinstallation).
When the implant was outside of incision 7710,
the non-needle bound end of the suture was tied to hole 7703; then an
endoscopic needle driver delivered the suture needle
and accompanying distal suture through the skin from inside to out preferably
a distant region of the subcutaneous and/or
soft tissue implant pocket (distant from the entrance incision), such as at
one or more corners of the implant pocket, resulting
in an externalized portion of the suture 7751e extending from within the
implant pocket 7705 through one or more openings
that may have been, as mentioned above, made via an endoscopic needle driver
in some preferred implementations, to be
accessible for grasping by a surgeon and/or grasping instrument. The external
portion suture(s) 7751e may then be pulled,
preferably with a suitable instrument, as the handle 7715 and releasably bound
shaft turn the remaining implant 7704
counterclockwise to unfurl implant 7704 like a flag. Suture materials may be
nonabsorbable for example polypropylene or
absorbable such as poliglecaprone and optionally secured by tying after
exiting the skin a desired distance. Once unwound
from the implant, the unbound/untethered FTIFS components may exit the
incision/entrance wound 7710 leaving the implant
in place. Any holes with attached sutures remaining may penetrate the skin in
a similar fashion from inside out via an
endoscopic needle driver to be sutured to opposite corners; this is possible
if holes 7703 have been loaded with stitch prior
to loading/winding the implant on shaft 7714 before the insertional process
began (such holes may be the ones adjacent to
the shaft and any protruding attachment elements, as stitch may be relatively
small, taking little space). In some
embodiments, screw threads 7711 on dilators may be manufactured
counterclockwise to suit a surgeon/patient's needs. For
the purposes of this submission, suture 7751i, may be considered a medical-
surgical instrument. Implants are foreign
bodies, and with the trauma accompanying implant pocket formation, seroma
formation may occur; thus, a temporary drain,
for example 2-3mm diameter tubing, may be sewn into the entrance wound as a
countermeasure. As well, external
counterpressure may ameliorate seroma formation, for example corner sutures
7751e placed in peripheral holes 7703 may
be of sufficient length to be attached to the implant yet reach through the
implant pocket 7705 periphery and penetrate
through the dermis and epidermis. Once the implant is in place, the long
sutures may be externally pulled tight to create
lengths sufficient to become tie-down sutures for a temporary external
pressure bolus, such as cotton or polyester fiberfill.
[00770] Fig. 78a depicts an example of a wireless charging system 7800
comprising an external/transmitting inductance
coil device 7814e that may be used to, for example, recharge or otherwise
provide power to an internal implant 7814i.
External/transmitting inductance coil device 7814e may be positioned adjacent
to a corresponding receiving/internal
Date Recue/Date Received 2022-12-30
129
inductance coil 7814i, which may be a standalone coil or part of an implant,
to wirelessly transfer power to an implant as
needed. However, human skin epidermis/dermis 7840e and subcutaneous fat 7840s
lie between the coils which may heat
the skin structures. In some embodiments and implementations, inductance coil
7814e and/or 7814i may comprise multiple
coils, which may enhance the efficiency and/or functionality of the system.
For example, in some embodiments, a butterfly
inductance coil may be used to facilitate communication and/or transfer of
power to the implant. Additional details regarding
such butterfly coils may be found in U.S. Patent Application Publication No.
2008/0027513 titled "Systems and Methods
for Using a Butterfly Coil to Communicate with or Transfer Power to an
Implantable Medical Device", which is hereby
incorporated herein in its entirety by reference. Due to the potential heating
of skin and/or surrounding tissues, Fig. 78b
depicts optional elements to system 7800 comprising plastic bladder 7860 with
water/fluid inlet port 7861i and outlet port
78610 to circulate cool water/fluid thus cooling the skin to reduce the
effects of heating from wireless energy transfer. In
some implementations, the plastic bladder may be flexible. However, in other
embodiments and implementations, the
bladder may be rigidified.
[00771] Fig. 79a depicts a branched/dendritic flexible subcutaneous electronic
neuro stimulative (FSQENS) implant 7901a
comprising an auxiliary implant unit 7908a positioned in a subcutaneous and/or
soft tissue implant pocket 7905a preferably
made via a minimally invasive entrance incision. In further contemplated
embodiments, a similar configuration may be used
as a branched/dendritic flexible subcutaneous electronic muscular stimulative
(FSQEMS) implant. More particularly,
implant 7901a may be positioned within implant pocket 7905a that may be made
by a minimally invasive dissection and/or
beaded dissector as previously described. A coil (for example as shown in Fig.
62 but not shown here for space
considerations) with or without additional electronics such as auxiliary
implant 7908a may be deposited in various implant
pockets made similarly to others described by methods described elsewhere
within this application, including Figs. 1 & 57
and connected via wiring/connection 7915a. In some implementations, the
branched/dendritic FSQENS implant may be
oriented along the dermatomal, sclerotomal, or myotomal, or nerve map areas.
[00772] In this embodiment, dendrite/branches, such as branches 7921a, may
extend from the primary, elongated axis of
implant 7901a. In the depicted embodiment, these branches 7921a may extend
perpendicular, or at least substantially
perpendicular, to the axis of implant 7901a. Implant 7901a may comprise
terminal electrodes 7911a, optional
peripheral/circumferential electrode 7912a, and positioning ring/hole 7922a,
external coupler/adapter 7923a, and internal
coupling 7909a. Positioning ring/hole 7922a may be used for positioning,
suturing, fixation or as per the other positioning
holes discussed elsewhere herein. The unit may be sealed within a container or
envelope, which is preferably both waterproof
and biocompatible. Terminal electrodes 7911a each may be electrically coupled,
directly or indirectly, to a CPU and/or other
suitable electrical circuitry and/or may also be wired independently of each
other, thus allowing for different programmable
control for each. In other contemplated embodiments, the wiring may be in
series, parallel or another form of independent
wiring or a combination thereof
[00773] Fig. 79b depicts an alternative embodiment of a branched/dendritic
flexible subcutaneous electronic neuro
stimulative (FSQENS) implant 7901b positioned in an subcutaneous and/or soft
tissue implant pocket 7905b preferably
made via a minimally invasive entrance incision. In further contemplated
embodiments, a similar configuration may be used
as a branched/dendritic flexible subcutaneous electronic muscular stimulative
(FSQEMS) implant. Unlike implant 7901a,
implant 79016 comprises branches 792 lb that extend at an acute angle relative
to the implant axis, preferably with both
opposing branches pointing towards the distal end of the implant having
positioning hole/ring 79226, as shown in the figure,
which may facilitate insertion of the implant. It is contemplated, however,
that in alternative embodiments one or more of
the branches may extend towards, rather than away from, this distal end.
Otherwise, implant 79016 may be similar to
implant 7901a and may comprise, for example, one or more terminal electrodes
7911b, which may be positioned at or
adjacent to the tips of each, or at least a subset, of the various branches
792 lb, along with one or more circumferential
electrodes 79126, which may be positioned to encircle or otherwise extend
about a portion of one or more of the various
Date Recue/Date Received 2022-12-30
130
branches 7921b.
[00774] In some embodiments, a plurality of branches 7911b may be used as
leads for an ECG implant. Thus, the
embodiment of Fig. 79b may be modified to include, for example, 3-12
branches/leads, which may be much longer than the
branches depicted in this figure if needed in order to be positioned at
desired locations adjacent a patient's heart.
[00775] Fig. 79c depicts a serpentine/sinuous flexible subcutaneous electronic
neuro stimulative (FSQENS) implant 7901c,
positioned in a subcutaneous and/or soft tissue implant pocket 7905c
preferably made via a minimally invasive entrance
incision. In further contemplated embodiments, a similar configuration may
instead be used as a serpentine/sinuous flexible
subcutaneous electronic muscular stimulative (FSQEMS) implant. More
particularly, implant 7901c may be positioned
within implant pocket 7905c that may be made by a minimally invasive
dissection and/or beaded dissector as previously
described.
[00776] In this embodiment, alternating bends such as bend 7921c, may be
formed such that the implant meanders back
and forth in a periodic manner. In some embodiments, the implant may form, or
at least substantially form, a sinusoidal
shape, at least in part, as shown in Fig. 79c. Each of the various bends or
periods of the implant may be substantially angled
relative to the overall implant axis, which is represented by the proximal
implant terminus. Again, the distal end of the
implant may comprise a positioning ring/hole 7922c, and the implant 7901c may
comprise terminal electrodes 7911c, which
may be positioned at the apex of each, or at least a subset, of the various
bends/periods of the implant. Optional
peripheral/circumferential electrodes 7912c may also be used if desired, as
discussed above. Each of the various electrodes,
such as electrodes 7911c and/or electrodes 7912c, may be electrically coupled,
directly or indirectly, to a CPU and/or other
suitable electrical circuitry and/or may also wired independently of each
other, thus allowing for different programmable
control for each. In other contemplated embodiments the wiring may be in
series, parallel or another form of independent
wiring or a combination thereof
[00777] Preferably, each of the peaks of the sinusoidal shape of implant
7901c, or at least a subset of these peaks, comprises
an electrode, which may maximize the distance between opposing and/or adjacent
electrodes. Also, preferably, the implant
7901c is configured to maintain its shape without requiring the surgeon to
reconfigure the implant 7901c in this shape.
Implant 7901c may therefore comprise a rigid material or a resiliently
flexible material, such as a material having shape
memory.
[00778] Fig. 80a depicts a top view of a circular, spiral implant (or
minimally invasive rotatably implantable unitary coil)
8001 with outer arm band terminus 8012 and inner arm band terminus 8011 and
space 8010 between the bands. In some
embodiments, spiral implant 8001 may be circular in overall shape and
rectangular in cross section. However, various other
shapes may be used in alternative embodiments. Spiral implant 8001 comprises 4
turns. In alternative embodiments, spiral
implants may comprise numbers of turns ranging as previously described with
reference to Fig. 37.
[00779] Spiral implant 8001 may be rigid or, if preferred, more flexible. In
some embodiments, the spiral implant 8001
may be compressible by being rollable and/or foldable. In some embodiments,
spiral implant 8001 may comprise a metal,
ceramic, cermet, glass, flexible plastic, organic polymer, biopolymer, or the
like, and therefore, due to the unique insertion
methods disclosed herein, need not be compressible. Other embodiments may
comprise a polymeric external lamination or
containment to retain more dissolvable materials such as hydrogels and the
like. Drugs, vitamins, or other chemicals,
including biologics, may also be bound, dissolved, or otherwise present in a
portion or all of the structure of spiral implant
8001 and/or elements contained therein. In some embodiments,
antibiotics/antimicrobials may be coated or otherwise
incorporated on and/or into the implant to prevent or at least inhibit
microbial growth on the implant. Use of a unitary coil,
as shown in Fig. 80a, may eliminate the need for an auxiliary implant
altogether. In contemplated embodiments, a unitary
coil may therefore be coupled with other implants, such as implants to which
the unitary coil is providing energy, without
the use of an auxiliary implant to aid the unitary coil in doing so. It is
also contemplated, however, that some coil
embodiments may have some, but not all, of the components that may be provided
on an auxiliary implant, and may therefore
Date Recue/Date Received 2022-12-30
131
be considered a "hybrid" coil implant.
[00780] Different regions and/or portions of spiral implant 8001 may also have
different medications or chemicals printed
or otherwise designed into them. In addition, electronics, micro-pumps, and/or
printed circuit boards may be present in the
spiral implant 8001 when properly protected. Radiographically, sonically,
and/or electromagnetically identifiable material
may also be present in implant 8001 to aid in locating and/or manipulating the
implant. Spiral implants may be inserted by
rotating/winding the implant into a minimally invasive entrance wound, as will
be discussed and depicted later in greater
detail. Spiral implants may also lend themselves to carrying electronics, such
as inductance coils, thin film batteries, printed
circuit boards as well as chemicals, medicines, and/or biopolymers. From the
inner terminus of the coil 8011,
wiring/connector 8015i may be electrically coupled to one or more of the
components of the implant 8001. Similarly, the
outer terminus of the coil 8012 may comprise wiring/connector 8015o, which may
be joined/coupled to various portions of
the coil to complete circuitry after, for example, a portion of the implant
has cleared the entrance incision.
[00781] Fig. 80b depicts a cross-sectional view of spiral implant 8001 taken
from Fig. 80a along the line and arrow depicted
therein. The cross-sectional view of spiral implant 8001 also depicts
electromagnetic interference (EMI) suppression
elements comprising magnet 8031 and shielding via ferro-metallic element 8032,
which may comprise 270 degree shielding
in some embodiments. In further contemplated embodiments, ferro-metallic
shielding element 8032 may be positioned and
configured such that this element lacks portions running down one or both
sides and therefore need not envelope any
elements laterally as shown in the figure. In further embodiments, EMI
suppression may comprise a magnet. The cross-
sectional view of spiral implant 8001 also depicts superstructure 8019
positioned on the upper surface of the implant. Of
course, in alternative embodiments, the superstructure 8019 may be positioned
on any other side and/or portion of the
implant. Spiral implant 8001 may also comprise temperature sensor 8019t, which
may protrude from another location on
implant 8001. The depicted embodiment also comprises various layers/elements,
including a metallic inductance coil 8021,
battery 8022 (thin film in this embodiment), printed circuit board/CPU 8023,
one or more additional inductance coils 8021a,
capacitor 8026, data storage 8027, lab-on-a-chip 8029, ancillary electronics
8024, such as a heating element, thin film
resistors, etc., and polymeric protective inner sheath 8025i, which may be
positioned adjacent to protective outer sheath
8025o. Ancillary electronics 8024 may also be used if desired, which may
comprise, for example, a heart rate sensor, oxygen
saturation monitor, or the like, any of which may be positioned adjacent to
protective outer sheath 8025o. In other
contemplated embodiments, one or more additional metallic inductance coils
8021a may be stacked to enhance the power
generation capabilities of the implant. As also shown in this figure, a hollow
space may be created between inner and outer
sheaths 8025i/8025o, which may be used to contain a fluid and/or gel, for
example, which may serve as a protective
sheath/seal, a superstructure, and/or a location for drug containment and/or
delivery. In some embodiments, microfluidic
channels (not shown later as 8029m) may be used, which may be configured to
deliver patient serum/blood/tissue fluid
located outside of the protected encasement/wrapper in contact with lab-on-a-
chip for analysis(es). In further contemplated
embodiments, temperature sensors may be placed in one or more locations on the
inside and/or outside of spiral implant
8001 or any of the other implants disclosed herein. Temperature sensors
located on the outside may, in some embodiments,
be configured to send temperature data to a CPU, which may be programmed with
a set temperature threshold such as, for
example, 45 C, to possibly shut down or reduce external wireless inductance
coil charging to protect delicate adjacent tissue.
Once external temperatures return to a preset safe threshold, for example 42
C, wireless charging may recommence.
Temperature sensors placed internally in the spirals may have preset
thresholds to alter the charging parameters to protect
one or more of the aforementioned internal elements of the spiral coil 8001.
An external transmitter may be adjusted by the
patient or healthcare personnel to transmit signals to internal antenna 80026
that in turn, may direct CPU 8023 to coordinate
functions of the implant. Some contemplated embodiments may comprise multiple
internal antennas.
[00782] Fig. 80c depicts a cross-sectional view of an alternative embodiment
comprising (EMI) suppression elements
comprising magnet 8031 and shielding via ferro-metallic element 8032c, which
comprises planar shielding. The
Date Recue/Date Received 2022-12-30
132
embodiment further comprises inductance coil 8021, one or more additional
inductance coils 8021a, battery 8022, printed
circuit board/CPU 8023, antenna 80026, capacitor 8026, data storage 8027, lab-
on-a-chip 8029, ancillary electronics 8024
(such as a heating elements, thin film resistors, etc.) and polymeric
protective inner sheath 8025i, which may be positioned
adjacent to protective outer sheath 8025o. Microfluidic channels 8029m may be
configured to deliver patient
serum/blood/tissue fluid located outside of the protected encasement/wrapper
in contact with lab-on-a-chip 8029 for
analysis(es). Fiberoptics 80290 may be configured to analyze patient
serum/blood/tissue fluid located outside of the
protected encasement/wrapper in concert with the lab-on-a-chip 8029. As
vascularization may occur through the implant
from below to nourish the tissues overlying the implant (for example, if the
implant is placed subcutaneously), placement
of Microfluidic channels 8029m and/or fiberoptics 80290 facing the spaces 8010
between the spiral arm/bands may be
beneficial for measurements following vascularization. In further contemplated
embodiments, placing the fiberoptics and/or
microfluidic termini away from the spaces may provide for more immediate
analyses until neovascularization occurs within
these spaces. Mini-tubules 8029t may serve similar functions to those
mentioned in the description of Fig. 11.
[00783] Fig. 80d depicts a cross-sectional view of an alternative embodiment
comprising (EMI) suppression elements
comprising magnet 8031 and shielding via ferro-metallic element 8032d, which,
in the depicted embodiment, comprises
wraparound, 360 degree shielding for one or more selected elements. The
embodiment further comprises inductance coil
8021, one or more additional inductance coils 8021a, battery 8022, printed
circuit board/CPU 8023, antenna 80026, capacitor
8026, data storage 8027, lab-on-a-chip 8029, ancillary electronics 8024 (such
as a heating elements, thin film resistors, etc.)
and polymeric protective inner sheath 8025i, which may be positioned adjacent
to protective outer sheath 8025o.
[00784] In some embodiments, wireless power transfer systems may require
electromagnetic interference (EMI)
suppression shields to protect electronic components from unwanted magnetic
field fluctuations. In some embodiments,
such EMI suppression shields may involve ferrite films, metal films, and/or a
hybrid material comprising both a metal and
ferrite component. Additional details regarding EMI suppression shields may be
found in 'Electromagnetic Interference
Shielding Effects in Wireless Power Transfer Using Magnetic Resonance Coupling
for Board-to-Board Level
Interconnections', Kim, InCompliance Magazine, 2013, which is hereby
incorporated by reference in its entirety.
[00785] In some embodiments, EMI suppression shields may comprise thin,
flexible magnetic shields. It some instances,
it may be beneficial to use a material having a high permeability, which may
lead to improved shielding performance through
magnetic field containment/absorption. In other embodiments, it may be
beneficial to use a material having a higher
resistance, which may lead to better noise suppression; however, particular
caution may be required, as even though higher
resistance values may absorb more magnetic field noise, they may create more
heat. In some instances, metallic shields may
be used as EMI suppression shields, as they can reflect such noise energy. In
other instances, magnetic shields may be used
as they may absorb such noise energy and convert it to heat. In some
embodiments, hybrid materials (for example, a ferrite
material and copper), which may comprise a magnetic sheet with a metallized
back layer, may be used to increase such EMI
suppression effects. In some embodiments, having a low permeability and a high
resistance may be desired. Such
embodiments may include those in which such EMI suppression shields are in
close proximity with inductance coils. In
some instances, hybrid materials may comprise a stack comprising an insulating
layer, a conductive layer, and a magnetic
sheet. Additional details regarding EMI suppression devices and materials may
be found in 'EMI Suppression Shields:
Understanding the Basics', Burket, Electronic Design, TechXchange: Delving
into EMI, EMC, and Noise, 2020, which is
hereby incorporated by reference in its entirety.
[00786] In some embodiments, magnetic flux diversion may be used to shield
components from EMI. In some
embodiments, shields may be constructed with high permeability, which may be
used to concentrate magnetic flux. In some
embodiments, such highly permeable metals may comprise nickel-iron alloys
comprising small percentages of copper,
chromium and/molybdenum. Additional details regarding magnetic flux diversion
shielding may be found in 'Inductive
Power Transmission Shielding', Electronics Notes, https://www.electronics-
notes.com/articles/equipment-items-
Date Recue/Date Received 2022-12-30
133
gadgets/wireless-battery-charging/inductive-power-transmission-shielding.php,
which is hereby incorporated by reference
in its entirety.
[00787] In some embodiments, passive and/or active cancellation loops may be
used to mitigate EMI. Such loops may
produce a magnetic field opposing an initial magnetic field. If a passive loop
is excited by a varying magnetic field, the loop
may acquire an EMF, generating a current in the loop, therefore generating a
magnetic field. In some instances, to enhance
shielding performance, a series capacitor may be used to induce a current
within the loop. Additional details regarding such
EMI suppression methods may be found in 'Active Shielding Design for Wireless
Power Transfer Systems', Cruciani, IEEE
Transactions on Electromagnetic Compatibility, Vol. 61, Issue 6, 2019, which
is hereby incorporated by reference in its
entirety.
[00788] In some embodiments, nanomagnetic structures may be used for EMI
suppression. In some embodiments, such
structures may comprise vertically aligned magnetic composite structures as
coupling inductors. In some embodiments,
magnetic nanoparticles may be surrounded by an amorphous insulating matrix,
which may comprise, for example, Fe and
Co-based thin films. In other embodiments, such structures may comprise
stacked layers of ferromagnetic fields alternating
with and separated by thin insulating polymer dielectric layers. In some
instances, the ferromagnetic layer may comprise
NiFe, NiFeMo, and/or CoZrO. In some embodiments, insulators used within such
stacks may comprise, for example,
alumina. Such insulator layers may be used to increase reflection loss.
Additional details regarding such EMI suppression
shields may be found in `Nanomagnetic Structures for Inductive Coupling and
Shielding in Wireless Charging Applications',
Mishra, IEEE, DOI: 10.1109/ECTC.2015.7159707, 2015, which is hereby
incorporated by reference in its entirety.
[00789] In some embodiments, fiber optics may be used in chemical sensing
devices. In some embodiments, connectors
between the fiber optic cable and the sensor head may comprise a sapphire ball
lens, retainer, a spring-giving
focus/collimation, and the like. Such arrangements may be used to launch and
receive beams of diameters such as 5 mm. In
some instances, certain emitted wavelengths may cause tissue damage, so it may
be beneficial to block such wavelengths
with a filter. In order to minimize unforeseen variations in specification,
collection fibers may have diameters of 200 or 400
micrometers. In some embodiments, errors may arise due to variations in the
intensity of the xenon arc lamp light source;
to minimize such errors, a light intensity controller may be used. Additional
details regarding the aforementioned fiber optic
device may be found in 'Optical Fiber-Coupled Ocular Spectrometer for
Measurements of Drug Concentration in the
Anterior Eye ¨ Applications in Pharmaceuticals Research', Miller, IEEE
Transactions on Biomedical Engineering, Vol. 57,
No. 12, December 2010, which is hereby incorporated in its entirety by
reference.
[00790] In some embodiments, fiber optic sensors may comprise interferometric
sensors, which may respond to an external
stimulus by a change in the optical path length, resulting in a phase
difference in the interferometer. In other embodiments,
fiber optic sensors may comprise intrinsic fiber optic sensors based on the
evanescent wave absorption effect. Such intrinsic
evanescent wave-based fiber optic sensors may use LED light sources. In some
embodiments, fiber optic cables used in
conjunction with intrinsic evanescent sensors may comprise multimode optical
fibers with silica cores and plastic cladding.
In some instances, functional coatings of fiber optic cables may comprise dip-
and spin-coatings, layer-by-layer deposition,
electrostatic self-assembly, chemical and physical vapor deposition, and the
like. In preferred embodiments, the outermost
layer of the coating may comprise porphyrin (TSPP). In preferred embodiments,
porphyrin films/compounds may be used
as sensitive elements for optical sensors due to their high sensitivity and
optical properties which depend on the
environmental conditions (in which the target molecule is present). In some
embodiments, fiber optic sensors may comprise
tapered optical fibers, the optical properties of which may be influenced by
the profile of the conical tapering sections. In
some instances, the optical fiber may act as a platform that may be exploited
to facilitate the detection of different chemicals
by coating the fiber with appropriate functional materials (such as mesoporous
PDDA/5i02 nanoparticles for ammonia). In
some embodiments, optical fiber coatings may comprise a PAH/Si02 film
(allowing for greater versatility of the sensor) for
the detection of organic compounds. Additional details regarding the
aforementioned fiber optic devices may be found in
Date Recue/Date Received 2022-12-30
134
"Fibre-Optic Chemical Sensor Approaches Based on Nanoassembled Thin Films: A
Challenge to Future Sensor
Technology", Korposh, 13 June 2013, DOI: 10.5772/53399, which is hereby
incorporated in its entirety by reference.
[00791] In some embodiments, Vascular Endothelial Growth Factor (VEGF) may be
used to increase blood vessel
proliferation. VEGF has been shown to significantly augment collateral vessel
as well as capillary development. VEGF has
four homodimeric species, each monomer having 121, 165, 189, or 206 amino
acids. VEGF121 and VEGF 165 are diffusible
after secretion, while VEGF 189 and VEGF206 are secreted but tend to be bound
to heparin-containing polyglycans. VEGF
stimulates angiogenesis, and even in neovascularization, as VEGF and VEGF
receptors colocalize with sites of
neovascularization. It should be noted that VEGF 165 demonstrates substantial
affinity for heparin. Circulating a1pha2-
macroglobin covalently binds to and inactivates VEGF; however, heparin may be
used to inhibit the binding and inactivation
of VEGF by a1pha2-macroglobin. Additional details regarding VEGF may be found
in 'Therapeutic Angiogenesis',
Takeshita, Journal of Clinical Investigation, Vol. 93, pp. 662-670, 1994,
which is hereby incorporated in its entirety by
reference.
[00792] Positive angiogenic factors may aid in blood vessel proliferation.
Positive angiogenic factors may also include
aFGF, 6F GF, VEGF, angiogenin, and others. Additional details regarding
angiogenic factors may be found in `Angiogenesis
in Cancer, Vascular Rheumatoid and other Disease', Follcman, Nature Medicine,
Vol. 1, No. 1, 1995, which is hereby
incorporated in its entirety by reference.
[00793] Fig. 81a is a top plan view of a composite system 8100 comprising a
minimally invasive implant for prolonged
and/or controlled drug/chemical delivery, which comprises a unitary coil 8114,
segmentation pod implants 8171a, 81716,
auxiliary implant 8108a, and/or a bladder-like compressible implant 8101.
Prolonged implantable drug administration of
water soluble medicines may require highly concentrated fluids or powdered
anhydrous storage if such a system is not to be
recharged/refilled. However, direct release of such concentrations may be
locally caustic, generally toxic and/or lethal.
Water insoluble medicines may therefore be stored concentrated in liposomes or
other means, mixed with water as per
'Liposomes for Enhanced Bioavailability of Water-Insoluble Drugs: In Vivo
Evidence & Recent Approaches, Pharmaceutics
2020, vol. 12, 264, which is hereby incorporated in its entirety by reference.
System 8100 may therefore be configured to
store highly concentrated medicines, harvest body fluids, such as water, to
admix with said medicines, as well as in some
cases monitor drug levels and mix/disperse medicines to maintain desired drug
levels over a prolonged period. This may
be of benefit to those living in remote areas, those too ill to care for
themselves, for example, mentally ill patients.
[00794] System 8100 in the vicinity of the unitary coil 8114 may comprise
space 8110, connecting segment
adapter/connector 8173, and one or more directional valves 8170v. System 8100
in the vicinity of segmentation pods
8171a/81716 may comprise connecting segments 8172a/81726/8172c as well as
bladder implant coupling 8180. System
8100 in the vicinity of bladder-like compressible implant 8101 may comprise
superstructure 8151 and, in one or more
portions, such as the upper half (when viewed from the edge) of the depicted
embodiment, complete and/or partial bound
stretch resisting form maintaining partitions (BSRFMP) 8191u. One or more
other portions, such as the lower half below
the complete and/or partial (BSRFMP) 8191L, may comprise an electronics
assembly 8120, which may comprise, for
example, inductance coil 8121, battery 8122, printed circuit board/CPU 8123,
antenna 81026, and capacitor 8126. These
elements may be delivered through the skin via entrance incision 8160.
System 8100 may be remotely
programmed/controlled by CPU 8198 with attendant software and associated
antenna 8199. Some contemplated
embodiments may comprise multiple internal antennas.
[00795] Fig. 816 depicts a cross-sectional view of spiral implant 8114 taken
from Fig. 81a along the line and arrow depicted
therein. The lower portion of spiral implant 8114, as shown in this figure,
may comprise (EMI) suppression element 8132,
which may comprise planar shielding. This portion of implant 8114 may further
comprise inductance coil 8121, battery
8122, printed circuit board/CPU 8123, antenna 81026, capacitor 8126, data
storage 8127, lab-on-a-chip 8129, ancillary
electronics 8124 (such as a heating elements, thin film resistors, etc.) and
protective inner layer 8125i, which may be
Date Recue/Date Received 2022-12-30
135
positioned adjacent to protective outer layer 8125o, which may comprise, for
example, a sheath or portion of a sheath or an
outer laminate. Polymeric protective inner layer 8125i, which again may
comprise, for example, a sheath or portion or a
sheath or an inner laminate, may be attached and divided into portions by one
or more partitions, such as the 'Y-shaped'
partition with upper limbs 81626, 8162c and lower limb 8162a shown in the
figure, which further subdivides the upper half
of the cross sectional view of the spiral coil implant 8114 into multiple
chambers comprising central upper chamber 816 lb
and lateral chambers 8161a and 8161c. Lab-on-a-chip 8129 may receive
information from biosensor 8197 to assess
drug/drug-moiety/chemical presence(s)/concentration(s). In some embodiments,
biosensors may comprise optical fibers,
electrochemical, nanomechanical and the like. It should be understood that any
number of chambers/partitions may be
provided as desired. For example, in some embodiments, only a single partition
may be provided to separate a portion of
the hollow inner core of spiral implant 8114 into just two chambers rather
than three.
[00796] Fig. 81c depicts a cross-sectional view of bladder-like compressible
implant 8101 taken from Fig. 81a along the
line and arrow depicted therein. Superstructure 8151 may be used to provide
rigidity to the implant 8101 and/or to bind the
upper half lamination 8101u with lower half lamination 810 IL as well as
midlayer 8101m. The upper BSRFMP 8191u may
also bind the upper half lamination 8101u with midlayer 8101m. The lower half
BSRFMP 8191L may also bind the lower
half lamination 8101L with midlayer 8101m which may house, protect and retain
the midlayer electronics group 8120. In
some embodiments, BSRFMP may facilitate disc-like shape maintenance of implant
8101 by preventing spherical inflation
and/or by maintaining intraluminal pressure which may facilitate drug passage
through porous lower half lamination 8101L
membrane. The
comparatively large size and/or surface areas of the spiral implant and/or the
relatively flattened
compressible implant may facilitate fluid collection and/or medicine/chemical
administration without vascular
catheterization/cannulation/penetration. In some embodiments, priming one or
more parts of the system with a desired
solvent(s) may facilitate operation. Bladder-like compressible implant 8101
may comprise pores 8101p, for example,
nanoscale agents responsive to stimuli, as previously discussed.
[00797] Fig. 81d depicts a further enlarged cross-sectional view of spiral
implant 8114 of that partially seen in Fig. 8 lb
including polymeric protective inner layer 8125i, outer layer 8125o. 'Y-
shaped' partition upper limbs 81626, 8162c and
lower limb 8162a, central upper chamber 8161b, upper lateral chambers 8161a
and 8161c. One or more gates 8138 may be
positioned along the exterior of implant 8114 to selectively allow
chemical/molecular passage into one or more of the
chambers defined therein. These gates may, for example, comprise electrically
actuatable smart nanoporous membranes (as
per Langer, Wireless on-Demand Drug Delivery, Nature Electronics, 2021).
Biosensor 8197 may be present inside or
exterior to any of the displayed chambers as well as extending external to the
implant to assess drug/drug-moiety/chemical
presence(s)/concentration(s). Internalized partition gates 8130 may also be
positioned along one or more of the internal
partitions, which may be configured to selectively allow chemical/molecular
passage. These internal gates 8130 may, for
example, comprise electrically actuatable smart nanoporous membranes.
[00798] Spiral implant 8114 may be configured to collect body fluids including
but not limited to saline and desalinated
water. For example, body fluid may be drawn into lateral chamber 8161a through
pore 8125p, which may be of a desired
average diameter to allow passage of molecules of a desired number of Dalton
molecular weight. The incoming fluid may
be further filtered by porous membrane 8136, which is shown only extending
adjacent to pore 8125p but may, in some
embodiments, extend about the entire perimeter of implant 8114, or at least
the portion of the implant adjacent to a particular
storage chamber with which the pore 8125p is functionally associated. Porous
membrane 8136 may comprise, for example,
a polymeric and/or nano-enhanced membrane for reverse osmosis. A negative
internal pressure may be assisted by
microfluidic pump 8139, which may comprise, for example, a piezoelectric
microfluidic pump/microdiaphragm pump or
the like. Internal pressure accumulation may be balanced elsewhere within or
external to the system via tube 8195, which
may comprise directional valves if desired. Thus, implant 8114 may be
configured to draw in filtered water from a patient's
body fluids into chamber 8161a. Such water may be distributed elsewhere within
the system 8100 via micropumps and
Date Recue/Date Received 2022-12-30
136
tubes for admixing with concentrated drugs for controlled expulsion into a
patient's tissues surrounding the implant, which
may be vascularized due to the new or foreign nature of the implant and/or
added to by virtue of exogenous
chemicals/hormones discussed elsewhere within.
[00799] Spiral implant 8114 may collect body fluids including but not limited
to saline and desalinated water. For example,
fluid may be drawn into lateral chamber 8161c through pore 8125p, which may be
of a desired average diameter to allow
passage of molecules of a desired number of Dalton molecular weight upon which
the fluid may be further drawn in by, for
example, an electro-osmotic-pump, which may comprising, for example, an outer
electrically charged porous membrane
8131, through electro-osmotic filter sandwich layer 8132 toward and through
outer electrically charged porous membrane
8133. Again, although structures 8131, 8132, and 8133 are shown only extending
adjacent to pore 8125p, this is for ease of
illustration and these structures may extend about the entire periphery of
chamber 8161c if desired. Thus, filtered water
may accumulate in chamber 8161c. Such water may be distributed elsewhere
within the system via, for example,
micropumps and tubes for admixing with concentrated drugs for controlled
expulsion into a patient's tissues surrounding
the implant which may be vascularized due to the new or foreign nature of the
implant and/or added to by virtue of exogenous
chemicals/hormones discussed elsewhere within. Piezoelectric element 8170 may
facilitate mixing and/or heating and/or
cleaning.
[00800] As shown in the perspective view of Fig. 81e, implant system 8100 may
further comprise, for example, auxiliary
implant 8108a, which may comprise CPU/printed-circuit-board 8183, battery
8184, memory/data storage element 8185,
antenna 81826, capacitor 8186, electronic heart rate sensor 8188, and/or lab-
on-a-chip 8187.
[00801] Fig. 8 If is an enlarged view of a powder mixing/distributing
segmentation pod 8171a, which may further comprise
fluidic tubing 8178, fluidic tubing 8179, which may be configured to deliver
fluids in the directions to/opposite directions
from tubings and/or storage bays such as 8177f. Such storage bays may house
drugs, fluids, powders, etc. and may be
coupled with means for distributing a drug, preferably in a dry form, such as
screw drives 8195 and 8194 or, for example, a
piston or the like. A preferably highly concentrated drug powder may be stored
in one or more bays, such as bay 8177f. In
some embodiments, this drug/powder may be moved/kept movable by piezoelectric
element 8170 and/or screw 8195 toward
screw 8194 which may facilitate transport of concentrated powder into
mixing/storage bay 8177m, which may further
comprise mixing element 8170s, such as a magnetic stirring element, that may
be configured to mix a powder with fluid
carried by one or more of fluidic tubing(s) 8178/8179, which may be received
from spiral implant 8114. Biosensor 8197
may be used to determine the mixed concentration of materials, a signal
indicative of which may be relayed to a CPU within
an element of the system, which may elicit a desired action. In further
contemplated embodiments, micro-pumps/motors
may be present between bays and/or tubing.
[00802] Fig. 81g depicts another example of a segmentation pod 8171g that may
be used in some embodiments, either in
place of or in addition to any of the other pods. Pod 8171g may comprise a gas
bubble delivery segmentation pod, which
may further comprise fluidic tubing 8178, fluidic tubing 8179, which may be
configured to deliver fluids in the directions
to/opposite directions from tubings and/or storage bays such as 8177g, and/or
storage bay 8 I77gg which may house fluids,
powders capable of reacting to form a gas on mixing directly and/or in the
presence of a catalyst and/or in the presence of
energy (heat, light, electricity, etc.) and/or may comprise micro-pumps/motors
8174, which may facilitate transport into
mixing/storage bay 8177m, which, again, may further comprise magnetic mixing
element 8197, which may be configured
to mix a powder or a fluid with another fluid carried by one or more of
fluidic tubing(s) 8178/8179. Again, a biosensor
8197 may be used to determine the mixed concentration of materials, which may
be relayed by way of a signal to a CPU
within an element of the system for a desired action. The highly concentrated
chemical solution and/or powder present in
bay(s) 8177h, and/or storage bay 8 I77hh may be moved/kept movable by
piezoelectric element 8170 and/or a stirring
element or the like. An example of chemical pairs that may possibly be used to
provide a nontoxic, relatively inert gas
source is sodium bicarbonate (baking soda) and acetic acid reacting to form
carbon dioxide. In some embodiments, the gas
Date Recue/Date Received 2022-12-30
137
bubble delivery segmentation pod 8171g may be placed in an advantageous
location, such as adjacent to the spiral implant
8114, to drive the system by gas contribution. In other embodiments, gas
bubble(s) 8187g may be used to separate various
liquid aliquots of various components and/or concentrations which may be
analyzed at any point along their paths via
biosensors.
[00803] Fig. 81h depicts another example of a possible modular segmentation
pod, namely, a liquid mixing/distributing
segmentation pod 817 lb, which may further comprise fluidic tubing 8178,
fluidic tubing 8179, which may be configured to
deliver fluids in the directions to/opposite directions from tubings and/or
storage bays, such as storage bay 8177h and/or
storage bay 8177hh, one or both of which may house drugs, fluids, powders,
etc. and/or may comprise micro-pumps/motors
8174 that may facilitate transport into mixing/storage bay 8177m.
Storage/mixing bay 8177m may optionally comprise a
mixing element, such as a magnetic stirring element, which may facilitate
mixing powders and/or fluids with fluids carried
by one or more of fluidic tubing(s) 8178/8179, which may be coupled to and/or
received from spiral implant 8114 and/or
one or more adjacent pods. Biosensor 8197 may be used to determine the mixed
concentration of materials, which may be
relayed via a signal to a CPU or other electrical element within the system,
which may be used to trigger a desired action.
The highly concentrated drug solution present in bay(s) 8177h, and/or storage
bay 8177hh may be moved/kept movable by
piezoelectric element 8170 and/or a stirring element or the like.
[00804] In further contemplated embodiments, a wrapper, such as the wrapper
shown in Fig. 46, may be placed overlying
the exterior of one or more of the segmentation pods and/or outside of
connection segments, which may facilitate sliding
the implant into an incision and past tissues. In some embodiments, this
wrapper may comprise a shrink wrap or may
otherwise be adherent to one or more of the pods, in which case the wrapper
may pinch/extend into the space overlying one
or more of segments between the pods.
[00805] In further implementations, inorganic draw solutes such as, for
example, magnesium and/or copper sulfate, may
be placed in/about/between laminates and/or compartments to facilitate solvent
movement.
[00806] In further contemplated embodiments and implementations, a variety of
devices may be used in conjunction with
those specifically mentioned in connection with the figures, including but not
limited to, thermopneumatic micropumps that
may transfer heat generated from RF transmission to a pump chamber, resulting
in drug flow, and microminiature infusion
devices that may comprise, for example, a reservoir for a therapeutic fluid, a
driver, and/or one or more electrodes which
may be used to deliver therapeutic electrical stimulation. In some instances,
the driver may comprise a pump, such as, for
example, a diaphragmatic, negative pressure, and/or peristaltic pump. In some
embodiments, the driver may be actuated by
electromagnetic means. Nanoscale agents may be used that may be configured to
respond to stimuli such as light, magnetic
fields, ultrasound, radio frequency, and/or x-ray, which may allow for
selective actuation from outside of the user/patient's
body. Magnetic fields may be used for magnetoporation and magnetic field drug
targeting. Electric current and/or voltage
may be used for electroporation and iontophoresis. Ultrasound may be used for
sonodynamic therapy and sonoporation.
Pulsed light may be used for optoporation and drug release. Temperatures may
be influenced for thermoporation.
[00807] In some embodiments, self-sustained carbon nanotube hollow fiber
scaffold supported polyamide thin film
composite (CNT TFC-FO) membranes may be used for forward osmosis. Such
membranes may be preferable due to their
high porosity, good hydrophilicity, excellent electro-conductivity, and great
electrically assisted resistance to organic and
microbial fouling. In some instances, the complete TFC-FO hollow fiber
membrane may comprise a salt-rejecting polyamide
active layer interfacially polymerized on the outer surface of the CNT hollow
fiber. The membrane may comprise an active
layer facing the feed solution and a support layer facing the draw solution.
Additional details regarding the disclosed
membrane may be found in 'Highly Permeable Thin-Film Composite Forward Osmosis
Membrane Based on Carbon
Nanotube Hollow Fiber Scaffold with Electrically Enhanced Fouling Resistance',
Fan, Environ. Sci. Technol., 2018, which
is hereby incorporated in its entirety by reference.
[00808] In some instances, graphene, graphene oxide, zeolites, carbon
nanotubes, silica, silver, and/or titanium dioxide
Date Recue/Date Received 2022-12-30
138
nanoparticles may be used to increase membrane water permeability. In some
embodiments, silica may be used to improve
hydrophilicity of osmotic membranes. In some instances, silver and titanium
dioxide may be used to reduce biofouling. In
some embodiments, polymeric membranes, such as cellulose acetate and
polyamide, may be integrated with other polymers
or nanoparticles to form reverse osmotic membranes. In some instances,
integration of nanoparticles with polymer-based
membranes may improve antifouling properties of RO membranes. Additional
details regarding such osmotic membranes
may be found in 'A Critical Review on Recent Polymeric and Nano-Enhanced
Membranes for Reverse Osmosis', Giwa,
RSC Advances, Issue 10, 2016, which is hereby incorporated in its entirety by
reference.
[00809] For membranes used in forward osmosis (FO), it may be preferable to
utilize thinner support layers to lessen the
concentration polarization impact on the FO process (higher concentration
polarization can lead to a decrease in water flux);
however, in some instances, thinner support layers may also compromise
mechanical strength. In some embodiments,
carbon-based nanomaterials (such as carbon nanotubes, graphene, and/or
graphene oxide) may be used to enhance water
flux, fouling propensity, and/or mechanical strength of FO membranes. In some
instances, hydrophilic nanomaterials may
be incorporated into FO membranes to increase membrane porosity and
hydrophilicity while decreasing the tortuosity of the
support layer, alleviating the effects of internal concentration polarization.
In some instances, graphene oxide derivatives
may be used to, for example, enhance selectivity, performance, and/or
productivity of such FO membranes. In some
embodiments, polymeric asymmetric membranes may be covered in functionalized
carbon materials. In a preferred
embodiment, an asymmetric FO membrane may comprise a dense, thin selective
layer for solute rejection and a porous
substrate layer to provide mechanical stability to the membrane. Synthetic
polymers used for the fabrication of supporting
layers of FO membranes may include, for example, cellulose derivatives,
polyethersulfone and polysulfone,
polyacrylonitrile, hydrophobic polyvinylidene fluoride, and the like. In some
embodiments, FO membranes may comprise
flat sheet FO membranes, hollow fiber FO membranes, and/or tubular FO
membranes. In some instances, conductive FO
membranes may be modified with a material (such as a metal, carbon, etc.) that
may act as a negative electrode. Applying
external voltages to FO membranes may result in an increased resistance to
fouling. In a specific embodiment, anti-fouling
double-skinned FO membranes may be used that may contain a polyamide salt-
rejection layer and a zwitterionic brush-
decorated, multiwalled carbon nanotube (MWCNT) foulant-resistant layer.
Materials used to improve FO membrane
performance may include, for example, carbon nanotubes, graphene, graphene
oxide, zeolites, metal-organic framework,
titanium dioxide, and the like. In some embodiments, active layers may
comprise polymeric active layers, which may
comprise polymers such as polyamide. In some instances, supporting substrates
may comprise nanocomposite substrates,
porous substrates, and the like. In certain embodiments, FO membranes may
comprise nanomaterial interlayers in between
the active layer and the supporting layer. Additional details regarding such
FO membranes may be found in 'Recent
Developments in Forward Osmosis Membranes Using Carbon-Based Nanomaterials',
Yadav, ScienceDirect, Desalination
482(2020), 114375, which is hereby incorporated in its entirety by reference.
[00810] In some embodiments, stimuli-responsive hydrogels may be used as draw
solutes in FO membranes. Stimuli-
responsive hydrogels may be preferred as they may be easily regenerated. In
preferred embodiments, draw solutes may
possess high osmotic pressure, be nontoxic, exhibit low reverse flux, and be
easily/rapidly regenerated. In some instances,
polyelectrolyte hydrogels, such as thermos-responsive poly(ionic liquid)
hydrogels, may be used as draw agents as they
produce high osmotic pressure. Such hydrogels may comprise, for example,
P(MTxE0y). In some instances, water flux may
be enhanced via composite hydrogels and/or reduced-size hydrogels. In some
instances, the dewatering rate may be
enhanced by changing the network structure of the hydrogel. It may be
preferable to have a heterogenous hydrogel as internal
microstructures may contribute to formation of water release channels by
grafting linear hydrophilic side chains onto
hydrogel networks. Additional details regarding such FO membranes may be found
in 'Recent Developments and Future
Challenges of Hydrogels as Draw Solutes in Forward Osmosis Process', Wang,
MDPI, Water 2020, 12, 692, which is hereby
incorporated in its entirety by reference.
Date Recue/Date Received 2022-12-30
139
[00811] In FO membranes, it may be preferable to have, for example: an active
layer that is ultra-thin, yet dense enough to
have a high solute rejection rate; a support layer that is both thin and able
to provide mechanical strength; a high
hydrophilicity to increase water flux, anti-fouling properties, and CP
alleviation; and a high pH, temperature, and oxidation
resistance range. In some embodiments, functionalized carbon nanotubes may be
blended into the polyethersulfone support
layer to enhance hydrophilicity and water flux. In some instances, thin-film
inorganic FO membranes may comprise
microporous silica xerogels immobilized onto a stainless steel mesh substrate.
In some embodiments, FO membranes may
undergo physical/chemical modifications to improve membrane properties. In
some embodiments, hydrophilic chemicals
may be added to membranes to improve water flux without compromising
rejection. Modification methods may include, for
example, blending, surface coating, in-situ interfacial polymerization, and
the like. In some embodiments, draw solutes may
comprise, for example, NaCI, NaNO3, KCl, and the like. Other draw solutes may
comprise organics, polymers, hydrogels,
ionic liquids, and the like. Additional details regarding FO membranes may be
found in 'Research on Forward Osmosis
Membrane Technology Still Needs Improvement in Water Recovery and Wastewater
Treatment', Li, MDPI, Water 2020,
12, 107, which is hereby incorporated in its entirety by reference.
[00812] In some embodiments, thin-film inorganic FO membranes may be used in
various implants, which membranes
may comprise, for example, micro-porous silica xerogels immobilized onto
stainless steel mesh substrates. In some
instances, NaC1 may be used in draw solutions. In some instances, microporous
inorganic silica membranes may be used to
remedy issues surrounding the severe internal concentration polarization
within the supporting layer of asymmetric
structured membranes. In some instances, the mechanically rigid stainless
steel mesh allows for the formation of self-
supporting thin-film structures, which may eliminate the need for a thick
supporting layer, enabling short-distance water
permeation with minimal internal polarization. Additional details regarding
such FO membranes may be found in 'Forward
Osmosis with a Novel Thin-Film Inorganic Membrane', You, Environmental Science
and Technology 2013, 47, 8733-8742,
which is hereby incorporated in its entirety by reference.
[00813] In some instances, ultrasound may be used in FO membranes to mitigate
the effects of ICP. In some instances, it
may be preferred to use low frequency ultrasound, such as 40 kHz. However, the
improvement in water flux may be realized
at the expense of increased reverse draw solute flux. In some instances,
magnesium sulfate and copper sulfate may be used
in draw solutions. Additional details regarding ultrasound in FO may be found
in 'Ultrasound-Assisted Forward Osmosis
Desalination Using Inorganic Draw Solutes', Qasim, Ultrasonics Sonochemistry,
2019, which is hereby incorporated in its
entirety by reference.
[00814] In some embodiments, low frequency ultrasonic vibrations may be
applied to the porous support structure of an
FO membrane to mitigate ICP. Low frequency, such as 20 kHz, may be effective
in improving water flux by even factors
of 2. It may be preferred to place the support layer against the draw solution
and the active layer against the feed solution.
Such ultrasonic vibrations may show highly enhanced water flux in membranes
such as, for example, a membrane
comprising a thin-film composite polyamide on polysulfone with embedded
support. In other instances, with membranes
comprising, for example, cellulose triacetate cartridges with embedded
polyester screen meshes, ultrasonic vibrations may
show little change in water flux, due to the membranes "ultrasound
transparent" nature. In some instances, sodium sulfate
may be used as a draw solution. Additional details regarding the
aforementioned ultrasound assisted FO membranes may be
found in 'Ultrasound-Assisted Forward Osmosis for Mitigating Internal
Concentration Polarization', Heiklcinen, Journal of
Membrane Science 528 (2017), 147-154, which is hereby incorporated in its
entirety by reference.
[00815] In some embodiments, piezoelectric pumps may be used that may comprise
a piezoelectric stack actuator and two
unimorph piezoelectric disk valves acting as inlet and delivery valves. Such
pump actuation mechanisms may comprise a
pumping chamber and a diaphragm attached to the stack actuator. Such
piezoelectric disk valves may aid in suppressing
back flow that normally accompanies valve operation. The resulting combination
of static and dynamic piezoelectric
functionality may aid in maximizing fluid output per stroke. Additional
details regarding such piezoelectric pumps may be
Date Recue/Date Received 2022-12-30
140
found in 'Design of a Piezoelectric-Hydraulic Pump with Active Valves', Gun
Lee, Journal of Intelligent Material Systems
and Structures, Vol. 15, Feb 2004, pp. 107-115, which is hereby incorporated
in its entirety by reference.
[00816] In some instances, micropumps may be used that may comprise brushless
mechanisms. Additional details
regarding such pumps may be found at TCS Micropumps, www.micropumps.co.uk.
[00817] In some embodiments, piezoelectric pumps may comprise diaphragm pumps,
normally closed valves, and/or
normally open valves. Such devices may be fabricated from titanium. The
normally closed valve can provide low leakage
rates while blocking the fluidic paths opening only when activated, while
normally open valves allow pressure release while
not actuated. Such piezoelectric actuation allows for energy efficient
driving, each piezoelectric device requiring only small
amounts of energy. Additional details regarding such piezoelectric pumps may
be found in 'Piezoelectric Titanium Based
Microfluidic Pump and Valves for Implantable Medical Applications', Beate
Bussmann, Sensors and Actuators A 323
(2021) 112649, which is hereby incorporated in its entirety by reference.
[00818] In some embodiments, electroosmotic pumps may be used, which may be
fabricated from porous nanocrystalline
silicone membranes. It may be possible, in some embodiments, to alter the rate
of electroosmotic flow via surface
modification. Ultrathin porous nanocrystalline silicone membranes operate with
high flow rates and low applied voltages
thanks to their small electrical resistance and high electrical fields across
their thin membrane. Additional details regarding
such electroosmotic pumps may be found in 'High-Performance, Low Voltage
Electroosmotic Pumps with Molecularly
Thin Silicon Nanomembranes', Snyder, PNAS, vol. 110, no. 46, 1825-18430, 2013,
which is hereby incorporated in its
entirety by reference.
[00819] In some instances, it may be possible to vary the flow rate of electro-
osmotic pumps by varying the aluminum
concentration of the aluminosilicate microparticles. In some embodiments,
simple electro-osmotic pumps may comprise
aluminosilicate frits and alizarin as an active electrode material. Such
electro-osmotic pumps may continue to function until
the electro-active material is exhausted. Additional details regarding such
osmotic pumps may be found in 'Low Voltage
non-gassing Electro-Osmotic Pump with Zeta Potential Tuned Aluminosilicate
Frits and Organic Dye Electrode', Lakhotiya,
Royal Society of Chemistry, 2014, which is hereby incorporated in its entirety
by reference.
[00820] In some embodiments, electroosmotic pumps may comprise multiple stages
and/or liquid metal electrodes.
Injection of liquid metal into a PDMS substrate may create a noncontact
electrode for micro electroosmotic flow (EOF)
pumps. PDMS may be used to fabricate microchannels of the EOF pump before
being bonded with a glass slide via plasma
treatment to create a microfluidic chip. Two liquid metal microchannels may be
located in parallel with the pumping area,
with only a small PDMS gap separating the liquid metal microchannel and the
ends of the parallel pumping channels. Five
identical straight pumping channels may be placed in parallel to form one
stage, with five stages being connected in serial.
Both electrode channels may be preferred in a vertical arrangement to the
pumping channels to give the maximum potential
gradient across the pumping direction. Additional details regarding the
disclosed EOF pump may be found in 'Development
of a Multi-Stage Electroosmotic Flow Pump Using Liquid Metal Electrodes', Gao,
MDPI, Micromachines 2016, 7, 165,
which is hereby incorporated in its entirety by reference.
[00821] In some embodiments, dispensing devices may be used, which may be
powered osmotically. Such devices may
comprise an inner wall formed of a collapsible material, with a layer of
solute deposited on the wall's outer surface, such
that the solute may create an osmotic gradient. The device may comprise an
outer wall with shape retaining properties and
permeable to water, but impermeable to the solute such that water may flow
into the space between both layers. As water
flows between both layers, the inner layer may collapse, dispensing an agent
through a dispensing pathway. Additional
details regarding the disclosed dispensing device may be found in U.S. Patent
No. 3,760,984, titled "Osmotically Powered
Agent Dispensing Device with Filling Means", which is hereby incorporated in
its entirety by reference.
[00822] In some instances, inductive power systems may be used to provide on-
demand activation and remote delivery
adjustments of implanted pumps. Such power systems may be used to power
implanted pumps for prolonged periods of
Date Recue/Date Received 2022-12-30
141
time. Such pumps may comprise an electrochemical actuator consisting of an
electrolyte (such as water) encased by a
Parylene bellows and a pair of interdigitated platinum electrodes on a rigid
glass substrate. The application of an electrical
current to the electrodes causes the water to split into hydrogen and oxygen,
increasing pressure, deflecting the bellows,
activating a one-way check valve, and displacing fluid out of the rigid
reservoir, through the outlet catheter. Once the current
is removed, the gasses may recombine to form water, allowing the bellows to
return to its original state. In some instances,
two refill ports may be integrated into the device to facilitate filling and
flushing of the reservoir. Such pumps may deliver
a range of doses (from microliters to nanoliters) at varying rates for
extended durations of time. It may be preferable to have
a closed-loop feedback system to enable pump performance monitoring.
Additional details regarding such pumps may be
found in 'A Wireless Implantable Micropump for Chronic Drug Infusion Against
Cancer', Cobo, Sensors and Actuators A,
2016, which is hereby incorporated in its entirety by reference.
[00823] In some embodiments, xerogel nanocomposites may be used in the
synthesis of ultra-filtration membranes. In some
instances, such xerogels may be synthesized by a sol-gel process in which
tetramethyl orthosilan and/or tetraethyl orthosilan
may be used as precursors. To obtain nano-xerogels, xerogels may be milled at
an ambient temperature in a high energy
planetary ball mill. In some embodiments, PES may be used as a polymer in the
formation of such membranes used in
conjunction with nano-xerogels. The addition of nano-xerogels may aid in
improving the hydrophilicity of the PES
membranes. In some instances, the presence of Silanol groups in the xerogels
may increase xerogel hydrophilicity, and
therefore membrane water flux. Additional details regarding such composite
membranes may be found in 'Preparation and
Characterization of PES-Xerogel Nanocomposite Ultra-Filtration Membrane',
Shamsodin, Cellulose, 5939-5950, 2018,
which is hereby incorporated in its entirety by reference
[00824] In some embodiments, water-permeable membranes may be made of
polyethersulfone (PES) and comprise
microfluidic channels and nanoporous membranes. Such membranes allow only for
low molecular weight molecules, such
as Na, K, Urea, and creatinine to pass through while blocking proteins and
larger molecules. Such PES membranes may be
formed by the phase inversion method, in which the casting solution can adjust
the permeability. In some embodiments the
PES membrane may be sandwiched by microchannels. In some instances, nanoporous
parylene and fluorinated diamond-
like carbon may be deposited onto the membrane surface to alter its
properties. In a preferred embodiment, the PED
membrane formed from the casting solution may comprise a PES concentration of
17.5%, balancing water permeability and
mechanical strength. Additional details may be found in 'Water-Permeable
Dialysis Membranes for Multi-Layered
Microdialysis System', To, Frontiers in Bioengineering and Biotechnology 3:70,
2015, which is hereby incorporated in its
entirety by reference.
[00825] In some embodiments, superhydrophilic-hydrophilic self-supported
monolayered porous polyethersulfone (PES)
membranes with nano/micropores at opposite surfaces may be used for
unidirectional liquid (such as water) transport. The
volume content of ethanol and water may be controlled to tune the
micro/nanopore sizes on each surface. In a preferred
embodiment, both sides of the membrane may portray high hydrophilicity. In
some embodiments, pores may be formed via
the phase transfer method. Additional details regarding the disclosed PES
membrane may be found in 'Highly Flexible
Monolayered Porous Membrane with Superhydrophilicity-Hydrophilicity for
Unidirectional Liquid Penetration', Zhang,
ACS Nano, DOI: 10.1021/acsnano.0c02558, 2020, which is hereby incorporated in
its entirety by reference.
[00826] In some embodiments, optical fibers may comprise chemically sensitive
polymeric layers for biosensing
applications. In some instances, such coatings may comprise polyelectrolytes,
such as, for example,
poly(diallyldimethylammoniumchloride), polyethyleneimine, poly(allylamine
hydrochloride), and the like. Different
polymers may show variations in sensitivity due to their polymeric structure,
so it may be beneficial to select polymers based
on intended applications. In some embodiments, optical fiber sensor arrays may
comprise excitation fibers to guide
excitation light and detective fibers to capture the luminescence. In some
instances, the detection fibers are placed at a right
angle to the excitation fibers. In some instances, optical fibers combined
with polymeric layers may not be limited to
Date Recue/Date Received 2022-12-30
142
detection of chemicals, but also may be used to sense physical parameters. In
some embodiments, the polymeric matrix may
be used as a solid support for the immobilization of a specific chemical
transducer, while in other embodiments, the
polymeric matrix may be used directly as a chemical transducer. Additional
details regarding such fiber optic sensors may
be found in 'Optical Fiber Sensors Based on Polymeric Sensitive Coatings',
River , MDPI, Polymers 2018, 10, 280, which
is hereby incorporated in its entirety by reference.
[00827] In some instances, biosensing devices may be used, which may comprise
optical biosensors, such as bio-optrode,
evanescent field-based sensors; electrochemical sensors, such as, for example,
amperometric, potentiometric, field-effect
transistor-based, and/or impedimetric sensors; piezoelectric sensors such as
quartz crystal microbalance sensors; and/or
nanomechanical sensors, such as nanocantilevers. Bio-optrode sensors may
comprise fiber-optic devices, while evanescent
field-based devices may include SPR-based, surface-enhanced Raman scattering,
total internal reflection fluorescence,
optical waveguide interferometer, and elipsometric and reflectrometric
interference spectroscopy biosensors. Fiber-optic
biosensors may comprise a biocatalyzer immobilized at the distal end of a
fiber-optic detection device, such that the
biocatalyzer mediates between a sensor and an analyte, forming a detectable
compound. In some instances, the surfaces of
biosensors may comprise a functionalized surface, chosen based on chemical
and/or physical properties and/or application.
Additional details regarding such biosensors may be found in 'Optical
Biosensors for Therapeutic Drug Monitoring',
Garzon, MDPI, Biosensors 2019, 9, 132, which is hereby incorporated in its
entirety by reference.
[00828] In some embodiments, magnetic polymer composites may be used for
separating particles in microfluidic devices.
Such magnetic polymers may aid in targeting/trapping magnetic microbeads or
magnetically labeled cells in microfluidic
devices. Magnetic fields used to manipulate magnetic micro/nanoparticles in
microfluidic devices may apply
repulsive/attractive forces. Magnetic sources in microfluidic systems may
generate localized micro-magnetic field gradients
via: current carrying micro-coils, microconcentrators made of sof ferromagnets
(such as Ni and Fe-Ni alloys) magnetized
by an external magnetic field, permanently magnetized micromagnets, comprising
hard ferromagnetic materials (such as
NdFeB), and the like. In some instances, polymers used to create composite
magnetic polymers may comprise elastomers
such as, for example, PDMS. Composite polymers based on PDMS may be obtained
by mixing soft (Fe, Ni, and alloys
thereof) or hard (NdFeB) magnetic powders with a PDMS mixture comprising a
base polymer and curing agent. Magnetic
PDMS may be integrated into pillars inside microchannels to aid in trapping
magnetic targets. Composite magnetic polymers
may comprise magnetic microparticles ranging from less than 10% to over 30%.
In some instances, ferrofluids may be used
to sort cells. An external magnetic field may be used to magnetize the
ferrofluid, which creates a gradient field that may be
used to attract magnetically tagged cells in side channels. Such ferrofluids
may comprise, for example, Fe304 nanoparticles
in concentrations as low as 0.01%. Additional details regarding such composite
magnetic polymers may be found in
'Magnetic Polymers for Magnetophoretic Separation in Microfluidic Devices',
Descamps, MDPI, Magnetochemistry 2021,
7, 100, which is hereby incorporated in its entirety by reference.
Date Recue/Date Received 2022-12-30
